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Summary 
 
Biological systems are made up of a plethora of organic components. Since 
nowadays attention has been focused on two important classes of bioinformative 
molecules, nucleic acids and proteins, whose large scale study has led to the rise of 
the so called “omics” sciences, genomics and proteomics. In particular the study of 
the proteome implies not only the protein complement of a given cell, but even the 
study on a high throughput scale of proteins post translational modifications, 
interactions, and functions. More than 50% of mammalian proteins are glycosylated 
and this observation has led to the conclusion that sugars attachment broadens 
variability among gene products. Glycans generally cover  cellular surfaces, ranging 
from viruses to the most complex multicellular organisms and they can be considered 
as a molecular code that dictates to cells how to communicate with each other. The 
wide range of important biological processes mediated by carbohydrates has given 
origin to glycomics, the large scale study of the whole set of glycans of an organism. 
This PhD thesis targeted the development of methodological platforms for the study 
of glycoproteins and glycoconjugates by the integration of affinity chromatography 
strategies together with high performance liquid chromatography and mass 
spectrometry. My first steps in the study of glycosylation were focused on the 
development of enrichment, derivatization, and mass spectrometry procedures, that 
were applied to the study of the protein content of egg. Peptides of egg 
glycoproteins, bearing N-glycosylation sites, were captured by Concanavalin A 
affinity chromatography and detected by LC-MS/MS after deglycosylation. 
Oligosaccharides were analyzed by MALDI-MS/MS before and after dansylhydrazine 
derivatization of the reducing end. This derivatization was introduced to enhance 
oligosaccharides fragmentation characteristics. Attempts to achieve more structural 
information on glycans were carried out using multi-stage mass spectrometry on 
MALDI-LTQ-Orbitrap. 
A proteomic approach was employed to investigate the molecular bases of 
myocarditis, a group of diseases that have in common the inflammation of the heart. 
In this case, the study of glycosylation anomalies in the sera sample of myocarditis-
affected patients came after a wider study including both the analysis of free peptides 
and a general overview on protein content by 2D gel electrophoresis. This study 
represents a starting point for further studies aiming at the screening of proteic 
biomarkers for this pathological status and involving different fields of clinical 
investigations, opening up new opportunities for therapeutics and early diagnostics. 
Glycoproteins-based therapeutics are generally produced in mammalian host 
systems, but plants can be considered a valuable alternative for their ability to 
produce homogeneously glycosylated recombinant proteins. The possibility of 
exploiting plants as host systems and the lack of consistent information concerning 
glycosylation in the plant model system Arabidopsis thaliana encouraged me to 
investigate its glycoproteome, using the strategies previously developed. 
The last part of my work was devoted to the study of innate immunity mechanisms 
triggered by lipopolysaccharides, bacterial glycoconjugates located on cell surfaces. 
The full exploitation of glycoconjugates potential for industrial biotechnological and 
pharmaceutical applications requires a deep knowledge of the immunological 
mechanisms at the base of host-pathogen recognition. The goal of the project was 
the development of a strategy to capture LPS-interacting proteins and glycoproteins 
in human serum, considering that some of these mechanisms are still unknown in 
non-human biological systems. 
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Riassunto. 
 
I glicani possono essere annoverati tra le componenti organiche più abbondanti sulla 
Terra e svolgono funzioni centrali in tutti gli organismi viventi, dagli organismi più 
semplici agli eucarioti più complessi, i quali impiegano in media l’1% dei loro genomi 
in enzimi coinvolti nella sintesi e modifica degli zuccheri. Questi enzimi sono molto 
conservati tra le specie viventi [1].  
L’acquisizione progressiva di informazioni riguardanti la centralità dei carboidrati in 
quanto macromolecole biologiche “bioinformative” ha dato l’impulso per la nascita 
della “glicomica”, intesa come studio sistematico e su larga scala del “glicoma”, 
l’intero set di carboidrati prodotto da un organismo [2]. Tuttavia la mappatura del 
glicoma mostra un più elevato livello di complessità rispetto al genoma e al 
proteoma, in quanto i glicani presentano un numero maggiore di unità costitutive, 
rispetto agli acidi nucleici (4 nucleotidi), e alle proteine (20 amminoacidi). Il processo 
di mappatura del glicoma è anche complicato dal fatto che la sintesi dei carboidrati 
non è guidata da uno stampo ed è quindi impossibile amplificarli per poterne facilitare 
l’analisi. Inoltre i glicani possono adottare delle strutture complesse, altamente 
ramificate, con differenti conformazioni anomeriche.  
I glicani possono trovarsi legati ad altre molecole a formare glicoconiugati. In tal 
senso la coniugazione di oligosaccaridi alle proteine aumenta considerevolmente la 
variabilità tra i prodotti genici. Infatti essi esistono come complesse miscele di varianti 
glicosidiche, dette glicoforme. 
Le glicoproteine svolgono svariate funzioni biologiche, in cui la componente glicidica 
è assolutamente indispensabile per garantire il raggiungimento della corretta 
conformazione tridimensionale, per prevenire il riconoscimento di specifici aminoacidi 
nello scheletro polipeptidico da parte di proteasi, per coordinare processi biologici 
basati su fenomeni di riconoscimento cellulare. In tutti questi casi il comune 
denominatore è la diversità nei profili di glicosilazione delle proteine, una diversità 
riscontrabile tra le differenti specie, all’interno di popolazioni, tra individui della stessa 
popolazione e persino tra differenti tipi cellulari dello stesso organismo [3]. I 
carboidrati che ricoprono le superfici cellulari costituiscono un “codice molecolare” 
che le cellule utilizzano per comunicare tra di loro, un sistema per controllare e 
coordinare innumerevoli processi biologici [4]. 
Gli oligosaccaridi sono responsabili del riconoscimento delle cellule ospiti da parte di 
organismi patogeni e tossine [5,6]: è questo il caso del virus dell’influenza [7], di 
Plasmodium falciparum, l’agente eziologico della malaria [8], di Helicobacter pylori, la 
cui adesione all’epitelio della mucosa gastrica, può provocare l’ulcera e 
l’adenocarcinoma gastrico [9]. Il riconoscimento di epitopi oligosaccaridici da parte di 
lectine localizzate sulle superfici cellulari, è generalmente alla base del 
riconoscimento del “self/non self”, nel senso che il sistema dell’immunità innata è in 
grado di riconoscere i glicani endogeni come “self”.  Molte malattie autoimmuni 
presentano un’alterazione in questo sistema di riconoscimento, connessa con la 
modifica del profilo di glicosilazione in glicolipidi e glicoproteine [10,11]. Alterazioni 
nel profilo di glicosilazione sono state riscontrate in molti altri fenomeni patologici, 
coinvolgenti processi di adesione intercellulare, come ad esempio il cancro e malattie 
infiammatorie. 
I glicani e le glicoproteine presentano enormi potenzialità di profitto nello sviluppo di 
farmaci. E’ chiaro che la produzione di farmaci a base di glicoproteine prevede 
un’accurata formulazione che deve tenere conto anche dei livelli qualitativi e 
quantitativi di glicosilazione. In questo contesto le industrie farmaceutiche sono alla 
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continua ricerca di nuovi sistemi di espressione, al fine di produrre glicoproteine con 
un profilo di glicosilazione adeguato. Il sistema di espressione più utilizzato è 
senz’altro costituito dalle cellule di mammifero, ma nuovi sviluppi nel campo della 
glicoproteomica non escludono l’utilizzo di sistemi di espressione differenti, che 
insieme alla nascente “glicoingegneria”, saranno in grado in un futuro molto 
prossimo, di fornire prodotti più omogenei e a costi più contenuti. 
Lo studio della glicosilazione trova applicazione anche in campo alimentare, in 
quanto un’alimentazione integrata con “cocktail” oligosaccaridici può indurre 
meccanismi di difesa atti a prevenire l’adesione di lectine batteriche all’epitelio della 
mucosa intestinale, fornendo un notevole supporto al sistema immunitario individuale 
[12]. 
La molteplicità di processi biologici che coinvolgono glicoproteine e glicoconiugati ha 
reso necessario lo sviluppo di metodologie analitiche e computazionali che hanno 
dato un grande impulso allo sviluppo della glicomica. Quest’ultima si basa 
sull’integrazione di procedure di arricchimento, sistemi cromatografici 
multidimensionali, spettrometria di massa ad alta risoluzione e strumenti 
bioinformatici. I risultati raccolti possono costituire uno strumento indispensabile 
nell’approccio di “systems biology” mediante l’integrazione di dati ottenuti da 
differenti tecniche analitiche complementari. 
In generale tutti i metodi analitici devono tenere in conto che le sequenze di glicani e 
glicoconiugati non possono essere amplificate, diversamente dagli acidi nucleici, in 
quanto la loro sintesi non è diretta da uno stampo. Per questo motivo il primo passo 
nell’approccio allo studio dei glicomi è sempre costituito dall’arricchimento, che può 
essere effettuato utilizzando diversi supporti, dalle lectine alle resine al boronato, alla 
cromatografia per esclusione molecolare. 
La finalità del presente progetto di dottorato è stata la messa a punto di 
piattaforme metodologiche basate sull’integrazione di strategie di cromatografia di 
affinità, accoppiate a cromatografia liquida ad alta prestazione e a tecniche di 
spettrometria di massa multidimensionale per lo studio di glicani e glicoproteine e la 
loro validazione in sistemi biologici modello e non.  In particolare l’attenzione è stata 
concentrata su sistemi modello, come l’uovo e Arabidopsis thaliana, ma studi sono 
stati effettuati anche per valutare eventuali anomalie nella glicosilazione nella 
miocardite. 
 
Messa a punto di tecniche integrate di spettrometria di massa e marcatura di 
oligosaccaridi. 
La caratterizzazione delle sequenze oligosaccaridiche e della loro funzione richiede 
procedure sperimentali sensibili e accurate in grado di ovviare all’assenza di 
cromofori. Per questo motivo la loro rivelazione viene facilitata dall’introduzione di 
molecole cromofore all’estremità riducente. A tal riguardo, derivati dell’idrazina 
vengono di solito impiegati per dar luogo ad idrazoni che, se necessario, possono 
essere ridotti dando luogo a strutture ad anello aperto [13]. La derivatizzazione 
influenza fortemente l’efficienza di ionizzazione dei glicani, introducendo cariche 
addizionali e fornendo un maggior carattere idrofobico [14]. 
I primi esperimenti volti alla caratterizzazione della N-glicosilazione sono stati rivolti 
alla messa a punto di metodologie di arricchimento e di marcatura in una matrice 
complessa, quale estratti proteici di uovo. Il tuorlo e l’albume sono stati trattati 
separatamente in maniera tale da poterne analizzare sia la componente glicidica, sia 
quella peptidica e riscontrare se le metodologie messe a punto fossero in grado di 
rivelare eventuali differenze. Infatti una cromatografia di arricchimento su resina 
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Concanavalina A è stata effettuata su entrambe le frazioni, dopo riduzione, 
alchilazione e idrolisi. Tutte le frazioni dell’arricchimento sono state trattate con 
endoglicosidasi F. L’identificazione delle proteine e la diretta localizzazione dei siti di 
N-glicosilazione è avvenuta mediante analisi LC-ESI-MS/MS, considerando che 
l’idrolisi del legame N-glicosidico comporta un incremento di massa di 0.98 Da a 
carico dell’asparagina, che viene così convertita in un residuo di aspartico. Questo 
incremento di massa, insieme alla presenza della sequenza consensus Asn-X-S/T 
ha determinato l’identificazione di un certo numero di siti sia di glicosilazione sia nei 
ritenuti che negli aspecifici della cromatografia di arricchimento, in maniera tale da 
poter identificare nell’aspecifico eventuali siti di N-glicosilazione recanti epitopi 
oligosaccaridici non riconosciuti dalla lectina Concanavalina A. 
La componente glicidica è stata analizzata mediante spettrometria di massa MALDI-
TOF/TOF, una tecnica particolarmente indicata per l’analisi dei glicani, in quanto 
richiede basse quantità di materiale e tollera relativamente la presenza di sali. Gli 
spettri relativi al profilo degli oligosaccaridi, sia nel ritenuto che nel rifiutato, hanno 
mostrato la stessa tipologia di glicani sia nell’albume, che nel tuorlo, con l’unica 
differenza che in quest’ultimo, le stesse strutture sono sialilate. Le strutture sono 
state determinate soprattutto grazie alla conoscenza della biosintesi delle 
glicoproteine, ma sono state anche confermate grazie alla frammentazione in 
MS/MS. 
Per migliorare la frammentazione dei glicani in MS/MS è stata messa a punto una 
nuova metodologia di derivatizzazione dell’estremità riducente con un derivato del 
dansile, la dansilidrazina, soprattutto grazie alla profonda esperienza con i derivati 
del dansile nel gruppo di ricerca in cui ho svolto le mie attività [15,16,17]. Inoltre 
recenti studi hanno dimostrato che la marcatura mediante derivati del dansile 
migliora la ionizzazione e frammentazione dei peptidi in spettrometria di massa 
MALDI [18]. La procedura di derivatizzazione è stata messa a punto su un 
oligosaccaride sintetico, e l’analisi di spettrometria di massa MALDI-MS/MS ha 
evidenziato un incremento nell’intensità dei segnali corrispondenti agli ioni di tipo B e 
C della nomenclatura di Domon e Costello [19]. Le stesse analisi sono state 
effettuate mediante ESI-MS ed anche in questo caso l’analisi ha rivelato un deciso 
miglioramento nella qualità dello spettro di frammentazione. La metodologia è stata 
applicata ai campioni di oligosaccaridi estratti dal tuorlo e dall’albume dell’uovo ed è 
stata possibile una più semplice caratterizzazione delle sequenze oligosaccaridiche, 
grazie al miglioramento dell’efficienza di ionizzazione degli analiti dopo marcatura 
con dansile, con un più alto rapporto segnale/rumore. 
Un manoscritto riportante i risultati ottenuti è stato sottomesso a Glycoconjugate 
Journal 
- Giangrande C, Melchiorre M, Marino G, Amoresano A. Oligosaccharides 
characterization by dansyl labelling and integrated mass spectrometry techniques.  
 
Caratterizzazione di oligosaccaridi mediante spettrometria di massa multi-
stadio 
In letteratura è riportato l’utilizzo della cromatografia multi-stadio nella 
caratterizzazione strutturale di oligosaccaridi, sfruttando la rapidità di analisi e la 
sensibilità della sorgente MALDI, associate alla capacità delle trappole ioniche 
quadrupolari di effettuare la frammentazione sequenziale di ioni prodotto [20,21]. 
Durante il mio dottorato ho svolto un periodo di permanenza presso l’École 
supérieure de physique et de chimie industrielles della città di Parigi, dove ho avuto 
la possibilità di condurre esperimenti di caratterizzazione strutturale di oligosaccaridi 
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mediante uno spettrometro di massa MALDI LTQ Orbitrap. Un recentissimo lavoro di 
Karas e collaboratori ha esplorato le potenzialità di questo strumento nell’analisi di 
oligosaccaridi mediante tre diverse tipologie di frammentazione, CID, PQD e HCD, 
mostrando vantaggi e svantaggi di ognuna di esse e concludendo che solo 
l’integrazione dei dati ottenuti può fornire una caratterizzazione esauriente sulla 
struttura degli oligosaccaridi esaminati [22]. Nel nostro caso lo spettrometro di massa 
MALDI LTQ Orbitrap è stato adoperato per l’analisi di glicani estratti da proteine 
standard N-glicosilate allo scopo di sfruttare le potenzialità di questo strumento negli 
esperimenti di spettrometria di massa tandem multidimensionale. Gli spettri MS/MS 
registrati in modalità CID hanno richiesto la messa a punto dei parametri di energia di 
collisione e di intensità del laser per l’ottimizzazione dello spettro. Tuttavia durante la 
frammentazione in CID, non è possibile intrappolare frammenti aventi un rapporto 
m/z inferiore al 30% del rapporto m/z del precursore. Questo motivo ci ha convinti ad 
esplorare le potenzialità della frammentazione multi-stadio, eseguendo esperimenti 
MS3 ed MS4. Purtroppo nonostante gli ulteriori eventi di frammentazione abbiano 
aumentato il numero di tagli all’interno dell’anello, i “cross-ring cleavages”, altamente 
informativi nella delucidazione strutturale, essi non sono stati sufficienti a fornire una 
completa caratterizzazione strutturale, a causa di problemi di sensibilità, dovuti 
probabilmente all’elevato consumo di campione da parte della sorgente MALDI. 
Questa sorgente, differentemente dalle altre sorgenti MALDI che sono state utilizzate 
durante il mio percorso di studi, è dotata di un sistema automatico di riconoscimento 
dei cristalli. Durante l’esperimento, l’utilizzo della matrice DHB insieme alla necessità 
di un’alta intensità del laser, ha determinato lunghi tempi di analisi, provocando un 
alto consumo di campione. 
- Questo progetto è stato svolto in collaborazione con i dottori Joelle Vinh e 
Giovanni Chiappetta presso l’ École supérieure de physique et de chimie 
industrielles. 
 
Il glicoproteoma nello studio della miocardite. 
Il termine “miocardite” indica un gruppo di patologie caratterizzate dall’infiammazione 
del muscolo cardiaco, che può avere origini infettive o può essere causata da 
meccanismi autoimmuni o ancora può essere provocata da ipersensibilità a farmaci 
[23,24,25,26,27]. 
Durante questo lavoro di tesi si è cercato di investigare le basi molecolari di questa 
patologia, utilizzando un approccio proteomico per lo studio delle proteine del siero. 
Gli esperimenti non sono stati ristretti alla sola componente del glicoproteoma, ma 
hanno previsto degli studi preliminari sul peptidoma, inteso come l’insieme dei peptidi 
endogeni del siero, e sulla componente proteica in generale, mediante un classico 
approccio di elettroforesi bidimensionale. Lo studio è proseguito con l’analisi della N-
glicosilazione impiegando due diverse metodologie di arricchimento. 
Lo studio dei peptidi liberi per LC-MS/MS ha evidenziato differenze qualitative e 
semi-quantitative tra i campioni provenienti da pazienti affetti da miocardite e pazienti 
sani. 
L’elettroforesi bidimensionale è stata effettuata successivamente alla deplezione 
delle proteine sieriche più abbondanti. Anche le mappe bidimensionali hanno 
evidenziato una maggiore espressione nel siero affetto da miocardite di proteine 
indubbiamente correlate con l’insorgenza di eventi infiammatori, come l’emopessina, 
la proteina del complemento C3 e la callicreina. 
Il vero e proprio esperimento per l’analisi della N-glicosilazione è avvenuto in seguito 
a procedure di arricchimento su resina derivatizzata con Concanavalina A e resina al 
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boronato. In entrambi i casi sono state analizzate per lo studio della glicosilazione sia 
la componente del ritenuto della cromatografia, sia quella del rifiutato, dopo 
trattamento con endoglicosidasi F. I peptidi contenenti il sito di N-glicosilazione sono 
stati identificati per LC-MS/MS, tenendo conto del fatto che l’idrolisi del legame N-
glicosidico introduce un incremento di massa di 0.98 Da nel peptide, incremento che 
insieme alla presenza della sequenza consenso Asn-X-Ser/Thr è diagnostico per 
l’identificazione del sito di N-glicosilazione. I risultati ottenuti da queste analisi hanno 
rivelato un profilo più o meno simile per i campioni di miocarditi rispetto a quelli sani. 
Tuttavia alcuni specifici peptidi sono stati identificati in una sola delle frazioni della 
Concanavalina A, suggerendo che differenze possono essere attribuibili al differente 
profilo di glicosilazione di queste glicoproteine nei due campioni (bisogna considerare 
che la Concanavalina A è in grado di legare strutture cosiddette “high mannose” e 
biantennarie). Per questo motivo è stato effettuato un profilo della componente 
glicidica ottenuta dall’idrolisi con endoglicosidasi F e separata dalla componente 
peptidica per cromatografia a fase inversa su resina C-18. Questi oligosaccaridi sono 
stati analizzati per spettrometria di massa MALDI-TOF e alcune specifiche strutture 
sono state frammentate per PSD. Se il profilo degli oligosaccaridi derivanti dal 
ritenuto della Concanavalina A presentano un profilo più o meno simile, quelli del 
rifiutato mostrano la presenza nei campioni patologici di strutture completamente 
assenti nei campioni da individui sani. Si può concludere che è stata riscontrata la 
correlazione di questa patologia con strutture peculiari, incomplete o tronche, 
insieme a strutture iperfucosilate. 
In definitiva questo approccio proteomico e glicobiologico rappresenta la messa a 
punto di metodologie per lo screening di marcatori proteici nella miocardite e pone le 
basi per lo sviluppo di nuove opportunità diagnostiche e terapeutiche. 
Questo lavoro è confluito in alcune recenti pubblicazioni: 
-  Carpentieri A, Giangrande C, Pucci P, Amoresano A. Glycoproteome study in 
myocardial lesions serum by integrated mass spectrometry approach: preliminary 
insights. Eur J Mass Spectrom (Chichester, Eng). 2010;16(1):123-49. 
- Andrea Carpentieri, Chiara Giangrande, Piero Pucci and Angela Amoresano 
(2011). A Proteomic Approach to Investigate Myocarditis, Myocarditis, Daniela 
Cihakova (Ed.), ISBN: 978-953-307-289-0, InTech 
-  Amoresano A, Carpentieri A, Giangrande C, Palmese A, Chiappetta G, Marino G, 
Pucci P. Technical advances in proteomics mass spectrometry: identification of 
post-translational modifications. Clin Chem Lab Med. 2009;47(6):647-65. 
 
Caratterizzazione del glicoproteoma in Arabidopsis thaliana 
La crescente domanda di proteine ricombinanti, soprattutto nell’industria 
farmaceutica, ha incoraggiato la ricerca di nuovi sistemi di espressione, in maniera 
tale da superare le basse capacità di espressione delle cellule di mammifero. A 
questo proposito le piante possono costituire una valida alternativa per i loro bassi 
costi di produzione e per la capacità di produrre proteine di mammifero perfettamente 
strutturate. Molte proteine di interesse biotecnologico sono state recentemente 
prodotte, utilizzando piattaforme vegetali, quali piante intere, sospensioni cellulari, 
radici e semi. Tuttavia, nonostante le piante siano in grado di fornire prodotti 
abbastanza omogenei per ciò che riguarda la N-glicosilazione, quest’ultima differisce 
dalla glicosilazione nei mammiferi.  
Per questo motivo è molto importante provvedere alla messa a punto di metodologie 
per la caratterizzazione di glicoproteomi di interesse vegetale, scegliendo come 
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oggetto di studio il glicoproteoma di Arabidopsis thaliana, specie vegetale il cui 
genoma è disponibile. 
L’estratto proteico di A.thaliana è stato dapprima frazionato per elettroforesi su gel di 
poliacrilammide e il gel ottenuto è stato colorato con un reattivo specifico per le 
glicoproteine. Alcune bande particolarmente visibili dopo colorazione sono state 
escisse dal gel e sottoposte ad idrolisi in situ e le proteine identificate per LC-MS/MS. 
Le proteine identificate sono state ricercate in banca dati e ne è risultato che la 
maggior parte di esse era effettivamente glicosilata. Purtroppo questa procedura non 
è stata in grado di individuare se una singola proteina fosse effettivamente glicosilata 
e quale fosse il sito di N-glicosilazione. Per rispondere  a queste domande è stato 
applicato ad A.thaliana il consueto protocollo di arricchimento con Concanavalina A. 
In questo caso però è stata utilizzata la endoglicosidasi A, in grado di effettuare 
l’idrolisi anche in presenza di α-1,3-fucosio. La procedura ha portato 
all’identificazione di una serie di siti di N-glicosilazione da differenti proteine. A 
queste analisi si affiancano le analisi della componente glicidica per MALDI-
TOF/TOF. Gli spettri di frammentazione sono stato interpretati con l’ausilio di 
software bioinformatci, confermando i dati già ottenuti precedentemente. 
-Questo progetto è stato svolto in collaborazione con il Prof. Edgardo Filippone e il 
Dott. Pasquale Chiaiese del Dipartimento di scienze del suolo e della pianta 
dell’Università degli studi di Napoli Federico II 
È in corso la stesura di un manoscritto che riporta i risultati ottenuti. 
- Giangrande C, Melchiorre M, Chiaiese P, Palomba F, Filippone E, Marino G, 
Amoresano A. Arabidopsis thaliana glycoproteome characterization by integrated 
mass spectrometry techniques 
 
Glicoconiugati di superficie: i lipopolisaccaridi nello studio dell’immunità 
innata. 
I glicani e i glicoconiugati che ricoprono le superfici cellulari svolgono un ruolo 
cruciale nell’interazione patogeno-cellula ospite. I batteri sintetizzano numerosi 
glicoconiugati, come i lipopolisaccaridi. La sintesi di lipopolisaccaridi e glicoproteine 
coinvolge una serie di proteine omologhe, caratterizzate da un’ampia specificità di 
substrato, che rende queste vie biosintetiche particolarmente interessanti 
nell’ingegnerizzazione di batteri per la produzione industriale di glicoconiugati, 
generando potenziali vaccini e farmaci [28]. Tuttavia l’utilizzo di queste molecole per 
scopi biotecnologici richiede una profonda conoscenza dei meccanismi immunologici 
alla base del riconoscimento patogeno-cellula ospite. Per quanto riguarda i 
lipopolisaccaridi questi meccanismi coinvolgono in primo luogo l’immunità innata, 
intesa come una serie di risposte non specifiche che hanno luogo in caso di infezione 
da parte di una minaccia esterna, e che non generano una memoria immunologica. Il 
mio lavoro specifico è consistito nella messa a punto di una metodologia per 
l’individuazione di proteine del siero che interagiscono con l’LPS. Questa procedura 
ha previsto la marcatura con biotina della porzione glicidica del lipopolisaccaride 
estratto da Salmonella typhimurium, e la sua successiva immobilizzazione su una 
resina di avidina, in maniera tale da poter essere utilizzato come esca per la cattura 
di putativi interattori nel siero umano. Il siero è stato preventivamente cimentato con 
una resina di avidina, alla quale non era stato aggiunto l’LPS. A valle del sistema di 
affinità è stato eseguito un gel di poliacrilammide monodimensionale su cui sono stati 
caricati il controllo (proteine che interagiscono specificamente con la resina 
derivatizzata con avidina) e il campione (contenente proteine che interagiscono con il 
lipopolisaccaride). Dall’identificazione per LC-MS/MS delle proteine escisse dal gel, 
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sono stati considerati putativi interattori soltanto le proteine esclusivamente presenti 
nel campione e non nel controllo. 
Le proteine identificate possono essere divise in due gruppi funzionali: il primo 
gruppo comprendente proteine che regolano il sistema del complemento (il fattore H, 
C4b, C4BP e α-2-macroglobulina), il secondo gruppo comprendente proteine 
coinvolte nell’inibizione dell’infiammazione indotta dall’LPS (HRG e le 
apolipoproteine). 
- Questo progetto è stato svolto in collaborazione con i Prof. Rosa Lanzetta e 
Antonio Molinaro del Dipartimento di Chimica Organica e Biochimica 
dell’Università degli studi di Napoli Federico II 
Un manoscritto riportante i risultati ottenuti è in preparazione 
- Giangrande C, Colarusso L, Lanzetta R, Molinaro A, Pucci P, Amoresano A. Innate 
immunity probed by lipopolysaccharides affinity strategy and proteomics 
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I. Introduction 
 
I.1. Glycobiology 
Glycans are among the most abundant organic components on the Earth and are 
critical constituents of all living organisms. Approximately 1% of each genome, from 
eubacteria to archea and eukaryotes, is devoted to sugar processing enzymes and 
these genes are highly conserved [1]. 
"Glycome" is a term meaning the whole set of glycans produced by individual 
organisms, and it can be considered the third class of bioinformative macromolecules 
to be elucidated as well as the genome and proteome [2]. 20th century research was 
essentially devoted to the study and comprehension of nucleic acids and proteins 
biology, while glycans represent an intriguing challenge for 21st century 
investigations. 
Glycome mapping shows a bigger level of complexity than genomics or proteomics, 
as glycans have a greater number of building blocks than nucleic acids (4 
nucleotides) and proteins (20 aminoacids). To make the process more complex, 
oligosaccharide biosynthesis is not template-driven. Furthermore glycans can adopt 
complex branched structures of monomeric units linked together, and these 
structures have different conformations. They can be covalently attached to other 
compounds forming glycoconjugates. Among them glycoproteins are particularly 
important for the huge number of biological functions they are involved in. They are 
ubiquitous proteins, essentially found in all living organisms, ranging from eubacteria 
to eukaryotes [3]. Conjugation of sugars to proteins considerably increases variation 
among gene products, with a total of 13 monosaccharides and 8 aminoacids forming 
at least 41 types of different glycosidic linkages [4]. Therefore glycoproteins exist as 
complex mixtures of glycosylated variants (glycoforms). The microheterogeneity is 
due to the incomplete nature of the enzymes involved in the glycosylation and 
deglycosylation reactions at specific sites and depends on the cell type and on the 
physiological status. Anomalous pattern of glycosylation may be caused by 
developmental events or pathological conditions [5]. 
 
I.1.1. Proteins glycosylation  
 
Four major types of proteins glycosylation have been essentially discovered: N-
linked, O-linked glycosylation, GPI anchors and C-glycosylation. N-glycosylation 
consists in the linkage at asparagines residues and needs a rather strict consensus 
sequence Asn-X-Ser/Thr, where X is any aminoacid except proline [6]. Together with 
this sequence, conformational factors influence oligosaccharides attachment during 
glycoproteins biosynthesis [7].  N-linked oligosaccharides presents a common 
trimannosyl-chitobiose core, deriving from a biosynthetic precursor 
Glc3Man9GlcNAc2. Biosynthesis starts in the endoplasmic reticulum and its first steps 
have been conserved during evolution, since the same precursor is synthesized in 
plants, mammals and fungi. The diversity which characterizes oligosaccarides linked 
to Asn residues in mature glycoproteins originates by differential processing 
reactions in Golgi apparatus [8]. Trimming by α-mannosidases without any 
subsequent addition leads to “high mannose” oligosaccharides whose composition is 
ManxGlcNAc2. In the case of glycosyl addition after α-mannosidases action “complex 
type” structures originates, characterized by the presence of a variable number of 
antennae, whose biosynthesis is initiated by the addition of Galβ1-4GlcNAc residues 
to the core structures (Man3GlcNAc2). Also “hybrid” between these two model 
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structures are common. Glycans can be further modified by the addition of sialic acid, 
fucose and xylose  [5]. 
O-glycosylation starts in the Golgi apparatus and consist of a single sugar addition on 
serine or threonine: a residue of N-acetylgalactosamine is transferred to the protein 
from a UDP-GalNAc donor and this reaction is catalyzed by (UDP)-GalNAc-
polypeptide N-acetylgalactosaminyltransferases (pp-GalNAc-Ts). Alternatively, it is 
reported that some other monosaccharides can initiate O-glycosylation, such as 
GlcNAc and Man-linked oligosaccharides [9,10] Then the protein moves to the trans-
Golgi vescicles, where the addition of galactose or N-acetylglucosamine residues 
elongates the glycan forming different O-glycans core structures, of which eight are 
reported in literature. Structural diversity is amplified by the transfer of fucose and 
sialic acid residues [11].  
Some specific enzymes are responsible for further modification of oligosaccharides 
by the addition of chemical groups, such as methylation, phosphorylation and 
sulfation [12]. 
Glycosylphosphatidylinositol anchor is a specific post-translational modification that 
attaches the protein to the outer leaflet of the cell membrane. The protein C-terminus 
is linked to a highly conserved core glycan (mannose(α1-2)mannose(α1-
6)mannose(α1-4)glucosamine(α 1-6)myo-inositol) by a phosphoethanolamine bridge. 
Anchorage to cell membrane is mediated by a phospholipid tail linked to the sugar. 
These structures vary not only for the lipid species but even for the oligosaccharidic 
side chains attached to the core [13]. 
C-glycosylation consists in the covalent attachment of an α-mannopyranosyl residue 
to the C2 of the tryptophan via a C-C covalent bond in a consensus sequence of Trp-
X-X-Trp or Trp-Ser/Thr-X-Cys [14]. 
 
I.1.2. Biological functions of glycoproteins 
 
Considering that 50% of mammalian proteins are glycosylated and that glycosylation 
presents a high level of complexity and microheterogeneity, it is now clear that 
glycoproteins play a wide range of roles in biological processes. 
One of the reasons for glycosylation at specific sites is the coating of protein 
backbone which is intended to protect it from recognition by proteases and 
antibodies, thus affecting its turnover and half life. 
However this function does not explain one of the most important features of protein 
glycosylation: diversity. Diversity is discovered between species, within populations, 
among individuals and even among different cell types of the same organism [15].  
Glycans covering cell surfaces can be considered a molecular code for cells to 
communicate with each other, a “glycocode” which controls several biological 
functions [16].  
Glycans on the surface of host cells can act as specific attachment sites or receptors 
for pathogens and toxins, in a mechanism defined “traitorous” by Varki: 
oligosaccharides are responsible for the first steps of infections. Noxious agents like 
bacteria, viruses, parasites and plant or microbial toxins gain entry into the cell 
thanks to these recognition phenomena [17,18]. Generally glycans carrying sialic 
acid at the terminal side are the most probable pathogens targets. This is the case 
for influenza virus: it is well known that hemagglutinin, the viral coat glycoprotein, 
binds to sialylated glycans receptors present on host cells [19] but only recently 
conformational analyses have revealed that only strains endowed with the ability to 
bind specifically Neu5α2-6 glycans present an efficient respiratory transmission 
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between humans, whereas avian and swine viruses are characterized by a specificity 
towards Neu5α2-3 glycans [20]. Another example is represented by Plasmodium 
falciparum, the parasites causing malaria: even in this case, it is a pathogen protein 
EBA-175 which binds to Glycophorin A, a sialylated O-glycosylated protein present 
on the surface of erythrocytes cells. Sialic acid presence is necessary but not 
sufficient for recognition, because optimal binding is achieved only with the correct 
protein chain [21]. Helicobacter pylori is a Gram negative bacterium, a very common 
pathogen of human stomachs, whose infection in some cases leads to very 
dangerous consequences such as ulcer disease and gastric adenocarcinoma. This 
bacterium adhere to fucosylated glycoproteins and sialylated glycolipids on human 
epithelium. Adhesion is mediated by a number of bacterial outer membrane proteins, 
the most studied of which are BabA and SabA [22] and depends on the blood group 
antigen exposed on the mucosa epithelium. In particular BabA has been shown to 
bind H1 and Lewis b antigens, characteristic of the blood group O phenotype, but 
babA gene is subjected to a high variation which explains the wider spectrum of 
binding of many strains that are able to recognize antigens on cells of individuals of 
blood group A and B [23]. Thus it is clear that both glycan binding pathogens and 
their host cells have developed biological strategies to perturb this equilibrium: the 
first ones are interested to broaden the spectrum of potential individual host cells, the 
second ones to expose on the surface different epitopes to escape pathogens 
recognition systems. The difference consists in the fact that microbial pathogens can 
evolve much more rapidly thanks to their short generation times and their high 
mutation rates. For this reason complex multicellular organisms have developed 
systems for changing their glycan profiles in order to evade glycan binding 
pathogens, even if a complete alteration of the glycosylation patterns usually leads to 
severe abnormalities or death [24].  
Multicellular organisms are also endowed with surface lectins, carbohydrate binding 
proteins able to bind specific sugar epitopes. Lectins covering mammalian cells of the 
innate immune system recognize microbial glycans (for example lipopolysaccharides 
of Gram negative bacteria) and activate an immune response against infections, as 
in the case of Toll-like receptors [25]. It can be inferred that lectins are involved in the 
mechanism of self/nonself recognition, in the sense that innate immunity system is 
able to recognize endogenous glycans as self. Autoimmune diseases present an 
alteration in self antigens recognition: some glycoproteins/glycolipids can trigger an 
immunogenic response as a consequence of a modification of the glycosylation 
pattern. In several inflammatory autoimmune diseases, such as lupus 
erythematosus, effector T cell populations bearing  GalNAc and Gal-β(1-4)-GlcNAc 
as terminal structures are highly upregulated. There is a strong evidence that 
galectins treatment can play a role in chronic inflammation suppression. Galectins 
constitute a class of lectins containing a carbohydrate-recognition domain towards N-
acetyllactosamine. In particular galectin-1 is able to induce T cell apoptosis in order 
to recover a balance in the cytokine profile [26]. In rheumatoid arthritis some studies 
have shown an aberrant glycosylation affecting both innate and adaptive immunity 
responses. N-glycosylation of Fc regions of IgGs seems to be particurarly relevant, 
with healthy individuals presenting little fluctuations in Fc glycoforms. On the contrary 
rheumatoid arthritis-affected individuals reveal a high level of agalactosylation on 
biantennary structures, and in some cases a higher level of outer arm fucosylation, 
leading to conformational changes in both the glycan moiety and polypeptide chain. 
These changes have as a consequence the uptake by mannose receptors on 
macrophages and dendritic cells and generating epitopes and the subsequent 
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activation of T cells. The interaction of the epitopes with certain lectins leads to an 
inappropriate activation of the complement cascade, giving rise to inflammatory 
molecules and cellular destructive activities [27].  
The central role of glycosylation in the coordination of biological processes at the 
interface between cells is underlined by its involvement in many aspects of 
reproductive biology. It is now clear that the egg-spermatozoa recognition process 
relies essentially on the zona pellucida, an extracellular matrix surrounding the 
oocyte. The use of lectins with oocytes deriving from different mammalian species 
has shown that different species have different lectin-binding patterns, explaining the 
fact that fertilization is strictly species-specific [28]. In particular human zona 
pellucida exposes mannose, N-acetylglucosamine and galactose, diagnostic of N-
glycosylated proteins. Sialylation has the function to mask β-Gal-(1-3)-GalNAc. Some 
O-glycosylated sites are also present. Recent studies have revealed that 
glycosylation is not critical for the oocyte recognition by the spermatozoa, but is 
essential for the acrosome exocytosis: the acrosome is a cap-like organelle at the 
head of the spermatozoon, that can be stimulated by external signals, such as 
hormones, in order to induce its fusion with the oocyte plasma membrane during 
fertilization [29]. 
Glycoproteins are key regulators of numerous events in other stages of reproduction: 
communication between the embryo and the endometrium is based on a complex 
network of signalling molecules that mediate cell-to-cell and cell-to-extracellular 
matrix interactions [30]. The fetomaternal interface is heavily glycosylated in all 
placental species and speciation is often accompanied by subtle changes in this 
structure. Differences concern changes in terminal glycans, especially in fucosylation 
and sialylation. In hemochorial placenta mammals most species are characterized by 
abundant bisecting bi/triantennary complex N-glycans and all species bear NeuAcα2-
3 [31]. 
Structural variations in the glycome of cell surfaces affect embryogenesis and 
morphogenesis: the expression of different glycosyltransferases in various 
combination, during different stages of development or during the same step but in 
different region of the embryo, could explain the extreme variety of ligands for cell-
cell interactions [19]. These differences consist in the loss of some glycans, or the 
expression of unusual ones, or in variations concerning the degree of branching, all 
leading to alterations in cell-cell adhesion, modulating embryonic stem cells 
proliferation and differentiation. In some cases anomalies in the glycosylation pattern 
can disrupt fertilization, following mechanisms not very well understood [32]. 
Therefore different cell types express characteristic glycans that in several cases are 
useful to identify different cellular populations. Cell cycle perturbation is often 
associated with changes in glycosylation pattern including both the under- and 
overexpression of naturally occurring glycans, as well as neoexpression of glycans 
normally restricted to embryonic tissues. Altered expression levels of Golgi 
glycosyltransferases are at the origin of these glycosylation modifications. The size 
and branching of N-linked glycans increase considerably in cancerous cells: in 
particular N-acetylglucosaminyltransferase V (GnT-V), responsible of β1,6GlcNAc 
branching is upregulated during malignancy, as well as sialyltransferases and 
fucosyltransferases, involved in linking terminal residues [33]. Adhesion between 
tumour cells can depend on N-linked glycosylation of E-cadherin, in the sense that 
the increase in branching by GnT-V results in a reduction in cell-cell adhesion and a 
consequent increase of cells motility and invasiveness, characteristic of metastasis. 
On the contrary GnT-III, whose activity is characterized by the formation of bisecting  
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β1,6GlcNAc structures,  results in an enhancement of cell-cell adhesion and tumour 
progression suppression in highly metastatic melanoma cells [34]. Some glycan 
epitopes are commonly found in transformed cells, such as Lewisa, sialyl- Lewisa, 
and their isomers Lewisx and sialyl- Lewisx. Sialyl- Lewisa antigen is now used as a 
tumour marker for pancreatic cancer, colorectal cancer and other tumors [35] and is 
responsible for cancer cells adhesion to E-selectin present on the surface of 
endothelial cells [36], whereas sialyl- Lewisx antigen plays a central role in cancer 
cells adhesion to E-selectin present on the surface of vascular endothelium, 
participating to tumour angiogenesis and metastasis [37]. 
Inflammation is based on the same processes as tumour metastasis. Inflammatory 
diseases, such as arthritis, psoriasis, asthma and diabetes, are characterized by 
leukocyte homing into the affected tissues. Circulating lymphocytes need adhesion to 
enter peripheral lymph nodes and also leukocyte emigrating into inflamed tissues 
have to adhere to activated endothelial cells lining blood vessel walls. Selectins (E-, 
P- and L-selectin), mediating the transient initial interaction responsible of the rolling 
of the leukocytes along the endothelial surface, bind sialylated and fucosylated 
epitopes which comprise a terminal component of glycans on most leukocytes, 
endothelial cells in the lymph node and the endothelium of inflamed tissues [38]. 
 
I.2.  Glycoproteins and biotechnology 
 
The wide range of important biological processes where glycoproteins are involved in 
has placed them among the most useful molecules in the biotechnological market. 
However, due to their non-template driven biosynthesis, oligosaccharides cannot be 
readily produced and their manufacture cannot be easily controlled [39]. 
 
I.2.1. Glycans and glycoproteins for diagnostics and therapeutics 
 
Glycans and glycoproteins present large potentials for benefits in drug development. 
Since the 1980s proteins have cornered the market with about 200 products, most of 
them represented by therapeutics with diagnostics and vaccines being a small share 
of the market [40]. 
It is clear that protein pharmaceuticals should be properly glycosylated to exhibit a 
therapeutic efficacy. Physiological glycosylation presents a high degree of structural 
variability, which sometimes constitutes a problem for the biopharmaceutical market, 
requiring structural homogeneous products with humanized glycosylation patterns. In 
this context engineered expression systems together with in vitro remodelling 
methods are usually explored by pharmaceutical industries. 
The demand for new therapeutic glycoproteins by the biopharmaceutical market is 
leading to the search of alternative expression systems.  
The preferred mammalian host system for biopharmaceuticals production is CHO 
cells, as they have not been implicated in adverse effects and they have a long 
history of regulatory approval for recombinant proteins to use as drugs. Many epoetin 
alpha products have been developed in CHO cells (Epogen, Procrit, Aranesp). Only 
a few recombinant proteins have been produced in BHK21 cells (Baby Hamster 
Kidney), a system generally used for the production of vaccines. An example is 
Kogenate, the recombinant Factor VIII by Bayer, an antihemophilic factor containing 
25 potential N-glycosylation sites and many O-glycosylation sites. Nevertheless the 
expression of therapeutics in murine systems might lead to the synthesis of 
potentially immunogenic recombinant products, exposing epitopes containing the 
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residue Neu5Gc. Furthermore BHK and CHO cells lack some sugar-transferring, 
such as α2-6 sialyltransferase, α1-3/4 fucosyltransferase, and bisecting N-
acetylglucosamine transferase). So several human expression systems are subject 
of study.  The cell line Human Embryo Kidney 293 (HEK293) is widely used for the 
production of recombinant proteins for research purposes and only one product, 
Xigris by Eli Lilly and Company is already on the market. Instead Dynepo, epoetin 
delta by Shire pharmaceuticals is produced in human fibrosarcoma cell line (HT1080) 
[41]. 
Although mammalian cells are the preferred host systems for recombinant 
expression of glycoproteins, they present several disadvantages such as long 
fermentation times, elevated risks of contamination, and higher costs for fermentation 
media. The use of different expression systems implies the introduction of an artificial 
glycosylation pathway where necessary. 
Yeasts and other fungi are very advantageous because their fermentation is simple 
and cost-effective. They are able to synthesize only high mannose structures which 
can contain up to 100 mannose units which are highly immunogenic. Recently a 
glycoengineering approach has been used for the production of recombinant proteins 
with human-type glycosylation in Pichia pastoris [42]. This implies the introduction of 
a new enzymatic machinery via genetic manipulations, and products result to be 
more homogeneous, possessing a controlled glycosylation pattern [43]. 
Pharmaceutical or diagnostic proteins have also been expressed in filamentous fungi 
due to their secretor qualities, to their capacity to grow on very inexpensive media 
and to their property of being GRAS (“generally regarded as safe”) [44]. 
Insect cells might constitute another choice for the expression of recombinant 
glycoproteins for their good qualities in protein folding and post-translational 
modifications. [45]. Insect cells are able to perform high mannose and 
paucimannosidic glycosylation, so that they are not routinely used as pharmaceutical 
host systems even though efforts have been made to the engineering of insect N-
glycosylation pathways for assembly of mammalian-style glycans on baculovirus-
expressed glycoproteins[46]. 
Recombinant proteins for human therapeutics can be produced also using plants as 
factories. Plants high mannose type glycoproteins have structures quite similar to 
mammalians whereas complex type plant N-glycans are characterized by the 
presence of α(1,3)-fucose instead of an α(1,6)-fucose,  and/or a β(1,2)-xylose 
residues on the core. Additional α(1,4)-fucose and β(1,3)-galactose residues have 
been identified on the terminal N-acetyl glucosamine (Lewis a antigens). Plants N-
linked glycans are recognized as IgE determinants and are responsible for some 
human allergies [47]. Two strategies have been developed to prevent the formation 
of highly immunogenic plant N-glycans on recombinant glycoproteins: recombinant 
glycoproteins can be retained in the ER so that the immunogenic oligosaccharide, 
generally achieved in the Golgi compartment, cannot be added. On the other hand, 
also in plants, the enzymatic machinery of the Golgi apparatus can be knocked out 
by antisense strategy and subsequently it can be replaced by adding new enzymes 
by transformation [48]. In Europe there are only a few plant-derived glycoprotein 
therapeutics, and most of them are still under clinical trials. Examples are Locteron 
by Biolex, the interferon alpha produced in Lemna minor, and glucocerebrosidase 
prCGD by Protalix, a candidate for the Gaucher disease, produced in carrot cells 
[49]. 
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Planning successful protein-based therapeutics means to optimize molecular stability 
as well as to improve pharmacokinetics and pharmacodynamics. These 
characteristics can be simultaneously improved by means of glycoengineering. 
In general, glycosylation has been found to protect protein products from proteolytic 
degradation and several products have been engineered in order to improve protein 
stability by preventing contact between proteins backbone and cleaving proteases, 
as in the case of thyroid stimulating hormone (ThyrogenOne, Genzyme) and 
granulocyte colony stimulating factor (G-CSF) (Granocyte, Chugai 
Biopharmaceuticals). In many cases glycosylation seems to impact proteins 
bioactivity also influencing solubility and conformational stability against pH, thermal 
and chemical denaturation, as in the case of interferon beta (REBIF, Pfizer/Serono 
and  AVONEX, Biogen). Moreover improperly glycosylated proteins are recognized 
by specific receptor-based mechanisms and removed from circulation. The 
formulation of a glycoproteins-based therapeutic should consider even the fact that 
the content of sialic acid (and of negatively charged monosaccharides in general) is 
directly connected to longer circulating lifetimes, probably decreasing the adhesive 
properties of the protein and increasing solubility. Planning a biopharmaceutical it 
should be taken into account also that the glycosylation pattern strongly affects the 
targeting to tissues and organs. 
In the last years several glycoengineering companies have arisen with the aim of the 
rational design of targeted glycoprotein structures (Neose Technologies, USA, 
GlycoFi,  USA, GlycArt, Switzerland, Glycoform, UK) [50].  
Glycoengineering approaches rely on modifications of the glycosylation pattern with 
the aim of influencing functional activities, namely binding to cognate ligands, 
resistance to proteolytic cleavages, stability and solubility. 
As concerning biotechnological production of drugs, it is very difficult to obtain highly 
homogeneous products, that often contain subtle differences as a consequence of 
the fermentation procedure. These differences are particularly significant from an 
economical point of view, especially when the patent for the production of a biological 
molecule expires. Other manufacturers can produce the same product, simply 
termed “generic” or similar products, generally referred to as “follow-on biologics” 
(FOBs) in United States, and “biosimilars” in European Union [51]. Biosimilars are 
similar but not identical to the reference products, because their characteristics 
depend on the manufacturing process, which is impossible to replicate exactly. In the 
European Community (EC) they need a marketing authorization (MA), different from 
both originators and generics. The main advantage for consumers is the reduced 
cost of biosimilars compared to their respective innovator products, although  savings 
are not comparable to generics, because their manufacturing procedures, the non-
clinical and clinical studies and the need for a pharmacovigilance program require 
many investments [52]. 
The most significant example for this strategy is suggested by erythropoietin, for the 
treatment of anaemia to stimulate the production of red blood cells in the bone 
marrow. rHuEPO (recombinant human erythropoietin) is produced by different 
manufacturers and the various products are not identical to each other. Epoetin alfa 
was the first producted rHuEPO (Epogen®, Procrit®, Eprex®) in Chinese hamster 
ovary (CHO) cells. Its biosimilars have been indicated with different Greek names, 
and their differences consist in the different cell lines and manufacturing methods. 
The second approved rHuEPO was epoetin beta (Recormon®, Neorecormon®), 
manufactured in CHO cells but presenting some minor differences in the 
microheterogeneity in the attached carbohydrate. Epoetin delta used human 
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fibrosarcoma (HT1080) cells in its manufacture, but since  December 2008 is no 
longer commercialized. Epoetin omega, produced in baby hamster kidney cells 
(BHK), showed a different  glycosylation profile from epoetin alfa and beta. The novel 
erythropoiesis-stimulating protein darbepoetinalfa (Aranesp®) is not a biosimilar but it 
can be considered an innovator pharmaceutical, containing two additional N-linked 
carbohydrate chains at positions 30 and 88 as a result of five aminoacid substitutions 
(Ala30/Asn, His32/Thr, Pro87/Val, Trp88/Asn, Pro90/Thr) in the protein backbone. 
The new sites were introduced with the aim of increasing the number of sialic acid 
residues from 14 to 22, thus increasing serum half life without interfering with  at 
Epo:EpoR interaction [53]. 
 
I.2.2. Glycans and glycoproteins for food formulations 
 
Homeopathic and traditional medicine, nutraceuticals and the study of bioactive 
components and probiotic bacteria are becoming matter of interest in recent years. 
One of the most promising application in food industry is constituted by bacterial anti-
adhesive. The principle of their activity lies on the fact that bacterial infections rely on   
adhesion mechanisms based on the recognition of surface carbohydrate structures. 
Nevertheless rational design of anti-adhesives requires a complete knowledge of 
human as well as pathogens’ glycome. [54]. 
Therefore glycans play an important role even in the food industry, providing a 
valuable alternative to conventional antibiotics. In several cases antibiotics are 
responsible for the microflora disruption in the gastrointestinal tract and the 
consequent growth of opportunistic pathogens. Defence mechanisms can be induced 
by cocktails of oligosaccharides to prevent adhesion of bacterial lectins to the 
gastrointestinal epithelium. Oligosaccharides possessing anti-adhesive properties 
can be found in numerous natural sources, and among them the most studied one is 
milk. In particular human milk oligosaccharides have been endowed with several 
biological functions, acting as prebiotics, anti-inflammatory agent, and it is thought to 
influence brain development and to drive the growth of intestinal cells [55, 56, 57] 
The principle on which human milk anti-adhesive properties are based, lies on its 
high content in oligosaccharides and glycoproteins, that can function as soluble 
receptor analogs of epithelial cells carbohydrates [58]. Commercially available infant 
formula do not possess oligosaccharides with such anti-adhesive properties. So, 
other food sources might provide this important supplement, such as bovine, goat or 
buffalo milk. Recent studies have emphasized therapeutic and/or prophylactic effects 
of pig milk in Helicobacter pylori infections. These effects are essentially based on 
the presence in porcine milk of glycoproteins bearing sialyl Lewisb and sialyl-Lewisx 
structures that are the principal epitopes responsible for H.pylori binding and 
colonization. These milk components may act as decoys simulating the microbial 
receptors [59]. Bioactivity against H.pylori infections has been shown even in butter 
milk, whose milk fat globule membrane contains various sialylated glycoproteins [60]. 
Human milk has shown therapeutic properties even towards Campylobacter jejuni 
infections. This activity is associated with fucosylated oligosaccharides and 
glycoproteins  [61]. 
Beyond milk another relevant food source for anti-adhesive agents is egg yolk 
contains high concentrations of oligosaccharides and since 1995  Koketsu et al. 
reported significant inhibitory effects of sialylated oligosaccharides from egg yolk 
towards rotavirus [62]. Moreover sialylated glycopeptides have been shown to 
prevent Salmonella enteritidis adhesion to epithelial cells [63]. 
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To sum up bacterial adhesion can be seen as a  multifactorial event and in several 
cases a cocktail of oligosaccharides with anti-adhesion capabilities may be the best 
solution not only from an economical point of view but even for anti-adhesive 
properties against a range of pathogens and toxins. The great advantages in such 
therapies reside in the easiness of supplementation with food. Furthermore these 
compounds are quite safe because they do not kill pathogens and do not arrest their 
growth so that resistance is rarely developed and they can be used instead of 
antibiotics, also thanks to the absence of any toxicity or immunogenicity [64]. 
 
 
I.3. Biochemical approaches to the study of protein glycosylation in the 
systems biotechnology era 
 
The recent advances in analytical and computational tools in proteomics research 
have stimulated the origin of glycomics as a new scientific challenge for the 
elucidation of important biological processes. Glycomics relies on the integration of 
sample enrichment methodologies, coupled with multidimensional chromatographic 
separations, high resolution mass spectrometry and bioinformatics, providing 
relevant resources for the scientific community. The results collected can constitute 
an even more important tool when combined with data coming from complementary 
analytical techniques in a systems biology approach, aiming at the integration of such 
data and the formulation of modelling systems. Together with single laboratories 
working on glycomics around the world, international consortia are starting to 
coordinate and manage the large amount of data obtained. Among them, the 
“Consortium for Functional Glycomics” (CFG; http://www.functionalglycomics.org) 
has arisen with the aim of investigating cell communication mediated by proteins-
carbohydrates interactions. It is structured in seven different scientific cores, one of 
which is the “Analytical Glycotechnology core”, whose main goal has been the mass 
spectrometry infrastructure implementation [65]. 
In general a typical workflow can be designed as in Fig. 1: the first steps for structural 
elucidation of glycoproteins are based on enrichment procedures, in order to select 
glycoproteins or glycopeptides to be analysed by mass spectrometry. MS procedures 
are able to detect entire glycopeptides, but often glycan pools are  released from the 
peptide component using glycosidases or chemical methods since the presence of 
the glycan moiety on proteins can prevent their sequence coverage in peptide 
mapping and can hamper the action of proteases by shielding specific residues. Both 
the glycan and peptidic components can be analysed and characterized by tandem 
mass spectrometry. Carbohydrates do not contain any chromophores, so a common 
practice is to derivatize them to increase UV absorption, fluorescence or mass 
spectrometric ionization. The data produced from these experiments can be 
interpreted by glycoinformatics tools and compared with data deposited in available 
databases. 
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Fig. 1: a workflow for a glycoproteomic experiment. Samples deriving from different sources 
are treated to characterize glycosylation profiles in detail. A typical experiment can begin with 
the chemical or enzymatic digestion of the sample in a mixture of peptides and glycopeptides, 
followed by enrichment procedures in order to select glycosylated peptides. Mapping 
experiments are generally carried out either by online nano-LC–ES-MS/MS or by MALDI-
TOF/TOF. Alternative fragmentation techniques can be used to characterize peptide backbone 
of glycopeptides. Glycomic analyses typically begin with the chemical or enzymatic release of 
specific pools of glycans. These can be derivatised and subjected to fingerprinting or 
sequencing. The data produced can then be analyzed and interpreted by softwares and 
compared to available databases. 
I.3.1. Sample enrichment techniques 
 
Understanding the structure and function of glycans and glycoproteins is the principal 
goal for the comprehension of central biological processes. Exploring glycans 
sequences and functions needs experimental procedures that could overcome the 
problem of the impossibility to amplify glycan structures, due to the non-template 
driven synthesis of these important biomolecules. In the complex mixtures of protein 
isoforms and variants within the cells, enrichment procedures are necessary for a 
successful analysis of post-translational modifications. Lectins are ubiquitous 
proteins of non-immune origin, specifically binding monosaccharides or 
oligosaccharides. They are diffuse among the living organisms, ranging from 
microorganisms to humans. Their carbohydrates-binding capability is widely used for 
the structural characterization of unknown glycoconjugates, identification of lectin-
reactive components in biological materials (body fluids, cells, tissues), affinity 
chromatography for the fractionation and purification of glycoconjugates [66]. Lectins 
have been extensively exploited as an analytical tool in glycoproteomics. Lectins are 
able to detect subtle differences in glycosylation of proteins, even if they do not 
possess an “absolute” specificity. The affinity constants (Ka) for lectin-carbohydrate 
binding is in the low micromolar range but can reach the millimolar range. This leads 
to the multivalency of naturally occurring carbohydrates and glycoconjugates, 
resulting in an increased avidity for lectins, thus allowing their use for 
chromatographic separations [67]. 
20 
 
The choice of the specific lectin to use is central in the set up of experiments for 
glycoproteins enrichments, because some lectins can target a broad class of glycans 
(for example Concanavalin A is able to enrich for high mannose and biantennary N-
glycans) [68], or glycans with specific structures (for example L-PHA, L-
phytohemagglutinin, binding β(1,6)-branched glycans, overexpressed in malignancy) 
[69]. 
In order to extend the range of glycoproteins to be targeted, multilectin affinity 
chromatography was set up by Hancock and co-workers combining ConA 
(Concanavalin A), WGA (wheat germ agglutinin) and Jacalin for the analysis of 
serum N-glycans, sialylated glycans and O-glycans, respectively [70]. In general 
glycoproteins enrichment is performed by agarose-bound lectins but Novotny and co-
workers developed silica-bound lectin microcolumns coupling aldehyde-modified 
silica with Con A or SNA in a reductive amination reaction. Their selectivity, binding 
capacity, reproducibility and sensitivity were tested and used for preconcentration of 
glycoproteins and glycopeptides from complex biological materials at trace levels. 
The system offered the advantage of online coupling with HPLC and MS 
equipements [71, 72]. 
In addition to this, alternatives to lectins affinity chromatography have been 
developed. Boronic acids are able to bind molecules carrying 1,2- or 1,3-cis-diols in a 
reversible esterification reaction leading to the formation of negatively charged cyclic 
boronate esters at alkaline pH [73]. This reaction has been exploited for 
glycoproteins and glycopeptides enrichments, with the development of different 
materials covered with boronic acid derivatives. An on-plate-selective method for 
MALDI mass spectrometry was developed using gold nanoparticles, allowing a rapid 
capture of glycosylated peptides. Elution was achieved after a washing step to 
remove unbound peptides and the deposition of a TFA-containing solution, capable 
to desorb bound peptides from the MALDI plate [74]. 
A frequently used alternative to lectins involves the use of activated graphitized 
carbon, generally employed for the separation of hydrophilic species, but often 
utilized for the absorption of glycans samples. Low amounts of glycoproteins, 
previously separated by gel electrophoresis, were digested in a double step 
enzymatic treatment in order to achieve small glycopeptides to purify and 
characterize after selection on graphite powder microcolumns in combination with 
mass spectrometry [75]. Recently Agilent Technologies introduced a new separation 
systems based on a microfluidic polymer chip for nanoflow liquid chromatography 
gradients [76]. Chips were packed with graphitized carbon both in the trapping 
column and separating one, allowing the detection of all the ribonuclease B 
glycoforms, undetected with C-18 stationary phase. However, larger and more 
hydrophobic glycopeptides remained undected on the carbon chip, showing that only 
the use of both chips achieved a full comprehension of a more complex system [77]. 
Size exclusion chromatography (SEC) proved to be advantageous for the enrichment 
of glycopeptides prior to LC-MS/MS. The principle is based on the difference in size 
between glycosylated and non-glycosylated peptides, providing, unlike lectin, an 
enrichment method not dependent on the specific glycoform to be detected [78]. 
HILIC chromatography (Hydrophilic Interaction Liquid Chromatography) is based on 
zwitterionic resins, that are able to enrich for glycans and glycopeptides, by forming 
hydrogen bonding, ionic interations and dipole-dipole interactions [79]. Several 
studies have been carried out on this methodology, which has been coupled to 
MALDI-MS [80] as well as to ESI-MS [81], allowing the detection of milk 
glycoproteins [82] and human plasma glycoproteins [83]. 
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Another approach for glycopeptides solid phase extraction is based on the hydrazide 
chemistry: glycoproteins or glycopeptides are subjected to periodate oxidation in 
order to allow the conversion of the cis-diols to aldehydes, that are known to react 
with hydrazine groups forming covalent stable hydrazones. In this system, hydrazide 
groups are immobilized on specific beads. After oxidation, protein extracts are 
incubated with hydrazine-beads.  The digestion with proteases allows the removal of 
non glycosylated peptides, whereas specific N- or O-glycosylated peptides are 
further released by the treatment with specific endoglycosydases. This method can 
be easily utilized for quantitative analyses, by stable isotope labelling of the 
immobilized glycopeptides [84]. Unfortunately one of the major drawbacks of this 
procedure is the fact that hydrazine reaction destroys the attached glycans, making 
them not available for further studies, even if it is allows easier recovery of peptides 
for MS analyses and then a higher number of glycosylation sites identified [85]. 
 
I.3.2. The role of mass spectrometry in glycomics 
 
Mass spectrometry, thanks to its high sensitivity and selectivity, is a powerful tool in 
glycomics and glycoproteomics, allowing characterization of glycoproteins either at 
the glycopeptides level or after deglycosylation, characterizing separately the 
peptides containing the glycosylation sites and the glycans. 
Mass spectrometry analytical power lies on its capability to measure mass to charge 
(m/z) ratio, providing structural information with high sensitivity and accuracy.   
The presence of the glycan moiety tends to increase the acidic characteristics of 
glycoproteins and glycopeptides, simultaneously increasing hydrophilicity and 
surface activity. This strongly affects ionization efficiency in the sense that 
unmodified peptides are more susceptible to form abundant positive ions, whereas 
glycopeptides are subjected to ion suppression [86]. This is the reason why 
glycopeptides are very difficult to detect in complex mixtures, generally requiring 
enrichment procedures prior to MS analyses.  
In a complex mixture of glycans, more hydrophobic compounds generally suppress 
less hydrophobic ones, and the same behaviour is shown by basic compounds, that 
in positive ion mode will suppress acidic ones. Thus it is strongly recommended to 
equalizing glycans chemical properties with derivatization procedures or separation 
methodologies, in order to infuse analytes with quite similar ionization efficiencies in 
the mass spectrometer. Glycomics takes advantage of mass spectrometers and 
techniques previously developed for proteomics research. 
Nowadays the vast majority of the published work on glycoconjugates relies on the 
matrix assisted laser desorption ionization (MALDI) and electrospray (ESI)  ionization 
techniques. MALDI mass spectrometry is based on the irradiation of sample 
molecules with a laser light (generally a pulsed nitrogen laser at 337 nm) to induce 
sample ionisation. The sample is pre-mixed on a metal target with a highly absorbing 
matrix, a small aromatic molecule, that upon drying, co-crystallises with the sample. 
This process takes place in the ion source under a high vacuum and a strong 
electrical field between the target and an extraction plate. Energy deposition into the 
matrix molecules induces sublimation of the matrix crystals and subsequent 
expansion into the gas phase. In positive ion mode, protonated molecular ions 
(M+H)+ are usually the dominant species, although they can be accompanied by salt 
adducts. In negative ionisation mode the deprotonated molecular ions (M-H)- are 
usually the most abundant species [87]. Carbohydrates generally ionize as MNa+ 
species but this ionization is not as sensitive as ionization of peptides, so a higher 
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laser power is generally required and sometimes it is difficult to maintain a stable 
signal. Signal intensity even depends on the nature of the matrix and the method of 
sample preparation. Numerous matrices have been studied for the analysis of 
glycans and glycoconjugates, and a matrix very effective with a class of compounds 
can be ineffective with others. One of the drawbacks of MALDI-MS for 
oligosaccharides analysis is the high frequency of in-source decay fragmentation in 
the delayed extraction process with long delay times, often leading to extensive 
losses of acidic residues, such as sialic acid, sulphate and phosphate [88]. However 
MALDI-MS is rather sensitive and tolerant to contaminants, allowing rapid analyses 
without much effort. 
Electrospray mass spectrometry (ES-MS) for biological sciences was developed by 
Fenn and is based on the application of a high voltage to the tip of a needle, from 
which the sample emerges forming a dispersed spray of highly charged droplets, with 
a co-axially introduced as nebulising gas. This gas is usually nitrogen, and its 
function is to aid the spray emerging from the capillary tip to direct towards the mass 
spectrometer. Solvent evaporation causes charged droplets to diminish in size, with 
the help of a drying. Multiply charged sample ions are extracted into the analyzer. An 
important feature of ESI-MS is that it confers  very little extra energy to the sample (it 
is known as a “soft” ionization method) generally preventing in source fragmentation 
of the sample ions [89]. As concerning glycans and glycoconjugates analysis, 
electrospray tends to generate ions at  different charge states and from different 
adducts, providing spectra very difficult to interpret. Samples should be free of salts, 
preventing the formation of multiple cation adduction and for this reason 
carbohydrates analysis by ESI-MS is generally preceded by derivatization and liquid 
chromatography, which can be carried out off-line or on-line. 
After ionization, analytes enter the second region of the mass spectrometer, the 
analyser, whose main function is the separation of the ions according to their m/z 
values. There are four main type of mass analysers currently used for analysis of 
biomolecules: quadrupole (Q), ion trap (IT), time-of-flight (TOF), and Fourier 
transform ion cyclotron resonance (FT-ICR) analysers. They can be self-consistent or 
they can be combined together in tandem. 
The quadrupole mass analyser is generally coupled to ESI ion source and consists of 
four parallel rods that have fixed DC and alternating RF potentials applied to them. 
The application of these voltages forces in a plane normal to the direction of ions drift 
allows ions oscillations which can be stable or unstable, according the m/z value. 
Only ions with stable trajectories will reach the detector, otherwise they will collide 
with the quadrupole rods. 
The ion-trap mass spectrometer uses three electrodes to trap ions in a small volume. 
The mass analyzer consists of a ring electrode separating two end-cap electrodes. 
The basic principle of quadrupole ion traps is the dynamic storage of ions in a three-
dimensional quadrupole device by the applied RF potentials. The RF and DC 
scanning can be used to eject successive m/z ratios to the detector. The compact 
size, the high sensitivity, the possibility to perform fragmentation experiments and the 
relative affordable cost of ion traps have encouraged their diffusion on the market. 
The main disadvantage is their relative low mass resolution due to their small 
volumes affecting the trapping efficiencies. These problems have been overcome 
thanks to the introduction of linear ion traps, characterized by a larger ion storage 
capacity and a higher trapping efficiency with higher scan ranges, larger electronic 
trap fields, increased sensitivity, higher resolution and mass accuracy [90, 91]. 
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MALDI ion source is generally coupled to Time-Of-Flight (TOF) analyser, consisting 
in a tube under a high vacuum. All ions entering the TOF tube are endowed with a 
fixed kinetic energy, proportional to the applied voltage and the charge. Separation is 
based on the principle that the higher is the mass of the ion, the lower its velocity. 
Thus ions can be separated measuring the time each ion takes to travel through the 
field free region of the tube. With delayed extraction (DE), the extraction voltage is 
applied after a defined interval of time (expressed in ns) from the laser pulse. During 
this “delay time”, the extraction voltage ,applied as a potential gradient, compensates 
for the distribution of initial kinetic energies, so that ions will not be influence by 
differences in initial kinetic energies in their path. Another point for kinetic energy 
correction concerns the introduction of an electrostatic mirror. Thereby the flight 
times of ions with identical m/z values, but different kinetic energy values will be 
corrected when the ions arrive to the detector. 
A Fourier-transform ion-cyclotron resonance (FT-ICR) mass spectrometer measures 
the cyclotron frequencies of ions oscillating around a constant magnetic field. This 
frequency is inversely related to the m/z ratio. The last released FT-ICR 
spectrometers are able of measuring frequencies with extremely high precision and  
a very high mass resolution, in the hundreds of thousands for instruments with 
magnetic field strength higher than 7 Tesla, as well as an accuracy under the ppm 
[92, 93]. Notwithstanding these enormous advantages, FT-ICR requires a 
superconducting magnet and it is very expensive. 
A new type of mass analyzer, capable of resolutions comparable to that of FT-ICR, 
has recently entered the proteomics research: the orbitrap mass analyzer, developed 
by Makarov, is a non conventional ion trap, utilizing a static electrostatic field for ion 
trapping. A central spindle electrode operates by radially trapping ions that are 
injected into the Orbitrap with a velocity perpendicular to it. The electrostatic field 
leads ions to move in complex spiral patterns. Mass/charge ratios are obtained by 
measuring the frequency of harmonic ions oscillations along the axis of the electric 
field. Mass spectra are obtained by acquisition of time-domain image current 
transients and fast Fourier transforms. This equipment results in peerless 
characteristics in terms of resolution, mass accuracy and dynamic range [94]. 
Combination of mass analyzers in series can be a way to broaden the possibilities of 
achieving structural information by the means of tandem mass spectrometry [95], in 
which two analyzers are separated by a cell where the collision with an inert gas 
causes the fragmentation of sample ions. The first analyzer is used to select an ion to 
be fragmented in the collision cell. After that the second analyzer records the m/z 
values of the dissociation products. This experiment is called MS/MS experiment and 
provides structural information on the sequence of peptides or oligosaccharides. Both 
peptides and glycans fragmentation in CID are well known. As concerning peptides 
(Fig.2) they can fragment along the NH-CH, CH-CO, and CO-NH bonds, giving rise 
to six different fragment ions, namely a, b, and c ions (with the charge retained on the 
N-terminal fragment), and the x, y and z ions (with the charge on the C-terminal 
fragment). The most common cleavage sites are at the CO-NH bonds which give rise 
to the b and/or the y ions [96].  
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Fig. 2: Schematic representation of nomenclature for fragmentation of peptide ions 
Even glycans fragmentation presents some main cleavage sites. A systematic 
nomenclature for labelling the fragment ions was established by Domon and Costello 
[97]. As shown in Fig. 3, the main cleavages, termed glycosidic cleavages, involve 
breaking a single bond between adjacent sugar rings. They provide much information 
on sequence and branching but little on linkage. Other cleavages, named cross-ring 
cleavages and involving two bonds cleavages are useful in the linkage determination. 
It is worth considering that ions retaining charge on the reducing terminus are 
labelled X (cross-ring), Y (C1→O-glycosidic) and Z (O→Cx glycosidic), while if the 
charge is retained at the non-reducing end, the produced ions are called A, B and C. 
The B and Y ions are usually the most abundant species. The cross-ring cleavages 
present additionally superscript prefixes, denoting the atoms of the two cleaved 
bonds. In case of branched oligosaccharides the nomenclature is based on the 
carbohydrate component of glycopeptides and glycoproteins, which consist of a 
“core” unit, and the branches, generally called “antennae”. Each antenna is identified 
by a Greek letter, of which the largest is given the “α” symbol; the following symbols 
are assigned considering the decrease in molecular weight. 
 
Fig. 3: Schematic representation of nomenclature for fragmentation of oligosaccharide ions 
Further fragmentation events can be achieved in multi-stage mass spectrometry, 
allowing re-fragmentation of product ions. MSn experiments can be carried out only 
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on ion traps, FT-ICR and Orbitrap instruments. In literature multi-stage tandem mass 
spectrometry experiments are reported: Harvey reports the use of MS3 and MS4 to 
achieve structural information on underivatised sugars using MALDI-QIT [98] 
whereas another work demonstrates the use of a hybrid MALDI-QIT-TOF mass 
spectrometer for the MSn analysis of complex branched oligosaccharides [99]. 
An alternative to CID was developed by by McLafferty and co-workers [100] and is 
known as Electron Capture Dissociation (ECD) whose mechanism consist in the 
reaction of peptide cations with low energy electrons leading to peptide dissociation 
in FT-ICR. The interesting aspect of ECD is the possibility of maintaining intact labile 
modifications, allowing the determination of glycosylation sites fragmenting peptide 
backbone of glycopeptides [101]. 
Electron Transfer Dissociation (ETD) induces peptides fragmentation relying on the 
transfer of an electron from a radical anion to a protonated peptide. In this case the 
peptide backbone fragments in correspondence of the Cα–N bond, creating 
complementary c and z-type ions instead of the typical b and y-type ions. As for 
ECD, ETD preserves labile modifications, but the real difference between ETD and 
ECD lies in the possibility to perform analyses in RF quadrupole ion traps for the first 
[102]. Even in this case analyses of glycopeptides have been performed [103]. 
The interpretation of peptides and oligosaccharides fragmentation spectra is 
facilitated by computer software, with the possibility to query databases with 
sequence and taxonomy data. 
 
I.4. Aim of the PhD thesis 
The issue of proteins correct glycosylation for the biotechnological products 
necessitates the development of sensitive analytical methodologies, as well as the 
need for sensitive and reliable diagnostic tools for glycosylation-associated diseases. 
This project aims at the development and setting up of new methodological platforms 
based on the integration of affinity chromatography strategies together with high 
performance liquid chromatography and mass spectrometry for the study of 
glycoproteins and glycoconjugates. 
 
Chapter 2 introduces the development of a derivatization procedure to improve mass 
spectrometric detection and fragmentation of oligosaccharides released from egg 
glycoproteins. Furthermore ConA enrichment procedure to capture glycosylated 
proteins is described. The last part of the chapter is devoted to use of multi-stage 
mass spectrometry for structural characterization of oligosaccharides. This part has 
been carried out using MALDI LTQ Orbitrap in collaboration with Dr. Joelle Vinh and 
Dr. Giovanni Chiappetta of the École supérieure de physique et de chimie 
industrielles de la ville de Paris. 
 
Chapter 3 describes a proteomic approach to investigate the molecular bases of 
myocarditis, a group of diseases characterized by the inflammation of the cardiac 
muscle. The study of the glycosylation profile in order to detect anomalies occurring 
as consequence of the onset of the pathological state is embodied in a wider study 
including even the analysis of free peptides and a general overview on protein 
content of human sera of myocarditis-affected individuals compared to healthy ones. 
 
In Chapter 4 the attention is focused on a plant model system, Arabidopsis thaliana, 
as plants are an intriguing alternative to mammalian host systems for the production 
of recombinant proteins. These protein products should be correctly homogeneous 
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as regards the glycosylation pattern, they should be properly glycosylated, depending 
on the target of the product. A. thaliana glycosylation is analyzed with the aim of a 
deep characterization of oligosaccharides structures as well as N-glycosylation sites 
assessment, considering that most of these sites are still signed as “potential” in 
proteins databases. 
 
The work in Chapter 5 deals with lipopolysaccarides, bacterial glycoconjugates, in 
order to detect LPS-interacting proteins potentially related to innate immunity 
response. Since some of these mechanisms are still unknown, especially in non- 
human biological systems, this work is aimed at the development of a “fishing for 
partners” strategy [104], able to capture proteins and maybe glycoproteins, involved 
in innate immunity reactions using an LPS bait. 
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II. Oligosaccharides characterization by dansyl labelling and integrated 
mass spectrometry techniques 
 
II.1. Introduction 
Glycomics data represent a very important resource for the scientific community. This 
information includes results obtained by complementary analytical procedures to be 
integrated in a systems biology approach [1]. 
This project aims at the development and setting up of new methodological platforms 
based on the integration of affinity chromatography strategies together with high 
performance liquid chromatography and multi-stage mass spectrometry (MSn) for the 
study of glycoproteins and glycoconjugates using a systems biotechnology approach. 
Analysis of glycoproteome can be performed by treating entire protein extracts with 
endoglycosidases so that oligosaccharides and peptides can be analysed separately. 
Experimental procedures are needed to explore glycan sequences and their function. 
However carbohydrates detection is not an easy task since no chromophores are 
available so far. In order to facilitate their detection, chromophores are generally 
introduced at the reducing end of oligosaccharides. Hydrazine derivatives are 
generally used to derivatize carbohydrates and their reaction leads up to hydrazone 
derivatives that, if needed, can be reduced to open ring structures [2]. Derivatized 
sugars can be analysed by mass spectrometry techniques in order to produce 
structural information. Both ESI-MS and MALDI-MS are generally used for 
oligosaccharides analysis. Derivatization strongly affects ionization efficiency by 
introducing additional charges and giving the sugar a more hydrophobic character. 
Moreover, labels influence glycans fragmentation behaviour and help the assignment 
of fragmentation spectra by tagging the reducing end [3].  
A novel approach involving dansyl derivatives has been reported to selectively label 
specific PTMs [4, 5, 6, 7, 8, 9]. The dansyl-derivatization introduces a hydrophobic 
and aromatic moiety and basic secondary nitrogen into the molecule thus enhancing 
ionization efficiency. Furthermore the dansyl moiety shows a distinctive 
fragmentation pattern with product ions at m/z 170 and 234 in MS2 and the 
diagnostic m/z  234→170 fragmentation inthe MS3 mode [10]. Recently it has been 
demonstrated that peptide dansylation resulted to be a rapid and convenient method 
to improve the performances in MALDI-MS/MS analysis at proteomic scale [11]. 
Here, a new derivatisation protocol of glycans reducing ends by dansylhydrazide is 
presented. Once set up on synthetic oligosaccharides, the procedure has been 
successfully applied to the characterisation of oligosaccharides from a complex 
matrix such as egg yolk and white. 
The above mentioned strategies are based on the release of the oligosaccharide 
component from the carrier glycoprotein, so that no information about glycosylation 
sites occupancy is provided. Nowadays most of the glycoproteomics procedures rely 
on the selective capture of glycosylated peptides by lectin affinity chromatography. 
Here the lectin Concanavalin A was used to simplify the identification of N-
glycosylation sites in the mixtures deriving from egg yolk and white. 
Structural characterization of glycans can be enhanced by MSn analyses of [M+Na]+ 
ions using instruments coupling the high sensitivity of MALDI-MS and its higher 
throughput  and requirement for small amounts of sample. Moreover it is more 
tolerant to salts contaminants that in most cases co-elute with oligosaccharides in 
purification procedures. Here the use of MALDI LTQ Orbitrap for the sampe purpose 
was discussed. 
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II.2. Materials and methods 
 
Protein extraction from egg white and yolk.  
Eggs were purchased at the local market. White and yolk were separately diluted in 
10 mL of MilliQ water and centrifuged at 13000 rpm for 30 min, in order to separate 
the soluble fraction from the other components. This fraction was then subjected to 
ammonium sulphate precipitation. 76 g of ammonium sulphate (Sigma Aldrich) were 
added to 1 L of solution. After 12-16 h at 4°C the solution was centrifuged for 30 min 
at 13000 rpm in order to induce proteins precipitation. The excess of salts was 
removed using Centricon (Millipore). 
 
Protein concentration determination. 
Egg protein concentration was determined by Bradford assay method, using BSA as 
standard. Known amounts of BSA were diluted in 800 μL of H2O and then mixed to 
200 μL of Comassie Brilliant Blue. 5 different BSA concentrations were determined 
by measuring absorbance at 595 nm. Determined absorbance data were interpoled 
on the calibration curve, allowing the determination of protein concentration in the 
different samples. Proteins were separated by SDS-PAGE, loading on a 1.5 mm, 
12.5 % gel both the white and yolk samples.The gel was run at constant 25 mA for 
1h. 
 
Reduction and alkylation.  
Samples were dissolved in 200 μL of denaturation buffer (guanidine 6 M, TRIS 0.3 M, 
EDTA 10 mM, pH 8). Reduction was carried out by using a 10:1 DTT : cysteins molar 
ratio. DTT was purchased from Fluka. After incubation at 37°C for 2 h, iodoacetamide 
(Fluka) was added to perform carboxyamidomethylation using an excess of alkylating 
agent of 5:1 with respect to the moles of thiolic groups. The mixture was then 
incubated in the dark at room temperature for 30 min. The alkylation reaction was 
stopped by addition of formic acid, in order to achieve an acidic pH. The excess of 
salts and reagents was then removed by gel filtration on PD-10 columns (GE 
Healthcare). Elution was performed using ammonium bicarbonate (Fluka) 10 mM 
buffer. The collected fractions were analyzed by a spectrophotometer Beckman DU 
7500, measuring the absorbance at 220 and 280 nm. Protein containing fractions 
were collected and concentrated in a centrifuge Speed-Vac. 
 
Trypsin digestion.  
Digestion was carried out in AMBIC 10 mM buffer using trypsin (Sigma Aldrich) at a 
50:1 trypsin : protein mass ratio (w/w). The sample was incubated at 37°C for 12-16 
h. 
 
Concanavalin A affinity chromatography.  
The peptide mixtures were incubated for 2 h with 500 μL of ConA Sepharose resin 
(Amersham Biosciences), which had been activated and washed in a 20mM Tris-HCl 
buffer; 0,5M NaCl; 1mM CaCl2at 4°C and pH 7.4. After 2 h the ConA containing 
Eppendorf was centrifuged at 3000 rpm at 4°C. The unbound peptides were removed 
in the supernatant. The resin was then washed six times with the same buffer 
described before. The elution phase was based on methyl-α-D-mannopyranoside 
(Sigma Aldrich) 0,25 M competition with glycopeptides and was performed for 30 min 
at 4°C. This procedure was repeated twice in order to be sure of having eluted all the 
glycopeptides bound to ConA. 
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RP-HPLC.  
Both the peptides and the glycopeptides needed a desalting step in order to remove 
salts and  methyl-α-D-mannopyranoside.  
Both the unbound and eluted peptides were desalted by HPLC on a C-18 resin. 
HPLC was performed on an Agilent chromatograph, at a flow rate of 0,2 ml/min and a 
linear gradient from 5% B (95% acetonitrile, 5% H2O e 0,07% trifluoroacetic acid) to 
95% B in 1 min, allowing the fast elution of the unfractionated peptides. 
 
Deglycosylation.  
Egg glycopeptides were treated with PNGase F in 50 mM ammonium bicarbonate. 
Reactions were performed for 12-16 h at 37°C. Deglycosylation was carried out also 
on unbound peptides, in order to release the glycans that had not been recognized 
by ConA. 
 
Oligosaccharide purification.  
For glycan purification, the sample was loaded on a C-18 silica based bonded phase 
(Sep-pak, Waters). The column was activated with 10 mL methanol and equilibrated 
with 10 mL isopropanol, 10 mL H2O and 10 mL acetic acid 5%. The oligosaccharide 
component was eluted in 3 mL of 5% acetic acid as eluent whereas peptides were 
collected in 3 mL of 40% isopropanol and 5% acetic acid.  Alternatively an RP-HPLC 
step was performed by using a C-18 column and a gradient profile as follows: 7 min 
at 5% B, 5 to 95% B in 2 min and 10 min at 95% B. 
 
LC-MS/MS.  
Peptides were analyzed by a HPLC-Chip/Q-TOF 6520 (Agilent Technologies). The 
capillary column works at a flow of 4 μL/min, concentrating and washing the sample 
in a 40 nL enrichment column. The sample was then fractionated on a C18 reverse-
phase capillary column (75 μm~43 mm in the Agilent Technologies chip) at flow rate 
of 300 nl/min, with a linear gradient of eluent B (0.2% formic acid in 95% acetonitrile) 
in A (0.2% formic acid in 2% acetonitrile) from 7% to 60% in 50 min. Data were 
acquired through MassHunter software (Agilent Technologies). Proteins identification 
was achieved by using Mascot software (Matrixscience), with a tolerance of 10 ppm 
on peptide mass, 0.6 Da on MS/MS, and choosing cysteine carbamidomethylation as 
fixed modification. Variable modifications were methionine oxidation, glutamine 
conversion in pyro-glutamic acid, and asparagine deamidation. 
 
Oligosaccharides derivatization.  
The reaction was set up on maltoheptaose (Sigma Aldrich).  
Glycans were subjected to chemical derivatization with dansyl-hydrazine (Sigma 
Aldrich). Liophylized sugars were dissolved in 3-6 μL of water, to which a solution 
containing 200 mM dansyl-hydrazine in 90% acetonitrile (Romil) and 10% TFA (Carlo 
Erba) was added. The reaction was carried out in the dark at 37°C for 3 h.  
 
MALDI-TOF/TOF analysis of glycans.  
Oligosaccharides were analysed on a 4800 Plus MALDI-TOF/TOF (Applied 
Biosystems). Samples were mixed on MALDI plate to the matrix consisting of a 
solution of 20 mg/mL DHB (Fluka), whose preparation consisted in the resuspension 
of DHB in water and acetonitrile 10:1 (v/v). The instrument was calibrated using a 
mixture of standard peptides (Applied Biosystems). Spectra were register even in 
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reflector positive or negative mode. MS/MS spectra were performed with CID using 
air as collision gas. Spectra were manually interpreted and checked against 
GlycoWorkbench software (14). 
 
Q-TRAP analysis of glycans. 
Supplementary MS experiments were performed on a 4000 Q-Trap system (Applied 
Biosystems). A micro-ionspray source was used at 2 kV with liquid coupling, with a 
declustering potential of 50 V, using an uncoated silica tip (o.d. 150 µm, i.d. 20 µm, 
tip diameter 10 µm) from New Objectives. In product ion scanning the scan speed 
was set to 4000 Da/s, the resolution of Q1 was set to “low” and the best collision 
energy was calculated as 35. 
 
MALDI-LTQ-Orbitrap analysis of glycans. 
N-glycans extracted from fetuin (Sigma Aldrich) were analyzed on MALDI-LTQ-
Orbitrap (Thermo Fisher scientific), using DHB as matrix. All the spectra were 
recorded in positive ion mode. Full scan mass spectra were carried out using a the 
Orbitrap mass analyzer, due to its high mass accuracy. Resolution was set to 30,000 
and 3 microscans were recorded for one position. The filling stats of the linear ion 
trap was regulated by automatic gain control(AGC). A system for the automatic 
recognition of crystals, the survey crystal positioning system(survey CPS) allowed 
the random choice of shot. Laser intensity was generally set at 60µJ. CID 
fragmentation spectra were performed using the ion trap as mass analyzer and 
collision energy (CE) was optimized to 75%; the activation Q value was set to 0.250 
and the activation time was 30 ms. 
 
II.3. Results and discussion 
 
In this study we provided a new methodology for the full characterization of N-
glycome in a complex sample probed by a proteomics approach. The preliminary 
step for N-glycosylation sites determination was the selection of specific glycoforms 
to simplify the initial peptidic mixture by concanavalin A affinity enrichment on egg 
proteins. 
White and yolk fractions were separated and proteins were precipitated in ammonium 
sulphate as described. SDS-PAGE was carried out on 50 µg of proteins deriving from 
both the white and the yolk to verify the correctness of separation procedure (Fig.1).  
 
Fig. 1: SDS-PAGE of 50 µg of egg white and egg yolk 
Aliquots of the two samples were reduced, carbamidomethylated and trypsin 
digested. Concanavalin A affinity chromatography was performed on both the 
digested fractions [12]. A key step in the procedure was endoglycosidase F 
treatment. The deglycosylation reaction leads to asparagine deamidation in the 
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consensus sequence. Therefore the m/z increment of 0.98 Da due to the hydrolysis 
of the N-glycosydic bond was used to detect N-glycosylated peptides. 
 
Protein identification.  
The identification of proteins and the direct localization of N-glycosylation sites was 
achieved by LC-MS/MS analysis. In ConA bound fractions, proteins identification was 
obtained exclusively by taking into account the peptides containing the N-
glycosylation consensus sequence. As described before [12], in order to identify not 
glycosylated peptides and glycopeptides bearing a different glycosylation pattern (not 
recognized by concanavalin A) an LC-MS/MS experiment was performed on the 
unbound fraction. 
Proteins identification was carried out by using a bioinformatics tool, namely Mascot 
MS/MS ion search program through the NCBI database, specifying Gallus gallus as 
taxonomy. The NCBI identified proteins were then searched against Swiss-prot 
database, in order to univocally recognize each protein. For the identification, we 
considered asparagine deamidation as a possible variable modification that took 
place in the consensus sequence N-X-S/T after glycosidase treatment. The data 
obtained are summarized in Table 1. It should be noted that several glycopeptides 
where detected in the unbound fraction from egg samples and identified by the 
diagnostic increment of 0.98 Da respect to the theoretical mass. Some proteins, as 
the vitellogenin-2, ovalbumin, ovotransferrin and clusterin, are indicated to be 
glycosylated on the basis of similarity with the counterpart from other species. For 
several egg proteins, the glycosylation sites are indicated in the SwissProt database 
as putative N-glycosylation sites.  
The MS analyses performed in this work, led to the direct identification of N-
glycosylation sites for several egg proteins. Some of them were exclusively 
expressed in one fraction, such as Cathepsin D, only present in the yolk, whereas 
others were expressed in both yolk and white, such as Apolipoprotein B. To the best 
of our knowledge, these results represent the first  data on the fine localisation of N-
glycosylation sites thus complementing the data already available on the 
characterisation of egg proteome. 
 
Table 1: List of the proteins identified by LC-MS/MS analyses. N-glycosylation sites are marked 
with an asterisk after the asparagines residue. BY and BW indicate the bound fraction of egg 
yolk and white samples, respectively; UY and UW indicate the unbound fraction of egg yolk 
and white, respectively. 
Protein Sequence 
Vitellogenin-1 (P87498)  MSFTCSFN
*
K 
BY, UY, UW
 
EVHINTSSAN
*
ITICPAADSSLLVTCNK
 BY
 
Ovomucoid (P01005) FPN
*
ATDK
 BY, BW, UY, UW
 
PMN
*
CSSYAN
*
TTSEDGK
 BY, BW, UY, UW
 
CNFCNAVVESN
*
GTLTLSHFGK
 BY, BW, UY, UW
 
LAAVSVDCSEYPKPDCTAEDRPLCGSDN
*
K
 BY, BW, UY, UW
 
Vitellogenin-2 (P02845) VQVFVTN
*
LTDSSK
 BY
 
LLVDGAESPTAN
*
ISLISAGASLWIHNENQGFALAAPGHGIDK
 BY, UY
 
Apovitellenin-1 (P02659) NFLIN
*
ETAR
 BY, UY, UW
 
Serum albumin (P19121) KQETTPINDN
*
VSQCCSQLYANR
 BY
 
Apolipoprotein B 
(Q197X2) 
VASPLYN
*
VTWR
 BY, BW
 
SLHN
*
STLGSLVPK
 BY, BW
 
NQYGMMTEVN
*
QTLK
 BY, BW
 
INSPSNQILIPAMGN
*
ITYDFSFK
 BY, BW
 
LNIPEADFSSQADLVNN
*
MTTEVEAGR
 BY, BW
 
VASPFFTLSTQAEVHN
*
TTASANSPEFDTSLSAQATSK
BY,BW
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Characterization of egg oligosaccharides.  
Oligosaccharides characterization is arousing a particular interest even being a 
challenging analytical problem. Glycan molecules present extremely various 
structures as concerning the type of monosaccharides they are built of, the 
branching, the anomericity of the glycosydic linkage and the global structure that the 
carbohydrate moieties confer to proteins. Nowadays mass spectrometry 
methodologies resolve most of the challenges connected to the study of glycans 
such as the glycoforms heterogeneity achieving qualitative and quantitative 
information on oligosaccharides structures present in the analyte, with enormous 
sensitivity [13]. MALDI-TOF mass spectrometry technique is able to detect any 
difference between the analytes in terms of speed and sensitivity in the analyses. 
The bound or the unbound ConA fractions both from yolk and white were treated with 
PNGase F. Oligosaccharides were purified from peptides by RP-HPLC and analysed 
by MALDI-MS in reflectron positive and negative mode. Oligosaccharides 
characterization by MALDI-MS was achievable on the basis of the m/z value together 
with the knowledge of oligosaccharides biosynthesis. Hypothetical structures were 
then confirmed through tandem mass spectrometry. MS/MS spectra were interpreted 
using the software Glycoworkbench [14], which simulates glycans fragmentation and 
compares the theoretical fragments with the experimental ones. 
MALDI-TOF spectra of oligosaccharides, released from protein backbone as 
described, were recorded in reflector mode. Peaks were manually attributed and then 
confirmed by MALDI-MS/MS. 
In positive ion mode oligosaccharides usually ionize as MNa+ but sometimes we 
noticed the presence of sodium adducts, especially when the structure contains sialic 
acid residues. It is quite useful to register negative spectra in order to detect 
oligosaccharides bearing sialic acid residues due to ionize as MH- of sugars. Fig. 2  
shows the mass spectra in positive ion mode of the ConA bound and unbound 
fraction from egg white.  The attribution of each peak is reported in Table 2.  
Complement C3 (Q90633) FEIDHALSN
*
R
 BY
 
AAN
*
LSDIVPNTESETK
 BY
 
Ig mu chain C region (P01875) VNVSGTDWR
 BY, UY 
VTHN
*
GTSITK
 UW 
Cathepsin D (Q057441) DTLQISN
*
ISIK
 BY
 
Arylsulfatase K (Q5ZK90) NDFLN
*
VSAPR
 BY
 
Complement factor B-like 
protease (P81475) 
TGN
*
WSTKPSCK
 BY
 
Ovotransferrin (P02789) TAGWVIPMGLIHN
*
R
 BW
 
FGVN
*
GSEK
 BW, UY, UW
 
Ovalbumin-related protein Y 
(P10114) 
SAN
*
LTGISSVDNLMISDAVHGVFMEVNEEGTEATGSTGAIGNIK
BW,UW
 
Ovoglycoprotein (Q8JIG5) LN
*
ETCVVK
 BW, UY, UW
 
HN
*
STLTHEDGQVVSMAELTHSDK
 BW
 
Clusterin (P14018) RYDDLLSAFQAEMLN
*
TSSLLDQLNR
 UY, UW
 
Ovalbumin (P01012) YN
*
LTSVLMAMGITDVFSSSANLSGISSAESLK
 UW
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Fig. 2: positive ion mode MALDI-MS spectrum of ConA bound (panel A) and unbound fraction 
(panel B) oligosaccharides released from egg white glycoproteins. 
 
Table 2: list of the oligosaccharides structures detected by MALDI-MS, where BY=ConA bound 
fraction of yolk, UY=ConA Unbound fraction of yolk, BW=ConA bound fraction of white, 
UW=ConA unbound fraction of white 
m/z Composition Structure 
 
1095.37
BY 
 
 
HexNac2Hex4 
 
 
 
 
1136.39
BY 
 
 
HexNAc3Hex3 
 
 
 
 
1257.42
 BY,BW
 
 
HexNac2Hex5 
 
 
 
 
1298.42
BY 
 
 
HexNAc3Hex4 
 
 
 
 
1339.44
 BY,BW,UY,UW 
 
 
HexNAc4Hex3 
 
 
 
 
1419.47
 BY,BW 
 
 
HexNAc2Hex6 
 
 
 
 
1460.50
 BY,BW,UY 
 
 
HexNAc3Hex5 
 
 
 
 
1501.53
 BY,BW,UY,UW 
 
 
HexNAc4Hex4 
 
 
 
 
1542.55
 BY,BW,UY,UW 
 
HexNAc5Hex3  
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1581.52
 BY 
 
 
HexNAc2Hex7 
 
 
 
 
1622.55 
 BW 
 
 
HexNAc3Hex6 
 
 
 
 
1663.58
 BY,BW 
 
 
HexNac4Hex5 
 
 
 
 
1704.61
 BY,BW,UY,UW 
 
 
HexNAc5Hex4 
 
 
 
 
1745.63
 BY,BW,UY,UW 
 
 
HexNAc6Hex3 
 
 
 
 
1850.66
 BY,UY 
 
 
FucHexNAc5Hex4 
 
 
 
1866.66
 BW,UY,UW
 
 
 
HexNAc5Hex5 
 
 
 
1905.63
 BY UY 
 
 
HexNAc2Hex9 
 
 
 
 
1907.68
 BW,UW 
 
 
HexNac6Hex4 
 
 
 
 
1948.71
 BW, UY,UW
 
 
HexNac7Hex3 
 
 
 
 
 
1954.67
 BY, UY 
 
 
HexNac4Hex5Sia 
 
 
 
 
2028.71
 BW, UY 
 
 
HexNac5Hex6 
 
 
 
 
2067.69
 BY,UY 
 
 
HexNAc2Hex10 
 
 
 
 
2110.76
 UY,UW 
 
 
HexNAc7Hex4 
 
 
 
2151.79
 UY,UW
 
 
HexNAc8Hex3 
 
 
 
 
2245.77
 BY, UY 
 
 
HexNAc4Hex5Sia2 
 
 
 
 
2272.82
 UY,UW 
 
 
HexNAc7Hex5 
 
 
 
2303.81
 BY,UY
 
 
FucHexNAc5Hex5Sia 
 
 
 
2313.84
 UY,UW 
 
 
HexNAc8Hex4 
 
 
 
 
2319.81
 BY, UY 
 
 
HexNac5Hex6Sia 
 
 
 
 
2475.90
 UY,UW 
 
 
HexNac8Hex5 
 
 
 
The glycans detected belonged to the complex type as confirmed by MS/MS data. 
However, it should be noted that some peaks could be attributed to more than one 
structure. The MS/MS analysis let us to confirm the presence of isobaric structures or 
to discriminate between the different structure only for the most abundant species. As 
41 
 
an example, the peak occurring at m/z 1542,5 was identified as a biantennary glycan 
carrying a bisecting β-1,4-GlcNAc rather then as a triantennary complex structure.  
The heterogeneity in the peak attribution still remained for the less abundant ones.  
The main differences between the fractions consisted in the higher branching of 
unbound oligosaccharides. 
Fig. 3 displays the positive ion mode mass spectra of ConA bound and unbound 
fractions of yolk. In both fraction the presence of sialylated structures, which were not 
detected in the white sample can be observed. These structures were identified in 
positive ion mode due to the presence of a negative charge for each sialic acid, 
which was neutralized by a sodium ion. For this reason we performed the analyses in 
negative ion mode in order to confirm the presence of sialic acid residues. A high 
heterogeneity was found in the MALDI spectra of the glycan moieties essentially 
belonging to the complex type. Moreover, differences between egg white and yolk 
could be appreciated and were essentially ascribed to the total absence of sialic acid 
in the oligosaccharides from white egg fraction. 
 
Fig. 3: positive ion mode MALDI-MS spectrum of ConA bound (panel A) and unbound fraction 
(panel B) oligosaccharides released from egg yolk glycoproteins. 
 
Set up of a dansyl-labeling procedure of glycans reducing ends. 
In order to improve MS/MS glycan fragmentation a novel derivatisation method was 
proposed. Despite the fact that the MALDI ionization mechanism is not yet 
completely understood, it is widely acknowledged that the ionization efficiency 
depends on the chemical physical properties of the analyte. In particular, the 
presence of basic and/or hydrophobic groups [15] enhances the yields of the 
ionization process. Dansyl chloride (DNS-Cl) is a fluorescent reagent which has 
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extensively used in biochemistry during the eighties [16] and used to selectively label 
specific post-translational modification in a selective proteomics approach [9, 10, 17]. 
In a recent paper it was demonstrated that dansylation labeling improves the MALDI 
ionization and fragmentation of peptides [11]; moreover this derivatisation was 
applied to fragmentation of glycosylated peptides whose analysis is often problematic 
[18]. On the basis of the experience recently made with dansyl chloride and other 
dansyl derivatives, we used a commercially available dansylated reagent, namely 
dansyl-hydrazine, to selectively label free oligosaccharides (Fig.4).  
 
Fig. 4: Dansylhydrazine 
Our experimental procedure was set up on a synthetic oligosaccharide, 
maltoheptaose, by using dansyl-hydrazine as label. The reaction was carried out as 
described in the experimental section. To monitor the effects of glycan dansylation, 
we diluted the unlabeled sample with a volume of ACN and we used it as control for 
the further experiments. The analyses were carried out by MALDI-TOF mass 
spectrometry where the labelled oligosaccharides showed an increment of 247.3 Da 
compared to the unmodified signal. Tandem mass spectrometry was performed on 
both the labelled and unlabelled oligosaccharide. Signals were assigned according to 
the nomenclature proposed by Domon and Costello [19]. 
Fig.5 shows the MS/MS spectra of maltoheptaose registered on a MALDI-TOF/TOF 
mass spectrometer where the DNS-sugar undergoes a loss of 234 Da, 
corresponding to the dansyl unit. We noticed the presence of Y and B ions, as well 
as cross-ring cleavages. As shown in the figure, the intensity strongly increased for 
the labelled specie. The difference in ionization efficiency could be appreciated in  
the difference in quality of the MS/MS data between dansylated and native 
oligosaccharides because the fragmentation profiles are modified. The fragmentation 
pattern of dansylated oligosaccharide exhibited enhanced B-ion and C-ion series in 
MS/MS experiments (Fig. 5B) compared to the native ones (Fig. 5A). This 
improvement in fragmentation could be attributed to the presence of the dansyl 
fluorescent moiety at the reducing end. This behavior was in agreement with 
previous data where dansyl moiety was added at the N-terminus of different peptides 
[11]. 
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Fig. 5: positive ion mode MALDI-MS/MS spectrum of DNS-labelled maltoheptaose (B) compared 
to the unmodified one(A). 
  
Fig. 6: ESI-MS/MS spectrum of DNS-labelled maltoheptaose (B) compared to the unmodified 
one(A) performed on a 4000 Q-TRAP. 
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The same analysis was performed by using an hybrid Q-Trap instruments and the 
results are reported in Fig.6. As shown, the ESI-MS/MS spectrum of the DNS- 
oligosaccharide reveals a better fragmentation, when compared to the unmodified 
one. Even in this case both Y and B ions were present, but cross-ring cleavages 
were less frequent than for MALDI-MS. 
Once set up, the dansyl labelling procedure was applied to the characterisation of 
glycans in a real sample, namely the oligosaccharides released from egg 
glycoproteins. The N-glycans enzymatically released from glycoproteins were 
derivatised and subjected to MS/MS analysis in order to assign the correct structure. 
As an example, Fig 7 showed the MALDI-MS/MS spectrum of the precursor ion at 
m/z 1419.39, compared to the dansyl-labelled form. The oligosaccharide was 
identified as a high mannose structure on the basis of the interpretation of the 
fragmentation spectrum. Similar analyses were carried out on the other glycans thus 
confirming previous results. As a whole the data obtained by MALDI-MS/MS 
analyses of glycans are summarised in Table 1. It should be worth noting that DNS-
derivatives are characterized by higher ionization efficiency than the unlabelled ones, 
producing better spectra with a higher S/N ratio with respect to the unmodified ones 
(Fig. 7B).  
 
Fig. 7: positive ion mode MALDI-MS/MS spectrum of DNS-labelled oligosaccharide at m/z 
1666.38 released from egg white ConA eluted fraction (B) compared to the unmodified one(A) 
 Thus, the derivatization protocol by dansyl-hydrazine was effective in the 
improvement of ionization efficiency, introducing a strong basic group. This labelling 
strategy not only increased peaks resolution in MS/MS spectra, but also introduced 
the possibility for further analysis of sugars by exploiting the potential of precursor ion 
scan analysis as already performed for the selective identification of other PTMs [10]. 
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Fragmentation of oligosaccharides using MALDI LTQ Orbitrap for multi-stage MS 
The use of MALDI LTQ Orbitrap for oligosaccharides fragmentation has been very 
recently reported by Karas and coworkers [20]. The authors explored the potential of 
MALDI source coupled to Orbitrap analyzer in three fragmentation techniques, 
namely CID, PQD and HCD. Fragmentation is higly influenced by the activation Q-
values, depending on the radio frequency amplitude. The higher is this value, the 
greater is the dissociation efficiency, but this improvement is obtained at the expense 
of trapping fragments at low m/z [21]. During CID fragmentation Q-value remains 
constant and it is not possible to trap fragments at m/z lower than the 30% of the 
precursor. For this reason PQD (Pulsed-Q Dissociation) overcomes this limitation 
with a higher activation Q-value for precursor fragmentation followed by a rapid pulse 
to a lower Q-value, in order to capture fragments with lower m/z. Another attempt to 
solve the low mass cutoff problem is the use of HCD (Higher energy C-trap 
dissociation) for instruments endowed with a “C-trap”, functioning as a quadrupole-
like ion storage device between the LTQ and the Orbitrap analyzer. Fragments are 
detected with high resolution in the Orbitrap [22]. Unfortunately both PQD and HCD 
suffer from a very low signal intensity so that structural information to cover the entire 
mass range can be achieved only combining the three fragmentation procedures 
[20]. In addition to this a strong electronic noise sometimes suppresses ion detection. 
Here the use of MALDI LTQ Orbitrap is exploited for oligosaccharide fragmentation 
using a multi-stage mass spectrometry approach. The use of MSn procedures in 
glycans characterization was already reported [23]. Experiments were carried out on 
a MALDI-LTQ Orbitrap at the École supérieure de physique et de chimie industrielles 
de la ville de Paris. 
N-glycans from fetuin were analyzed by full scan MS, using DHB matrix as reported 
in Fig. 8, with resolution set at 60000 and a very high laser intensity at 60 µJ. 
 
 
Fig. 8: MALDI-LTQ-Orbitrap full scan mass spectrum of oligosaccharides extracted from fetuin  
The spectrum revealed a high mass accuracy due to orbitrap analysis. This 
characteristics offered the advantage to perform a reliable glycan profiling based on 
full scan spectra. 
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However structural elucidation of glycan molecules can be achieved only by 
fragmentation techniques. An important parameter for a good fragmentation is 
normalized collision energy. The first experiments were devoted to the optimization of 
this parameter for sugars, as reported in Fig.9 and 10, showing the MS/MS spectrum 
of the ion at m/z 1663.59. Fragmentation was achieved in CID using a constant Q-
value of 0.25 and confirming the so-called “one third rule” stating the low mass cutoff 
during the trapping of fragments. Fig.9 reports the spectrum obtained with a collision 
energy of 35, whereas in Fig.10 spectrum this parameter was set up at 60, revealing 
an improvement in fragmentation efficiency. 
 
Fig. 9: MS/MS spectrum of ion at m/z 1663.59 with CE=35 
 
Fig. 10: MS/MS spectrum of ion at m/z 1663.59 with CE=60 
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The absence of significant signals at low masses and the need for this information in 
structural elucidation of oligosaccharides sequences convinced us to explore the 
potential of multi-stage fragmentation. 
 
Fig. 11: MS
3 
and MS
4
 experiments for fragment ions at m/z 1298.65 and 1077.49, respectively 
The ion at m/z 1298.65 was chosen for the further fragmentation event in MS3. The 
spectrum revealed the presence of essentially b and y-type ions, unfortunately 
covering a narrow mass range. A wider sequence coverage was achieved performing 
an MS4 experiment. The lower detected mass was at m/z 388.37, corresponding to 
the b2 fragment (Fig.11). 
Permethylation derivatization was carried out in order to improve structural 
characterization, trying to obtain data about branching via cross ring cleavages. 
Fig. 12 represents the MS/MS spectrum of ion at 2070.47, corresponding to the 
biantennary structure at m/z 1663.59, after permethylation. 
 
Fig. 12: MS/MS spectrum of ion at m/z 2070.47, corresponding to the biantennary structure 
after permethylation 
Even in this case we assist to a prominence of b and y-type ions but z-type and cross 
ring cleavages started to be detected. 
Further fragmentation events were carried out on this ion as illustrated in Fig. 13. 
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Fig. 13: MS
n
 experiments on fragment ions belonging to the permethylated biantennary 
structurein Fig.12. In the figure MS
3 
 MS
4
 and MS
5
 are shown in panel A, B and C, respectively. 
Precursor ions are signed with a rectangle. 
A 
B 
C 
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Fig.13A represents the MS3 spectrum of fragment ion at m/z 1606.93, corresponding 
to the Y5 fragment. In panel B the MS
4 spectrum of fragment ion at m/z 1143.64 is 
shown. This fragment was interpreted with two possible attributions from the MS3 
spectrum, but the MS4 and MS5 experiments gave rise to fragments belonging solely 
to the Y4α Y4β fragment. These considerations led to the conclusion that multi-stage 
mass spectrometry is a valuable tool for oligosaccharides analysis. 
Unfortunately, although permethylation allowed an increment in the number of 
cleavages, fragmentation spectra were very poor, probably due to sensitivity 
problems associated with the use of MALDI source. In particular a high sample 
consumption was observed using this MALDI source. This consumption was 
probably caused by the need for a high laser energy together with the use of the CPS 
system (Survey Chrystal Positioning system), which allowed the random choice of 
shot position by automatic crystal recognition. During the recognition process of DHB 
crystals the systems was not able to detect most of the sample and the analysis took 
a very long time leading to a high sample consumption. To conclude, the use of 
MALDI-LTQ Orbitrap did not satisfied our need for good fragmentation spectra, 
useful for structural characterization of oligosaccharides, demonstating that MALDI-
TOF/TOF analyses of derivatized sugars is still the gold standard in glycomics. 
However the extremely high accuracy and a very high resolution of the Orbitrap 
analyzer can be used for unambiguous assignment of structures during glycan 
profiling analyses. 
 
II.4. Conclusions 
As a whole, in this work an optimized dansylation protocol for glycoproteomic studies 
by MALDI-MS/MS analysis is reported. The presence of the aromatic 
dimethylaminonaphthalene group at the reducing end increased the glycan 
fragmentation leading to a better coverage of the oligosaccharide sequence. This 
tendency could be rationalized considering that the UV-adsorbing naphthalene group 
in the reducing end could increase the energy transfer from the laser in PSD-like 
fragmentation, favoring the glycan bond destabilization/protonation as observed for 
peptides. Glycan dansylation was demonstrated to be a rapid and cost-effectively 
valuable method useful to optimize the ionization efficiency of oligosaccharides. Well 
established techniques were conjugated with novel derivatisation procedure thus 
providing a new method for the glycoproteome investigation. The set up of a multi-
stage mass spectrometry procedure opened the way for structural elucidation of 
glycans sequences  with a novel mass spectrometer, MALDI LTQ Orbitrap. 
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III. N-glycoproteome in the study of myocarditis 
 
III.1. Introduction 
Myocarditis is a group of diseases characterized by the inflammation of the cardiac 
muscle which might be related to viral (mainly parvovirus B19 and many others), 
protozoan (Borrellia burgdoferi, Trypanosoma cruzi, Toxoplasma gondi), bacterial 
(Brucella, Corynebacterium diphtheriae, Gonococcus, Haemophilus influenzae, 
Actinomyces, Tropheryma whipplei, Vibrio cholerae, Borrelia burgdorferi, Leptospira, 
Rickettsia), fungal (Aspergillus) and other non viral pathogens infections[1, 2, 3]; it 
has been reported that some types of myocarditis are caused by autoimmune 
mechanisms and this association is evidenced by concomitance with other 
autoimmune diseases and by the presence of autoantibodies [4]. However, this kind 
of inflammation might be caused by an hypersensitivity response to drugs [5]. 
Anyway, in each case the final effect is represented by myocardial infiltration of 
immunocompetent cells following any kind of cardiac injury and myocytes necrosis. 
Myocarditis symptoms are various, ranging from chest pain that spontaneously 
resolves without treatment, to cardiogenic shock and sudden death [6, 7]. The major 
long-term consequence is dilated cardiomyopathy with chronic heart failure[8, 9]. 
Diagnostic tools currently available for this disease are essentially based to general 
investigations (such as electrocardiography) and analysis of the most abundant 
serum proteins, whose alteration is related to cardiac pathology, however not 
specifically related to myocarditis itself. 
Inflammatory events generally involves different kinds of biological macromolecules, 
included proteins. Proteomics investigations offer all useful tools to deeply investigate 
this kind of alterations. Two dimensional electrophoresis coupled with software 
mediated image analysis, affinity chromatographies and especially Mass 
Spectrometry (MS) present high levels of sensitivity, accuracy and reproducibility to 
use in comparative studies of pathological status. 
Thanks to the high sensitivity of the most modern analytical techniques, several 
research groups focus the research at level of peptides rather than at protein level 
[10, 11, 12]. In fact, these endogenous peptides are referred to as the peptidome. 
Initially, peptidomic analyses were conducted as a method to study neuropeptides 
and peptide hormones; these are signaling molecules that function in a variety of 
physiological processes [13, 14]. Recent studies have found large numbers of 
cellular peptides with half-lives of several seconds, raising the possibility that they 
may be involved in biological functions [15].  
Here some preliminary data on the molecular basis of myocarditis have been 
collected using a proteomic approach. The analyses were focused on the serum 
proteins profiling, namely the study of the expression level and the characterization of 
glycoproteins involved in the pathology. A classical two-dimensional gel 
electrophoresis procedure to obtain protein maps and a “gel-free” comparison of the 
glycoproteomes in healthy and myocarditis human sera by using advanced mass 
spectrometry was reported. Free peptides identification in myocardytis affected 
patients (compared to healthy individual), was achieved in order to provide possible 
specific markers for this pathology. Moreover a comparison on the glycoproteomes in 
healthy and pathological human sera was carried out, by using single affinity 
chromatography (ConA) step and boronate affinity chromatography coupled with 
mass spectrometry techniques. 
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III.2. Materials and methods 
Materials 
Human serum samples from 8 healthy donors (all Caucasian 4 males and 4 females 
aged between 60 and 80 years, all other clinical informations were covered by laws 
on privacy) and from 5 myocarditis affected patients (all Caucasian 3 males and 2 
females aged between 60 and 85 years, all other clinical informations were covered 
by laws on privacy), respectively, have been obtained from the “Servizio Analisi” 
Policlinico, Napoli. Aliquots of serum samples from different donors were pooled in 
order to obtain an average overview of glycoforms distribution. 
Guanidine, dithiothreitol (DTT), trypsin, α-cyano-4-hydroxycinnamic acid were 
purchased from Sigma. Iodoacetamide (IAM), tris(hydroxymethyl)aminomethane, 
calcium chloride and ammonium bicarbonate (AMBIC) were purchased from Fluka as 
well as the MALDI matrix 2,5-, α-cyano-4-hydroxycinnamic. Methanol, trifluoroacetic 
acid (TFA) and acetonitrile (ACN) are HPLC grade type from Carlo Erba, whereas 
the other solvents are from Baker. Gel filtration columns PD-10 are from Pharmacia, 
the HPLC ones from Phenomenex, whereas the pre-packed columns Sep-pak C-18 
are from Waters. Comassie Brilliant Blue was from Bio-Rad. PNGase F were 
purchased from Boheringer. Ion exchange resins Dowex H+ (50W-X8 50-100 mesh) 
was provided by BDH. Concanavalin A sepharose resin was purchased from 
Amersham Biosciences. 
 
Protein concentration determination 
Sera protein concentration was determined by Bradford assay method, using bovine 
serum albumin (BSA) as standard. Known amounts of BSA were diluted in 800 μL of 
H2O and then mixed to 200 μL of Comassie Brilliant Blue. 5 different BSA 
concentration were determined by measuring absorbance at 595 nm and used to 
obtain a linear calibration curve. Three different sera dilutions were measured at 595 
nm. Absorbance data were interpoled on the calibration curve, allowing the 
determination of protein concentration in the different samples. 
 
Serum depletion 
The depletion of the most abundant proteins from each serum sample was performed 
using Multiple Affinity Removal Spin Cartridges from Agilent. The procedure was 
performed at room temperature according to manufacturer’s instructions and then 
immediately frozen to -20°C. 
 
Free peptides analysis 
300 μL acetonitrile was added to 100 μL of serum, incubated at room temperature for 
30 minutes and then centrifuged at 13000 rpm. Supernatants were collected and 
concentrated by vacuum centrifugation (SAVANT) and resuspended in 20 μL formic 
acid 0.1%. Samples were desalted by C18 Zip Tip (Millipore) and diluted 100 times 
prior mass spectrometry analyses. 
Peptides were analyzed by a HPLC-Chip/Q-TOF 6520 (Agilent Technologies). The 
capillary column works at a flow of 4 μL/min, concentrating and washing the sample 
in a 40 nL enrichment column. The sample was then fractionated on a C18 reverse-
phase capillary column (75 μm~43 mm in the Agilent Technologies chip) at flow rate 
of 400 nl/min, with a linear gradient of eluent B (0.2% formic acid in 95% acetonitrile) 
in A (0.2% formic acid in 2% acetonitrile) from 7% to 60% in 50 min. 
Data were acquired through MassHunter software (Agilent Technologies). Proteins 
identification was achieved by using Mascot software (Matrix science), with a 
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tolerance of 10 ppm on peptide mass, 0.6 Da on MS/MS, and choosing methionine 
oxidation and glutamine conversion in pyro-glutamic acid as variable modifications. 
Peptides were also analyzed by MALDI-TOF/TOF using a 4800 Plus MALDI-
TOF/TOF (Applied Biosystems). Samples were mixed on MALDI plate to the matrix 
consisting of a solution of 10 mg/mL α-cyano-4-hydroxycinnamic, whose preparation 
consisted in the resuspension of α-cyano-4-hydroxycinnamic in water and acetonitrile 
10:1 (v/v). The instrument was calibrated using a mixture of standard peptides 
(Applied Biosystems). Spectra were register even in reflector positive. MS/MS 
spectra were performed with CID using air as collision gas. Spectra were manually 
interpreted. 
 
2-D gel electrophoresis 
IEF (first dimension) was carried out on non-linear wide-range immobilized pH 
gradients (pH 4-7; 7 cm long IPG strips; GE Healthcare, Uppsala, Sweden) and 
achieved using the EttanTM IPGphorTM system (GE Healthcare, Uppsala, Sweden). 
Analytical-run IPG-strips were rehydrated with 125μg of total proteins in 125μl of 
rehydratation buffer (urea 8 M, 11 CHAPS 2%, 0,5% (v/v) IPG Buffer, bromophenol 
blue 0,002%) for 12 h at 20°C. The strips were then focused according to the 
following electrical conditions at 20°C: 500 V for 30 min, from 1000 V for 30 min, 
5000 V until a total of 15000 Vt was reached. After focusing IPG strips were 
equilibrated for 15 min in 6 M urea, 30% (vol/vol) glycerol, 2% (wt/vol) SDS, 0.05 M 
Tris-HCl, pH 6.8, 2% (wt/vol) DTT, and subsequently for 15 min in the same 
urea/SDS/Tris buffer solution but substituting the 2% (wt/vol) DTT with 2.5% (wt/vol) 
iodoacetamide. The second dimension was carried out on 12% polyacrylamide gels 
at 25 mA/gel constant current until the dye front reached the bottom of the gel. MS 
gel was stained with colloidal comassie. 
 
Image analysis 
Gels images were acquired with an Epson expression 1680 PRO scanner. 
Computer-aided 2-D image analysis was carried out using the ImageMasterTM 2D 
Platinum software (GE Healthcare, Uppsala, Sweden). Differentially expressed spots 
were selected for MS analysis. In order to find differentially expressed proteins, 
Comassie stained gel image of serum proteins from healthy individual was matched 
with the one of myocarditis affected patient. The apparent isoelectric points and 
molecular masses of the proteins were calculated with ImageMaster 2D Platinum 6.0 
using identified proteins with known parameters as references. Relative spot volumes 
(%V) (V=integration of OD over the spot area; %V = V single spot/V total spot) were 
used for quantitative analysis in order to decrease experimental errors. The 
normalized intensity of spots on three replicate 2-D gels was averaged and standard 
deviation was calculated for each condition. 
 
In situ digestion 
Protein spots were excised from the gel and destained by repetitive washes with 0.1 
M NH4HCO3 pH 7.5 and acetonitrile. Enzymatic digestion was carried out with trypsin 
(12.5 ng/Tl) in 10 mM ammonium bicarbonate buffer pH 7.8. Gel pieces were 
incubated at 4 °C for 2 h. Trypsin solution was then removed and a new aliquot of the 
same solution was added; samples were incubated for 18 h at 37 °C. A minimum 
reaction volume was used as to obtain the complete rehydratation of the gel. 
Peptides were then extracted by washing the gel particles with 10mM ammonium 
bicarbonate and 1% formic acid 1 in 50% acetonitrile at room temperature. 
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Mass spectrometry and protein identification 
LC-MS/MS analyses were performed as previously described for free peptides. Mass 
spectrometric obtained data were used for protein identification using the software 
MASCOT that compare peptide masses obtained by MS and MS/MS data of each 
tryptic digestion with the theoretical peptide masses from all the proteins accessible 
in the databases (Peptide Mass Fingerprinting, PMF). Database searches were 
performed in NBCI databank (National Center for Biotechnology Information), 
restricting the analysis to the pertinent taxonomies. The parameters used for the 
identification were: tolerance of 10 ppm on peptide mass, 0.6 Da on MS/MS, and 
cysteine carbamidomethylation as fixed modification. Variable modifications were 
methionine oxidation, glutamine conversion in pyro-glutamic acid, and asparagine 
deamidation. 
 
Reduction and carbammidomethylation 
An aliquot (1 mg) of each serum was lyophilized and dissolved in 200 μL of 
denaturation buffer (guanidine 6 M, tris 0.3 M, EDTA 10 mM, pH 8). Reduction was 
carried out by using a 10:1 DTT:cysteins molar ratio. After incubation at 37°C for 2 h, 
carboxyamidomethylation was performed by adding iodoacetamide in an excess of 
alkylating agent of 5:1 with respect to the moles of thiol groups. The mixture was then 
incubated in the dark at room temperature for 30 min. The alkylation reaction was 
stopped by addition of formic acid, in order to achieve an acidic pH. 
The excess of salts and reagents was then removed by gel filtration on PD-10 
columns. Elution was performed using AMBIC 10 mM buffer. The collected fractions 
were analyzed by a spectrophotometer Beckman DU 7500, measuring the 
absorbance at 220 and 280 nm. Protein containing fractions were collected and 
concentrated in a centrifuge Speed-Vac. 
 
Enzymatic digestions 
Trypsin digestion was carried out in AMBIC 10 mM buffer using a 50:1 trypsin:protein 
mass ratio (w/w). The sample was incubated at 37°C for 12-16 h.   
 
Concanavalin A Affinity chromatography 
The peptide mixtures were incubated in batch, with 50 μL of ConA sepharose resin, 
which had been activated and washed in a 20mM Tris-HCl buffer; 0,5M NaCl; 1mM 
CaCl2 at pH 7.4, 4°C, for 2 h,. Then the ConA containing eppendorf was centrifuged 
at 3000 rpm at 4°C. The unbound peptides were removed in the supernatant. The 
resin was then washed six times with the same buffer described before. 
The elution phase was based on methyl-α-D-mannopyranoside 0,25 M competition 
with glycopeptides and  was performed for 30 min at 4°C. This procedure was 
repeated twice. 
 
Boronate affinity chromatography 
Some glycopeptides were purified within the peptide mixture using PBA-bound 
agarose (Sigma-Aldrich, Munich, Germany). 
500 μL of previously diluted sample (1:1) in equilibration buffer (50 mM 
taurine/NaOH, pH 8.7, containing 3–10 mM MgCl 2 ) was incubated with 200 μL of 
pre-washed immobilized ligand resin for 1 h on ice and with gentle shaking. After 
transfer of the resin into 1,5 ml eppendhorf tubes, the non-binding fraction was 
collected by low speed centrifugation (10 s, 500 × g). The resin was then thoroughly 
rinsed with equilibration buffer (six washes of 150 μL each) and 1 N NaCl (three 
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washes of 150 μL each). For final elution of the bound fraction, a total of six washes 
(150 μL each) with taurine buffer containing 50 mM sorbitol were used. 
Three successive fractions (150 μL each) were pooled before further analysis. 
 
RP-HPLC 
Both the peptides and the glycopeptides needed a desalting step. Both the unbound 
and eluted peptides were desalted by HPLC on a C-18 resin. HPLC was performed 
on an Agilent chromatograph, at a flow rate of 0,2 ml/min and a linear gradient from 
5% B (95% acetonitrile, 5% H2O e 0,07% trifluoroacetic acid) to 95% B in 1 min, 
allowing the fast elution of the unfractionated peptides. 
 
Deglycosylation 
Glycopeptides were lyophilized, resuspended in 10 mM AMBIC and incubated with 
PNGase F (5 U), for 12-16 h at 37°C. Deglycosylation was carried out also on 
unbound peptides, in order to release the glycans not retained during the affinity 
purifications. 
 
Oligosaccharide purification 
For glycan purification, the sample was loaded on a C-18 silica based bonded phase 
(Sep-pak). The column was activated with 10 mL methanol and equilibrated with 10 
mL isopropanol, 10 mL H2O and 10 mL acetic acid 5%. The oligosaccharide 
component was eluted in 3 mL of 5% acetic acid as eluent whereas peptides were 
collected in 3 mL of 40% isopropanol and 5% acetic acid. Alternatively, a RP-HPLC 
step was performed by using a C-18 column and a gradient profile as follows: 7 min 
at 5% B, 5 to 95% B in 2 min and 10 min at 95% B. 
 
Glycans MALDI-profiling 
Glycans were collected and lyophilized. Then they were resuspended in 50 μL of 
acetic acid 5% and treated with the ion exchange resin Dowex, in order to eliminate 
salts and other contaminants. 
Both positive and negative MALDI-MS analyses and MALDI PSD experiments were 
carried out on a Voyager DE-STR-Pro instrument operating in reflectron mode 
(Applied Biosystems, Framingham, MA). The MALDI matrices were prepared by 
dissolving 25 mg of DHB (2,5 dihydroxy benzoic acid) or THAP (2,4,6 –
Trihydroxyacetophenone) in 1 mL water/acetonitrile 10:1 or 10 mg *-cyano-4-
hydroxycinnamic acid in 1 mL of acetonitrile/0.2% trifluoroacetic acid (70:30 v/v). 
Typically, 1 µL of matrix was applied to the metallic sample plate and 1 µL of analyte 
was then added. Acceleration and reflector voltages were set up as follows: target 
voltage at 20 kV, first grid at 66% of target voltage, delayed extraction at 200 ns to 
obtain the best signal-to-noise ratios and the best possible isotopic resolution with 
two-point external calibration using maltoheptose (exact isotopic mass, 1153.02 Da) 
and tetrantennary sialylated oligosaccharide (exact isotopic mass, 2686,03 Da) as 
calibrants, resulting in a mass accuracy of 300 ppm. Each spectrum represents the 
sum of 1500 laser pulses from randomly chosen spots per sample position. All 
analyses were conducted in triplicate. 
The PSD fragment spectra were acquired after pseudomolecular cation selection 
using the time ion selector. Fragment ions were refocused by stepwise reducing the 
reflector voltage by 20%. The individual segments were then stitched together using 
the Applied Biosystems software. Raw data were analysed using the computer 
software provided by the manufacturers and are reported as monoisotopic masses. 
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Peptides LC-MS/MS 
Samples were diluted in formic acid 0.1% in order to obtain a final concentration of 
20 fmol/μL. 8 μL were loaded and analyzed.  
NanoLC-MS2 experiments were performed on a 4000 Q-Trap mass spectrometer 
(Applied Biosystems) coupled to an 1100 nanoHPLC system (Agilent Technologies). 
Peptides were separated on a Agilent reversed-phase column (Zorbax 300 SBC18, 
150 mm), at a flow rate of 0.2 uL/min using 0.1% formic acid, 2% ACN in water as 
solvent A 0.1% and formic acid, 2% water in ACN as solvent B. The elution was 
accomplished by a 5-65% linear gradient of solvent B in 60 min. A micro-ionspray 
source was used at 2.5 kV with liquid coupling, with a declustering potential of 50 V, 
using an uncoated silica tip from New Objectives (Ringoes, NJ). Alternatively 
peptides were analyzed by a HPLC-Chip/Q-TOF 6520 (Agilent Technologies). The 
capillary column works at a flow of 4 μL/min, concentrating and washing the sample 
in a 40 nL enrichment column. The sample was then fractionated on a C18 reverse-
phase capillary column (75 μm~43 mm in the Agilent Technologies chip) at flow rate 
of 400 nl/min, with a linear gradient of eluent B (0.2% formic acid in 95% acetonitrile) 
in A (0.2% formic acid in 2% acetonitrile) from 7% to 60% in 50 min. Data were 
acquired through MassHunter software (Agilent Technologies).  
Proteins were identified by searching the MS/MS spectra against the SwissProt or 
NCBI databases using the Mascot in house search engine (Matrix Science, London, 
UK). 
 
III.3. Results and discussion 
 
Free peptides analysis 
The analyses to investigate free peptides both in healthy and in pathological samples 
were accomplished by using a gel-free approach. The peptide component of the 
serum was separated precipitating proteins by ACN precipitation and recovering 
supernatants. Collected fraction were desalted and analyzed by tandem mass 
spectrometry. The stringency of scoring parameters of the MASCOT algorithm 
minimized the number of false positive identifications. Most MS/MS spectra giving 
positive hits were derived from doubly and triply charged precursor ions that resulted 
predominantly in y-ion series. 
Triplicate LC-MS/MS analysis of supernatants after ACN precipitation of serum 
proteins, showed the occurrence of many free peptides in both analyzed sera. As 
reported in Table 1, the total number of detected and identified peptides was 41. 
Among these, 9 peptides were unique in the pathologic sample. It should be noted 
that some peptides were identified in both samples. 
 
Table 1: List of free peptides identified by LC-MS/MS. Averaged area of chromatographicpeaks 
from healthy(H) and myocarditis (M) ratio, indicates that some of them weredifferently 
represented. Peptide sequences were validated by MALDI-TOF/TOF analyses too. 
m/z RT Sequence Peptide Protein H/M 
567.95 17.09 QAGAAGSRMNFRPGVLS (650-666) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
513.78 17.70 YYLQGAKIPKPEASFSPR (627-644) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
823.17 22.11 MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF     (658-687) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
1005.98 22.78 QLGLPGPPDVPDHAAYHPF (669-687 Q14624 Inter-alpha- 0.68±0.18 
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trypsin inhibitor heavy 
chain H4 
757.71 19.96 SRQLGLPGPPDVPDHAAYHPF (667-687) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
0.27±0.09 
681.85 22.07 PGVLSSRQLGLPGPPDVPDHAAYHPF (662-687) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
0.18±0.03 
576.90 20.69 PGVLSSRQLGLPGPPDVPDHAAYHPFR (662-688) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
379.71 0.55 LAEGGGVR  (28-35) 
P02671 Fibrinogen 
alpha chain 
25±3.11 
453.24 3.65 FLAEGGGVR  (27-35) 
P02671 Fibrinogen 
alpha chain 
2.48±0.57 
510.76 11.29 DFLAEGGGVR (26-35) 
P02671 Fibrinogen 
alpha chain 
1.33±0.76 
539.27 11.70 GDFLAEGGGVR  (25-35) 
P02671 Fibrinogen 
alpha chain 
3.15±1.02 
597.77 15.59 SGEGDFLAEGGGV  (22-34) 
P02671 Fibrinogen 
alpha chain 
0.85±0.23 
603.79 12.57 EGDFLAEGGGVR (24-35) 
P02671 Fibrinogen 
alpha chain 
2.42±0.63 
632.30 13.50 GEGDFLAEGGGVR (23-35) 
P02671 Fibrinogen 
alpha chain 
2.72±0.71 
655.28 16.03 DSGEGDFLAEGGGV (21-34) 
P02671 Fibrinogen 
alpha chain 
1.23±0.36 
675.81 13.67 SGEGDFLAEGGGVR (22-35) 
P02671 Fibrinogen 
alpha chain 
2.32±0.58 
690.80 16.13 ADSGEGDFLAEGGGV (20-34) 
P02671 Fibrinogen 
alpha chain 
3.25±0.82 
733.33 14.04 DSGEGDFLAEGGGVR (21-35) 
P02671 Fibrinogen 
alpha chain 
1.59±0.12 
768.85 14.08 ADSGEGDFLAEGGGVR (20-35) 
P02671 Fibrinogen 
alpha chain 
6.16±1.01 
851.71 13.58 SSSYSKQFTSSTSYNRGDSTFES (576-598) 
P02671 Fibrinogen 
alpha chain 
0.65±0.17 
693.06 13.06 SSSYSKQFTSSTSYNRGDSTFESKS (576-600) 
P02671 Fibrinogen 
alpha chain 
M: not 
detected 
733.83 14.48 SSSYSKQFTSSTSYNRGDSTFESKSY (576-601) 
P02671 Fibrinogen 
alpha chain 
M: not 
detected 
619.75 17.89 QGVNDNEEGFF (31-41) 
P02675 Fibrinogen 
beta chain 
3.25±0.89 
663.26 16.54 QGVNDNEEGFFS  (31-42) 
P02675 Fibrinogen 
beta chain 
1.97±0.41 
696.28 17.64 QGVNDNEEGFFSA (31-43) 
P02675 Fibrinogen 
beta chain 
2.31±0.53 
404.55 18.90 RIHWESASLL 
 (1310-
1319) 
P01024 Complement 
C3 
H: not 
detected 
402.22 14.29 THRIHWESASLLR 
 (1308-
1320) 
P01024 Complement 
C3 
H: not 
detected 
445.25 16.98 SKITHRIHWESASLL 
 (1305-
1319) 
P01024 Complement 
C3 
H: not 
detected 
415.20 7.60 HWESASL 
(1312-
1318) 
P01024 Complement 
C3 
H: not 
detected 
471.74 16.21 HWESASLL 
 (1312-
1319) 
P01024 Complement 
C3 
H: not 
detected 
851.07 22.22 TLEIPGNSDPNMIPDGDFNSYVR 
 (957-
979) 
P0C0L4 Complement 
C4-A 
H: not 
detected 
1054.53 25.86 DDPDAPLQPVTPLQLFEGR 
(1429-
1447) 
P0C0L4 Complement 
C4-A 
H: not 
detected 
489.96 20.26 RHPDYSVVLLLR (169-180) 
P02768 Serum 
Albumin 
0.43±0.17 
417.91 16.67 KFQNALLVRY (426-435) 
P02768 Serum 
Albumin 
H: not 
detected 
547.31 16.25 KVPQVSTPTLVEVSR (438-452) 
P02768 Serum 
Albumin 
H: not 
detected 
868.11 21.57 AVPPNNSNAAEDDLPTVELQGVVPR (14-38) 
P00488 Coagulation 
factor XIII A  
2.40±0.84 
920.14 21.09 RAVPPNNSNAAEDDLPTVELQGVVPR (13-38) 
P00488 Coagulation 
factor XIII A 
23.60±3.61 
837.93 21.39 TAFGGRRAVPPNNSNAAEDDLPTVELQGVVPR (7-38) 
P00488 Coagulation 
factor XIII A 
91.32±7.39 
781.37 17.84 TATSEYQTFFNPR (315-327) P00734 Prothrombin H: not 
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detected 
868.46 25.47 TGIFTDQVLSVLKGEE  (86-101) 
P02655Apolipoprotein 
C-II 
H: not 
detected 
572.95 12.91 DALSSVQESQVAQQAR  (45-60) 
P02656Apolipoprotein 
C-III 
H: not 
detected 
803.76 21.14 AATVGSLAGQPLQERAQAWGERL (210-232) 
P02649Apolipoprotein 
E 
0.02 
 
The identification of poorly present peptides demonstrated that LC-MS/MS proved to 
be a very sensitive and reproducible analysis. A confirmation of  these data was 
provided by another fragmentation technique, MALDI-TOF/TOF. As Fig. 1 shows, the 
fragmentation pattern of the peptide –ADSGEGDFLAEGGGVR- (from alpha 
fibrinogen protein) confirmed the data collected by using LC-MS/MS analysis. Most of 
these peptides are related to different proteolytic activities on proteins involved in 
acute phase or inflammatory events, such as myocarditis itself. Among identified 
peptides, the molecular species, namely, peptide 662-668 from inter-alpha-trypsin 
inhibitor heavy chain H4 and peptide 1305-1319 from complement C3 correspond to 
free bioactive peptides, whose activity might be related again to inflammatory events 
[16, 17]. Qualitative and semi-quantitative differences were detected in the analysis 
of the peptidomas from healthy and pathological samples. In fact, as reported in the 
Table 1, averaged area of each peak of all detected peptides resulted to be different, 
showing that some of them were differently represented in each sample. The above 
mentioned peptides from complement C3 and inter-alpha trypsin inhibitor were poorly 
represented in the healthy serum samples, whereas fibrinogen alpha chain peptides 
were strongly represented in these sera, as well as coagulation factor XIII A peptides. 
 
Fig. 1: Positive ion mode MALDI-TOF/TOF fragmentation spectrum of m/z 1536.44 
corresponding to peptide 20-35 from fibrinogen alpha chain protein from healthy serum. 
2-D gel electrophoresis 
After depletion of the most abundant proteins, the two sera samples were separated 
by two dimensional gel electrophoresis, thus leading to the construction of 2D protein 
maps of healthy and myocarditis samples. Each gel was blue coomassie stained. 
Image analysis was performed on the two sets of 2D maps (from healthy control and 
60 
 
pathologic sera) clearly showing that the protein profile is quite different, as reported 
in figure 2. 
 
Fig. 2: Two-dimensional electrophoresis gels of healthy (A) and myocarditis affected (B) sera 
proteins. Arrows and numbers in (B) correspond to numbers of identified spots in Table 2. 
All the selected spots were taken by the myocarditis sample and they are 
summarized in table 2. 
 
Table 2: List of proteins identified by LC-MS/MS of spots excised from two-dimensional gels 
of sera taken from myocarditis affected patients. 
Spot Accession 
number 
Protein 
1 P02790 Hemopexin 
2 P02790 Hemopexin 
3 P02790 Hemopexin 
4 P02790 Hemopexin 
5 P02790 Hemopexin 
6 P02787 Serotransferrin 
7 P01008 Antithrombin III 
8 P01008 Antithrombin III 
9 P01011 Alpha-1 antichymotrypsin 
10 P01024 Complement C3 
11 P04196 Histidine rich glycoprotein 
12 P01024 Complement C3 
13 P00738 Haptoglobin 
14 P04196 Histidine rich glycoprotein 
15 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 
16 P08603 Complement factor H 
17 P08603 Complement factor H 
18 P03952 Plasma kallikrein 
19 P06727 Apolipoprotein A-IV 
20 P00738 Haptoglobin 
21 P00738 Haptoglobin 
22 P36955 Pigment epithelium-derived factor 
23 P36955 Pigment epithelium-derived factor 
24 P36955 Pigment epithelium-derived factor 
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Protein spots indicated as differentially expressed were excised from the gel, in situ 
digested and then submitted to LC-MS/MS according to the peptide mass 
fingerprinting procedure. MS and MS-MS obtained data were used to search for a 
non redundant sequence using the in-house MASCOT software, taking advantage of 
the specificity of trypsin and of the taxonomic category of the samples. The number 
of measured masses that matched within the given mass accuracy of 20 ppm was 
recorded and the proteins that had the highest number of peptide matches were 
examined. 
This approach allowed the identification of many proteins differently expressed in the 
two sera. Among identified proteins, hemopexin [18] complement C3 [19,20], plasma 
kallikrein [21] are undoubtedly related to inflammatory events and most interestingly 
they resulted clearly over expressed in the pathologic sample. 
A preliminary speculation on identified proteins might be focused on  hemopexin. As 
shown by literature data [18,22,23], hemopexin is a serum protein committed to the 
heme scavenging; heme is released or lost by the turnover of heme proteins such as 
haemoglobin, or by haemolysis caused by parasitic infection. Thus hemopexin might 
have a protection role from the oxidative damage that free heme can cause[23]. 
Myocarditis itself is not related to haemolysis phenomena, but some viral infections 
may cause it, therefore, finding an association between very high level of hempoxin 
and myocarditis affection might open the way to novel putative biomarkers. Moreover 
we found a certain association between these data and the data collected in the 
peptidoma analysis; in particular we could detect among free peptides, some from 
proteins Complement C3, Inter-alpha-trypsin inhibitor heavy chain H4, Antithrombin 
III which results over expressed in pathologic serum 
 
Assessment of N-glycosylation sites 
Aliquots of serum sample from different donors were pooled together in order to 
obtain an average distribution of glycoforms. Intact serum samples without any 
previous depletion were used for the determination of N-glycosylation sites 
occupancy. The two pooled samples were reduced, alkylated, digested with trypsin 
and then subjected to Concanavalin affinity selection, directly performed in batch 
after trypsin digestion. The recovered glycopeptides were then subjected to N-
glycosidase F treatment in order to enhance the identification of N-glycosylation sites 
by using LC-MS/MS and obtaining a glycan profiling by MALDI-MS. The strategy is 
illustrated in Fig. 3. 
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Fig. 3: scheme of the procedure used to obtain an overview of the glycosylation profiling by 
enriching for N-linked glycopeptides to be analyzed by LC-MS/MS, obtaining a glycan 
distribution to be analyzed by MALDI-MS.  
The presence of putative N-glycosylation sites was inferred by the increase of 0.98 
Da in the peptide mass value, due to PNGase F treatment leading to the conversion 
of asparagine residues to aspartic acid. The fine localization of the modified 
asparagines was achived by LC-MS/MS on a a 4000 Q-Trap mass spectrometer 
coupled to a nanoLC system. Fig. 4 shows the daughter ion mass spectrum of a 
peptide retained by ConA affinity resin after deglycosylation. The MS/MS spectrum of 
the precursor ion at m/z 878.96 revealed a clear series of y-ions, which make the 
sequence of the peptide easily interpretable as YLGN*ATAIFFLPDEGK. BLAST 
analysis of this sequence attributed the peptide as the fragment 268-283 of the 
human alpha-1-antitrypsin precursor in which Asn271 shows the consensus 
sequence for glycosylation (Asn-X-Ser/Thr). The effective occurrence of a N-
glycosylation site at Asn-271 was demonstrated by the key y12 fragment ion at m/z 
1308.68 in the MS/MS spectrum. This fragment occurred 0.98 Da lower than 
expected showing the loss of Asp271 instead of Asn thus confirming the conversion 
of the asparagine to aspartic acid following PNGase F stripping. 
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Fig. 4: MS/MS spectrum of the doubly charged precursor ion at m/z 878.96. The fragmentation 
spectrum shows the presence of a N-glycosylation site at Asn-271 
Fig.5 shows the MS/MS spectrum of the triply charged precursor ion at m/z 536.52 
corresponding to the fragment 3405-3419 of Apolipoprotein B. The series of y ions 
from which peptides identification was inferred is clearly visible in the daughter ion 
spectrum. Again, the N-glycosylation site could easily be assigned by the presence of 
the key y8 fragment ion that occurred 1 Da lower than expected (836.40 instead of 
837.47) demonstrating that Asn3411 was glycosylated and then had been converted 
to Asp by PNGase F. 
 
Fig. 5: MS/MS spectrum of the triply charged precursor ion at m/z 536.14. The fragmentation 
spectrum shows the increment of 0.98 Da for Asn3411 conversion into Asp 
64 
 
Similar analyses were carried out on the unbound Con A fractions, mainly containing 
non-glycosylated peptides and highly branched glycopeptides. The unbound fraction 
was also deglycosylated by PNGase F treatment, yielding a mixture of 
deglycosylated and unmodified peptides that was directly analysed by LC-MS/MS. 
Figure 6 shows the daughter ion spectrum of the precursor ion at m/z  628.38 that 
was assigned to the peptide 1004-1014 from the alpha-2-macroglobulin precursor. 
The key y5 ion at m/z 624.48 clearly demonstated the occurrence of an asparagine 
residue at position 1009 that resulted to be unmodified following the deglycosylation 
step. 
Spontaneous deamidation of Asn residues has been reported, but it seems rather 
frequent in peptides containing the sequence Asn-Gly [25], therefore for the 
unambiguous assignment of the N-glycosylation site the presence of the N-X-S/T 
motif is absolutely necessary. 
 
Fig. 6: fragmentation spectrum of a doubly charged precursor ion at m/z 628.38. In this case, 
asparagines residue is unmodified. 
The overall data from the LC-MS/MS analyses of both the ConA bound and unbound 
fractions were summarised in Table 3. The table exhibits a  total of 49 glycoproteins 
containing 68 N-glycosylation sites. Among these sites, 50 had already been 
described and were confirmed while 18 were only annotated as potential 
glycosylation sites due to the presence of the NX(S/T) consensus sequence and 
were then newly identified. 
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Table 3: LC/MSMS analysis for the identification of glycosylation sites by ConA (UH = unbound 
fraction of healthy serum; UL = unbound fraction of myocardial lesions serum; UK = unbound 
fraction of hepatic carcinoma serum; EH =  eluted fraction of healthy serum serum; EL = eluted 
fraction of   myocardial lesions serum;  EK = eluted fraction of  hepatic carcinoma serum) 
 Protein Sequence Peptide  
P01011  Alpha-1-
antichymotrypsin  
YTGN*ASALFILPDQDK
UL 
268-283 Confirmed 
P02763 Alpha-1-acid 
glycoprotein 
SVQEIQATFFYFTPN*KTEDTIFLR
EH 
QDQCIYN*TTYLNVQR
UH,UL 
58-81 
87-101 
Confirmed 
Confirmed 
P01009 Alpha-1-
antitrypsin  
YLGN*ATAIFFLPDEGK
EH,UH,EL,UL 
268-283 Confirmed 
P01023 Alpha-2-
macroglobulin  
SLGNVN*FTVSAEALESQELCGTEVPSVPEHGRK
EH 
864-886 Confirmed 
P43652 Afamin  DIENFN*STQK
EH,EL 
YAEDKFN*ETTEK
EH 
28-37 
396-407 
Confirmed 
Confirmed 
P01008 Antithrombin III  LGACN*DTLQQLMEVFK
EH 
SLTFN*ETYQDISELVYGAK
EH 
124-139 
183-201 
Confirmed 
Confirmed 
P04114 Apolipoprotein B-
100  
FN*SSYLQGTNQITGR
EH,EL 
FVEGSHN*STVSLTTK
EH 
AEEEMLEN*VSLVCPK
EL 
YDFN*SSMLYSTAK
EL 
1522-1536 
3405-3419 
27-41 
3462-3474 
Confirmed 
Potential 
Potential 
Confirmed 
P05090  Apolipoprotein D ADGTVNQIEGEATPVN*LTEPAK
EL 
83-104 Confirmed 
P02749  Apolipoprotein H VYKPSAGN*NSLYR
EH 
LGN*WSAMPSCK
EL 
155-167 
251-261 
Confirmed 
Confirmed 
O75882  Attractin  IDSTGN*VTNELR
EH,EL 
GPVKMPSQAPTGNFYPQPLLN*SSMCLEDSR
EH 
411-422 
1023-1052 
Confirmed 
Confirmed 
P00450 Ceruloplasmin  EHEGAIYPDN*TTDFQR
EH,EL 
EN*LTAPGSDSAVFFEQGTTR
EH,EL 
129-144 
396-414 
Confirmed 
Confirmed 
P08603 Complement 
 factor H 
ISEEN*ETTCYMGK
EH 
MDGASN*VTCINSR
EH,EL 
IPCSQPPQIEHGTIN*SSR
EL 
SPDVIN*GSPISQK
UH 
907-919 
1024-1036 
868-885 
212-224 
Confirmed 
Potential 
Confirmed 
Potential 
P10909 Clusterin  LAN*LTQGEDQYYLR
EH,EL 
372-385 Confirmed 
Q8IWV2  Contactin-4  LN*GTDVDTGMDFR
EL 
64-76 Confirmed 
P05156  Complement 
factor 1 
FLNN*GTCTAEGK
EH,EL 
100-111 Confirmed 
P01024  Complement C3  TVLTPATNHMGN*VTFTIPANR
EH 
74-94 Confirmed 
P0C0L4  Complement C4-
A  
GLN*VTLSSTGR
EH,EL 
1326-1336 Confirmed 
P02748 Complement 
component C9  
AVN*ITSENLIDDVVSLIR
EH 
413-430 Confirmed 
Q14517 Protocadherin-fat 
1 
QVYN*LTVRAKDK
EL 
FSMDYKTGALTVQN*TTQLRSR
EL 
994-1005 
1930-1950 
Potential 
Potential 
P02765  Alpha-2-HS-
glycoprotein 
VCQDCPLLAPLN*DTR
EH 
AALAAFNAQNN*GSNFQLEEISR
EH 
145-159 
166-187 
Confirmed 
Confirmed 
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Q03591  Complement 
factor H related 
protein 1  
LQNNENN*ISCVER
EH 
120-132 Confirmed 
Q13439 Golgin subfamily 
A member 4 
HN*STLKQLMREFNTQLAQK
EH 
1990-2008 Potential 
P02790  Hemopexin  SWPAVGN*CSSALR
EH,EL 
ALPQPQN*VTSLLGCTH
UH,EH,EL 
181-193 
447-462 
Confirmed 
P00738 Haptoglobin VVLHPN*YSQVDIGLIK
UH,UL,EH,EL 
MVSHHN*LTTGATLINEQWLLTTAK
EH,EL 
236-251 
179-202 
Confirmed 
Confirmed 
P04196  Histidine rich 
glycoprotein  
VEN*TTVYYLVLDVQESDCSVLSR
EH 
VIDFN*CTTSSVSSALANTK
EH,EL 
61-83 
121-139 
Confirmed 
Confirmed 
P05155  Plasma protease 
C1 inhibitor 
VGQLQLSHN*LSLVILVPQNLK
EH 
344-364 Confirmed 
P01857  Ig alpha-1 chain 
C region 
LSLHRPALEDLLLGSEAN*LTCTLTGLR
EH 
127-153 Potential 
P01859  Ig gamma-2 
chain C region 
TKPREEQFN*STFR
EH 
TPLTAN*ITK
EH 
168-180 
200-208 
Confirmed 
Potential 
P01860  Ig gamma-1 
chain C region 
EEQYN*STYR
UH,EL 
136-144 Potential 
P01861  Ig gamma-4 
chain C region 
EEQFN*STYR
UH,EH,EL 
173-181 Potential 
P01591  Immunoglobulin J 
chain 
EN*ISDPTSPLR
EH,EL 
48-58 Confirmed 
P40189  Interleukin-6 
receptor beta  
QQYFKQN*CSQHESSPDISHFER
EL 
812-833 Potential 
P56199   Integrin alpha-1  SYFSSLN*LTIR
EL 
1096-1106 Potential 
P29622  Kallistatin  DFYVDEN*TTVR
EH 
232-242 Confirmed 
P01042  Kininogen-1  LNAENN*ATFYFK
UH,EL 
389-400 Potential 
P11279  Lysosome-
associated 
membrane 
glycoprotein 1  
DPAFKAAN*GSLR
EL 
314-325 Confirmed 
P01871  Ig mu chain C 
region 
YKN*NSDISSTR
EH 
GLTFQQN*ASSMCVPDQDTAIR
EL 
44-54 
204-223 
Confirmed 
Confirmed 
Q9HC10  Otoferlin NEMLEIQVFN*YSKVFSNK
UH,UL,EL 
59-76 Potential 
Q5VU65  Nuclear pore 
membrane 
glycoprotein 210-
like 
EVVVN*ASSR
EH 
1551-1559 Potential 
Q9Y5E7  Protocadherin 
beta 2  
ETRSEYN*ITITVTDFGTPR
EL 
414-432 Potential 
P36955  Pigment 
epithelium 
derived factor  
VTQN*LTLIEESLTSEFIHDIDR
EH 
282-303 Confirmed 
P27169  Serum 
paraoxanase/aryl
esterase1 
HAN*WTLTPLK
EH 
250-259 Confirmed 
P49908  Selenoprotein P  EGYSN*ISYIVVNHQGISSR
EH 
79-97 Confirmed 
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Q9Y275  Tumor necrosis 
factor ligand 
superfamily 
member 13B 
CIQNMPETLPN*NSCYSAGIAK
EL 
232-252 Confirmed 
P40225  Thrombopoietin  IHELLN*GTRGLFPGPSRR
EL 
250-267 Confirmed 
P02787  Serotransferrin  QQQHLFGSN*VTDCSGNFCLFR
EH,EL 
622-642 Confirmed 
P07996  Thrombospondin 
1  
VVN*STTGPGEHLR
EH,EL 
1065-1077 Confirmed 
P04004  Vitronectin  NN*ATVHEQVGGPSLTSDLQAQSK
EL 
85-107 Confirmed 
P25311  Zinc-alpha-2-
glycoprotein  
DIVEYYN*DSN*GSHVLQGR
EH,EL 
100-117 Confirmed 
These results demonstrated that ConA affinity chromatography on serum tryptic 
digests was effective in capturing most of the glycopeptides bearing biantennary and 
high mannose glycan structures, which are the epitope specifically recognized by this 
lectin. A further advantage of the strategy relies on performing the lectin affinity 
chromatography on glycopeptides instead of glycoproteins, avoiding fractionation of 
the extract by chromatograophic and/or electrophoretic methods. Moreover, this 
selection allowed both the identification of the individual glycoprotein and the direct 
assessment of the N-glycosylation site during the same analysis. Finally, the affinity 
procedure was instrumental for the detection of the less abundant glycopeptides 
together with the most abundant ones, such as those deriving from albumins or 
immunoglobulins. 
Results obtained by LC-MS/MS analyses revealed a quite similar profile for 
myocarditis and control samples, in the same that most of the proteins were identified 
in both the samples. However some individual glycopeptides were only found in one 
sample; in a few cases the same glycopeptide was recovered in the ConA bound 
fraction in one sample and in the unbound fraction in the other. This suggests that 
small differences can be appreciated in the glycosylation profile of glycoproteins from 
healthy or pathological sera with these differences very likely confined to the 
branching structures of the glycan moieties. 
To reduce the complexity of the whole sample, in alternative to ConA affinity 
chromatography Boronate affinity purification can be rapidly performed in batch after 
tryptic digestion. The principle of purification is based on the vicinal diols binding 
capacity, so that no discrimination on the basis of the glycan type was performed 
thus, theoretically, all glycopeptides could be selected. The recovered glycopeptides 
were then deglycosylated by PNGase F treatment and the peptide mixtures directly 
analysed by LC-MS/MS. 
Even in this case as for ConA the analyses were performed on intact serum samples 
without any pre-purification step or removal of most abundant proteins. The peptide 
component of the eluted fraction was analysed by tandem mass spectrometry. 
Similar analyses were carried out on the unbound Boronate fractions, mainly 
containing non-glycosylated peptides. 
As a whole, using Boronate affinity approach we could confirm most of the previously 
identified glycosylation sites based on ConcanavalinA enrichment and 5 more 
glycosylation sites were identified thus refining previous data on myocarditis 
glycoproteome. 
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Table 4: LC/MSMS analysis for the identification of glycosylation sites by boronate affinity 
chromatography (UH = unbound fraction of healthy serum; UL = unbound fraction of 
myocardial lesions serum; UK = unbound fraction of hepatic carcinoma serum; EH =  eluted 
fraction of healthy serum serum; EL = eluted fraction of   myocardial lesions serum;  EK = 
eluted fraction of  hepatic carcinoma serum) 
 Protein Sequence Peptide 
P01011  Alpha-1-antichymotrypsin  YTGN*ASALFILPDQDK
H,M 
268-283 
P02763 Alpha-1-acid glycoprotein SVQEIQATFFYFTPN*KTEDTIFLR
H,M 
QDQCIYN*TTYLNVQR
H,M 
58-81 
87-101 
P01009 Alpha-1-antitrypsin  YLGN*ATAIFFLPDEGK
H,M 
QLAHQSN*STNIFFSPVSIATAFAMLSLGTK
H
 
ADTHDEILEGLNFN*LTEIPEAQIHEGFQELLR
H,M
 
268-283 
64-93 
94-125 
P01023 Alpha-2-macroglobulin  SLGNVN*FTVSAEALESQELCGTEVPSVPEHGRK
H 
864-886 
P43652 Afamin  DIENFN*STQK
H,M 
YAEDKFN*ETTEK
H 
28-37 
396-407 
P01008 Antithrombin III  LGACN*DTLQQLMEVFK
H,M 
SLTFN*ETYQDISELVYGAK
H,M 
124-139 
183-201 
P04114 Apolipoprotein B-100  FN*SSYLQGTNQITGR
H,M 
FVEGSHN*STVSLTTK
H 
AEEEMLEN*VSLVCPK
M 
YDFN*SSMLYSTAK
M 
1522-1536 
3405-3419 
27-41 
3462-3474 
P05090  Apolipoprotein D ADGTVNQIEGEATPVN*LTEPAK
M 
83-104 
P02749  Apolipoprotein H VYKPSAGN*NSLYR
H 
LGN*WSAMPSCK
M 
155-167 
251-261 
O75882  Attractin  IDSTGN*VTNELR
H,M 
GPVKMPSQAPTGNFYPQPLLN*SSMCLEDSR
H 
411-422 
1023-1052 
P00450 Ceruloplasmin  EHEGAIYPDN*TTDFQR
H,M 
EN*LTAPGSDSAVFFEQGTTR
H,M 
129-144 
396-414 
P08603 Complement 
 factor H 
ISEEN*ETTCYMGK
H 
MDGASN*VTCINSR
H,M 
IPCSQPPQIEHGTIN*SSR
M 
SPDVIN*GSPISQK
H 
907-919 
1024-1036 
868-885 
212-224 
P10909 Clusterin  LAN*LTQGEDQYYLR
H,M 
372-385 
Q8IWV2  Contactin-4  LN*GTDVDTGMDFR
M 
64-76 
P05156  Complement factor 1 FLNN*GTCTAEGK
H,M 
100-111 
P01024  Complement C3  TVLTPATNHMGN*VTFTIPANR
H 
74-94 
P0C0L4  Complement C4-A  GLN*VTLSSTGR
H,M 
1326-1336 
P02748 Complement component C9  AVN*ITSENLIDDVVSLIR
H,M 
413-430 
Q14517 Protocadherin-fat 1 QVYN*LTVRAKDK
M 
FSMDYKTGALTVQN*TTQLRSR
M 
994-1005 
1930-1950 
P02765  Alpha-2-HS-glycoprotein VCQDCPLLAPLN*DTR
H,M 
AALAAFNAQNN*GSNFQLEEISR
H 
145-159 
166-187 
Q03591  Complement factor H related protein 1  LQNNENN*ISCVER
H 
120-132 
Q13439 Golgin subfamily A member 4 HN*STLKQLMREFNTQLAQK
H 
1990-2008 
P02790  Hemopexin  SWPAVGN*CSSALR
H,M 
ALPQPQN*VTSLLGCTH
H,M 
181-193 
447-462 
P00738 Haptoglobin VVLHPN*YSQVDIGLIK
H,M 
MVSHHN*LTTGATLINEQWLLTTAK
H,M 
NLFLN*HSEN*ATAK
H,M
 
236-251 
179-202 
203-215 
P04196  Histidine rich glycoprotein  VEN*TTVYYLVLDVQESDCSVLSR
H 
VIDFN*CTTSSVSSALANTK
H,M 
61-83 
121-139 
P05155  Plasma protease C1 inhibitor VGQLQLSHN*LSLVILVPQNLK
H,M 
344-364 
P01857  Ig alpha-1 chain C region LSLHRPALEDLLLGSEAN*LTCTLTGLR
H 
127-153 
P01859  Ig gamma-2 chain C region TKPREEQFN*STFR
H 
TPLTAN*ITK
H 
168-180 
200-208 
P01860  Ig gamma-1 chain C region EEQYN*STYR
H,M 
136-144 
P01591  Immunoglobulin J chain EN*ISDPTSPLR
H,M 
48-58 
P40189  Interleukin-6 receptor beta  QQYFKQN*CSQHESSPDISHFER
M 
812-833 
P56199   Integrin alpha-1  SYFSSLN*LTIR
M 
1096-1106 
P29622  Kallistatin  DFYVDEN*TTVR
H 
232-242 
P01042  Kininogen-1  LNAENN*ATFYFK
H,M 
389-400 
P11279  Lysosome-associated membrane 
glycoprotein 1  
DPAFKAAN*GSLR
M 
314-325 
P01871  Ig mu chain C region YKN*NSDISSTR
H 
GLTFQQN*ASSMCVPDQDTAIR
M 
44-54 
204-223 
Q9HC10  Otoferlin NEMLEIQVFN*YSKVFSNK
H,M 
59-76 
Q5VU65  Nuclear pore membrane glycoprotein 210-
like 
EVVVN*ASSR
H 
1551-1559 
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Q9Y5E7  Protocadherin beta 2  ETRSEYN*ITITVTDFGTPR
M 
414-432 
P36955  Pigment epithelium derived factor  VTQN*LTLIEESLTSEFIHDIDR
H 
282-303 
P27169  Serum paraoxanase/arylesterase1 HAN*WTLTPLK
H 
250-259 
P49908  Selenoprotein P  EGYSN*ISYIVVNHQGISSR
H 
79-97 
Q9Y275  Tumor necrosis factor ligand superfamily 
member 13B 
CIQNMPETLPN*NSCYSAGIAK
M 
232-252 
P40225  Thrombopoietin  IHELLN*GTRGLFPGPSRR
M 
250-267 
P02787  Serotransferrin  QQQHLFGSN*VTDCSGNFCLFR
H,M 
CGLVPVLAENYN*KSDNCEDTPEAGYFAVAVVK
M 
622-642 
421-452 
P07996  Thrombospondin 1  VVN*STTGPGEHLR
H,M 
1065-1077 
P04004  Vitronectin  NN*ATVHEQVGGPSLTSDLQAQSK
M 
85-107 
P25311  Zinc-alpha-2-glycoprotein  DIVEYYN*DSN*GSHVLQGR
H,M 
100-117 
P02766 Transthyretin ALGISPFHEHAEVVFTAN*DSGPR
H 
101-123 
 
Glycan profiling 
The glycan profiling of the two sera samples was performed in a further attempt to 
investigate differences in N-glycosylation possibly occurring between myocarditis and 
healthy donors sera. Several papers have demonstrated an association between N-
glycosylation changes in the serum glycome and  cancer, with changes concerning 
the levels of highly branched glycan structures, sialyl Lewis X epitopes and 
agalactosylated bi-antennary glycans. Moreover, several of these glycans have been 
linked to chronic inflammatory diseases, thus leading to the hypothesis of possible 
connections between inflammation and cancer [26]. 
Samples were subjected to the ConA affinity selection step, desalted by HPLC to 
remove salts and methyl-α-D-mannopyranoside, then the entire set of 
oligosaccharides was released from glycopeptides occurring in both the Con A bound 
and unbound fractions by incubation with PNGase F to isolate high mannose, hybrid 
and biantennary structures as well as higher branched glycans. 
Oligosaccharides released from enzymatic hydrolysis were desalted by in batch ion 
exchange chromatography on a Dowex mixed bed resin and directly analyzed by 
MALDI-MS on a reflectron instrument, both in positive and negative mode. Since 
significant desialylation might occur during analysis of the samples, MALDI mass 
spectra were also performed using THAP as matrix that was reported to avoid most 
of the problems associated with loss of sialic acids by fragmentation [27]. 
Each peak detected in the MALDI spectra was tentatively attributed to a glycan 
structure based on the knowledge of N-glycan biosynthetic pathway and literature 
data. Manual interpretation was confirmed by using Expasy Glycomod software, 
available on line for the prediction of possible oligosaccaridic structures from mass 
values. Selected mass signals were also fragmented by MALDI PSD experiments to 
confirm glycan structures and to discriminate between isobaric components. As a 
whole, these MALDI analyses constituted a real oligosaccharide profiling of the 
samples allowing us to describe the microheterogeneity of glycosylation within the 
different serum samples in details and to identify specific changes in glycan 
structures occurring in the pathological sera. 
Fig.7 shows the positive MALDI spectra of glycans deriving from the healthy (A) and 
myocarditis (B) glycopeptides retained on the ConA affinity step and incubated with 
PNGase F. The oligosaccharides composition and structures corresponding to the 
recorded mass signals are summarised in Table 5. More than fifty structures were 
detected in the MALDI profiling, essentially belonging to high mannose and 
biantennary type, thus indicating a high degree of glycan heterogeneity. These data 
indicated that the two ConA bound fractions essentially consisted of peptides 
carrying biantennary and hybrid as well as high mannose structures. This finding is in 
perfect agreement with the reported affinity of ConA that generally binds complex 
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biantennary, hybrid type and high- mannose-type N-linked glycans. The MALDI 
profiling revealed the occurrence of only three triantennary structures, at m/z 2028.7, 
2174.8 and 2320.8 respectively that were attributed to HexNAc5Hex6, 
FucHexNAc5Hex6 and HexNAc5Hex6Sia glycans. PSD analysis performed on the 
precursor ion at m/z 2174.8 localised the fucose residue on the 3-antenna. In the 
fucosylated triantennary structure the position of the fucose residue plays a very 
important biological role. As an example, alpha-1-acid glycoprotein, one of the 
identified glycoproteins in this study, is an non specific marker, whose temporary 
increase in the serum level is generally associated with many acute phases 
syndromes (infections, inflammation, cancer)[28]. Previous data reported that the 
fucose residue on the triantennary glycans in alpha-1-acid glycoprotein was generally 
found on the 3-antenna and not on the terminal core GlcNAc [29.30]. 
 
 
 
 
 
  
  
A 
B 
Fig. 7: Positive ion mode spectra of glycans deriving from ConA bound fractions 
of healthy (panel A) and myocariditis sera samples (panel B) 
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Table 5: Glycans detected by MALDI MS analysis of the glycans from ConA eluates of the 
different sera samples (H = healthy serum; L = myocardial lesions; K = hepatic carcinoma) 
 
 
MALDI (m/z [M+Na]
+
) 
 
 
 
 
Monosaccharides 
composition 
 
 
 
 
 
Structure 
 
 
 
 
 
PSD 
  
Calculated 
 
 
Found 
1 1257.4 
 
1257.4 
H 
1257.3 
L
 
HexNAc2Hex5 High mannose 
 
X 
2 1298.5 
 
1298.4 
H
 
1298.3
 L
 
HexNAc3Hex4 Complex, 
monoantennary 
 
X 
3 1419.5 
 
1419.5 
H
 
1419.3 
L
 
HexNAc2Hex6 High mannose 
 
X 
4 1444.5 1444.5 
H
 
1444.4
 L
 
FucHexNAc3Hex4 Complex, fucosylated 
 
X 
5 1460.5 
 
1460.4 
H
 
1460.4
 L
 
HexNAc3Hex5 Hybrid  
 
 
6 1485.5 1485.4 
H
 
1485.4
 L
 
FucHexNAc4Hex3 Complex, biantennary, 
fucosylated  
X 
7 1501.5 1501.5 
H
 
1501.3
 L
 
HexNAc4Hex4 Complex, biantennary 
 
X 
8 1542.6 1542.4 
H
 
1542.4
 L
 
HexNAc5Hex3 Complex, bisecting 
 
X 
9 1581.5 1581.5 
H
 
1581.4
 L
 
HexNAc2Hex7 High mannose 
 
 
10 1611.5 1611.4 
H
 HexNAc3Hex4SiaNa Complex, 
monoantennary, 
sialylated  
 
11 1622.5 1622.5 
H
 
1622.4
 L
 
HexNAc3Hex6 Hybrid  
 
 
12 1647.6 1647.5 
H
 
1647.3
 L
 
FucHexNAc4Hex4 Complex, biantennary, 
fucosylated  
X 
13 1663.6 1663.5 
H
 
1663.3
 L
 
HexNAc4Hex5 Complex, biantennary 
 
X 
14 1685.6 1685.8 
H
 
1685.4
 L
 
HexNAc4Hex5Na 
 
Complex, biantennary 
 
Calculated  
15 1688.6 1688.5 
H
 
1688.3
 L
 
FucHexNAc5Hex3 Complex, fucosylated, 
bisecting 
 
X 
16 1704.6 1705.5 
H
 HexNAc5Hex4 Complex, bisecting 
 
 
17 1743.6 1743.4 
H
 HexNAc2Hex8 High mannose 
 
 
18 1809.6 1809.5 
H
 
1809.3
 L
 
FucHexNAc4Hex5 Complex, biantennary, 
fucosylated 
 
 
X 
19 1814.6 
 
1815.4 
H
 
1816.3
 L
 
HexNAc4Hex4SiaNa Complex, biantennary, 
sialylated 
Calculated  
20 1825.6 1825.5 
H
 
1825.3
 L
 
HexNAc4Hex6 Hybrid Calculated  
21 1832.6 1831.3
 L
 FucHexNAc4Hex5Na Complex, fucosylated, 
biantennary 
Calculated  
22 1850.7 1850.5 
H
 
1850.3
 L
 
FucHexNAc5Hex4 Complex, fucosylated, 
bisecting  
 
23 1866.7 1866.5 
H
 
1866.4
 L
 
HexNAc5Hex5 Complex, bisecting 
 
 
24 1881.6 1880.8 
H
 
1880.5
 L
 
Fuc2HexNAc3Hex4Sia Complex, difucosylated, 
sialylated, 
monoantennary 
Calculated  
25 1905.6 1906.5 
H
 
1905.4
 L
 
HexNAc2Hex9 High mannose 
 
 
26 1910.7 1910.5 
H
 
1910.3
 L
 
HexNAc5Hex5Na2 
 
Complex, 
triantennary/bisecting 
Complex, biantennary, 
fucosylated, sulfated 
Calculated  
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27 1935.6 1936.5 
H
 
1936.3
 L
 
HexNAc3Hex6SiaNa Hybrid, sialylated 
 
 
28 1955.7 1954.5 
H
 
1954.3
 L
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
Complex, biantennary, 
sialylated 
Complex, biantennary, 
difucosylated 
 
X 
29 1960.7 1958.5 
H
 
1957.3
 L
 
FucHexNAc4Hex4SiaNa Complex, fucosylated, 
sialylated, biantennary 
Calculated  
30 1971.7 1970.3
 L
 FucHexNAc4Hex6 Hybrid, fucosylated Calculated  
31 1976.7 1975.4 
H
 
1976.3
 L
 
HexNAc4Hex5SiaNa Complex, biantennary, 
sialylated 
 
 
32 1995.7 
 
1996.7 
1996.5 
H
 
 
1997.2
 L
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Sialylated, 
triantennary/bisecting 
Difucosylated , 
triantennary/bisecting 
Calculated  
33 2012.7 2012.5 
H
 
2012.3
 L
 
FucHexNAc5Hex5 Complex, fucosylated, 
bisecting 
 
 
34 2028.7 2029.5 
H
 
2029.3
 L
 
HexNAc5Hex6 Complex, triantennary 
 
 
35 2100.7 2100.5 
H
 
2101.4
 L
 
FucHexNAc4Hex5Sia Complex, fucosylated, 
sialylated, biantennary  
 
X 
36 2123.7 2122.5 
H
 
2122.3
 L
 
FucHexNAc4Hex5SiaNa Complex, fucosylated, 
sialylated, biantennary 
Calculated  
37 2 144.7 2145.4 
H
 
2144.2
 L
 
FucHexNAc4Hex5SiaNa2 Complex, fucosylated, 
sialylated, biantennary 
 
X 
38 2157.1 2158.3
 L
 HexNAc5Hex5Sia Complex, sialylated, 
triantennary/bisecting 
Calculated   
39 2166.7 2166.3 
H
 FucHexNAc4Hex5SiaNa3 Complex, fucosylated, 
sialylated, biantennary 
 
X 
40 2174.8 2175.5 
H
 
2175.2
 L
 
FucHexNAc5Hex6 Complex, fucosylated, 
triantennary 
 
 
41 2197.7 2193.6 
H
 
2194.5
 L
 
FucHexNAc5Hex6Na Complex, fucosylated, 
triantennary 
Calculated  
42 2245.8 2246.5 
H
 
2245.3
 L
 
HexNAc4Hex5Sia2 Complex, disialylated, 
biantennary 
 
X 
43 2262.8 2262.2
 L
 FucHexNAc4Hex6Sia Hybrid, sialylated, 
fucosylated 
Calculated  
44 2268.8 2267.5 
H
 
2267.4
 L
 
HexNAc4Hex5Sia2Na Complex, disialylated, 
biantennary 
 
X 
45 2284.8 2283.4 
H
 
2283.2
 L
 
FucHexNAc4Hex6SiaNa Hybrid, fucosylated, 
sialylated 
 
X 
46 2290.8 2289.5 
H
 
2289.3
 L
 
HexNAc4Hex5Sia2Na2 Complex, disialylated, 
biantennary 
 
 
47 2306.8 2305.4 
H
 FucHexNAc4Hex6SiaNa2 Hybrid, fucosylated, 
sialylated 
Calculated  
48 2325.8 2326.5 
H
 FucHexNAc5Hex5SiaNa Complex, fucosylated, 
sialylated, 
triantennary/bisecting 
Calculated  
49 2434.8 2435.5 
H
 FucHexNAc4Hex5Sia2Na2 Complex, fucosylated, 
disialylated, biantennary 
Calculated  
50 2627.9 2625.4 
H
 
2625.5
 L
 
FucHexNAc5Hex7Sia Hybrid, sialylated Calculated  
54 2649.8 2647.0
 L
 FucHexNAc5Hex7SiaNa Hybrid, fucosylated, 
sialylated 
Calculated  
 
Negative MALDI spectra performed on the same ConA bound fractions essentially 
confirmed the above reported data showing the presence of few sialylated variants, 
corresponding to biantennary glycans. 
Higher branched glycopeptides were not retained onto the lectin originating the 
unbound fraction of the affinity purification. Thus, ConA affinity chromatography led to 
the relative concentration of tri- and tetraantennary oligosaccharides in this fraction. 
Without this step, these usually less abundant glycans could have been escaped 
detection. PNGase F was directly added to the unbound fraction, glycans were 
73 
 
separated from peptides by HPLC and directly analysed by MALDI-MS following the 
procedures described above. 
Figure 8 shows the positive MALDI-MS analyses of glycans deriving from the 
unbound fractions of the healthy (A) and pathological (B) serum samples. Mass 
signals were tentatively assigned as described before and, when necessary, 
confirmed by PSD fragmentation experiments. Negative MALDI analyses were also 
performed on the same ConA unbound fractions to highlight the presence of 
sialylated structures(data not shonw). All the data are summarised in Tables 6. 
 
 
Fig. 8: Positive ion mode spectra of glycans deriving from ConA unbound fractions of healthy 
(panel A) and myocariditis sera samples (panel B) 
 
Table 6: Glycans detected by MALDI MS analysis of the glycans from ConA unbound fractions 
of the different sera samples (H = healthy serum; L = myocardial lesions; K = hepatic 
carcinoma) 
 
MALDI (m/z [M+Na]
+
) 
 
 
 
Monosaccharides 
composition 
 
 
Structure 
 
 
 
 
 
PSD 
  
Calculated 
 
Found 
 
1 1282.4 1282.1 
H
 FucHexNAc3Hex3 Complex, fucosylated, 
monoantennary   
 
2 1298.5 1298.1
 H 
 
HexNAc3Hex4 Complex, monoantennary 
 
X 
A 
B 
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3 1339.5 1339.1
H 
HexNAc4Hex3 Complex, biantennary 
 
 
4 1485.5 1485.1
 H 
1485.0 
L 
FucHexNAc4Hex3 Complex, fucosylated, 
biantennary  
X 
5 1501.5 1501.0
 H 
1500.9
 L 
HexNAc4Hex4 Complex, biantennary 
 
X 
6 1542.6 1542.0
 H 
HexNAc5Hex3 Complex, bisecting 
 
 
X 
7 1647.6 1647.0
 H 
1646.9
 L 
FucHexNAc4Hex4 Complex, fucosylated, 
biantennary  
X 
8 1663.6 1663.0
 H 
1662.9
 L 
HexNAc4Hex5 Complex, biantennary 
 
X 
9 1685.6 1684.6
 H 
1685.1 
L 
HexNAc4Hex5Na 
 
 
Complex, biantennary 
 
 
Calculated  
10 1688.6 1688.0 
H 
FucHexNAc5Hex3 Complex, fucosylated, 
bisecting 
 
 
11 1704.6 1705.0 
H 
1703.9
 L 
HexNAc5Hex4 Complex, bisecting 
 
 
12 1809.6 1809.0
 H 
1809.9
 L 
FucHexNAc4Hex5 Complex, biantennary, 
fucosylated 
 
X 
13 1831.6 1830.1 
H 
1830.8 
L 
FucHexNAc4Hex5Na Complex, fucosylated, 
biantennary 
 
X 
14 1850.7 1850.0
 H 
1849.9
 L 
FucHexNAc5Hex4 Complex, fucosylated, 
bisecting  
 
15 1866.7 1867.2
 H 
1865.8 
L 
HexNAc5Hex5 Complex, bisecting 
 
 
16 
 
1889.7 1889.2 
H 
1886.4 
L 
HexNAc5Hex5Na 
 
Complex, 
triantennary/bisecting 
Calculated  
17 1913.7 1912.0 
H 
1911.8 
L 
HexNAc3Hex6Sia Hybrid, sialylated 
 
X 
18 1955.7 1954.0
 H 
 
1953.8 
L 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
Complex, sialylated, 
biantennary 
Complex, biantennary, 
difucosylated 
 
X 
19 1977.7 1975.9
 H
 
1975.8 
L 
HexNAc4Hex5SiaNa Complex, sialylated, 
biantennary 
 
X 
20 1995.7 
 
1996.7 
1996.0
 H
 
 
1996.8
 L 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Complex, sialylated, 
triantennary/bisecting 
Complex, difucosylated, 
triantennary/bisecting 
Calculated  
21 2012.7 2011.9
 H
 
2011.8
 L 
FucHexNAc5Hex5 Complex, fucosylated, 
bisecting 
 
 
22 2028.7 2028.0
 H
 
2028.7
 L 
HexNAc5Hex6 Complex, triantennary 
 
X 
23 2050.7 2049.9
 H
 
2047.8
 L 
HexNAc5Hex6Na Complex, triantennary Calculated  
24 2081.6 2081.3
 H
 
2081.7
 L 
FucHexNAc3Hex6Sia Hybrid, fucosylated, 
sialylated 
Calculated  
25 2123.7 2121.9
 H 
FucHexNAc4Hex5SiaNa Complex, fucosylated, 
sialylated, biantennary 
 
X 
26 2174.8 2174.7
 L 
FucHexNAc5Hex6 Complex, fucosylated, 
triantennary 
 
 
27 2179.8 2179.6 
L 
HexNAc5Hex5SiaNa Complex, sialylated, 
triantennary/bisecting 
Calculated  
28 2245.8 2244.9
 H 
HexNAc4Hex5Sia2 Complex, disialylated, 
biantennary 
 
X 
29 2267.8 2266.9
 H
 
2267.5
 L 
HexNAc4Hex5Sia2Na Complex, disialylated, 
biantennary 
 
X 
30 2284.8 2282.8
 H
 
2283.7
 L 
FucHexNAc4Hex6SiaNa Hybrid, fucosylated, 
sialylated 
Calculated  
31 2290.8 2288.9
 H 
HexNAc4Hex5Sia2Na2 Complex, disialylated, 
biantennary 
 
 
32 2320.8 2318.8
 H
 
 
2319.7
 L 
HexNAc5Hex6Sia 
 
Fuc2HexNAc5Hex6 
Complex, sialylated, 
triantennary 
Complex, difucosylated, 
triantennary 
  
X 
33 2325.8 2324.9
 H 
FucHexNAc5Hex5SiaNa Complex, fucosylated, Calculated  
75 
 
2324.7
 L 
sialylated, 
triantennary/bisecting 
34 2342.8 2341.8
 H 
2340.7
 L 
HexNAc5Hex6SiaNa Complex, sialylated, 
triantennary 
Calculated  
35 2360.9 2359.9
 H 
2359.8
 L
 
HexNAc6Hex5Sia Complex, sialylated, 
tetraantennary 
Calculated  
36 
 
2393.7 2392.9
 H 
2392.6
 L 
HexNAc6Hex7 
 
Complex, tetraantennary 
 
  
 
X 
37 2413.8 2412.3
 L 
FucHexNAc4Hex5Sia2Na Complex, fucosylated, 
disialylated, biantennary 
Calculated  
38 2466.8 2465.6
 L 
FucHexNAc5Hex6Sia Complex, fucosylated, 
sialylated, triantennary 
Calculated  
39 
 
2488.8 2487.7
 L 
FucHexNAc5Hex6SiaNa Complex, fucosylated, 
sialylated, triantennary 
Calculated  
40 2539.9 2539.4
 L
 FucHexNAc6Hex7 Complex, fucosylated, 
tetraantennary  
 
41 2611.9 
 
2610.7
 H
 HexNAc5Hex6Sia2 Complex, disialylated, 
triantennary 
Calculated  
42 2633.9 
 
2632.8
 H 
2632.6
 L 
HexNAc5Hex6Sia2Na Complex, disialylated, 
triantennary 
Calculated  
43 2651.9 
 
2649.7
 H 
2648.6
 L 
HexNAc6Hex5Sia2 Complex, disialylated, 
tetraantennary 
Calculated  
44 2654.9 2653.8
 H 
HexNAc5Hex6Sia2Na2 Complex, disialylated, 
triantennary 
Calculated  
 
Compared to the glycans of the bound fraction, 
these oligosaccharides showed the presence of 
higher branched, sialylated and fucosylated 
structures. Table 6 shows the presence of 
essentially sialylated triantennary glycans with 
the occurrence of some fucosylated and 
sialylated tetraantennary structures and few 
biantennary oligosaccharides. When peaks 
could not be unambiguously interpreted, the 
ultimate definition of the correct glycan structure 
was achieved by tandem mass spectrometry 
exsperiments using the MALDI PSD technique. 
As an example, the signal at m/z 2392.8 in the 
MALDI spectrum was tentatively assigned to two 
different isobaric structures. Following PSD 
fragmentation, the correct biantennary sialylated 
and fucosylated glycoform could be inferred.  
As shown in Tables 5 and 6, the 
microheterogeneity of glycans detected in the 
healthy sera resulted to be in general very 
similar to the glycan profiling observed for the 
myocardial lesions serum. However, a number 
of differences could be detected in the high 
mass region of the spectra and particularly in the 
unbound fraction of the myocarditis sample with 
respect to the healthy glycans. Myocardial 
glycan profiling showed the occurrence of 
peculiar structures, the persistence of 
incomplete and truncated structures, the 
accumulation of precursors and the appearance 
of novel structures, thus leading to a higher 
degree of heterogeneity, with respect to the 
Fig. 9: PSD analysis of the non 
sialylated (panel A), monosialylated 
(panel B) and disialylated biantennary 
structure (panel C). 
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healthy one. In particular, the myocardial lesions serum revealed the presence of 
hyper-fucosylated oligosaccharides. It has been demonstrated that the N-linked 
glycans attached to proteins generally associated with inflammation, like haptoglobin, 
alpha1-acid glycoprotein and a1-antichymotrypsin, have increased SLex epitopes, 
during chronic inflammation.  
It is clear that this work is by far a non-exhaustive analysis of a system as complex 
as serum. A complete profiling of the glycosylation in the different sera was 
accomplished, but a detailed quantitative evaluation of all the oligosaccharide 
structures detected was not performed. However, preliminary quantitative 
speculations can be made considering the most abundant glycan structures 
observed in the myocarditis sera in comparison with the healthy ones. The analysis 
performed on the ConA eluted glycan fractions showed a quite similar amount of the 
different glycan structures in both the pathological samples. However, the relative 
abundance of the healthy oligosaccharides resulted to be quite 5 times higher. On 
the contrary, the same analysis carried out on the unbound ConA fractions revealed 
a higher level of heterogeneity within the relative abundance of the glycan structures. 
In fact, some species resulted to be expressed at lower level with respect to the 
healthy sample; other structures resulted to be over expressed. More interestingly, 
the myocarditis samples showed the occurrence of structures completely absent in 
the reference sample. MALDI-MS analysis of glycans deriving from the unbound 
fraction allowed the detection of plethora of different glycans, together with those 
identified in the eluted fraction. The glycan profiling of myocarditis samples was 
characterized by abnormal glycosylation patterns, taking into account branching, 
sialylation and fucosylation, presenting an excessive expression of peculiar 
structures, the persistence of incomplete and truncated structures, the accumulation 
of precursors and the appearance of novel structures, thus leading to a higher 
degree of heterogeneity, with respect to the healthy one. In details, the onset of this 
disease seems to be connected with the presence of hyper-fucosylated signals. 
These data are in agreement with previous data. It has been demonstrated, in fact,  
that the N-linked glycans attached to proteins generally linked to inflammation like 
haptoglobin, a1-acid glycoprotein and a1-antichymotrypsin have increased SLex 
epitopes in cancer and again, more generally, during chronic inflammation [31]. 
 
III.4. Conclusions 
In biomedical applications, a comparative approach is usually employed to identify 
proteins that are up and down regulated in a disease specific manner for use as 
diagnostic markers or therapeutic targets.  
This work is not only concentrated on the study of glycosylation but it can be 
considered an overview of the investigation at molecular level of myocarditis by using 
a proteomic approach. Serum proteins and glycoproteins and free peptides occurring 
in human sera from healthy donors were compared to the ones from myocarditis 
patients. The high resolution, the sensitivity and the reproducibility of the used 
techniques led to the identification of some up regulated proteins in the serum from a 
myocarditis affected patient, all these proteins are connected to inflammatory events 
and one in particular (hemopexin) opens the way to new speculations in serum 
proteins as a specific marker for pathologic state. Mass spectrometry techniques 
allowed the detection of some very weakly represented free peptides, whose 
presence might be connected to the pathology itself. This procedure, allowed the 
identification of several N-glycosylation sites, contemporarily allowing the profiling 
and characterization of several oligosaccharides once released from peptides. 
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Finally, this proteomic and glycobiological approach represents a new opportunity for 
therapeutics and early diagnostics, for the screening of proteic biomarkers in 
pathological status. Finding a biomarker molecule that precisely indicates certain kind 
of pathology, is something quite difficult to achieve since it requires a huge 
background in many different fields of clinical investigation. 
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IV. Arabidopsis thaliana glycoproteome characterization by integrated mass 
spectrometry techniques 
 
IV.1. Introduction 
The increasing demand for recombinant proteins, in particular for the pharmaceutical 
industry, has encouraged the search for novel expression systems, to overcome the 
low production capacities of the mammalian ones. Plants can represent a valuable 
alternative to mammalian and microbial expression systems for their scalability and 
low production costs, as well as for their ability to produce perfectly folded 
mammalian proteins [1]. Recently, biotechnological relevant proteins, such as 
monoclonal antibodies, vaccine antigens, blood proteins, cytokines, interleukins, 
growth factors and growth hormones, have benefited from the use of plant-based 
production platforms [2,3,4], essentially based on “molecular farming”. These 
platforms rely on several techniques including whole-plants, suspension cells, hairy 
roots, moss, duckweed, microalgae, etc. Plant cell cultures are prepared from the 
callus, an undifferentiated tissue, forming single cells and small aggregates, able to 
grow in shaker flasks or fermenters [5].  An alternative is constituted by field-grown 
crops, producing high quantities of recombinant proteins for human use, at the 
competitive costs of agricultural production and without the risk of human and animal 
pathogens contamination, leading to safer products [6]. Seed-specific expression is 
becoming an attractive alternative to conventional leaf-based platforms, due to the 
protecting function of seed environment, allowing long time storage at room 
temperature of the protein products accumulated in the small volume of seeds [7]. 
Neverthless, even if plants expression systems can provide very homogeneous 
protein products as regards N-glycosylation, their glycosylation deviates to some 
extent from mammalian one and this can have positive and negative effects on 
recombinant proteins. The positive aspect can lie in the exploitation of plant-specific 
N-glycans as “cis-adjuvants” in vaccine administration, for their ability to stimulate 
antigen uptake via lectin receptors, followed by degradation and antigen presentation 
of dendritic cells to T cells. The negative effects are restricted to a minor 
immunological response, leading to allergic reactions [8]. For these reasons, the set 
up of plant-based expression systems for glycoproteins production and the possibility 
to exploit plant glycans as adjuvant in vaccines forumulations, have focused 
investigators’ attention on the study of glycosylation in plants.  
Plant and mammals glycosylation differ in the synthesis of complex type N-glycans, 
occurring in the Golgi compartment. Plants are characterized by the presence of β-
1,2-xylose and α-1,3-fucose residues on the core structure, but they lack β-1,4-
galactose and sialic acid.  
Several proteomic approaches have been applied in tha analysis of plant cell wall 
proteins, but the deep characterisation of glycoproteome is still poor. Recently, 
Zhang and co-workers proposed a complex and interesting study addressed to the 
implementation of information on plant cell wall glycoproteome by combining different 
biochemical strategies and bioinformatics tools [9]. Here, we report the investigation 
of glycoproteome from total protein extract in Arabidopsis thaliana by using ConA 
affinity purification and LC-MS/MS for protein identification. Oligosaccharides 
analysis was carried out by MALDI-TOF/TOF. 
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IV.2. Materials and methods 
 
Protein extraction from Arabidopsis thaliana  
Leaves of Arabidopsis thaliana Columbia-0 ecotype were collected from young plants 
at three weeks after sowing. Plants were grown in a controlled growth chamber with 
a 16-h-light/8-h-dark photoperiod at 22/18 °C. Tissues were homogenized by grinding 
them with a pestle and mortar in liquid nitrogen. Then, 1 ml of 2X ice cold extraction 
buffer (Na2HPO4 10 mM, KH2PO4 2 mM, NaCl 136.9 mM, KCl 2.7 mM, at pH 7.4) and 
1 mM PhenylMethil-Sulfonil Fluoride were added for each gr of fresh tissue. Two 
centrifugation steps were performed at 4 °C for 20 minutes at 14000 rpm to remove 
the cell debris. 
 
Protein concentration determination 
Arabidopsis thaliana extract concentration was determined by BCA assay. 5 different 
concentrations of BSA were incubated with 980 μL of reagent A and 20 μL of reagent 
B. Such points were used to obtain a linear calibration curve. 
The sample was prepared in the same way and everything was incubated at 37°C for 
30 min. At the end absorbance at 562 nm was measured. 
 
SDS-PAGE and selective staining of glycoproteins 
SDS-PAGE was performed, loading on a 1.5 mm, 12.5 % gel three different amounts 
of total proteins, 20, 50 and 100 µg respectively, together with a negative and a 
positive control. The gel was run at constant 25 mA for 1h and stained by a 
glycoprotein staining kit (Thermo Scientific). Briefly, after electrophoresis, the gel was 
fixed by completely immersing it in 100 ml of 50% methanol for 30 minutes. Then it 
was washed three times in 3% acetic acid and transfered in 25 ml of an Oxidizing 
Solution for 15 minutes. Then it was washed three times in 3% acetic acid for 5 
minutes and after transferred in 25 mL of Glycoprotein staining reagent, under gentle 
agitation for 15 min. 25 mL of Reducing solution were used for 5 min and then the gel 
was washed extensively with 3% of acetic acid and water. 
 
In situ hydrolysis 
Samples were treated as reported in chapter III. 
 
Reduction and alkylation and trypsin digestion.  
Samples were treated as reported in chapter II. 
 
Concanavalin A affinity chromatography.  
Samples were treated as reported in chapter II. 
 
RP-HPLC.  
Samples were treated as reported in chapter II. 
 
Deglycosylation 
Glycopeptides from Arabidopsis thaliana were lyophilized and resuspended in 100 
mM sodium citrate phosphate (Fluka) pH 5 and incubated with 5 U ofPNGase A 
(Roche). 
 
Oligosaccharide purification 
Samples were treated as reported in chapter II. 
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LC-MS/MS 
Samples were treated as reported in chapter II. 
 
MALDI-TOF/TOF analysis of glycans 
Samples were treated as reported in chapter II. Firstly spectra were manually 
interpreted and checked against GlycoWorkbench [10] software and Simglycan 
software [11]. 
 
IV.3. Results and discussion 
The possibility to obtain plant produced biopharmaceuticals is promising as a more 
compliant alternative "factory" to classical systems. However, approaches to 
overcome and solve the associated challenges of this culture system that include a 
non-mammalian glycosylation are emerging in the field of plant cell-based protein 
production [12]. In this study we provided a viable strategy to gain new insights to 
increase the information available on plant glycoproteome. The strategy is basically 
based on three steps: a) a simple enrichment glycoproteins treatment; b) 
identification of protein and localisation of the glycosylation sites by mass spectral 
techniques, c) N-linked glycosylation characterization. Prior to the enrichment, 
Arabidopsis thaliana protein extract was subjected to SDS-PAGE and the resulting 
gel was stained by a specific glycoprotein staining kit. As a valid step for enrichment, 
selecting specific glycoforms and simplifying the initial peptide mixture, concanavalin 
A affinity chromatography was applied to complex matrix from Arabidopsis thaliana 
total cell extract. 
 
SDS-PAGE and glycoproteins staining. 
In order to specifically realize the content in glycosylated proteins of the A. thaliana 
extracts, a gel containing separated proteins was treated with an oxidation reagent 
which exploits the oxidizing properties of periodate directed to the cis-diol sugar 
groups in glycoproteins. The treatment determines the formation of aldehyde groups, 
which react with the staining reagent to form Schiff-base bonds, producing a 
magenta staining corresponding to glycosylated proteins. Different amounts of total 
extract were loaded on the gel, as well as a positive and a negative control. Fig.1 
shows an intense band in the positive control lane, and no staining was detected for 
the negative control. 
 
Fig. 1: SDS-PAGE gel stained with glycoprotein staining kit. The first two lanes contain a 
positive and negative control, A.thaliana extract was loaded in three different concentration 
82 
 
Some more intense bands were detected in the A.thaliana extracts, and some bands 
were excised from the gel as reported in Fig.1 in order to detect potentially 
glycosylated proteins by in situ hydrolysis and LC-MS/MS. Table 1 summarizes all 
the results obtained. Among the entire pool of identified proteins, most of them were 
glycosylated, as reported in Swissprot database. 
 
Table 1: List of glycoproteins identified after in situ digestion and LC-MS/MS analyses 
Potentially glycosylated proteins 
 
Band 1 
Myrosinase 1 P37702 
Fasciclin-like arabinogalactan protein 8 O22126 
Fasciclin-like arabinogalactan protein 10 Q9LZX4 
Endoplasmin homolog Q9STX5 
Beta-galactosidase 6 Q9FFN4 
Probable glycerophosphoryl diester phosphodiesterase 3 Q7Y208 
Fasciclin-like arabinogalactan protein 1 Q9FM65 
Subtilisin-like protease O65351 
Fasciclin-like arabinogalactan protein 7 Q9SJ81 
Endoglucanase 2 Q9FXI9 
Band 2 
Myrosinase 1 P37702 
Protein disulfide isomerase-like 1-1 Q9XI01 
Beta-glucosidase 18 Q9SE50 
Monocopper oxidase-like protein SKU5 Q9SU40 
Reticuline oxidase-like protein Q9SVG4 
Fasciclin-like arabinogalactan protein 8 O22126 
ABC transporter B family member 17 Q9LSJ6 
Protein disulfide isomerase-like 1-2 Q9SRG3 
Fasciclin-like arabinogalactan protein 10 Q9LZX4 
ABC transporter B family member 22 Q9LSJ2 
Probable cellulose synthase A catalytic subunit 9 [UDP-forming] Q9SJ22 
Band 3 
GDSL esterase/lipase ESM1 Q9LJG3 
Peroxidase 34 Q9SMU8 
Peroxidase 33 P24101 
Peroxidase 12 Q96520 
Myrosinase 1 P37702 
Fasciclin-like arabinogalactan protein 9 Q9ZWA8 
Peroxidase 32 Q9LHB9 
Fasciclin-like arabinogalactan protein 13 Q9FFH6 
Peroxidase 22 P24102 
Peroxidase 38 Q9LDA4 
Cysteine proteinase RD21a P43297 
Peroxidase 68 Q9LVL1 
GDSL esterase/lipase At1g54020 Q9C5N8 
Fasciclin-like arabinogalactan protein 2 Q9SU13 
Beta-glucosidase 18 Q9SE50 
Band 4 
Myrosinase 1 P37702 
Vegetative storage protein 1 O49195 
Germin-like protein subfamily 3 member 3 P94072 
Pectinesterase/pectinesterase inhibitor 3 O49006 
Germin-like protein subfamily 3 member 1 P94040 
Auxin-induced in root cultures protein 12 Q94BT2 
Germin-like protein subfamily 2 member 2 Q9FZ27 
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GDSL esterase/lipase ESM1 Q9LJG3 
Peroxidase 34 Q9SMU8 
Vegetative storage protein 2 O82122 
Band 5 
Myrosinase 1 P37702 
Vegetative storage protein 1 O49195 
 
Unfortunately this procedure was not able to pinpoint if a protein, indicated as a 
potentially glycoprotein in databases, is actually glycosylated, and where the 
glycosylation site is located. 
 
Concanavalin A affinity chromatography on Arabidopsis thaliana. 
To answer the above mentioned questions investigations about Arabidopsis thaliana 
glycoproteome were carried out. The philosophy behind the choice to study 
glycoproteome in this specie relies in the lack of information about global plant 
glycoproteins and glycosylation pattern. Moreover, the availability of the entire 
genome sequence, a huge set of natural variants and an ever increasing number of 
molecular tools, made A. thaliana a useful biological system for proteomic approach 
[13]. It should be noted that generally, procedures for PTM characterization are 
developed to investigate yeast and mammalian biology and later adopted to elucidate 
plant systems. In mammalian systems, the study of N-linked glycoproteins or 
glycopeptides is generally accomplished by removing the glycans and the associated 
microheterogeniety. Following this step, the relative abundance of the modified 
peptides increases greatly resulting in an improved peptide identification [14]. 
Although the general pathway of N-glycan biosynthesis and maturation is conserved 
in plants, their structure has been reported to be different in different species. 
However, the plant machinery generally produces glycoproteins with high-Mannose 
N-glycans, as well as complex N-linked oligosaccharides containing b1,2 xylose, a1,3 
fucose and terminal GlcNAc or Lea antennae [15]. The main difference with respect 
mammalian glycoproteins relies in the presence of  α1,3-fucose instead of α1,6-
fucose at GlcNAc proximal to Asn [16]. This substitution makes  α1,3-fucose not 
recognizable by PNGase-F. Thus, we used the enzyme PNGase A for the release of 
the glycan from the protein moiety.  
 After cold acetone precipitation, proteins were subjected to: reduction, 
carbamidomethylation and trypsin hydrolysis. Then the peptides mixture was 
subjected to lectin affinity chromatography (Krusius et al. 1976), by using a specific 
Concanavalin A, a lectin binding glucopyranosidic and mannopyranosidic groups 
(Ogata, 1975). Such step not only facilitate glycopeptides selection in the bound 
fraction, but even in the unbound fraction thus removing the suppression phenomena 
and leading to less abundant species to be observed. Affinity chromatography was 
carried out in order to isolate glycopeptides in a complex mixture and to identify N-
glycosylation sites by LC-MS/MS. ConA bound peptides were then incubated with 
PNGase A, in order to cleave N-glycan chains linked to asparagine from 
glycopeptides. The enzyme catalyzes the cleavage of structures with or without 
alpha-1,3-linked core fucose residues, characteristic of insects and plants. Peptides 
were separated from oligosaccharides by RP-HPLC, using a C-18 as stationary 
phase. Oligosaccharides were characterized by MALDI-MS (see later), whereas 
peptides were analysed by LC-MS/MS. We performed the enrichment on tryptic 
digests so that we identified glycoproteins together with N-glycosylation sites. 
Peptides component of ConA bound and unbound fractions were analysed via LC-
MS/MS demonstrating the efficiency of such chromatography in the identification of 
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glycoproteins. In  fact, all the selected peptides contained the conserved motif N-X-
S/T for the N-glycosylation.  
LC-MS/MS on deglycosylated peptides enabled the identification of several N-
glycosylation sites as shown in Table 1. As expected, ConA bound fraction sub-
glycoproteome was characterized uniquely by peptides containing one or more 
putative N-glycosylation sites. Such presence was supported by the increment of 
0.984 Da on the mass of the peptide, due to the conversion of asparagine into 
aspartic acid as an effect of N-glycosydase treatment. In contrast, LC-MS/MS 
analyses performed on the unbound fraction identified more abudant peptides with 
not glycosylated sites. These results underlined the high sensitivity of concanavalin A 
to bind specific oligosaccharidic structures as high mannos. The superior mass 
accuracy of the Q-TOF 6520 enabled N-glycosylation sites identification with high 
reliability. The main advantage of the strategy relies on the lectin affinity 
chromatography that was performed on glycopeptides instead of glycoproteins, 
without the SDS-PAGE step and the isolation and identification of the individual 
glycoproteins by in situ digestion.  
 
Table 2: List of N-glycosylation sites identified after ConA affinity chromatography, 
deglycosylation and LC-MS/MS analysis. N-glycosylation sites are in bold. 
Protein Peptide Sequence 
Peroxidase 34 
(Q9SMU8) 
40-49 
314-328 
SCPNVTNIVR 
MGNITPTTGTQGQIR 
Myrosinase (P37702) 100-113 DIDVMDELNSTGYR 
Early nodulin-like protein 3 (Q8LC95) 77-97 DAYINCNTTNPAANYSNGDTK 
Peroxidase 12 (Q96520) 246-261 TCPTANSSNTQVNDIR 
Lamin-like protein (Q39131) 96-104 DIVTLNQTK 
Fasciclin-like arabinogalactan protein 8 
(O22126) 
272-284 NNISTLATNGAGK 
LysM domain-containing GPI-anchored 
protein2(O23006) 
66-79 SILGANNLPLNTSR 
GDSL esterase/lipase ESM1 
(Q9LJG3) 
143-152 SNWNDSYIEK 
Monocopper oxidase-like protein SKU5 
(Q9SU40) 
291-298 
424-434 
VVNETIWR 
VATSIINGTYR 
Uncharacterized GPI anchored protein 
At5g19240 (Q84VZ5) 
42-50 ESVNLTNLK 
Fasciclin-like arabinogalactan protein 7 
(Q9SJ81) 
99-107 NPPLSNLTK 
Uncharacterized GPI-anchored protein 
At3g06035 (Q84MC0) 
41-50 TTQNLTILSK 
Wall-associated receptor kinase 3 
(Q9LMN8) 
293-308 DIDECISDTHNCSDPK 
Probable pectate lyase 22 
(Q93Z25) 
63-70 KINESISR 
 
 
However, some non-specific peptides, namely non-glycosylated peptides, were 
detected in the eluted ConA fraction, and identified as belonging to most abundant 
proteins like RuBisCO. As a whole, the LC-MS/MS analysis led to the selective 
identification of 13 glycosylated proteins present in the Arabidopsis thaliana sample. 
2 of them being identified as arising by more than one unique peptide sequence and 
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11 arising from single-peptide matching. No N-glycosylation sites were detected in 
the unbound fraction. 
As for Arabidopsis thaliana, proteins databases only contain the indication of the 
putative N-glycosylation sites. Most of the data on glycosylation in plants come from 
studies using transgenic plants or from the biochemical characterization of few 
proteins [17]. 
Methods for enrichment in glycoproteins and mass spectrometry (MS) techniques 
were applied to the characterization of cell wall glycoproteome of etiolated hypocotyls 
in A. thaliana  by Zhang [9]. Most glycoproteins were found to be putative N-
glycoproteins and N-glycopeptides were predicted from MS data using the 
ProTerNyc bioinformatics software. The results obtained in this paper, complement 
the data available on plant glycoproteome so far. For the first time, in this work, 
several plant glycosylation sites were effectively demonstrated. This methodology, in 
fact, confirmed the genuine glycosylation of those putative sites, giving new insights 
to the structural elucidation of glycoproteome in such plant specie. 
 
Characterization of oligosaccharides 
Considering the growing interest in the exploitation of novel protein expression 
systems and the development of glycoengineering as a new tool for the production of 
recombinant proteins with specific N-glycan profiles, the study of glycosylation in 
plants is arousing a particular interest. 
In this field, MALDI-TOF/TOF mass spectrometry can be considered the best 
technique in terms of speed and sensitivity in the analyses to analyse 
oligosaccharide mixtures and to detect any difference between the analytes. 
In order to obtain a more complete and detailed glycan profiling without any 
discrimination, PNGase A was directly added to the bound and unbound fraction after 
Concanavalin A affinity chromatography. Glycans were separated from peptides by a 
HPLC step and analysed by MALDI-MS and MALDI-MS/MS. Fig.2A-B shows the 
positive ion mode spectrum of the oligosaccharide-bound and unbound fractions of 
the A. thaliana sample. Figure 2A reported the MALDI-TOF spectrum of the bound 
fraction and the attribution of each peak as reported in table 3. High mannose type 
glycans were the main identified structures. 
 
Fig. 2: positive ion mode MALDI-MS of ConA bound(A) and unbound (B) fractions of 
oligosaccharides extracted from A.thaliana glycoproteins 
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Table 3: list of oligosaccharides structures identified by MALDI-MS in ConA bound and 
unbound fractions. 
m/z Composition  ConA fraction 
 
1065.22 
 
XylHexNAc2Hex3 
 
 
 
 
Bound, unbound 
 
1078.86 
 
FucHexNAc2Hex3 
 
 
 
 
Bound, unbound 
 
1095.20 
 
 
HexNac2Hex4 
 
 
 
 
Bound 
 
1211.21 
 
XylFucHexNAc2Hex3 
 
 
 
 
Unbound 
 
1257.56 
 
 
HexNac2Hex5 
 
 
 
 
Bound 
 
1268.32 
 
 
XylHexNAc3Hex3 
 
 
 
 
Unbound 
 
1414.23 
 
FucXylHexNAc3Hex3 
 
 
 
 
Bound, unbound 
 
1419.11 
 
HexNac2Hex6 
 
 
 
 
Bound 
 
1581.11 
 
HexNac2Hex7 
 
 
 
 
Bound 
 
1617.11 
 
FucXylHexNAc4Hex3 
 
 
 
 
Unbound 
 
1742.05 
 
HexNac2Hex8 
 
 
 
 
Bound 
 
1905.01 
 
HexNac2Hex9 
 
 
 
 
Bound 
 
The higher representative structures in the unbound fractions (fig 2B and table3) 
belong to paucimannosidic compunds. These data are in agreement with the 
literature data on the characterisation of N-glycans in plant consisting only of the 
Man3GlcNAc2 core or of a restricted Man2GlcNAc2 core or even shorter modifications 
carrying α-1,3-linked Fuc and β-1,2 Xyl [18]. Moreover, MALDI spectra showed the 
occurrence of peaks that have been interpreted as polymers of xilose and mannose. 
The main differences between the fractions consisted in the presence of high 
mannose structures solely in the ConA eluted fraction. 
Peaks were manually attributed taking in account the byosinthetic pathway on plant 
N-linked glycans and then confirmed by MALDI-MS/MS. Fragmentation spectra were 
interpreted manually with the help of Glycoworkbench software [10] which simulates 
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glycans fragmentation and compares the experimental values for m/z of fragments 
with the theoretical ones. 
In addition to this, one more software was used and tested to support glycans 
structural characterization. This software, Simglycan was developed by 
Premierbiosoft [11] and can be used as a bioinformatic tool in different phases of 
glycomics studies: the most intuitive application of the software is the support in the 
prediction of glycans structures on the base of the MS/MS spectra and the precursor 
m/z, matching them with specific databases. The software generates a list of 
probable glycan structures, scoring them on the base of how they are close to the 
experimental data. It is able to provide other biological information about the 
identified structures with links to numerous databases. Fig.3 depicts the output of the 
prediction of the structure of ion at m/z 1065.27. It is worth noting that the software 
predicted 4 different structures and scores were assigned considering the number of 
glycosidic fragments and cross ring fragments.  
 
 
 
Fig. 3: Simglycan identification for the ion at 1065.27 on the basis of MS/MS spectrum 
 
Another form of output of the software is the creation of an annotated spectrum with 
matched fragment ions. Fig.4A represents the experimental MS/MS spectrum of ion 
at m/z 1065.27 and Fig.4B depicts the spectrum generated by Simglycan, where the 
x-axis contains the m/z values and the y-axis the experimental intensities of each 
peak extrapolated from the original spectrum. Each peak was automatically 
annotated with the correct fragment ion. Fig.5A-B shows the fragmentation spectrum 
of ion at m/z 1257.32. Even in this case an annotated spectrum was generated 
(Fig.5B). 
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Fig. 4: (A) fragmentation spectrum obtained on a MALDI-TOF/TOF spectrometer, corresponding 
to ion at m/z 1065.27. (B) spectrum generated by Simglycan, where the x-axis contains the m/z 
values and the y-axis the experimental intensities of each peak extrapolated from the original 
spectrum. This spectrum was automatically annotated 
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Fig. 5: (A) fragmentation spectrum obtained on a MALDI-TOF/TOF spectrometer, corresponding 
to ion at m/z 1257.32. (B) spectrum generated by Simglycan, where the x-axis contains the m/z 
values and the y-axis the experimental intensities of each peak extrapolated from the original 
spectrum. This spectrum was automatically annotated 
Moreover the software presents the possibility to extract many kinds of report, in 
particular it is possible to visualize graphical representations of ion fragments. 
 
IV.4 Conclusions 
As a whole, this paper report on the isolation and analysis of glycoproteins in 
Arabidopsis thaliana by coupling lectin affinity chromatography with MS/MS 
techniques. Thus revealing that this integration could be considered as a powerful 
strategy to study the glycoproteome in plant systems. However, to the best of our 
knowledge only few works are still present [19] on the analysis of plant glycoproteins. 
The value of this approach is illustrated by the characterization of glycoproteins that 
are expressed in ripe tomato (Solanum lycopersicum) fruit. This strategy allowed the 
isolation of a fraction of A. thaliana glycoproteome with an extremely high proportion 
of proteins that are predicted to be glycosylated, and the identification of new putative 
N-glycosylation sites. The structural characterization of glycan moieties was 
performed by using MALDI-TOF/TOF mass spectrometry. The elucidation of glycan 
structures resulted of interest in the analysis of the plant system for protein 
production. Moreover, the direct localization of N-glycosylation sites and the 
structural characterization of N-linked glycans were reported thus providing better 
insights in glycoproteome investigation useful for plant cell-based protein factories. 
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V. Cell surface glycoconjugates: innate immunity probed by 
lipopolysaccharides affinity strategy and proteomics 
 
V.1. Introduction 
As it is illustrated in chapter I, glycans and glycan-binding proteins (lectins) play a 
crucial role in the host-pathogen interaction as concerning the onset of innate and 
adaptive immune processes. Bacteria synthesize several glycoconjugates, including 
lipopolysaccharides (LPS), peptidoglycan, glycoproteins, capsules, teichoic acids and 
exopolysaccharides by using nucleotide-activated sugars as substrates for different 
glycosyltransferases. LPS and glycoproteins biosynthetic pathways involve 
homologous proteins, often characterized by a wider substrate specificity, that make 
them the ideal candidates to be exploited in engineered living bacteria for industrial 
glycoconjugate production, generating potential vaccines and therapeutics [1]. The 
full exploitation of glycoconjugates potential for industrial biotechnological and 
pharmaceutical applications requires a deep knowledge of the immunological 
mechanisms at the base of host-pathogen recognition. 
In a biological context, the term immunity refers to the set of events and biological 
cascades that protect organisms against infectious diseases. This protection system 
is based on complex interconnections between cells and molecules whose synergic 
action determines the immune response. The main physiological function of immune 
system is the protection against infectious agents or simply against exogenous 
elements. The ability to distinguish “self” from “non-self” is critical to prepare an 
effective immune response [2]. 
Immune system response can be classified into two categories: adaptive immunity 
and innate immunity. The adaptive immune system is based on specialized 
processes whose function is to eliminate external threats during the late phase of 
infection with the generation of  immunological memory. Specificity is developed by 
clonal gene rearrangements form a range of antigen-specific receptors on 
lymphocytes [3]. Only vertebrates are provided with this type of immunity, allowing 
the organism to recognize and remember the “non-self”. Innate immune system is 
necessary to activate adaptive immune system. It acts in a non-specific manner and 
does not confer any memory of the challenge. It is widespread amongst all animals 
and even in plants, and its main function is to provide immediate protection against 
pathogens. Innate immunity relies on specific cells as primary mediators, namely 
phagocytic cells and antigen presenting cells (APCs), such as granulocytes, 
macrophages, and dendritic cells (DCs) [4]. Innate immunity mechanisms do not 
have specific pathogen targets, the principal targets are evolutionarily conserved 
molecular structures, termed “pathogen associated molecular patterns” (PAMPs) 
whose expression is common to different pathogens. These structures are generally 
recognized by receptors on the membrane of the host cells that are responsible for 
the immune response. Such structures are called “pattern recognition receptors” 
(PRR). PRRs are constitutively expressed in the host on all cells of a given type [5]. 
Lipopolysaccharide (LPS) is a glycolipid, generally referred to as endotoxin in Gram 
negative bacteria, belonging to PAMP family. It is a potent inducer of the innate 
immune system and the main cause of septic shock [6]. Lipopolysaccharides are 
amphiphilic macromolecules composed of a hydrophilic heteropolysaccharide 
covalently linked to a lipophilic moiety termed lipid A, which anchors these 
macromolecules to the outer membrane. The polysaccharidic region is divided into a 
core oligosaccharide and a region called O-chain. Lipopolysaccharides not 
possessing the O-chain are termed rough lipopolysaccharides or 
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lipooligosaccharides (LOSs). Lipid A is the lipophilic portion of LPS responsible for 
anchoring the entire macromolecule to the outer membrane of bacteria through 
electrostatic and hydrophobic interactions and it represents the endotoxic principle of 
Gram negative. The basic structure of lipid A consists of two units of glucosamine 
called GlcN I and GlcN II, linked by a glycosidic linkage β-(1 → 6), and repeated 
throughout the lipopolysaccharide.  Linked to the disaccharidic backbone there are 
fatty acid chains responsible of the hydrophobic nature of lipid A. Positions 1 and 4' 
of the lipid backbone are occupied by two phosphate groups known as "polar heads", 
not present in stoichiometric quantities. They can be linked to different substituents 
such as ethanolamine or glucosamine, to neutralize the negative charge of 
phosphates. In position 6 of GlcN II a characteristic monosaccharide of LPSs is 
linked, namely 2-Keto-3-deoxy-D-manno-octonic acid which represents the 
conjunction factor between the lipid (lipid A) and the sugar (the core) portion. The 
Core consists of about fifteen monosaccharides, and is divided into two distinct 
domains called inner-core and outercore. The inner-core consists of characteristic 
monosaccharides, such as KDO, L-glycero-D-manno-heptose, D-glycero-D-manno-
heptopyranose; the outer-core instead, consists of a few glycosidic residues: neutral 
sugars, uronic acids and amino sugars. The core is always negatively charged due to 
the presence of acid or phosphorylated sugar substituents. The O-specific chain is 
the structure protruding outside from the cell surface and contains up to fifty 
repeating oligosaccharide units. Most of lipopolysaccharides heterogeneity is given 
by the extremely variable structure of O-chain [7]. 
The recognition of this endotoxin is achieved by the interplay of a variety of proteins, 
either receptors or serum secreted proteins. The cascades of events following LPS 
infection has been investigated in numerous studies. However, most of them focused 
on the interaction of single specific proteins with LPS, such as the LPS-binding 
protein (LBP), whose mechanism of action was clarified in many works [8,9]. Further 
studies showed that other proteins possess LPS-binding domains [10,11,12]. 
Intracellular pathways elicited by LPS infection was investigated by in vitro and in 
vivo analyses on different cell types, ranging from  immune cells to epithelial cells 
[13;14].  
Toll-like receptor 4 (TLR-4) is the signal transducing receptor of lipopolysaccharides; 
lipid A is the real effector required to activate TLR4 signalling pathway in conjunction 
with a soluble co-receptor protein myeloid differentiation protein 2 (MD2), which 
directly and physically binds to LPS [15;16]. Entry of LPS or lipid A into the blood 
stream is responsible for the onset of septic shock [17]. Aggregates of LPS bind to 
certain plasma proteins, such as albumin, LBP and soluble CD14 to facilitate the 
interaction with host cells, via TLR4. The complex of protein bound LPS, TLR4, and 
MD2, activates two intracellular pathways [18]: the MyD88-dependent pathway, 
responsible for early-phase NF-κB and MAPK activation, which controls the induction 
of proinflammatory cytokines TNF-a, IL-1, IL-6, and the MyD88-independent, TRIF-
dependent pathway that activates IRF3, which is necessary for the induction of IFN-
β- and IFN-inducible genes [19]. The activation of the TLR4-MD2 complex triggers 
the induction of inflammatory cytokines acting as endogenous mediator of infection, 
as well as the superoxide anion (O2-), hydroxyl radicals (OH), nitric oxide and 
antimicrobial peptides [20]. 
The low and balanced concentrations of these mediators and soluble immune 
response modulators leads to a resulting inflammation, one of the most important 
and ubiquitous aspect of the immune host defence against invading microorganisms. 
Beside these positive effects, an uncontrolled and massive immune response, due to 
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the circulation of large amount of endotoxins, leads to the symptoms of the sepsis 
and of the septic shock. Therefore identification of all the molecular actors involved in 
the recognition cascade is of pivotal importance with particular emphasis on the 
differences in elicitation and reaction by different LPSs. 
Numerous studies have been performed following pro-inflammatory expression 
patterns via microarray analyses [21] and the phage display method was used to 
capture new LPS-binding peptides [22]. 
Recently, proteomics approaches were addressed to the study of innate immunity. 
Comparative analysis of the human plasma proteome prior and after LPS injection 
was performed [23] and the human innate immunity interactome was investigated 
using 58 genes involved in transcriptional regulation of type I IFN tagged with the 
FLAG epitope following cells stimulation with LPS [24].  
The aim of this study was the setting up of a new methodology for the development 
of lipopolysaccharides analyses to be used to capture LPS-interacting proteins in 
order to better elucidate the molecular mechanism of the innate immunity. Here, a 
strategy based on chemical manipulations, biochemical procedure and mass 
spectrometry techniques, integrated in a functional proteomic workflow is proposed. 
The procedure was developed using an LPS derived from Salmonella typhimurium 
and the proteomic study was carried out by using human serum from a healthy donor 
as a model. 
 
V.2. Material and methods 
 
LPS extraction 
Dried cells of Salmonella typhimurium were extracted by the phenol/water method 
[25]. The extracted phases were dialysed three times against distilled water and 
subjected to enzymatic digestions in order to remove nucleic acids and protein 
contaminants. Both water and phenol fractions were analysed through SDS.PAGE 
13.5%. 
 
LPS biotinylation 
LPS biotinylation was achieved by a transesterification reaction with biotin-p-
nitrophenylester (Sigma Aldrich). Lyophilized LPS was solubilised in 200 µL pyridine 
(Romil), to which a certain amount of biotin-p-nitrophenylester was added. LPS: 
biotin-p-nitrophenylester ratio was calculated as 1:3 (weight:weight). The reaction 
was carried out in the dark for 2 hours at 80°C.  The reaction mixture was dried under 
nitrogen and then the sample was dissolved in MilliQ water. The excess of reagents 
was removed by molecular exclusion chromatography on PD-10 columns (GE-
Healthcare). LPS containing fractions were pooled and lyophilized. Unlabelled and 
biotinylated LPS were dissolved in Laemmli buffer, supplemented with 100 mM DTT 
and separated by SDS-PAGE in a 12.5% polyacrylamide gel. LPS was detected by 
silver nitrate staining for carbohydrates (Tsai Frash, 1982) or electrotransferred onto 
a PVDF membrane (Millipore). The membrane was blocked with 3% non fat dry milk, 
1% BSA (Sigma Aldrich), in PBS containing 0.05% Tween 20 (Sigma Aldrich). Then 
it was incubated with 1:1000 streptavidin/HRP conjugate (Sigma Aldrich). 
Biotinylated sample was detected using SuperSignal West Femto Chemiluminescent 
Kit from Pierce. 
 
LPS immobilization onto avidin beads 
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Biotin-LPS immobilization was carried out using 3 mg biotin-LPS/mL of settled avidin 
agarose resin (settled gel, Pierce). 
An aliquot of resin was extensively washed with binding buffer (0.1 M Na3PO4; 0.3 M 
NaCl; pH 7.2) and incubated with biotin-LPS at 4°C overnight under shaking. Then 
the resin was washed three times with binding buffer. 
 
Biotin-LPS and human serum interaction 
The affinity experiment was preceded by a “precleaning step”. A protease inhibitors 
cocktail (Sigma Aldrich) was added to 5 mg human serum (Servizio Analisi, 
Policlinico), to a final concentration of 1 mM. This sample was diluted to a final 
volume of 600 µL with binding buffer and incubated with 150 μL of settled resin 
overnight at 4°C. The unbound fraction of precleaning step was therefore incubated 
with 150 μL of biotin-LPS immobilized resin overnight at 4°C. Later on, the two 
aliquots of resin, that we term “control” and “test” were subjected to repeated washes 
with binding buffer. Elution was performed boiling the resin in Laemmli buffer and 
DTT. 
SDS-PAGE was performed, loading on a 1.5 mm, 12.5 % gel all the samples deriving 
from the different steps of the fishing experiment. The gel was run at constant 25 mA 
for 1h. The gel was stained with colloidal Coomassie (Pierce). 
 
In gel trypsin digestion 
The analysis was performed on the Coomassie blue-stained protein bands excised 
from the gels. Gel particles were washed first with acetonitrile and then with 0.1 M 
ammonium bicarbonate. Protein samples were reduced incubating the bands with 10 
mM dithiothreitol (DTT) for 45 min at 56 C. Cysteines were alkylated by incubation in 
5 mM iodoacetamide for 15 min at room temperature in the dark. The bands were 
then washed with ammonium bicarbonate and acetonitrile. Enzymatic digestion was 
carried out with trypsin (12.5 ng/μl) in 50 mM ammonium bicarbonate buffer, pH 8.5. 
Gel particles were incubated at 4°C for 2h, in order to allow the enzyme to enter the 
gel. The buffer solution was then removed and a new aliquot of buffer solution was 
added for 18 h at 37 C. A minimum reaction volume, enough for complete gel 
rehydration was used. At the end of the incubation the peptides were extracted by 
washing the gel particles 0.1% formic acid in 50% acetonitrile at room temperature 
and then lyophilised. 
 
LC-MS/MS analyses 
Peptides mixtures were analyzed by LC-MS/MS, using a HPLC-Chip LC system 
(Agilent 1200) connected to a Q-TOF 6520 (Agilent Technologies). Samples were 
diluted in 10 µL 0.1% formic acid. After loading, the peptide mixtures were  
concentrated and washed at 4 µL/min in 40 nL enrichment column with 0.2% formic 
acid in 2% acetonitrile. Fractionation was carried out on a C-18 reverse phase 
column (75 µm x 43 mm) at a flow rate of 0,4 µL/min with a linear gradient of eluent B 
(95% acetonitrile and 0.2% formic acid) in A (2% acetonitrile  and 0.1% formic acid) 
from 7% to 80% in 51 min.  
Mass spectrometry analyses were performed using data dependent acquisition MS 
scans (mass range 300-2400 m/z), followed by MS/MS scans (mass range 100-2000 
m/z) of the most intense ions of a chromatographic peak.  
Raw data from LC-MS/MS were converted to mzData. The spectra were searched 
against the NCBI database (2006.10.17 version) using the licensed version of 
Mascot 2.1 (Matrix Science). The MASCOT search parameters were: taxonomy 
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Homo sapiens; allowed number of missed cleavages 2; enzyme trypsin; variable 
post-translational modifications, methionine oxidation, pyro-glu N-term Q; peptide 
tolerance 10 ppm and MS/MS tolerance 0.6 Da; peptide charge, from +2 to +3. 
 
V.3. Results and discussion 
The innate immune system constitutes the first line of defence against 
microorganisms and plays a primordial role in the activation and regulation of 
adaptive immunity. In humans, components of the innate immune system include 
members of the complement cascade and soluble pattern recognition molecules 
(PRRs), functional ancestors of antibodies [26]. In particular, the complement system 
plays a key role in the elimination of micro-organisms after entrance in the human 
host. 
The integrated strategy based on functional proteomic approach represents a new 
starting point to elucidate the molecular mechanisms elicited by bacterial LPS and 
involved in the different steps of innate immunity response. Identification of the 
specific LPS-binding proteins in human serum was rarely addressed since most 
investigations focused on the LPS-mediated effects on cellular pathways and 
transcriptional responses. Only recently, a single example was reported using a 
solid-phase chemically immobilised LPS [27]. 
Immobilisation of the LPS represents the key step in the entire strategy to generate a 
labeled bait that could be linked to agarose beads. Biotinylation of LPS was chosen 
as the best suited derivatization process both for the simple modification reaction and 
to take advantage of the strong and specific interaction of biotin with avidin. 
Biotinylated LPS was analysed by SDS-PAGE following both silver staining and 
immunodetection with streptavidin/HRP conjugate. Figure 1 shows the corresponding 
gel. Staining procedures displayed the occurrence of two sample bands. The low 
molecular mass bands corresponds to the LipidA core component of LPS (R-type 
LPS) whereas the high molecular mass band represents the whole LPS molecule 
comprising the O-chain moiety (S-type LPS). Both components were responsive to 
western blot analysis demonstrating that they had been derivatised by biotin.  
Biotin-LPS was conjugated to avidin agarose beads by incubation in 0.1 M Na3PO4 
overnight. Both unbound and bound fractions were analyzed by SDS-PAGE followed 
by blotting and incubation with streptavidin/HRP conjugate. Fig. 2 shows the results 
of the immobilization procedure; two immunoresponsive bands corresponding to LPS 
and the Lipid A moiety were clearly detected in the bound fraction while no 
immunoresponsive bands occurred in the unbound material. 
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Fig. 1: (A) SDS-PAGE of LPS after biotin-p-nitrophenylester derivatition detected by silver 
staining (on the left) and blotting with streptavidin/HRP incubation (on the right). (B) 
immobilization procedure probed by blotting with streptavidin/HRP incubation. Two bands 
corresponding to LPS and Lipid A moiety were clearly detected in the bound fraction while no 
bands occurred in the unbound material 
 
The final step of the proposed strategy relies on the use of the immobilised LPS as 
bait in a functional proteomic experiment [28] aiming at capturing specific LPS 
interactors to investigate innate immunity molecular mechanisms in human serum. 
An aliquot of human serum proteins was incubated with underivatised avidin agarose 
beads overnight at 4°C as a pre-cleaning step to remove all the proteins that non 
specifically interact with agarose or avidin. The unbound fraction was then incubated 
with biotin-LPS avidin agarose beads and after extensively washing in binding buffer 
both the bound fractions (control and sample) were eluted in Laemmli buffer and 
fractionated by SDS-PAGE gel. An aliquot of 15 μg of human serum was also loaded 
onto the gel (Fig.3). Due to the complexity of the gel patterns and the low resolution 
of 1D electrophoresis, several proteins can occur in the same gel band. Therefore, 
protein bands specifically present in the sample lane and absent in the control lane 
cannot be identified by simply comparing the two gel profiles. Thus the entire sample 
lane of the gel was cut in 25 slices. Each slice was destained and in situ trypsin 
digested. To check for non specific proteins, the same procedure was applied to the 
control lane. The resulting peptide mixtures were extracted from the gel and 
submitted to nanoLC-MS/MS analysis generating sequence information on individual 
peptides. 
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This information, together with the peptide mass values, was then used to search 
protein databases, leading to the identification of the protein components. The 
experiments were performed in two biological replicates and each protein mixture 
was run through LC/MS/MS three times. All proteins identified in both the sample and 
control lanes were discarded, while only those solely occurring in the sample lane 
and absent in the control lane were selected as putative LPS interactions. As further 
selection criteria, only proteins found in both biological replicates and identified with 
at least 2 significative peptides in MASCOT search were considered, providing a full 
list of putative LPS interactors. The results are summarised in Table 1. 
 
Table 1: Table 1: list  of putative LPS-interacting proteins after in situ digestion of the bands 
from control and sample bound fractions. As selection criteria only proteins solely present in 
the sample lane and completely absent in the control lane were considered putative 
interactors. Analyses were carried out in replicates and only proteins proteins present in both 
replicates and identified with at least 2 peptides in MASCOT search were considered 
ID Protein Score Peptides 
P01023 Alpha 2 macroglobulin 170 8 
P08603 Factor H 44 2 
P00450 Ceruloplasmin 136 6 
P80108 Phospholipase D 114 4 
P00734 Coagulation factor II (Thrombin) 56 4 
P07225 S plasma protein 140 8 
P04196 Histidine rich glycoprotein 54 2 
P04003 C4 binding protein C4bp 266 16 
P02749 Beta 2 glycoprotein I 91 5 
P02647 Proapolipoprotein A1 86 3 
P0C0L5 Complement C4B 92 3 
P05090 Apolipoprotein D 56 2 
P06727 Apolipoprotein A-IV 74 4 
P12273 Prolactin inducible precursor 64 2 
Fig. 2: 12,5% SDS-PAGE gel containing 15 μg of human serum together with control and sample 
bound fractions after elution in Laemmli buffer.  The entire control and sample lanes of the gel 
were cut in 25 slices. Each slice was destained and trypsin digested, in situ. 
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The strategy based on affinity capture procedure using biotin LPS as a bait was 
optimized and human serum from a healthy donor was used as model. A number of 
proteins were specifically retained by the LPS bait and subsequently identified by 
mass spectrometric methodologies. The identity of these proteins represented per se 
a validation of the developed affinity-capture procedure. These proteins, in fact, 
essentially gathered within two functional groups, regulation of the complement 
system (Factor H, C4b, C4BP and alpha 2 macroglobulin) and inhibition of LPS 
induced inflammation (HRG and Apolipoproteins). Both groups are functionally 
correlated with the biological role of LPS. 
The complement system is an essential component of the innate immune system that 
participates in elimination of pathogens. Three different pathways synergistically 
contribute to the protection mechanism elicited by the complement proteins, the 
classical pathway, the alternative pathway and the lectin pathway. Despite the 
specific pathway they belong to, complement proteins provide host defence towards 
bacterial infections by binding to cell surface components of exogenous 
microorganisms. In contrast, pathogenic microorganisms have evolved several 
strategies to escape these defence mechanisms. The most common procedure 
consists in the recruitment of complement inhibitory proteins to the bacterial surface 
thus impairing the immune system.  
In this respect, the identification of well characterized protein inhibitors of the 
complement system among the LPS interactors has a clear biological significance. 
C4BP, Factor H and alpha 2 macroglobulin are all complement inhibitors able to 
downregulate activation of the classical, alternative and lectin pathways respectively. 
Streptococcus pyrogenes, the ethiologic agent of important human infections, was 
shown to bind Factor H, C4BP and other complement proteins as a crucial step in the 
pathogenesis of these infections [29]. Bordetella pertussis was able to escape the 
classical pathway of complement by binding the classical pathway inhibitor C4BP. In 
addition, very recently it was shown that this pathogen can also evade the alternative 
complement pathway by recruitment of Factor H on the cell surface [30]. 
On the other hand, alpha 2 macroglobulin exerts a specific inhibitory activity towards 
the lectin pathway by binding the mannose-binding lectin (MBL) and the MBL 
associated serine proteases MASP-1 and MASP-2 [31]. Adding of alpha 2 
macroglobulin to human serum totally reversed killing of Neisseria gonorrhoeae, 
preventing MBL mediated activation of the complement system [32]. 
However, the most effective complement inhibitor is Factor H, a soluble protein 
regulator essential for controlling the alternative immune pathway [33]. Recognition 
and binding Factor H constitutes the infection mechanism adopted by several 
pathogens as a common immune evasion strategy. In addition several recent reports 
pointed out that besides its role as an alternative pathway downregulator, Factor H 
has an additional complement regulatory role in inhibiting activation of the classical 
pathway [34,35]. 
A totally different biological role can be ascribed to the second group of proteins 
identified by the LPS affinity capture strategy. HRG and Apolipoproteins, in fact, are 
known to exert protective effects against LPS induced systemic inflammation 
preventing inhibition of the complement immune system. HRG binds strongly to 
several complement protein inhibitors including Factor H and C4BP thus assisting in 
maintainance of normal immune function and enhancing complement activation [36]. 
S. pyrogenes was shown to grow more efficiently in HRG-deficient plasma while the 
presence of overexpressed HRG greatly increased clots formation, bacterial 
entrapment and killing [37]. 
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Apolipoproteins AI, A-IV and D are all components of the high density lipoproteins 
(HDL) that have long been reported to bind bacterial LPS neutralizing its toxicity and 
preventing initiation of innate immunity. More recently evidences for an Apo AI-LPS 
specific interaction have been obtained [38]. 
Moreover, the adenovirus mediated overexpression of this protein led to protection of 
mice against LPS-mediated systemic inflammation [39]. 
A further consideration on this study is the fact that most of the identified proteins are 
glycosylated, confirming previous data on glycoproteins involvement as PRRs 
(Patterns Recognition Receptors) in innate immunity response in plants and animals 
[5]. 
 
V.4. Conclusions 
In conclusion, the novel LPS-mediated affinity capture strategy developed in this 
work proved to be very effective in specifically binding proteins involved either in 
inhibiting the activation of the complement system or in preventing bacterial infection 
by sequestering the LPS moiety. Both processes are of relevant biological 
significance and the results obtained makes sense with the bait used. Moreover, 
although a proper sensitivity test was not performed, the LPS affinity procedure led to 
the identification of low abundant serum proteins even without any depletion step. 
The sensitivity of the LC-MS/MS analyses allowed us to identify specific proteins 
even when the protein band showed only a very faint staining. A further advantage of 
this procedure concerns the possibility of determining both the proteins directly 
bound to LPS bait and other components involved in the functional complex but not 
linking the LPS moiety. It will be now possible to foresee applications of this strategy 
to investigate biological mechanisms exerted by pathogenic bacteria at the molecular 
level and to possibly define new mechanisms of infection. 
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Several human diseases are associated with the deposition of stable ordered protein aggregates known as
amyloid ﬁbrils. In addition, a large wealth of data shows that proteins not involved in amyloidoses, are able to
form, in vitro, amyloid-like preﬁbrillar and ﬁbrillar assemblies indistinguishable from those grown from
proteins associated with disease. Previous studies showed that early preﬁbrillar aggregates of the N-terminal
domain of the prokaryotic hydrogenase maturation factor HypF (HypF-N) are cytotoxic, inducing early
mitochondria membrane depolarization, activation of caspase 9 and eventually cell death. To gain knowledge
on the molecular basis of HypF-N aggregate cytotoxicity, we performed a differential proteomic analysis of
NIH-3T3 cells exposed to HypF-N preﬁbrillar aggregates in comparison with control cells. Two-dimensional
gel electrophoresis followed by protein identiﬁcation by MALDI-TOF MS, allowed us to identify 21 proteins
differentially expressed. The changes of the expression level of proteins involved in stress response (Hsp60
and 78 kDa glucose-regulated protein) and in signal transduction (Focal adhesion kinase1) appear
particularly interesting as possible determinants of the cell fate. The levels of some of the differently
expressed proteins were modiﬁed also in similar studies carried out on cells exposed to Aβ or α-synuclein
aggregates, supporting the existence of shared features of amyloid cytotoxicity.
© 2009 Elsevier B.V. All rights reserved.
1. Introduction
Amyloid diseases are a group of protein misfolding pathologies
including either systemic forms (i.e. type II diabetes mellitus,) and
neurodegenerative diseases (Alzheimer's, Parkinson's, Huntington
and prion diseases) (reviewed in [1,2]). The molecular basis of these
clinically different pathologies can be traced back to the presence, in
the affected tissues and organs, of proteinaceous deposits of ﬁbrillar
aggregates of one out of a number of peptides or proteins, each found
aggregated speciﬁcally in each disease (reviewed in [1,3]). In the last
ten years it has became increasingly clear that the ability to
oligomerize into amyloid assemblies is not a speciﬁc feature of the
proteins and peptides found aggregated in tissues affected by amyloid
diseases; in fact, since 1998, an increasing number of reports support
the idea that protein misfolding following mutations, chemical
modiﬁcations, presence of destabilizing surfaces or any other altera-
tion of the chemical environment, can result a structural reorganiza-
tion, favouring oligomerization/polymerization of peptides and
proteins into amyloids [4,5].
In addition to amyloid aggregation, aggregate toxicity has also
recently resulted as a generic property of proteins and peptides. In
particular, it is increasingly recognized that amyloid oligomers,
preceding the appearance of mature ﬁbrils, known as preﬁbrillar
aggregates, are the most toxic species, among amyloid assemblies
associated or not associated with disease [6,7]. This view supports the
idea that any protein can potentially become the source of toxic
species impairing cell viability and that the cytotoxicity of preﬁbrillar
aggregates results, at least in part, from shared basic structural
features of the latter [8]. Moreover, a growing number of studies
suggest that, in most cases, the cell membrane, can also favour
protein/peptide misfolding favouring the appearance of aggregating
nuclei [9]. Conversely, toxic preﬁbrillar aggregates from disease-
associated or disease-unrelated proteins can interact with the cell
membranes modifying their structural order resulting in the early
impairment of ion and redox homeostasis [10,11]. Intense efforts are
presently dedicated at unravelling the molecular basis of the
appearance in tissue of protein aggregates and their cytotoxicity.
However, muchmust still be learnt to gain enough knowledge to allow
designing therapeutic strategies aimed at counteracting the clinical
symptoms of amyloid diseases. On this respect, it can be important to
investigate the cytotoxic effects on cells exposed to amyloid
aggregates of proteins/peptides not associated with any amyloid
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disease. Such study can highlight cell modiﬁcations resulting from
shared structural features in amyloids excluding those associated with
the speciﬁc features of any aggregated peptide/protein.
The advent of proteomics has allowed the simultaneous analysis of
changes in the expression pattern of multiple proteins in complex
biological systems. This appears particularly important in the case of
cell dysfunctions resulting from protein aggregation. The effects
protein aggregates have on cells appear highly complex and hetero-
geneous. Such a complex pattern of cell impairment makes proteo-
mics one of the most useful tools to integrate these modiﬁcations into
a whole systematic picture. The reports that recently appeared on the
proteomic analysis of amyloid diseases such as Alzheimer's disease,
Parkinson's disease and others have provided valuable data on some
cell modiﬁcations allowing to explain, at least in part, cell impairment
in these diseases [12–16]. Proteomic studies provided useful informa-
tion on the changes in pattern of protein expression in cells exposed to
toxic aggregates of speciﬁc peptides/proteins found aggregated in the
corresponding diseases.
In the present study we performed a proteomic analysis of NIH-
3T3 cells exposed to toxic aggregates of a protein domain not involved
in any amyloid disease, the N-terminal domain of the prokaryotic
HypF hydrogenase maturation factor (HypF-N) whose aggregation
properties and aggregate cytotoxicity were previously characterized
[8,10,17]. To our knowledge, this is the ﬁrst proteomic study on the
alterations of the protein expression proﬁles in cells exposed to toxic
amyloid aggregates of a disease-unrelated protein.
Our results highlight some generic changes in protein expression
pattern elicited by the shared features of amyloids such as the basic
cross-beta structure and the exposure of hydrophobic patches. We
found signiﬁcant differences in the protein expression patterns in
the exposed cells, with a number of up- or down-regulated proteins.
Some of these proteins were also found in similar studies carried
out on cells exposed to Aβ or α-synuclein aggregates in agreement
with the generic nature of the cellular changes underlying amyloid
cytotoxicity. Among the differentially expressed proteins, the
reduced expression of Fak1 observed in the exposed cells can be
related to the apoptotic process, whereas the increased expression
of Hsp60 can provide protection against cell stress induced by HypF-
N preﬁbrillar aggregates. Furthermore the treated cells showed a
marked increase of the expression of both glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) and enolase. These two proteins
are involved in energy metabolism and Gapdh has also been shown
to bind the β-amyloid precursor protein [18] and to be involved in
transcriptional regulation of cell-cycle [19]. Finally, we observed an
increase in the expression level of actin as previously shown in cell
exposed to the intracellular domain of the β-amyloid precursor
protein [20].
2. Materials and Methods
2.1. HypF-N expression and puriﬁcation
HypF-N was expressed and puriﬁed as previously described [17].
HypF-N preﬁbrillar aggregates were obtained by incubating the
protein for 48 h at room temperature at a concentration of 0.3 mg/
ml in 30% (v/v) triﬂuoroethanol, 50 mM sodium acetate, 2 mM
dithiotreitol (DTT), pH 5.5, as previously reported [17]. At the end of
the incubation the solution was centrifuged, and the resulting pellet
was dried under N2 to remove the residual solvent, dissolved in DMEM
at 200 μM (monomeric protein concentration) and immediately
added to the cell culture medium at 2 μM ﬁnal concentration.
2.2. Cell culture and treatment
Cell culture media and other reagents, unless otherwise stated,
were from Sigma-Aldrich Fine Chemicals Co. NIH-3T3 murine
ﬁbroblasts (ATCC,Manassas, VA)were routinely cultured inDulbecco's
modiﬁed Eagle's medium (DMEM) with 4.5 g/l glucose, containing
10% bovine calf serum (HyClone Lab, Perbio Company, Celbio), 3 mM
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, in a 5%
CO2 humidiﬁed environment at 37 °C. Cells were used for a maximum
of 10 passages. Sub-conﬂuent NIH-3T3 cells were treated for differing
lengths of time with 2 μM toxic HypF-N preﬁbrillar aggregates. Under
these conditions itwas previously shown that the aggregates are stable
in the culturemedia [8]. Controlswere performed byexposing the cells
to the same amount of native, soluble HypF-N. At the end of each
treatment, the cells were washed twice with phosphate-buffered
saline (PBS), dried and stored at−80 °C.
2.3. Sample preparation and 2D-GE
Cells were scraped in RIPA buffer (50 mM Tris–HCl pH 7.0, 1% NP-
40, 150 mM NaCl, 2 mM EGTA, 100 mM NaF) containing a cocktail of
protease inhibitors (Sigma). The cells were sonicated (10 s) and
protein extracts were clariﬁed by centrifugation at 8000 g for 10 min.
Proteins were precipitated following a chloroform/methanol protocol
[21] and the pellet was resuspended in 8Murea, 4% CHAPS and 20mM
DTT. Three independent experiments were performed and each
sample was run in triplicate in order to assess biological and analytical
variation. IEF (ﬁrst dimension) was carried out on non-linear wide-
range immobilized pH gradients (pH 3.0–10; 18 cm long IPG strips; GE
Healthcare, Uppsala, Sweden) and achieved using the Ettan™
IPGphor™ system (GE Healthcare, Uppsala, Sweden). Analytical-run
IPG strips were rehydratedwith 60 μg of total proteins in 350 μl of lysis
buffer and 0.2% carrier ampholyte for 1 h at 0 V and for 8 h at 30 V, at
20 °C. MS-preparative IPG strips were loaded with 400 μg of proteins.
The strips were focused at 20 °C according to the following electrical
conditions: 200 V for 1 h, from 300 V to 3500 V in 30 min, 3500 V for
3 h, from 3500 V to 8000 V in 30 min, and 8000 V until a total of
80,000 V/hwas reached. After focusing, analytical and preparative IPG
strips were equilibrated for 12 min in 6 M urea, 30% glycerol, 2% SDS,
2% DTT in 0.05M Tris–HCl buffer, pH 6.8, and subsequently for 5min in
the same urea/SDS/Tris buffer solution where DTT was substituted
with 2.5% iodoacetamide. The second dimensionwas carried out on 9–
16% polyacrylamide linear gradient gels (18 cm×20 cm×1.5 mm) at
10 °C and 40 mA/gel constant current until the dye front reached the
bottom of the gel. Analytical gels were stained with ammoniacal silver
nitrate as previously described [22]; MS-preparative gels were stained
with colloidal Coomassie [23].
2.4. Western blotting analysis of proteomic candidates
For 1-DE 30 μg of protein extracts was separated by 12% SDS-PAGE
and transferred onto a PVDF membrane (Millipore). To conﬁrm the
results obtained from 2D-GE analysis, the relative amount of Hsp60
and Fak proteins were assessed by Western blot with appropriate
antibodies (Santacruz). For quantiﬁcation, the blots were stained with
Coomassie brilliant blue R-250 and subjected to densitometric
analysis performed using Quantity One Software (Bio-Rad). Statistical
analysis of the data was performed by Student's t-test; p-values 0.05
were considered statistically signiﬁcant. The intensity of the immu-
nostained bands were normalized with the total protein intensities
measured by Coomassie brilliant blue R-250 from the same blot.
2.5. Image analysis and statistics
The gel and Western blot images were acquired with an Epson
expression 1680 PRO scanner. For each condition, three biological
replicates were performed and only the spots present in all the
replicates were taken in consideration for subsequent analysis.
Computer-aided 2D image analysis was carried out using Image-
Master 2-DE Platinum software version 6.0 (GE Healthcare). The
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relative spot volume calculated as %V (V single spot/V total spots,
where V=integration of OD over the spot area) was used for
quantitative analysis in order to decrease experimental errors. The
normalized intensity of the spots on replicate 2D gels was averaged
and standard deviation was calculated for each condition. A two-tiled
non paired Student's t-test was performed using ORIGIN 6.0
(Microcal Software, Inc.) to determine whether the relative change
was statistically signiﬁcant.
2.6. In-gel trypsin digestion and MALDI-TOF mass spectrometry
The analysis was performed on the Coomassie blue-stained spots
excised from the gels. The spots were washed ﬁrst with acetonitrile
and then with 0.1 M ammonium bicarbonate. Protein samples were
reduced by incubation in 10 mM dithiothreitol (DTT) for 45 min at
56 °C. The cysteines were alkylated by incubation in 5 mM
iodoacetamide for 15 min at room temperature in the dark. The gel
particles were then washed with ammonium bicarbonate and
acetonitrile. Enzymatic digestion was carried out with trypsin
(12.5 ng/μl) in 50 mM ammonium bicarbonate buffer, pH 8.5, at
4 °C for 4 h. The buffer solutionwas then removed and a new aliquot of
the enzyme/buffer solution was added for 18 h at 37 °C. A minimum
reaction volume, enough for complete gel rehydration was used. At
the end of the incubation the peptides were extracted by washing the
gel particles with 20 mM ammonium bicarbonate and 0.1% TFA in 50%
acetonitrile at room temperature and then lyophilised. Positive
Reﬂectron MALDI spectra were recorded on a Voyager DE STR
instrument (Applied Biosystems, Framingham, MA). The MALDI
matrix was prepared by dissolving 10 mg of alpha cyano in 1 ml of
acetonitrile/water (90:10 v/v). Typically, 1 μl of matrix was applied to
the metallic sample plate and then 1 μl of analyte was added.
Acceleration and reﬂector voltages were set up as follows: target
voltage at 20 kV, ﬁrst grid at 70% of target voltage, delayed extraction
at 100 ns to obtain the best signal-to-noise ratios and the best possible
isotopic resolution with multipoint external calibration using a
peptide mixture purchased from Applied Biosystems. Each spectrum
represents the sum of 1500 laser pulses from randomly chosen spots
per sample position. Raw data were analyzed using the computer
software provided by the manufacturers and are reported as
monoisotopic masses.
2.7. nanoLC mass spectrometry
A mixture of peptide solution was subjected to LC-MS analysis
using a 4000Q-Trap (Applied Biosystems) coupled to an 1100 nano
HPLC system (Agilent Technologies). The mixture was loaded on an
Agilent reverse-phase pre-column cartridge (Zorbax 300 SB-C18,
5×0.3 mm, 5 μm) at 10 μl/min (A solvent 0.1% formic acid, loading
time 5min). The peptides were separated on an Agilent reverse-phase
column (Zorbax 300 SB-C18,150mm×75 μm, 3.5 μm), at a ﬂow rate of
0.3 μl/min with a 0% to 65% linear gradient in 60 min (A solvent 0.1%
formic acid, 2% acetonitrile in MQwater; B solvent 0.1% formic acid, 2%
MQ water in acetonitrile). Nanospray source was used at 2.5 kV with
liquid coupling, with a declustering potential of 20 V, using an
uncoated silica tip from NewObjectives (O.D. 150 μm, I.D. 20 μm, T.D.
10 μm). The data were acquired in information-dependent acquisition
(IDA) mode, in which a full scan mass spectrumwas followed by MS/
MS of the 5 most abundant ions (2 s each). In particular, spectra
acquisition of MS-MS analysis was based on a survey Enhanced MS
Scan (EMS) from 400m/z to 1400m/z at 4000 amu/s. This scanmode
was followed by an Enhanced Resolution experiment (ER) for the ﬁve
most intense ions and thenMS2 spectra (EPI) were acquired using the
best collision energy calculated on the basis of m/z values and charge
state (rolling collision energy) from 100 m/z to 1400 m/z at
4000 amu/s. The data were acquired and processed using the Analyst
software (Applied Biosystems).
2.8. MASCOT analysis
The spectral data were analyzed using the Analyst software
(version 1.4.1) and the MS-MS centroid peak lists were generated
using the MASCOT.dll script (version 1.6b9). The MS-MS centroid
peaks were threshold at 0.1% of the base peak. MS-MS spectra with
less than 10 peaks were rejected. The spectra were searched against
the Swiss Prot database (2006.10.17 version) using the licensed
version of Mascot 2.1 (Matrix Science), after converting the acquired
MS-MS spectra in MASCOT generic ﬁle format. The MASCOT search
parameters were: taxonomy mus musculus; allowed number of
missed cleavages 2; enzyme trypsin; variable post-translational
modiﬁcations, methionine oxidation, pyro-glu N-term Q; peptide
tolerance 200 ppm andMS/MS tolerance 0.6 Da; peptide charge, from
+2 to +3 and top 20 protein entries. Spectra with a MASCOT score
b25 having low quality were rejected. The score used to evaluate the
quality of matches for the MS-MS data was higher than 30. However,
the spectral data were manually validated and contained sufﬁcient
information to assign peptide sequence.
3. Results
3.1. Comparative proteomic analysis between control cells and
cells exposed to HypF-N preﬁbrillar aggregates
Previous experiments performed by Bucciantini et al. showed that
preﬁbrillar HypF-N aggregates induced early Ca2+ increase and
oxidative stress followed by mitochondria depolarization and caspase
activation in exposed NIH-3T3 cells. After 24 h, the cells died with
necrotic features possibly since the ATP levels were too low to sustain
the initially triggered apoptotic program [10]. In order to investigate
the changes (if any) in protein expression induced in the same cells
upon exposure to HypF-N preﬁbrillar aggregates, we performed a 2D-
GE followed by mass spectrometry. In all the experiments carried out
in this study, the cells were exposed to 2 μM preﬁbrillar aggregates.
This protein concentration was chosen to investigate ﬁnely regulated
biochemical processes, such as the activation of pro-apoptotic factors,
which could be hidden by a stronger cell injury [10]. The cells were
treated for 5 and 24 h and proteins extracts were prepared as
described under Materials and methods. Then the proteins were
separated by 2D-GE and the resulting silver-stained gels were
analyzed using the ImageMaster 2D Platinum 6.0 software. The
differences of protein expression between control and treated cells
were taken into consideration if the relative volume of the spots
differed reproducibly more than 1.5-fold and this difference was
statistically signiﬁcant. An average of about 1300 spots was detected
in each silver-stained gel. Cell exposure to HypF-N preﬁbrillar
aggregates did not affect the overall proteomic proﬁles both after
5 h and after 24 h (Figs. 1 and 2). However, the computer analysis
highlighted 19 variations between cells treated for 5 h with 2 μM
HypF-N preﬁbrillar aggregates (Fig. 1B) and the control cells treated
for the same length of timewith an equivalent amount of native HypF-
N (Fig. 1A). Among these variations, only two were still present after
24 h of treatment with aggregates (Fig. 2) indicating that the
alteration of the expression is a transient event, at least for this
group of proteins, except two. On the other hand, the comparison
between cells treated for 24 h with 2 μM HypF-N preﬁbrillar
aggregates and control cells showed a variation of 9 spots, whose
expressionwas not affected after 5 h, indicating that some proteins are
up- or down-regulated as a consequence of the prolonged exposure to
the aggregates.
3.2. Identiﬁcation of differentially expressed proteins
In order to identify the proteins of interest, 400 μg of protein
lysates was loaded on preparative gels and stained with colloidal
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Coomassie. The spots indicated byarrows in representative gels shown
in Figs. 1 and 2 were selected for mass spectral identiﬁcation after
merging the images of preparative and analytical gels. The proteins
excised from the gels were reduced, alkylated and in situ digestedwith
trypsin. The resulting peptide mixtures were directly analyzed by
MALDI/MS according to the peptide mass ﬁngerprinting procedure.
The peaks detected in theMALDI spectrawere used to search for a non
redundant sequence database using the in house MASCOT software,
taking advantage of the speciﬁcity of trypsin and the taxonomic
category of the samples. The number of measured masses that
matched within the given mass accuracy of 200 ppm was recorded
and the proteins that received the highest number of peptide matches
were examined. Some spots could not be identiﬁed unambiguously
either due to the low protein content of the spot or to the presence of
more than one protein per spot. Among the 19 spots differentially
expressed after 5 h of cell exposure to the aggregates, 13 spots were
successfully identiﬁed and are indicated by arrows and letters in Fig. 1.
Among the 9 spots differentially expressed in cells treated for 24 hwith
2 μM HypF-N preﬁbrillar aggregates, 8 spots were identiﬁed and are
indicated by arrows and numbers in Fig. 2. Some spots gave no
conﬁdent identiﬁcation by the peptide mass ﬁngerprinting procedure.
Additional data were then provided by nanoLC/MS/MS experiments.
The peptide mixtures were fractionated by nanoHPLC and sequenced
by tandemmass spectrometry leading to the unambiguous identiﬁca-
tion of the protein candidate. The lists of proteins identiﬁed by these
approaches are reported in Table 1 (5 h treatment) and in Table 2 (24 h
treatment). The identiﬁed proteins included cytoskeleton elements
(actin, tubulin alpha 1C chain, microtubule-actin cross-linking factor
1), enzymes involved in energy metabolism and transcriptional
regulation (Gapdh, enolase), proteins involved in stress response
(Hsp60 and 78 kDa glucose-regulated protein) and the focal adhesion
kinase, Fak1. Among these proteins only Fak1 and Hsp60 showed an
Fig. 2. 2D images of silver stained gels of total proteins extracted from control and HypF-N preﬁbrillar aggregate treated cells for 24 h. Arrows indicate variations between control
(panel A) and treated cells (panel B). Numbers indicate the identiﬁed proteins. Controls were performed by exposing the cells to native, soluble HypF-N.
Fig. 1. 2D images of silver stained gels of total proteins extracted from control and HypF-N preﬁbrillar aggregate treated cells for 5 h. Arrows indicate variations between control
(panel A) and treated cells (panel B). Letters indicate the identiﬁed proteins. Controls were performed by exposing the cells to native, soluble HypF-N.
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expression variation persisting over time, since it was observed both
after 5 and after 24 h of cell exposure to the aggregates.
3.3. Validation of proteomics results
In order to validate the proteomic results, the amounts of Fak1 and
Hsp60 were evaluated by Western blot analysis with speciﬁc
antibodies as shown in Fig. 3, panels A and B, respectively. Thirty μg
of proteins was loaded on 12% SDS-PAGE and transferred onto a PVDF
membrane. For quantiﬁcation, the intensities of the immunostained
bands were normalized to the total protein intensities in the same
blot, as measured by Coomassie brilliant blue. In Fig. 3, panel C the
histograms representing the variation of the expression of Fak1 and
Hsp60 are also reported. Such analysis conﬁrmed the decrease of
Fak1 expression and the increase of Hsp60 expression both after 5.0
and 24 h.
3.4. Protein expression changes in cells exposed for 5 h to HypF-N
preﬁbrillar aggregates
In cells exposed to HypF-N preﬁbrillar aggregates for 5 h, 6 spots (A
to F in Table 1) appeared up-regulated, whereas 7 spots (G to M in
Table 1) appeared down-regulated. Among the up-regulated proteins,
we found the heat shock protein Hsp60 (spot A). Hsp60 belongs to a
family of highly homologous chaperone proteins that are induced in
response to environmental, physical and chemical stresses, including
accumulations of misfolded proteins and reactive oxygen species [24,
25]. The increase of Hsp60 expression limits the consequences of
damage facilitating cell recovery. Hsp60 was also identiﬁed in the spot
K, which was down-regulated upon cell treatment with the
aggregates. However, the position in the gel and the peptide coverage,
indicates that this spot is probably a fragment arising from a
proteolytic cleavage of Hsp60.
A further indication of a stress condition induced in cells exposed
to the HypF-N aggregates is the marked increase in the expression of
the key glycolytic enzyme Gapdh (spot D). This protein plays a central
role in glycolysis, catalyzing the reversible conversion of glyceralde-
hyde-3-phosphate to 1,3-bisphosphoglycerate. More recent studies
have highlighted unexpected non-glycolytic functions of Gapdh in
physiological and pathological processes, including transcriptional
regulation of cell-cycle [19]. In addition two spots corresponding to
actin were up-regulated. Among the proteins whose expression
appeared decreased upon exposure to HypF-N preﬁbrillar aggregates,
the focal adhesion kinase (Fak1; spot G) is particularly interesting.
Table 2
Relative change in protein expression in cells treated for 24 h with HypF-N preﬁbrillar aggregates versus control cells.
Spot Protein name Accession
number
MASCOT
score
No. of matched
peptides
Sequence
coverage (%)
Fold
change
p-value Functional categorization
Up-regulated by HypF-N
1 Ovostatin homolog Q3UU35 48 4 15% +1.4 0.028 Proteases inhibitor
2 Hsp60 P63038 162 5 12% +1.58 0.0005 Protein folding and stress response
Down-regulated by HypF-N
3 Microtubule-actin
cross-linking factor 1
Q9QXZ0 82 14 10% −1.66 0.035 F-actin-binding protein which may
play a role in cross-linking actin to
other cytoskeletal proteins
4 Microtubule-actin
cross-linking factor
Q9QXZ0 88 10 8% −2.24 0.023
5 Pol protein Q7M6W3 73 10 17% −1.67 0.1 Unknown
6 Pdia2 protein Q14AV9 43 2 5% −3.21 0.004 Protein disulﬁde isomerase
7 Poly(rC)-binding
protein 2
Q61990 71 2 6% −3.78 0.014 Single-stranded nucleic acid
binding protein
8 Fak1 focal adhesion
kinase
P34152 77 17 22% −1.53 0.015 Non-receptor protein-tyrosine
kinase involved in cell motility,
proliferation and apoptosis
Table 1
Relative change in protein expression in cells treated for 5 h with HypF-N preﬁbrillar aggregates versus control cells.
Spot Protein name Accession
number
MASCOT
score
No. of matched
peptides
Sequence
coverage (%)
Fold change p-value Functional categorization
Up-regulated by HypF-N
A Hsp60 P63038 162 5 12% +1.58 0.0005 Protein folding and stress response
B Actin P60710 79 5 22% Only in treated cells. N.D. Cytoskeletal organization
C Actin P60710 241 7 18% +9.8 0.007 Cytoskeletal organization
D Glyceraldehyde-3-phosphate
dehydrogenase
P16858 120 7 33% +9.7 0.0081 Energy related (glycolysis)
E 78 kDa glucose-regulated
protein
P20029 78 2 5% +4.8 0.1 Protein folding and stress response
(response to unfolded proteins)
F Nucleophosmin Q61937 165 5 15% Only in treated cells. N.D. Associated with nucleolar
ribonucleoprotein structures and
bind single-stranded nucleic acids
Down-regulated by HypF-N
G Focal Adhesion kinase-1 P34152 77 17 22% −1.6 0.01 Non-receptor protein-tyrosine kinase
involved in cell motility. Proliferation
and apoptosis.
H Enolasi-1 P17182 118 12 32% −2.4 0.09 Energy related (glycolysis)
I Tubulin alpha-1C chain P68373 80 9 31% −8.3 0.015 Major constituent of microtubules
J Annexin-A3 O35639 111 13 43% −2 0.019 Inhibitor of phospholipase A2
K Hsp60 P63038 85 2 5% −1.6 0.032 Protein folding and stress response
L Transgelin-2 Q9WVA4 171 7 41% Only in control cells N.D. Belongs to the calponin family
M Heparan sulfate glucosamine
3-O-sulfotransferase 2
Q673U1 47 2 4% Only in control cells N.D. Catalyzes the O-sulfation of glucosamine
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Fak1 is a non-receptor cytoplasmic tyrosine kinase that plays a key
role in the regulation of proliferation and migration of normal and
tumour cells [26, 27]. Interestingly, Fak1 and Hsp60 are the only two
proteins, among those differentially expressed after 5 h of cell
exposure, that do not recover a normal expression level after 24 h.
3.5. Protein expression changes in cells exposed for 24 h to HypF-N
preﬁbrillar aggregates
It was previously shown that NIH-3T3 cells treated for 24 h with
10 μM HypF-N preﬁbrillar aggregates die with necrotic features,
including cytoplasmic vacuolization and nuclear swelling after an
initial apoptotic activation [10]. The amount of HypF-N aggregates
(2 μM, soluble protein concentration) used in this work is not so high
to induce cell death, thus allowing the cells to overcome damage. After
24 h of cell exposure to HypF-N aggregates, few other proteins, besides
Fak1 and Hsp60, displayed altered expression. In particular, we
identiﬁed 6 new spots (1 up-regulated and 5 down-regulated).
Among the proteins down-regulated, the microtubule-actin cross-
linking factor 1 (MACF1, spot 3) belongs to the Plakin family, that
includes proteins involved in the linkage of cytoskeletal elements and
the junctional complex. MACF1 was found to regulate microtubule
remodelling in response to the activation of signal transduction
pathways, although its function has not yet been fully explored
[28, 29].
4. Discussion
To our knowledge, this study is the ﬁrst proteomic investigation
focused on highlighting the alterations of the protein expression
proﬁles in a cultured cell model exposed to toxic amyloid aggregates
of a protein not involved in any amyloid disease. Our analysis was
performed using a non lethal dose of HypF-N preﬁbrillar aggregates,
allowing the detection of ﬁne variations more directly implicated in a
response to the cell injury given by the aggregates, instead of the
complex pattern of changes arising during the process of cell death.
Our approach led us to identify a subset of cell proteins whose levels
were signiﬁcantly altered upon cell exposure to the aggregates for 5 h or
24 h. Some of the proteins detected in our investigation, including
Hsp60, actin, enolase-1 and Gapdh had previously been identiﬁed in
other proteomic studies carried out on cells exposed to Aβ42 or α-
synuclein. In Table 3 a comparison between the protein identiﬁed in our
study and the proteins identiﬁed in other studies is shown, indicating
that there is a general response of cells to toxic aggregates that is not
sequence speciﬁc [12,13,30,31,32]. Actually, changes in the expression
levels of Gapdh, actin, tubulin and heat shock proteins have frequently
Table 3
Protein expression changes observed in this study in comparison to previous protein reported in other studies.
Protein Amyloid aggregates Cell type or animal model
GAPDH HypF-N NIH3T3 ﬁbroblast cells This study
Amyloid β-peptide Mitochondria from primary neuron [30]
Tg2576 transgenic mice [31]
3xTgAD Alzheimer's mice (hippocampal protein) [12]
β-amyloid (1–42) P301L tau overexpressing SH-SY5Y [32]
Tubulin α-chain HypF-N NIH3T3 ﬁbroblast cells This study
β-amyloid (1–42) SN56.B5.G4 cholinergic cells [13]
3xTgAD Alzheimer's mice (hippocampal protein) [12]
β-amyloid (1–42) Amygdalae from P301L tau transgenic mice [32]
78 kDa glucose-regulated protein HypF-N NIH3T3 ﬁbroblast cells This study
3xTgAD Alzheimer's mice (hippocampal protein) [12]
β-amyloid (1–42) P301L tau overexpressing SH-SY5Y [32]
Enolase HypF-N NIH3T3 ﬁbroblast cells This study
Tg2576 transgenic mice [31]
3xTgAD Alzheimer's mice (hippocampal protein) [12]
Hsp60 3xTgAD Alzheimer's mice [12]
Actin HypF-N NIH3T3 ﬁbroblast cells This study
β-amyloid (1–42) Amygdalae from P301L tau transgenic mice [32]
Fig. 3. Validation of proteomic results by western blot analysis. Western blot were probed with antibodies against Fak1 and Hsp60 proteins identiﬁed by proteomic screening. The
intensity of immunostained bands was normalized with the total protein intensities measured from the same blot stained with Coomassie brilliant blue (in panel A and panel B a
representative band of the lane is reported). (A) Aggregate-induced reduced expression of Fak1 after 5 and 24 h of treatment: lane 1, cells exposed to native HypF-N; lane 2, cells
exposed to HypF-N preﬁbrillar aggregates. (B) Aggregate-induced increased expression of Hsp60 after 5 and 24 h of treatment: lane 1, cells exposed to native HypF-N; lane 2, cells
exposed to HypF-N preﬁbrillar aggregates. (C) Histograms representing Fak1 and Hsp60 protein expression variation. The two-tailed non paired Student’s t-test was performed using
ORIGIN 6.0. (pb0.05).
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been reported in amyloid-linked proteomic studies possibly because
they are related to a generic response to stress conditions [33] such as
that associated with the growth of amyloid aggregates. In our
experiments, cell exposure to toxic amyloid aggregates induced an
increase of the expression levels of several proteins such as Hsp60. In
addition to its chaperone activity, Hsp60 has been suggested to perform
complex functions, producing both anti- and pro-apoptotic effects. In
fact, cytosolic Hsp60, can promote either cell survival or caspase-
mediated cell death by preventing the translocation of the pro-apoptotic
protein Bax into the mitochondria or by favouring the maturation of
procaspase-3, respectively [34–38]. In a recent study, Hsp60, Hsp70, and
Hsp90 were shown to provide differential protection against intracel-
lular stress caused by β-amyloid by maintaining the efﬁciency of the
mitochondrial oxidative phosphorylation and the tricarboxylic acid
cycle enzymes. In particular, Hsp60was shown to prevent the inhibition
of complex IV activity by β-amyloid, thus preventing apoptosis [39].
We also found signiﬁcantly increased levels of Gapdh and actin. As far
as Gapdh is concerned, several recent studies have shown that, in addition
to glycolysis, it is involved in several glycolysis-unrelated activities; these
include a role in vesicle fusion and transport [40], microtubule bundling
[41], nuclear RNA transport [42], and transcription [43]. Furthermore,
increased expression and nuclear translocation of Gapdh have recently
been reported to participate to the apoptotic pathway in different cell
types [44–47]. Finally, Gapdh has also been reported to bind to a variety of
proteins involved in neuronal diseases, including the amyloid precursor
protein and huntingtin [18]. The increased levels of actin expression in
cells exposed to preﬁbrillar HypF-N aggregates are similar to the effects
previously reported byMuller et al.; these authors found up-regulation of
the actin gene expression in cells harbouring the cytoplasmic domain of
the amyloid precursor protein [20].
Finally, we found a signiﬁcant decrease of Fak1 in cells exposed
both 5 h and 24 h to the HypF-N aggregates. The repression of Fak1
synthesis in exposed cells, conﬁrmed by Western blot analysis, is one
of the major results of this proteomic analysis. In vivo animal studies
have shown that Fak1 expression is increased in a number of human
cancers, thus contributing to tumour development and malignancy
[48]. Moreover, Fak1 has recently been shown to be a critical protein in
survival signalling, since it blocks apoptosis induced by several stimuli
[49]. Fak1 expression decrease following proteolytic cleavage in
various cell types has been associated with various cell dysfunctions
including c-Myc-induced apoptosis of chicken embryo ﬁbroblasts
(CEF) [49], growth factor deprivation-induced apoptosis of human
umbilical vein endothelial cells [50], and detachment-induced cell
death (anoikis) of intestinal epithelial cells [51]. In a recent study,
different epithelial cell lines treated with thimerosal displayed
increased levels of hydrogen peroxide resulting in caspase activation,
Fak1 cleavage and apoptosis [52]. All these observations suggest that
the decreased Fak1 expression in NIH-3T3 cells treated with HypF-N
aggregates could be related to the apoptotic process: in particular its
decreased intracellular levels could be the consequence of a
proteolytic cleavage making the cells more vulnerable to death.
The reported changes in protein expression proﬁles in exposed
cells suggest some alterations in speciﬁc signalling pathways involved
in the control of gene transcription and translation and/or in protein
degradation pathways. These alterations could be triggered, at least in
part, by modiﬁcations of signalling pathways following the reported
interaction of amyloid aggregates with the cell membrane [10, 11, 53].
Overall, our results can provide useful information on the crucial
events underlying cytotoxicity induced by amyloid aggregates of
different peptides or proteins both related and unrelated to disease.
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Abstract
The importance of post-translational modifications
(PTMs) of proteins has become evident in the proteo-
mic era as it plays a critical role in modulating cellular
function, and can vary in response to different stimuli
thereby tuning cellular mechanisms. Assessment of
PTMs on a proteomic scale is a challenging task since
they are substoichiometric, transient and reversible.
Moreover, the amount of post-translationally modi-
fied proteins is generally very small when compared
to their unmodified counterparts. Existing methodol-
ogies for identification of PTMs essentially relies on
enrichment procedure to selectively increase the
amount of modified peptides. These procedures need
to be integrated with sophisticated mass spectromet-
ric methods to enable the identifications of PTMs.
Although the strategies developed so far are not opti-
mal, a number of examples will be given where the
combination of innovative separation methods along
with advanced mass spectrometric analyses provide
positive results. These experiences are leading the
way for the next generation of proteomic approaches
for identification of a wide range of PTMs.
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Introduction
Over the past few years following the conclusion of
the Human Genome Project, the challenge has again
shifted from the gene to protein, giving rise to what
has been termed the ‘‘proteomic era’’. The aim of this
new era is to identify and characterize proteins locat-
ed within a given organelle, cell or organism, as well
as to unravel the in vivo protein pathways (1–3).
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These new goals are not easily achieved because
the challenge increases by several orders of magni-
tude when moving from genome to proteome
research. The static nature of the genome cannot be
compared to the dynamic properties of the proteome.
Expression profiles of proteins change several times
during the cell cycle and are significantly influenced
by a number of intra- and extra-cellular stimuli includ-
ing temperature, stress, apoptotic signals, and others
(4). In addition, alternative splicing and post-transla-
tional modifications (PTMs) has resulted in re-thinking
of the paradigm ‘‘one gene-one protein’’ that no long-
er reflects the true nature of the cellular proteome.
Modern proteomics research is focused on two
major areas, expression proteomics and functional
proteomics. Expression, or differential, proteomics
aims to investigate changes that occur in the expres-
sion of protein profiles following specific stimuli and/
or pathophysiological conditions. The goal here is to
assess up regulation and down regulation of protein
concentrations in abnormal cells compared with nor-
mal cells. Thus, expression proteomic studies are
strictly concerned with transcriptomics experiments.
However, mRNA concentrations do not necessarily
correlate with the amount of corresponding protein
due to translation regulation mechanisms. Thus,
expression proteomics complements microarray
investigations. This comparative approach is usually
employed in the identification of proteins that are up
regulated or down regulated in specific disease proces-
ses and therefore, may be used as diagnostic markers
or therapeutic targets (5). It is not enough to map and
identify all the proteins in cells; they must also be
categorized with respect to their function and inter-
actions with other proteins or genes. Therefore, the
proteome must be studied in vivo, and the dynamic
properties of the proteome used to obtain this infor-
mation. This is the target of functional proteomics, an
emerging area of proteomic study to investigate pro-
tein function in vivo through the isolation of function-
al complexes within the cell and the identification of
their protein components. It is well understood that
many cellular processes are governed by the rapid
and transient association of protein complexes that
fulfill specific biologic functions. The association of an
unknown protein with others belonging to a specific
complex would be strongly suggestive of its biologi-
cal function.
In this scenario, the importance of PTMs is notably
increased. Protein modification can affect biological
function, thereby playing a critical role in cellular
function. Also, they can vary in response to environ-
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mental stimuli allowing cellular mechanisms to be
finely tuned. Deregulation might be involved in the
development of disease.
Several mass spectrometry (MS)-based strategies
have previously been developed to identify and char-
acterize PTMs. With these techniques, a single, largely
homogeneous protein was digested, with the result-
ing peptide mixture analyzed using MS procedures.
The site and nature of the PTM could be easily
inferred from the anomalous mass value detected for
the modified peptide(s). The analytical problems
faced today by proteomic laboratories are far more
complicated. First, the sample very often consists of
a complex mixture of proteins, some of which are
modified. Second, the PTMs involved in the regula-
tion of important cellular processes, such as phos-
phorylation, methylation, acetylation, nitration, etc.,
are substoichiometric, affect only a minor portion of
the protein, are transient and are reversible. There-
fore, the amount of modified peptides within a pro-
teomic digest will generally be very small. Also, they
will always occur in the presence of a much larger
concentration of the corresponding unmodified frag-
ments. Thus, an understanding of cellular mecha-
nisms and processes requires a comprehensive
assessment of PTMs and the changes that occur fol-
lowing signaling events (6). New strategies will have
to be employed based on the integration of specific
enrichment procedures with sophisticated mass spec-
trometric experiments.
This paper will review current existing methodolo-
gies to identify PTMs in proteomic experiments, with
a focus on some specific examples.
Mass spectrometry
MS had been the method of choice to elucidate PTMs
in protein chemistry. Today, MS plays a key role in
proteomics studies since it is the only method with
the sensitivity, accuracy, reproducibility and speed
required for identifying unknown proteins and char-
acterizing transient PTMs (7–9).
MS is based on the production of ions in a gaseous
phase that allow for the determination of the molec-
ular mass of analytes. A wide variety of mass spec-
trometers are now available; all sharing the ability to
assign mass-to-charge values to ions, even though,
the principles of operation and the types of experi-
ments that can be done on these instruments differ
greatly. The sample has to be introduced into the ion
source of the instrument where molecules are ion-
ized. The ions are extracted into the analyzer region
where they are separated according to their mass-to-
charge ratio (m/z) and then detected.
Mass spectrometers can be classified according to
its ionization system; an essential component that
defines the measurable mass range, sensitivity and
resolution. Many ionization methods are available.
However, the most widespread ion sources in bio-
chemical analyses are electrospray ionization (ESI)
and matrix assisted laser desorption ionization (MAL-
DI) (10, 11). Over the last few years, ESI (12, 13) has
had a tremendous impact on the use of MS in biolog-
ical research because it is well suited to the analysis
of polar molecules. During standard ESI, the sample
is dissolved in a polar, volatile solvent and pumped
through a narrow, stainless steel capillary (12–14).
High voltage, 3–5 kV, is applied to the tip of the cap-
illary within the ion source. Sample emerging from
the capillary tip is dispersed into a spray of highly
charged droplets. This process is aided by a nebuliz-
ing gas flowing around the outside of the capillary.
The charged droplets decrease in size by solvent
evaporation which is assisted by a flow of warm nitro-
gen gas. This is also known as the drying gas and it
passes across the front of the ionization source. Even-
tually, charged sample ions that are free of solvent
are released from the droplets and pass into the ana-
lyzer of the mass spectrometer. One peculiar aspect
of this technique is that it gives rise to
multiple, charged molecular-related ions such as
(MqnH)nq in positive ionization mode and (M-nH)n–
in negative ionization mode.
MALDI-MS is based on bombardment of sample
molecules with a laser to induce sample ionization.
The sample is pre-mixed on a stainless steel plate
with a highly absorbing matrix such as a weak aro-
matic acid. Once excited, the matrix is able to transfer
energy and protons to the sample. After drying, the
matrix molecules crystallize and solid crystals con-
sisting of sample and matrix are formed. A laser,
usually a pulsed nitrogen laser at 337 nm, is fired into
the sample. The absorbance of the laser energy by the
matrix molecules results in a desorption event. This
energy is used to transfer a proton from the matrix to
the analyte resulting in the formation of MHq ions.
Mass analyzers may incorporate quadrupoles (Q),
ion traps (IT), time-of-flight (TOF), or some combina-
tion of these in ‘‘hybrid instruments’’ in order to
obtain good resolution and sensitivity. The ESI source
is usually employed with quadrupole and ion trap
analyzers (15, 16). The advantages of the ion-trap
mass spectrometer includes compact size, and the
ability to trap and accumulate ions in order to
increase the signal-to-noise ratio. It is also possible to
use this type of mass spectrometer in fragmentation
experiments (see below). Conventional ion trap mass
spectrometers operate with a three-dimensional (3D)
quadrupole field. This confers very high efficiency
with respect to the time required to fill the ion trap
and generate a complete mass spectrum. However,
there are some problems with respect to trapping effi-
ciency, primarily due to the small volume. These pro-
blems have been overcome by the introduction of
linear ion traps (LIT) (17–19), characterized by a larger
ion storage capacity and greater trapping efficiency
(see below).
TOF analyzers are typically used in combination
with MALDI sources. Following MALDI ionization,
ions pass into a TOF tube for mass analysis. The TOF
tube is under high vacuum (10–6–10–8 mbar) and con-
sists of a field-free drift region. All ions entering the
TOF tube have a fixed kinetic energy that is propor-
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Figure 1 MS/MS peptide fragmentation pattern.
Fragment ions are labeled with a, b, and c ions carrying the
charge on the N-terminal fragment. The x, y and z ions hav-
ing the charge retained on the C-terminal fragment.
tional to the applied voltage and the charge. The high-
er the mass of the ion, the lower its velocity and the
longer it takes before the ion reaches the detector.
Ions of different mass can be separated based on their
different velocities in the TOF-tube. Their m/z values
are determined by measuring the time each ion takes
to travel through the field free region.
MALDI and electrospray sources are known as soft
ionization methods because the sample is ionized by
the addition or removal of a proton, with very little
energy remaining to cause fragmentation of the sam-
ple ions. Tandem mass spectrometry (MS/MS) must
then be used to produce structural information about
the compound by fragmenting specific sample ions
inside the mass spectrometer, and then identifying
the fragment ions. MS/MS uses two stages of mass
analysis; the first to pre-select an ion and the second
to analyze fragments. These are separated using a
collision cell into which an inert gas, such as argon
or xenon, is introduced to produce fragmentation.
MS/MS also enables specific compounds to be detect-
ed in complex mixtures based on their characteristic
fragmentation patterns.
Peptides fragment in a well-described manner (20).
There are three different types of bonds that can frag-
ment along the amino acid backbone: NH-CH, CH-CO,
and CO-NH bonds. Each bond break gives rise to two
species, one neutral and the other one charged, with
only the charged species monitored by the mass
spectrometer. Thus, there are six possible fragment
ions for each amino acid residue as shown in Figure
1. The a, b, and c ions carry the charge on the N-
terminal fragment, and the x, y and z ions retain the
charge on the C-terminal fragment. The most com-
mon cleavage sites are the CO-NH bonds which give
rise to the b and/or the y series of ions.
Protein identification by mass spectrometry
The key step in any proteomic study consists in the
identification of proteins that have been separated
either by gel electrophoresis and digested, or cleaved
directly using enzymatic procedures in the so-called
‘‘bottom-up’’ approach (21). Protein identification
from 2D gel electrophoresis is usually obtained by
MALDI-MS analyses (22, 23). Following colloidal
Coomassie staining, protein components are excised
from the gel, reduced and alkylated with iodoacet-
amide to irreversibly block the cysteine residues and
digested with trypsin. The resulting peptide mixture
is extracted from the gel and analyzed directly using
MALDI-MS (24, 25).
Identification of the different proteins is performed
using the peptide mass fingerprinting procedure (26).
This procedure uses the mass values, together with
other information such as the protease used for the
hydrolysis. This information is input into the Mascot
mass search software or analogous programs avail-
able on the internet (27). The experimental mass val-
ues are compared to those obtained from a
theoretical digestion of all proteins present in the
database, allowing for identification of the protein(s).
Alternatively, if the fingerprinting procedure is un-
able to identify the proteins, combined liquid chro-
matography-tandem mass spectrometry (LC-MS/MS)
methods can be used. Peptide mixtures are fraction-
ated by capillary HPLC. The fractions that elute from
the column are applied directly into the electrospray
MS and mass values determined. Peptide ions will be
simultaneously isolated and fragmented within the
mass spectrometer, producing daughter ion spectra
from which information on sequence of individual
peptides can be obtained. This information, together
with the peptide mass values, is then used to search
protein databases enabling identification of the pro-
tein components. It has been shown that sequence
information from just two peptides is sufficient to
identify a protein by searching protein and expressed
sequence tag databases.
Recently, ‘‘top-down’’ proteomics has become pop-
ular in the assessment of PTMs. In this approach, the
multicharged ions of intact proteins are used as pre-
cursor ions and fragmented to provide sequence
information and protein identification. Technically
demanding, sophisticated instrument setup consti-
tutes the main challenge of top-down proteomics (28).
However, recent developments in instrumentation
have been introduced, such as specifically designed
Fourier transform ion cyclotrone resonance (FTICR)
mass spectrometers, making the top-down approach
suitable even for PTM studies (29).
Post-translational modifications (PTMs)
Protein PTMs are thought to be one of the major
determinants for the complexity of life. These modi-
fications increase the molecular heterogeneity of
gene products, adding a further dimension to the pro-
teome as compared to the genome. Greater than 5%
of the genes in the human genome encode for
enzymes that perform such modifications. These
include hundreds of protein kinases and phospha-
tases, ubiquitinyl ligases, acetylases and deacety-
lases, methyl transferases and glycosyl transferases
(30). The repertoire of PTMs is very complex consid-
ering that no -15 out of the 20 common amino acids
may be modified. These modifications range from
addition of a single group to the linkage of a complex
oligosaccharide moiety or glycosyl phospohatidyl
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inositol (GPI) anchor. More than 250 PTMs have been
described to date (31). Genomic studies have not
been able to elucidate complex mechanisms such as
development of disease, aging, differentiation, devel-
opment, and others that are finely regulated by
dynamic changes in protein function mediated
through PTMs.
The pattern of protein PTMs constitute a molecular
code that dictates protein conformation and folding,
cellular localization, cellular interactions and cell
activities, tissue and environmental conditions.
Understanding this code constitutes a major chal-
lenge of proteomics. It should be emphasized that
detection of PTMs, while important, does not distin-
guish the number and type of PTMs that may be pres-
ent on any one intact protein. This disconnection from
the parent protein modifications may lead to the loss
of information on the synergies between PTMs. New
methods and strategies have been developed, and
many more are needed to fully characterize PTMs in
a specific proteome and to describe their changes.
Glycosylation
Glycosylation is a co- and post-translational modifi-
cation where oligosaccharide chains are covalently
linked to proteins. Glycoproteins are ubiquitous,
being found in all living organisms from eubacteria to
eukaryotes (32). They fulfill their biological roles as a
complex mixture of glycosylated variants called gly-
coforms. This microheterogeneity is primarily due to
the fact that oligosaccharide biosynthesis is not tem-
plate driven. Assembly of the glycan moieties is gov-
erned by the relative amount of different glycosidic
enzymes (33), the cell type, and physiological status.
In addition, the reactions involved in glycosylation
and deglycosylation are frequently incomplete, result-
ing in an increase in the heterogeneity of glyco-
proteins.
A new discipline, glycobiology, emerged in the
1980s, with a focus on the structural and functional
characterization of glycoproteins and glycoconjugates
(34). Recently, glycobiology has evolved into glyco-
mics, the investigation of the complete set of glyco-
conjugates and carbohydrates that occur in an
organism. Glycomics show a higher level of complex-
ity than genomics, or even proteomics, primarily due
to the microheterogeneity of glycoforms described
above. Furthermore, glycans have a larger number of
building blocks compared with nucleic acids and pro-
teins. These can be assembled in complex branched
structures in which monomeric units can adopt vari-
ous conformations and binding positions.
Biosynthesis of glycopeptide linkages
The enzymes responsible for glycosylation are
membrane-bound glycosyltransferases and glycosi-
dases that are active in the endoplasmic reticulum
(ER) and Golgi compartments. Their activity can gen-
erate two large classes of glycoforms; N-linked and
O-linked glycans. O-linked oligosaccharides have the
glycosidic component linked to the hydroxyl group of
serine or threonine residues. N-glycosylation is char-
acterized by the formation of an N-glycosidic linkage
on the amide of asparagine residues. This glycosyla-
tion requires a strict consensus sequence Asn-X-Ser/
Thr (35). Although this sequence frequently occurs, it
is not always a site that is gylcosylated. This is most
probably due to conformational factors. N-glycosyla-
tion begins in the ER (36) where a biosynthetic
precursor, a dolichol-P-P-linked oligosaccharide
(Glu3Man9GlcNAc2), is transferred to Asn residues in
nascent polypeptide chains. This glycan is a well-con-
served structure in evolution; the same compound is
seen in plant, fungal and mammalian cells.
Further processing of the oligosaccharide may
occur in the Golgi complex. The structural diversity
found in Asn-linked oligosaccharides from different
organisms, cell types or tissues, originates from pro-
cessing reactions occurring in the Golgi apparatus
(37, 38).
O-glycosylation also occurs in the Golgi and con-
sists of the step-wise addition of sugar residues
directly onto the polypeptide chain. This process
starts from an N-acetylgalactosamine residue linked
to the hydroxyl group of Ser or Thr residues (39). A
specific glycosyltransferase then adds the galactose
residue to the GalNAc. The last steps in biosynthesis
of typical O-glycans are the additions of two N-ace-
tylneuramic acid (sialic acid) residues in the trans-
Golgi reticulum. O-oligosaccharides can vary in size
from a single GalNAc residue, referred to as the Tn
antigen, to oligosaccharides comparable in size to
complex N-oligosaccharides.
The role of glycosylation
The oligosaccharide moiety confers specific physico-
chemical properties to glycoproteins, and fulfills sev-
eral biological functions. Several studies dealing with
the importance of N-glycosylation in the folding pro-
cess have been reported. Glycans constitute bulky
hydrophilic moieties that reduce aggregation and pro-
mote solubility. This feature helps the protein follow
a specific folding pathway. However, the principal
role in the folding process is played by deglycosyla-
tion and reglycosylation in the ER, which occurs
repeatedly during the biosynthesis of glycoproteins.
This system is recognized as a central component of
a quality control and chaperone pathway in the ER
lumen (37, 40–42).
Some oligosaccharides play an important role in
the coating of many glycoproteins, protecting them
from proteases and antibodies and affecting their
turnover and half-life (43, 44). Oligosaccharides can
act as specific receptors for pathogens, being respon-
sible for interactions with vertebrate cells through
lectins. Lectins are specialized glycoproteins that can
recognize vertebrate glycan structures with high spec-
ificity (45). The variable nature of surface glycans may
be a way to escape pathogens’ recognition systems.
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Figure 2 Carbohydrate fragmentation pattern.
Ions retaining the charge at the reducing terminus are
named X, Y and Z. Complementary ions are labeled A, B and
C.
Recognition by ligands or receptors is a constant
characteristic of glycoproteins. Most are cell-surface
receptors, whose glycosylation affects binding and
activity. Cells are covered with a high-density coating
of oligosaccharides, indicating that oligosaccharides
are responsible for cell-cell and cell-matrix interac-
tions and adhesion (43).
Glycoproteome characterization
Understanding the structure, enzymology and cellular
biology of glycosylation is the main goal of glycomics
with the ultimate goal being the comparison of organ-
isms in normal and pathological conditions (44). How-
ever, difficulties exist in the analysis of complex
mixture of glycoconjugates, primarily due to their
microheterogeneity as stated above. These difficulties
largely prevent the simple and direct approach of ana-
lyzing the entire set of glycans following their release
from glycoproteins or glycoconjugates. Several pro-
tocols (46–49) have been developed to release the oli-
gosaccharides from both O-linked and N-linked
glycoproteins. However, the ensemble of all these
glycans constitute a far too complex mixture to be
analyzed directly by any mass spectrometric method.
These analyses can provide information only on the
most abundant glycoforms, leaving the vast majority
of minor glycans undetected.
Various methods have been developed to enrich
glycoproteins in a complex mixture. One approach
relys on capturing N-linked glycoproteins using
hydrazine chemistry. The oligosaccharides of the
glycoproteins are oxidized to form the corresponding
di-aldehydes that can be covalently linked to hydra-
zide beads. The captured glycoproteins are then
digested and the unmodified peptides washed out.
Captured glycopeptides can be deglycosylated with
PNGase F and quantified by isotopic labeling (50).
Chemical derivatization presents several side
reactions. Thus, lectin affinity chromatography has
recently been developed as an analytical tool in gly-
coproteomics. Several lectin-derivatized media are
commercially available for enrichment of glycopro-
teins and glycopeptides. A single lectin recognizes
specific glycoforms, whereas the use of a set of lec-
tins allows the complete set of glycoproteins to be
captured in a single step. Multilectin affinity columns
have been developed combining different lectins:
Hancock and co-workers combined concanavalin A
(ConA), wheat germ agglutinin (WGA) and Jacalin for
the analysis of the serum glycoproteins (51). Com-
parative serum glycoproteomics has been applied to
the study of pathological samples using a multilectin
affinity approach to identify oligosaccharide markers
in such diseases (33, 52–54).
Alternative methods rely on the chemical and/or
enzymatic hydrolysis of glycoproteins, followed by
affinity capture of the entire ensemble of glycopep-
tides with multiple lectins. Selective isolation of gly-
copeptides allows larger recovery of glycoforms since
the steric hindrance of glycoproteins severely affect
the interaction with lectins.
The structural characterization of glycans is still a
difficult task due to the presence, in most cases, of
several different structures at the same glycosylation
site (46). Unfortunately, although MS cannot differ-
entiate between the different hexoses and hexose-
amines, it has become a valuable tool in their
characterization (55).
The determination of the entire structure of oligo-
saccharide chains requires that the intact sugar
moieties be released from the glycoproteins/glyco-
peptides pool using either PNGase F or chemical
methods (56–61). Glycan profiling is then achieved by
MALDI-MS analysis of the intact glycan mixture. The
MALDI-MS spectra show the presence of intense
quasi-molecular ions originating from the whole oli-
gosaccharide moieties; assignment of the different
glycoforms is then performed on the basis of the
molecular weight of the oligosaccharides and their
known biosynthetic pattern (46).
This analysis is not sufficient to provide structural
information about the sequence and linkages of gly-
cans. Combination of MALDI-profiling with post-
source decay (PSD) or collision-induced dissociation
(CID) analyses is generally required (62). Glycan frag-
mentation spectra present some main cleavage sites.
A systematic nomenclature for oligosaccharide frag-
ment ions was established by Domon and Costello
(63), following that already in use for peptides. How-
ever, the structure of carbohydrates necessitates the
use of a more complex annotation due to possible
breakages occurring within the sugar ring. The pri-
mary cleavage sites, termed glycosidic cleavages,
involves the breaking of a single bond between adja-
cent sugars (Figure 2). They provide information on
sequence and branching, but little information on link-
age. Other cleavage sites, termed cross-ring cleav-
ages involving cleavage of two bonds are useful in
determination of the linkage. It is worth noting that
ions retaining the charge on the reducing terminus
are labeled X (cross-ring), Y (C1™O-glycosidic) and Z
(O™Cx glycosidic), while if the charge is retained at
the non-reducing end, the produced ions are called A,
B and C. The B and Y ions are usually the most abun-
dant species.
Cross-ring cleavage necessitates additional super-
script prefixes, denoting the atoms of the two cleaved
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Figure 3 Flow chart showing the strategy to characterize N-linked glycoproteomes in sera from healthy and diseased
individuals.
bonds. The situation becomes more complicated in
cases involving branched oligosaccharides. The
nomenclature is based on the carbohydrate compo-
nent of glycopeptides and glycoproteins, which con-
sist of a ‘‘core’’ unit and the branches, usually called
‘‘antenna’’. Each antenna is identified by a Greek let-
ter with the largest being given the symbol ‘‘a’’ and
the other symbols assigned based on decreasing
molecular weight.
CID provides focused ions and nanospray technol-
ogy provides good sensitivity. It is possible to per-
form MS/MS or MS3 experiments in order to obtain
extensive fragmentation of oligosaccharides or gly-
copeptides. This analysis helps elucidate the different
glycosidic structures present in glycoproteins includ-
ing the branching pattern, the sequence of antenna
and the possible occurrence of modifying groups,
such as sulfate, phosphate, acetyl groups, and others
(64).
Glycoproteome in tumor and inflammation: a case
study
Recently, our group introduced a simple strategy that
provides preliminary insight on the comparison of
glycoproteomes in sera from healthy and diseased
individuals. This technique uses a single affinity chro-
matography step coupled with MS (Figure 3). The N-
linked glycopeptides resulting from digestion of sera
samples with trypsin were selectively enriched in
order to enhance identification of N-glycosylation
sites using LC-MS/MS, and to obtain glycoform pro-
files using MALDI-MS analysis. Human sera from
patients with either myocardial damage or hepatic
carcinoma were evaluated since they represent exam-
ples of inflammatory and malignant disease.
Myocarditis is a group of diseases caused by infec-
tion, toxins, or autoimmune mechanisms character-
ized by inflammation of the heart, leading to necrosis
of myocytes (65, 66). Glycan moieties might be
responsible for the increase in leukocytes in damaged
tissue. Hepatic carcinoma is a primary malignancy of
the liver. There are several hypotheses about the role
that glycans play in the development of cancer. C gly-
can structures are known to contribute to oncogenic
signaling, transformation and metastasis (67).
Aliquots of serum from the two different patient
groups, and healthy donors, were pooled and digest-
ed with trypsin. The three peptide mixtures were sub-
jected to ConA affinity purification. The glycopeptides
were then deglycosylated using PNGase F treatment
and analyzed by MS. Similar analysis was performed
on the unbound ConA fractions which contained
primarily non-glycosylated peptides and highly
branched glycopeptides. The ConA affinity step spe-
cifically retained the high mannose, hybrid and bian-
tenna structures, separating them from the rest of the
glycans.
The oligosaccharides retained by ConA were eluted
and the glycans analyzed with MALDI-MS. Each signal
in the MALDI spectra was tentatively attributed to a
glycan arrangement on the basis of the mass value
and the known N-glycan biosynthetic pathway. Since
desialylation might have occurred in both positive
and negative ion mode, MALDI analyses were also
performed using 2,4,6 trihydroxyacetophenone as
matrix. This has been reported to minimize loss of
sialic acids (68).
More than 50 arrangements were detected, belong-
ing primarily to high mannose and biantenna classes,
indicating a high degree of glycan heterogeneity.
While some qualitative and quantitative differences
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could be recognized in the three glycan profiles, the
amounts did not significantly. However, differences in
the relative intensities of the most abundant peaks
were detected in the samples from patients with dis-
ease compared with those from healthy individuals.
Non-glycosylated peptides and peptides containing
O-glycans and large complex glycans were not
retained on the lectin. These constituted the unbound
fraction from the affinity purification. PNGase F was
added to this fraction, glycans were separated from
peptides by HPLC and analyzed by MALDI-MS. Figure
4A–C shows the negative MALDI spectra of the oli-
gosaccharide unbound fraction of the samples from
the diseased and healthy individuals.
The structure of the various glycoforms was
inferred on the basis of their mass value and the
known biosynthetic pathway. The most common gly-
cans were also selected for PSD fragmentation anal-
ysis to confirm oligosaccharide assignments. As an
example, Figure 5 shows the PSD spectrum of the gly-
coform at m/z 2391.10. This glycoform displays the
classic fragmentation pattern leading to the recon-
struction of the sialylated fucosylated biantenna
glycan.
In contrast to the fraction retained with ConA,
MALDI-MS analysis of the unbound glycan fraction
led to the detection of a plethora of glycoforms, and
highlighted differences in the profiling of the three
sample types. Glycans from patients with disease
were characterized by abnormal glycosylation pat-
terns, with differences in branching, sialylation and
fucosylation. These patients showed an excessive
expression of peculiar structures, the persistence of
incomplete and truncated structures, the accumula-
tion of precursors and the appearance of novel struc-
tures. This resulted in a higher degree of
heterogeneity compared with healthy patients. The
presence of more than 60 different glycoforms was
observed in patients with hepatic carcinoma (K-hepat-
ic). The increased size and branching of N-linked gly-
cans created additional sites for terminal sialic acid
residues; whose role in promoting metastasis is gen-
erally recognized. Myocardial lesions revealed the
presence of hyper-fucosylated signals, whereas K-
hepatic sera were characterized by hyper-fucosylation
and hyper-sialylation.
This study provided an overview of the abnormal
glycosylation that occurs in disease. The ConA affinity
step was instrumental in depleting commonly occur-
ring glycoforms. Without this step, highly branched,
less common glycoforms might have escaped mass
spectral analyses. Our data for K-hepatic serum were
in perfect agreement with results obtained by Zhao
et al. (52) who conducted a similar study on patients
with pancreatic cancer.
Selective labeling procedures in PTMs
Identification of post-translationally modified proteins
requires direct observation of both the modified pep-
tides and the specific residues involved. Due to the
complexity of proteomic samples, identification of
modified proteins often relies on the use of ‘‘specific’’
antibodies able to recognize individual PTMs (70–75).
Once the modified proteins have been labeled with
the specific antibody, they can be identified by MS
procedures such as peptide mass fingerprinting and/
or LC-MS/MS. Frequently, however, the actual modi-
fied peptides cannot be identified. Moreover, the
occurrence of more than one protein in a specific
location of the gel makes identification of PTMs
problematic.
Several new methods based on selective labeling
of modified peptides have recently been proposed
(76–79). The strategy behind these methods consist
of the direct selective analysis of labeled peptides
with the mass spectrometer without the use of 2D
gels and enrichment steps needed to reduce the com-
plexity of the peptide mixture prior to MS analysis.
Methods specifically tailored for the qualitative and
quantitative determination of PTMs have recently
emerged (80–83). The use of stable isotope labeled
tags (light and heavy tags) (78, 79) can also address
the problem of quantitative determination of PTMs.
While the tagging method currently described can tar-
get some PTMs more specifically than others, the
development of suitable selective chemical labeling
strategies that can identify a larger number of PTMs
should provide increased confidence in the identifi-
cation of PTMs.
Reporter ion generating tag strategy (RIGhT)
Several groups have reported on the potential of
chemical derivatization in conjunction with ESI-MS for
the analysis of synthetic and naturally occurring com-
pounds. Treatment with an appropriate derivatizing
agent can improve the ionization of a compound and
thus the detection of the analyte by ESI-MS.
Recently, our group proposed a novel strategy for
identification of PTMs (79, 84). Our strategy has gen-
eral applicability and is based on selective labeling of
phospho-Ser/Thr residues. We proposed that the deri-
vatizating agent may include a chemical moiety capa-
ble of fragmenting in a particular, thus allowing for
selective mass spectral analysis of modified peptides
through use of MSn techniques.
This strategy was given the acronym reporter ion
generating tag (RIGhT) to indicate a common deriva-
tization method based on the labeling of target resi-
dues with reagents capable of generating reporter
ions in MS2/MS3 experiments. Dansyl chloride (DNS-
Cl), a very well-known fluorescent derivatizing re-
agent commonly used in protein chemistry, was
chosen as the reporter tag. Approximately 40 years
ago we discovered that fragmentation of dansyl deriv-
atives gave rise to the typical m/z 170 and m/z 234
daughter ions fragments in electron impact experi-
ments (85).
The RIGhT method is based on: 1) selective modi-
fication of target residues with DNS-Cl or other avail-
able dansyl reagents and, 2) selective detection and
identification of labeled peptides by their character-
istic fragmentation pathway in MS/MS experiments
and the diagnostic m/z 234–170 transition in MS3
mode. Precursor ions scans (PIS) of the m/z 170 frag-
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Figure 4 MALDI-MS profiling in negative ion mode of the oligosaccharide extracted from the unbound fraction of ConA
affinity chromatography.
(A) Healthy serum, (B) myocardial lesions serum, (C) K-hepatic serum. The most important oligosaccharides are depicted;
structures present only in sera from individuals with disease are indicated by a star.
ment can then be combined with MS2 and MS3 anal-
ysis to specifically detect only the parent ions
producing the m/z 234–170 fragmentation (Figure 6).
Application of the RIGhT approach is dependent on
the availability of high-performance MS instruments
able to perform analysis with high-sensitivity and
accuracy. LIT mass spectrometers developed by the
combination of triple quadrupole MS with LIT tech-
nology is one such device capable of this type of anal-
ysis (86). LIT mass spectrometers combine the
advantages of very selective scanning of precursor
ion with a triple quadrupole along with sensitive MS/
MS capabilities of the ion trap (87). This hybrid instru-
ment is suitable for highly sophisticated MSn analysis.
Phosphorylation
Phosphorylation is a reversible modification that acts
as a switch to turn ‘‘on’’ or turn ‘‘off’’ protein activities
or cellular pathways. Phosphorylation acts in a revers-
ible manner by promoting the folding and function of
proteins, enzyme activities or substrate specificities,
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Figure 5 The MNaq ion at m/z 2391.10 was selected and submitted to PSD fragmentation.
Y and B ions as well as fragments originated by double cleavages are indicated.
Figure 6 Fragmentation of dansyl derivatives.
The typical m/z 170 and m/z 234 daughter ions fragments in MS/MS experiments as well as the diagnostic m/z 234-170
fragmentation in MS3 mode are indicated.
regulating protein localization, and complex forma-
tion and degradation. A wide range of cellular pro-
cesses including cell cycle progression, differentiation,
development, peptide hormone response, signal
transduction, metabolic maintenance and adaptation
are all regulated by protein phosphorylation (88). The
variety of functions in which phosphoproteins are
involved necessitates a wide diversity of phosphory-
lation. Several amino acids can be phosphorylated by
four types of phosphorylation. O-phosphates are the
most common class and attach most often to serine-,
threonine- and tyrosine-residues. However, O-phos-
phates can also attach to unusual amino acids such
as hydroxyl-proline. N-, S- and acyl-phosphorylation
are far less common and occur on histidine and lysine
(N-phosphates), cysteine (S-phosphates) and aspartic
and glutamic acid residues (acyl-phosphates).
Another characteristic of phosphorylation is the
ratio of phosphorylated and non-phosphorylated pro-
teins present in the cell. Protein phosphorylation usu-
ally occurs at substoichiometric level in the cell; some
residues are always phosphorylated, while others are
modified only transiently. Phosphorylation rates and
phosphoproteins abundance are very low in signal-
ing pathways, accounting for only 1%–2% of the
entire protein content present in the phosphorylated
form.
Protein phosphorylation is tightly regulated by a
complex set of kinases and phosphatases which are
responsible for protein phosphorylation and dephos-
phorylation, respectively. Kinases and phosphatases
are highly regulated, and phosphorylation cycles may
take place on a very short timescale. In addition to
problems concerning regulation, analysis is compli-
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cated by the complexity of phosphorylation patterns
and the sheer number of phosphorylation sites. In
many cases, phosphorylation effects are combinato-
rial and multiple sites are phosphorylated (89).
It has been estimated that as many as one-third of
the proteins within a given eukaryotic proteome
undergoes reversible phosphorylation, and there are
more than 100,000 estimated phosphorylation sites in
the human proteome. Deciphering the phosphopro-
teome will be a huge and challenging task due to the
different types of phosphorylation generating a vari-
ety of phosphoproteins that are not easily analyzed.
Phosphoproteome analysis
An important part of phosphorylation analysis is sam-
ple preparation that preserves protein phosphory-
lation. Detection of phosphorylated proteins within
complex mixtures is usually not possible without
prior separation of the proteins. Although 2D-gel elec-
trophoresis has been used primarily for separation
and quantification of proteins from different systems,
methods are also being developed to characterize the
phosphoproteome. Phosphoproteins can be visual-
ized directly in 2D gels using phospho-specific stains
or Western blotting.
Commercially available phospho-specific stains are
less sensitive than methods that use radioisotopes,
but the handling of these non-isotopic reagents is
more convenient (90). As an example, Pro-Q Diamond,
(Molecular Probes) a fluorescent dye, allows detection
of 1–20 ng of phosphoproteins in polyacrylamide gel,
depending on the phosphorylation state of the pro-
tein. For individual phosphoproteins, the strength of
the signal correlates with the number of phosphate
groups. Depending on the principle used for staining,
this method is more specific for Ser/Thr phos-
phorylations.
Antibodies can be used to discriminate between
phosphorylation of serine, threonine and tyrosine
(91). The specificity and sensitivity of immunostaining
is highly dependent on the antibody used. Various
antibodies of good specificity toward phospho-tyro-
sine are available with very little cross-reactivity.
Once phosphorylated, protein can be detected on a
gel using either specific staining or immunotech-
niques. A 2D gel can be prepared and developed
using colloidal Coomassie Blue or Silver staining. Fol-
lowing image analysis, phosphorylated protein spots
are matched to protein spots on the preparative gel.
Proteins of interest can then be excised from the gel,
digested and identified by MS. Major advantages
of this approach are in the detection of N-,
S- and O-phosphorylation and in the possibility of
quantitating the modified proteins (92, 93). To meas-
ure changes in the state of protein phosphorylation,
two distinct proteome samples can be analyzed and
immunoblotted, and the intensity of corresponding
spots compared.
The main drawback of the method is that indirect
identification of phosphorylated proteins by staining
methods for direct detection of modified peptides is
very unlikely using MS (94, 95). Moreover, when
many proteins are present in the same location on the
gel, identification of the actual modified protein is not
trivial.
Over the years, several strategies have been devel-
oped to increase the sensitivity of phosphoproteome
analysis that eliminate the need for specific staining
and antibody labeling (96, 97).
Recently, MS based methods have emerged as
powerful and preferred tools for the analysis of PTMs,
including phosphorylation, due to higher sensitivity,
selectively, and speed compared with other biochem-
ical techniques. However, despite advances in MS for
analysis of phosphorylation, many difficulties remain.
First, the generally low phosphorylation stoichiome-
try of proteins, including phosphopeptides, results in
low amounts of protein in the peptide mixtures. Sec-
ond, the increased hydrophilicity results in reduced
retention of phosphopeptides on reversed-phase col-
umns. Finally, there is selective suppression of the
ionization/detection efficiency in the presence of large
amounts of unphosphorylated peptides when using
MS analysis in positive mode. For these reasons,
several technologies such as affinity, liquid reverse
phase, ion exchange chromatography and capillary
electrophoresis, or some combination of these prior
to MS analysis, have been used in proteomics to
enrich phosphoproteins that might otherwise not be
detected. The enrichment step combined with the
high-sensitivity of MS technologies provides great
potential for characterization of the phosphoproteome
(98).
The use of miniaturized immobilized metal affinity
chromatography (IMAC), in which phosphopeptides
are non-covalently bound to resins that chelate Fe(III)
or other trivalent metals, followed by base elution,
has proved to be a potentially valuable method for
enrichment of phosphopeptides (99–102). With fur-
ther refinements, this technique may offer the best
potential for large-scale phosphorylation analysis.
Another approach to enrich phosphoproteins is
based on the use of specific antibodies to immuno-
precipate proteins from complex lysates. With this
approach, the extraction of phosphoproteins leads to
substantial simplification of the protein pattern, and
enrichment phosphoproteins present in low concen-
trations (103).
Several methods for selective enrichment of phos-
phoproteins and phosphopeptides utilize chemical
modification of the phosphate group. This approach
does not distinguish between O-glycosylated and
phosphorylated analytes, thus requiring additional
analysis to confirm phosphorylation. Zhou et al.
established a multi-step derivatization method capa-
ble of enriching not only Ser/Thr-phosphorylated pep-
tides, but all types of phosphorylated peptides as well
(6, 104). Phosphopeptides are bound to sulfidryl-con-
taining compounds via phosphoamidate-bonds and
can, therefore, be linked covalently to a solid support
with immobilized iodoacetyl-groups. The phosphate-
groups are not cleaved off the respective residues, so
native phosphopeptides are obtained after elution
with trifluoroacetic acid (TFA). A drawback of this
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Figure 7 Identification of phosphoSer/Thr by b-elimination
of the phosphate group from Ser/Thr residues, selective
addition of a dansyl derivative on the newly generated dou-
ble bond, and detection by precursor ion/MS2/MS3 mass
spectral analysis.
Figure 8 Synthesis of dansyl-cysteamine.
method is the extensive work is required to quanti-
tatively block all amino- and carboxy-groups within
the peptides to prevent intramolecular and intermo-
lecular condensation.
Another chemical tagging reaction is based on the
b-elimination of phosphate groups in phospho-Ser-
ine/phospho-Threonine (pSer/pThr) residues under
alkaline conditions, followed by a Michael-type addi-
tion of a thiol compound on the resultant double bond
(105).
Dansyl labeling of pSer/pThr
In an attempt to improve and simplify the plethora of
methods described, we employed the RIGhT strategy
(84) to the selective identification of phosphoSer/Thr
peptides. The method consists of (a) b-elimination of
the phosphate group from Ser/Thr residues; (b) selec-
tive addition of a dansyl derivative on the newly
formed double bond, and (c) the selective detection
and identification of labeled peptides by precursor
ion/MS2/MS3 mass spectral analyses (Figure 7).
This approach was first developed using bovine a-
casein as a model phosphoprotein. The phosphate
moieties from a tryptic a-casein digest were removed
from pSer and pThr using barium hydroxide ion-
mediated b-elimination (79). The peptide mixture was
then analyzed using MALDI-MS which showed ions
corresponding to the b-eliminated peptides that were
98 Da lower than expected. However, although DNS-
Cl is known to react with primary NH2 groups, it is
unable to give a Michael addition to double bonds. A
novel dansyl derivative of cysteamine was, therefore,
synthesized following the synthetic route depicted in
Figure 8. The free SH group of dansyl-cystamine was
then reacted with the b-eliminated peptide mixture
via Michael-type addition. The yield of this addition
reaction was monitored with MALDI-MS, showing
that the extent of the reaction was not quantitative as
expected for a typical Michael reaction addition (84).
In a proof-of-principle experiment, a tryptic digest
from ten standard proteins was spiked with a mini-
mum amount of an a-casein tryptic mixture modified
with dansyl-cysteamine. An aliquot of 1 pmol of the
peptide mixture was analyzed by LC-MS/MS with a
LIT instrument, combining a PIS (m/z 170) with MS3
analysis (see above) (Figure 9).
Figure 10 shows a typical reconstructed ion chro-
matogram for the transition m/z 234/170 in MS3 mode
that is dominated essentially by two signals. The cor-
responding MS2 spectra led to reconstruction of the
entire sequence of the b-eliminated phosphopeptides
104–119 and 106–119 that carried a dansyl-cyste-
amine moiety. The modified ion is stable during CID,
providing easily interpretable product ion spectra. In
fact, the y and b product ions still retain the modifying
group linked to the b-eliminated Ser residue, allowing
exact localization of the site of phosphorylation.
However, this approach seems amenable only for
monophosphorylated peptides since the diphospho-
rylated and pentaphosphorylated a-casein tryptic
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Figure 9 Flow chart showing bidimensional mass spectral
analysis.
In PIS mode the Q1 was scanned across the full mass range,
and ions are fragmented in the collision cell. The Q3 was
set to transmit only the mass of the diagnostic product ion
(m/z 170). Therefore, only those precursor ions that origi-
nated the ion at m/z 170 by fragmentation were detected (A);
these selected precursor ions were then submitted to a com-
bined MS2/MS3 experiment to specifically detect only those
ions that produce the transition m/z 234/170 in the MS3 scan
mode leading to the detection of the dansyl peptides (B).
Figure 10 Ion chromatogram for PIS mode analysis (A) and reconstructed ion chromatogram for the transition m/z 234/170
in MS3 mode (B).
The MS3 TIC showed the presence of only two peaks with a large increase in the signal-to-noise ratio.
peptides could not be detected. This is probably due
to steric hindrance and high hydrophobicity of highly
modified dansyl peptides. The detection of multi-
phosphorylated peptides is a difficult challenge.
Among the proposed derivatization procedures, only
the modification strategy that we have proposed
based on the use of dithiothreitol (79) has resulted in
mass spectrometric analysis of multiphosphorylated
peptides that we have confidence in.
Nitration
Nitration can occur in cells during oxidative stress
and inflammation, likely through generation of
peroxynitrite (ONOO–) which is a potent oxidizing and
nitrating agent. Peroxynitrite is produced by the reac-
tion of superoxide anion in the presence of excess
nitric oxide (106, 107). Targets of nitration include
nucleic acids, sugars, lipids, alcohols, small organic
molecules and aromatic amino acids (108). Sites of
nitration in proteins are phenylalanine, tryptophan
and tyrosine residues, with the phenolic ring being
particularly active toward this modification.
Tyrosine nitration is increasingly recognized as the
prevalent, functionally significant post-translational
protein modification that serves as an indicator of
nitric oxide (NO–) mediated oxidative inflammatory
reactions (109). Tyrosine nitration, in fact, reflects the
extent of oxidant production that occurs in both phys-
iological and pathological conditions. Two catalytic
mechanisms have been proposed for in vivo nitration.
Both mechanisms involve the formation of tyrosyl
radicals that can react with nitric dioxide to generate
NO2Tyr. In addition to this principal pathway, tyrosyl
radicals can also react with another tyrosyl radical to
produce the 3-39-dityrosine specie which can generate
intramolecular cross-links or protein multimerization.
Another possible mechanism of protein nitration in
vivo is the reaction of tyrosyl radicals with nitric oxide
(NO), resulting in the formation of 3-nitrosotyrosine
(108). Apparently, nitrotyrosine is not stable and is
oxidized by two electrons to form 3-nitrotyrosine.
Addition of a NO2 group to the orto position of tyro-
sine decreases the pKa of the phenolic group approx-
imately three pH units. This gives a net negative
charge that is approximately half of that of nitrated
tyrosine residues at physiological pH.
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Nitration of proteins modulates catalytic activity,
cell signaling and cytoskeleton organization. This
bulky anionic constituent can induce changes in
protein conformation, resulting in the generation of
antigen epitopes, altered enzyme catalytic activity,
modulation of metabolic pathways and inhibition of
tyrosine phosphorylation by protein kinases. NO2Tyr
is considered the most important biomarker for iden-
tification of cellular processes associated with RNS
formation leading to PTMs of proteins. RNS is the
acronym for Reactive Nitrogen Species used to indi-
cate all chemicals derived by nitrogen metabolism.
These chemicals have a crucial role in regulation of
many biological functions, but if their concentration
increases too much, these species might initiate var-
ious types of cellular damage. It is well-known that
some PTMs due to oxidative stress are linked to the
pathogenesis of different diseases (109). In this
respect, it is important to find biological markers that
can provide information on the localization and phy-
siological effects of oxidative stress. Molecules mod-
ified by oxidation, nitration and nitrosilation can act
as such cellular biomarkers.
For these reasons many research groups have
focused their attention on 3-nitrotyrosine residues,
developing various methodologies for identification
of NO2Tyr residues. Protein nitration has been
observed in connection with more than 60 human dis-
orders including Alzheimer’s disease, atherosclerosis,
acute lung disease, amyotrophic lateral sclerosis
(ALS) and others. Nitration is detected primarily by
immunodetection using antibodies raised against
nitrotyrosine (110).
From the limited number of experiments simulating
in vivo conditions, it is apparent that tyrosine nitration
is a selective process. Not all proteins or all tyrosine
residues are targets for nitration (108). However, nei-
ther the abundance of a protein nor the abundance of
tyrosine residues in a protein can predict nitration.
Several factors such as the nitrating agent, protein
folding, and the presence of glutamate in the local
environment of the tyrosine residue are expected to
contribute to nitration of specific tyrosine residues.
Nitroproteome analysis
Detection and quantification of nitroproteins has been
accomplished essentially using 2D gel electrophoresis
and Western blotting. In particular, a 2D gel contain-
ing an aliquot of the protein sample is stained with
anti-3-nitrotyrosine antibody. The spots containing
modified protein are selectively detected. The remain-
ing portion of the sample can be loaded onto a
preparative 2D gel stained either with colloidal Coo-
massie or Silver stain. Detection of nitrated protein
spots is performed using image analysis by compar-
ing the antibody stained and the preparative gels. The
corresponding protein can then be identified using
conventional mass spectral techniques. Although
widely employed, this procedure has a number of
drawbacks. Recognition of nitroproteins is done with
an antibody which might show some non-specific
detection. Moreover, when two or more proteins are
present in the same spot, definitative identification of
the nitrated component cannot be accomplished.
Finally, oftentimes localization of the site of modifi-
cation within the nitrated protein sequence is impos-
sible unless the modified peptides are detected
during the identification procedure.
Other authors have employed methods using liquid
chromatography separation combined with electro-
chemical detection or GC-MS techniques (111, 112).
An alternative method to examining the overall
amount of 3-nitrotyrosine in proteins is based on the
use of electrospray MS. It has been shown by Peters-
son and co-workers that use of ESI-MS in PIS mode
for detection of nitrated peptides in complex mixtures
can be accomplished by taking advantage of charac-
teristic fragment ions of modified peptides (113). The
immonium ion of nitrotyrosine, in fact, provided un-
equivocal evidence for the presence of this modifica-
tion, suggesting that mass spectral analyses of intact
peptides might be a suitable analytical alternative.
The spectrum of nitrated peptides identified by use
of MALDI shows a specific and unique pattern of
molecular ions that can be used to identify this modi-
fication (113). The mass signal of the modified peptide
occurs 45 Da higher than the unmodified specie due
to substitution of an aromatic hydrogen with NO2.
This signal is usually accompanied by satellite ions
that are 16, 30 and 32 Da lower in mass. This unique
molecular ion pattern generated by photodecompo-
sition during MALDI analysis provides a unique sig-
nature for peptides containing 3-nitrotyrosine. This
fragmentation of nitrated peptides observed with
MALDI-MS reduces the abundance of signals for
nitrated peptides. This results in failure to detect mod-
ified peptides in very complex mixtures. It has been
shown by Petersson and co-workers (113) that ESI-MS
analysis of nitrated peptides prevents photodecom-
position and allows the nitrated peptides to be spe-
cifically detected in PIS mode using the immonium
ion of nitrotyrosine.
Dansyl labeling for the detection of 3-nitrotyrosine
residues
We extended the RIGhT strategy to the selective iso-
lation and identification of o-nitrotyrosine-containing
proteins (114). The philosophy of the method consist-
ed of the specific reduction of 3-nitroTyr to the cor-
responding aminotyrosine (NH2-Tyr). The amino
group of this residue is endowed with a particular low
pKa value, thus allowing selective labeling with
DNS-Cl at variance with aliphatic (10.4–11.1) and
N-terminal amino groups (6.8–8.0), which are largely
protonated.
The methodology was first tested on bovine serum
albumin (BSA) nitrated in vitro as a model protein and
then applied to more complex matrices. BSA was
nitrated in vitro with tetranitromethane (TNM) and the
TNM-induced modifications were determined with
MALDI MS. Spectral analyses led to 85% of BSA
sequence coverage. More importantly, however, 95%
of tyrosine residues could be verified. Two mass sig-
nals recorded at m/z 972.5 and m/z 1524.8 occurred
45 Da higher than the signals corresponding to the
peptides 137–143 and 396–409, respectively. This
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Figure 11 MS/MS spectra of nitrated BSA peptides 137–143 (A), 396–409 (B) and 448–458 (C).
Fragment ions are labeled as ‘‘y’’ or ‘‘b’’ according to the common peptide MS/MS fragmentation rules. Interpretation of the
spectra led to the localization of the original nitration sites and to the determination of the peptide sequence. Unlabeled
signals originated from secondary fragmentation pathways. Dansylated Tyr residues located at the level of Tyr137, Tyr399,
and Tyr451, are highlighted as Y* in the sequence.
suggests that they originated from the nitrated deriv-
atives of these fragments. However, signals corre-
sponding to the unmodified fragments were also
detected, indicating that the nitration reaction was not
quantitative.
Conversion of nitropeptides into their o-dansyl-
amino derivatives was accomplished by treatment
with Na2S2O4. Aminotyrosine residues were then
selectively labeled with DNS-Cl following the proce-
dure reported by Cirulli et al. (115). The reaction was
carried out at pH 5.0, exploiting the different pKa-
value of the o-aminotyrosine (4.7). MALDI-MS analy-
sis showed the presence of two new signals occurring
233 Da higher than the o-aminotyrosine-containing
peptides, corresponding to the expected dansyl deriv-
atives. Signals corresponding to the unmodified
o-aminotyrosine peptides indicated that the extent of
dansyl modification was about 60%. No modification
of the N-terminus or Lys residues was detected.
The exact location of the original nitro groups was
assessed by LC-MS/MS analysis of the peptide mix-
ture using the experimental procedure described
above (101, 103). LC-MS/MS full scan analysis
showed a highly complex mixture of peaks that pre-
vented identification of the modified peptides. The
total ion current (TIC) trace for the m/z 170 PIS dis-
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Figure 12 Flow chart of the analytical strategy for detecting labeled nitroproteins in bovine milk protein extract.
played a simplierd chromatogram with significantly
fewer number of signals. However, too many peaks
were still present and it was very unlikely they could
be related to dansyl derivatized peptides only. Finally,
once the m/z 170 precursor ion and the m/z 234/170
transition scan selectivity criteria were applied, the
MS3 TIC showed the presence of only three peaks
with a large increase in the signal-to-noise ratio. The
corresponding MS2 fragmentation spectra enabled
the determination of the entire sequence of these
species and allowed definitive identification of the
peptides. Of greater interest was the fact that the dan-
sylated Tyr residues were located at the level of
Tyr137, Tyr399 and Tyr451. The allowed for exact
identification of the original nitration sites (Figure 11).
It should be noted that LC-MS/MS analysis revealed
the occurrence of a further nitration site at level of
Tyr451 within the peptide 448–458, which had
escaped previous MALDI analysis.
The MS/MS spectra of o-dansylamino-Tyr-contain-
ing peptides showed additional peculiar features. A
stable fragment signal was always observed at m/z
384 corresponding to the immonium ion of o-dansyl-
amino-Tyr. This could then be used either as an alter-
native diagnostic fragment in the PIS, or to confirm
the presence of an o-dansylamino-Tyr residue in the
peptide sequence.
The feasibility of the MS procedure to identify o-
nitrotyrosine peptides in proteomics was evaluated
by mixing 100 mg of a mixture of BSA and nitrated
BSA with 10 mg of the entire cellular extract from
Escherichia coli. The total protein extract was then
submitted to the procedure described above. The
selection based on the MS3 scan removed a large
number of false positives leading to a simple ion
chromatogram that was dominated essentially by
three intense signals. The MS2 fragmentation spectra
of these signals confirmed the occurrence of the same
three BSA nitrated peptides detected previously.
The proposed strategy was finally employed to
identify o-nitrotyrosine residues in a more complex
sample, bovine milk (114). Bovine milk was nitrated
in vitro with TNM and an aliquot of milk proteins were
fractionated using SDS-PAGE and submitted to West-
ern blot analysis using antibody against o-nitrotyro-
sine to confirm the extent of nitration. The presence
of nitrated proteins was detected essentially in the
regions between 20–35 and 45–60 kDa. The entire
milk protein extract was dissolved in denaturizing buf-
fer and cysteine alkylation and reduction of nitro
groups were performed LC-MS/MS analysis using the
double selectivity criteria led to the identification of
nitropeptides from the high-abundant milk proteins,
a-casein and a-lactoglobulin. In addition, it was able
to assess the nitration sites occurring in proteins pres-
ent in low concentration, such as vimentin and clau-
din 2 (Figure 12).
Conclusions
At the turn of the last century, the international sci-
entific community witnessed a tremendous burst of
interest in the area of expression proteomics. There
was an enormous increase in numbers of papers
being published, new journals being launched and
large amounts of money invested by the pharmaceu-
tical industry in search of new biomarkers of disease
and therapeutic targets. In the last few years, interest
has subsided slightly due to the lack of any new effec-
tive biomarkers being discovered. Also, new applica-
tions in proteomics have begun to emerge. It is easy
to foresee that in the near future, most of proteomic
research will be addressed toward two main goals;
the investigation of cellular mechanisms through iso-
lation of functional complexes, and qualitative and
quantitative analysis of PTMs.
As discussed in this review, assessment of substoi-
chiometric and transient PTMs on a proteomic scale
is still a challenge. Existing procedures are not
endowed with general applicability. The successful
identification of PTMs is still dependent on a number
of factors including the nature and the extent of the
modifications, the amount of sample available, and
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other variables. Despite advances in technology, the
proteomic approach to PTMs still seem far from being
satisfactory and productive.
The recent trend shown by research in this field
suggests that scientists are moving along two main
paths that might also be combined. One path involves
particular attention to areas related to sample prepa-
ration and separation technologies, with particular
emphasis on enrichment procedures. The goal is to
develop selective methodologies able to increase the
amount of modified samples when compared to
unmodified ones.
The other path involves efforts made toward
addressing the utilization of advanced analytical
chemistry strategies focused on the development of
new instrumentation and technologies in the field of
MS. The introduction of sophisticated instrumenta-
tion, like the Orbitrap, or totally new concepts of ion
separation such as the ion mobility MS might open
up ways to utilize ‘‘bidimensional’’ or ‘‘multidimen-
sional’’ mass spectral analysis able to identify modi-
fied peptide ions in very complex mixtures.
The integration of innovative enrichment proce-
dures with these new mass spectrometric techniques
should enable a new generation of proteomic exper-
iments to be performed, thus providing a more gen-
eral approach to analysis of PTMs. In this respect,
specific chemical labeling of modified residues allow-
ing for both selective enrichment with affinity tags,
and sophisticated mass spectral experiments using
reporter tag fragmentation and quantitative analysis
by labeling with isotopes, will play a pivotal role in
the next generation of proteomics.
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the importance of investigation of post-translational modifica-
tions (PtM) is notably increased in the proteomic era, as they 
can affect biological functions, thus playing a critical role in 
cellular functioning. Moreover, they can vary in response to 
environmental stimuli or signalling modulators, thus finely 
tuning cellular mechanisms and their deregulation might be 
involved in the development of diseases. A huge number of 
different types of PtMs have been identified. the pattern of 
PtMs on proteins constitute a molecular code that dictates 
protein conformation, cellular location, macromolecular 
interactions and activities, depending on cell type, tissue and 
environmental conditions.
Glycomics shows a higher level of complexity than genomics 
or proteomics, as glycans have a greater number of building 
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blocks than nucleic acids (four nucleotides) and proteins (20 
amino acids). to make the process more complex, oligo-
saccharide biosynthesis is not template-driven and glycans 
can adopt complex branched structures of monomeric units 
linked together, whose structures have different conforma-
tions.1 the microheterogeneity of the oligosaccharides is 
essentially due to the reactions involved in glycosylation and 
deglycosylation at specific sites being frequently incomplete2 
and depends on the cell type and on the physiological status. 
Anomalous patterns of glycosylation may be caused by devel-
opmental events or pathological conditions.3–7 the problem of 
glycan heterogeneity has been overcome by mass spectrom-
etry methodologies, which allow qualitative and semi quanti-
tative information on oligosaccharides structures present in 
the mixture to be achieved with high sensitivity.8
the first step in glycoprotein identification is the isolation 
of glycosylated proteins from the remainder of the proteome. 
Several procedures have been developed aimed at glycoprotein 
enrichment and analysis including enzymatic and metabolic 
methods to chemically tag proteins to enable their isolation. 
Hydrazide trapping coupled to lectin affinity chromatography 
has also been proposed9 as well as combined multilectin 
affinity columns.10
once isolated, glycoproteins can be identified by mass spec-
trometry. Additional information can be obtained by using 
either enzymatic or chemo selective reactions to incorpo-
rate isotope labels at specific sites of glycosylation. Isotopic 
labelling facilitates mass spectrometry-based confirmation 
of glycoprotein identity, identification of glycosylation sites and 
quantification of the extent of modification.11
Several reports suggested that the alterations in protein 
glycosylation on the cell surface and in body fluids might be 
associated with the development of certain types of human 
cancer and other diseases (reference 12 and references 
therein). comparative serum glycoproteomics have been 
applied to the study of pathological samples, using a multi-
lectin affinity approach, in order to identify oligosaccharide 
markers in such diseases.13,14 A multi step method for broad 
analysis of human plasma N-glycoproteins was proposed by 
Smith and co-workers,15 based on a combination of immuno-
affinity subtraction and glycoprotein capture to reduce both 
the protein concentration range and the overall sample 
complexity.
Here, we report preliminary insights on the comparison 
of the glycoproteomes in healthy and myocarditis human 
sera, by using a single affinity chromatography (conA ) step 
coupled with mass spectrometry techniques. this strategy 
led to both the identification of 68 different glycosylation 
sites within 49 different proteins and to the definition of the 
glycosylation patterns. Moreover, to the best of our knowl-
edge, this study represents the first definition of glycoform 
distribution in myocarditis. the analysis of glycan profiling, 
once extracted from serum glycopeptides, is essential 
for comparative studies on different sera samples, thus 
providing a useful tool for the development of screening 
procedures. 
Materials and methods
Materials
Human serum samples from eight healthy donors and from 
five patients diagnosed with myocardial lesions have been 
obtained from the “Servizio Analisi” Policlinico, Napoli, 
Italy.
Guanidine, dithiothreitol (Dtt), trypsin, methyl-a-D-
mannopyranoside, a-cyano-4-hydroxycinnamic acid, 2,4,6 
trihydroxyacetophenone and sodium chloride were purchased 
from Sigma. Iodoacetamide (IAM), tris(hydroxymethyl)
aminomethane, calcium chloride and ammonium bicar-
bonate (AMBIc) were purchased from fluka as well as the 
MALDI matrix 2,5-dihydroxybenzoic acid (DHB). Methanol, 
trifluoroacetic acid (tfA) and acetonitrile (AcN) are HPLc 
grade type from carlo Erba, whereas the other solvents 
are from Baker. PD-10 gel filtration columns are from 
Pharmacia, the HPLc columns are from Phenomenex, 
whereas the pre-packed columns Sep-pak c-18 are from 
Waters.
comassie Brilliant Blue was from Bio-rad. PNGase f were 
purchased from Boheringer. Ion exchange resins Dowex H+ 
(50W-X8 50–100 mesh) were provided by BDH. concanavalin 
A sepharose resin was purchased from Amersham 
Biosciences.
Protein concentration determination
Sera protein concentration was determined by the Bradford 
assay method, using bovine serum albumin (BSA) as standard. 
Known amounts of BSA were diluted in 800 µL of H2o and 
then mixed to 200 µL of comassie Brilliant Blue. five different 
BSA concentrations were determined by measuring absorb-
ance at 595 nm and used to obtain a linear calibration curve. 
three different sera dilutions were measured at 595 nm. 
Absorbance data were interpoled on the calibration curve, 
allowing the determination of protein concentration in the 
different samples.
Reduction and carbamidomethylation
An aliquot (1 mg) of each serum was lyophilized and dissolved 
in 200 µL of denaturation buffer (guanidine 6 M, tris 0.3 M, 
EDtA 10 mM, pH 8). reduction was carried out by using a 
10 : 1 Dtt:cysteins molar ratio. After incubation at 37°c for 2 h, 
carboxyamidomethylation was performed by adding iodoa-
cetamide in an excess of alkylating agent of 5 : 1 with respect 
to the moles of thiol groups. the mixture was then incubated 
in the dark at room temperature for 30 min. the alkylation 
reaction was stopped by the addition of formic acid, in order to 
achieve an acidic pH.
the excess of salts and reagents was then removed by 
gel filtration on PD-10 columns. Elution was performed 
using ammonium bicarbonate (AMBIc) 10 mM buffer. the 
collected fractions were analyzed by a Beckman Du 7500 
 spectrophotometer, measuring the absorbance at 220 nm 
and 280 nm. Protein containing fractions were collected and 
concentrated in a centrifuge Speed-Vac.
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Enzymatic digestions
trypsin digestion was carried out in AMBIc 10 mM buffer using 
a 50 : 1 trypsin : protein mass ratio (w / w). the sample was 
incubated at 37°c for 12–16 h.
Affinity chromatography
Peptide mixtures were incubated in batches with 50 µL of 
conA sepharose resin, which was activated with calcium ion 
in 20 mM tris-Hcl buffer; 0,5 M Nacl; 1 mM cacl2 at pH 7.4, 
4°c, for 2 h, as suggested by the manufacturer. then the 
conA containing eppendorf was centrifuged at 3000 rpm at 
4°c. the unbound peptides were removed in the supernatant. 
the resin was then washed six times with the same buffer 
described before.
the elution phase was based on methyl-a-D-mannopyrano-
side 0,25 M competition with glycopeptides and was performed 
for 30 min at 4°c. this procedure was repeated twice.
RP­HPLC
Both the peptides and the glycopeptides needed a desalting step 
in order to remove salts and  methyl-a-D- mannopyranoside.
Both the unbound and eluted peptides were desalted by 
HPLc on a c-18 resin. HPLc was performed on an Agilent 
chromatograph, at a flow rate of 0,2 mL min–1 and a linear 
gradient from 5% B (95% acetonitrile, 5% H2o and 0,07% 
trifluoro acetic acid) to 95% B in 1 min, allowing the fast elution 
of the unfractionated peptides.
Deglycosylation
Glycopeptides were lyophilized, resuspended in 10 mM AMBIc 
and incubated with PNGase f (5 u), for 12–16 h at 37°c. 
Deglycosylation was also carried out on unbound peptides, in 
order to release the glycans not recognized by conA.
Oligosaccharide purification
for glycan purification, the sample was loaded on a c-18 
silica-based bonded phase (Sep-pak). the column was 
activated with 10 mL methanol and equilibrated with 10 mL 
isopropanol, 10 mL H2o and 10 mL acetic acid 5%. the 
oligosaccharide component was eluted in 3 mL of 5% acetic 
acid as eluent whereas peptides were collected in 3 mL of 
40% isopropanol and 5% acetic acid. Alternatively, a reversed-
phase, high-performance liquid chromatography (rP-HPLc) 
step was performed by using a c-18 column and a gradient 
profile as follows: 7 min at 5% B, 5 to 95% B in 2 min and 
10 min at 95% B.
Glycans matrix­assisted laser desorption/
ionization (MALDI)­profiling and post source 
decay (PSD) analyses
Glycans were collected, lyophilized, resuspended in 50 µL of 
5% acetic acid and submitted to batch ion exchange chro-
matography using a ready-for-use regenerable mixed bed 
Dowex MB50 resin, in order to eliminate salts and other 
contaminants. the sample prepared above was filtrated 
and mixed with an equal amount of resin solution in a test 
tube. the tube was then gently stirred and centrifuged. 
the supernatant was recovered and used for MALDI-MS 
analyses.
Both positive and negative MALDI-MS analyses and 
MALDI PSD experiments were carried out on a Voyager 
DE-Str-Pro instrument operating in reflectron mode 
(Applied Biosystems, framingham, MA, uSA). the MALDI 
matrices were prepared by dissolving 25 mg of DHB (2,5 
dihydroxy benzoic acid) or tHAP (2,4,6-trihydroxyacetophe-
none) in 1 mL water / acetonitrile 10 : 1 or 10 mg a-cyano-
4-hydroxycinnamic acid in 1 mL of acetonitrile / 0.2% trif-
luoroacetic acid (70 : 30 v / v). typically, 1 µL of matrix was 
applied to the metallic sample plate and 1 µL of analyte 
was then added. In positive ion mode, the target voltage 
was set at 20 kV, the first grid at 66% of target voltage 
and delayed extraction was 200 ns; in negative ion mode 
the target voltage was –20 kV, the first grid 60% of target 
voltage and delayed extraction was fixed at 400 ns.
conditions were optimised to obtain the best signal-to-
noise ratios and the best possible isotopic resolution with 
two-point external calibration using maltoheptose (exact 
isotopic mass, 1153.02 Da) and tetrantennary sialylated 
oligosaccharide (exact isotopic mass, 2686,03 Da) as cali-
brants, resulting in a mass accuracy of 300 ppm. Each 
spectrum represents the sum of 1500 laser pulses from 
randomly chosen spots per sample position. All analyses 
were performed in triplicate.
the PSD fragment spectra were acquired after pseudo 
molecular cation selection using the time ion selector. 
fragment ions were refocused by stepwise reducing the 
reflector voltage by 20%. the individual segments were 
then stitched together using the Applied Biosystems soft-
ware. raw data were analyzed using the computer software 
provided by the manufacturers and are reported as mono-
isotopic masses.
Peptide liquid chromatography tandem mass 
spectrometry (LC­MS/MS)
the samples were diluted in formic acid 0.1% in order to obtain 
a final concentration of 20 fmol µL–1. Eight µL were loaded and 
analyzed.
NanoLc-MS2 experiments were performed on a 4000 
Q-trap mass spectrometer (Applied Biosystems) coupled to 
an 1100 nanoHPLc system (Agilent technologies). Peptides 
were separated on an Agilent reversed-phase column 
(Zorbax 300 SB c-18, 150 mm, 3.5 µm, 0.75 µm), at a flow rate 
of 0.2 uL min–1 using 0.1% formic acid, 2% AcN in water as 
solvent A 0.1% and formic acid, 2% water in AcN as solvent 
B. the elution was accomplished by a 5–65% linear gradient 
of solvent B in 60 min. A micro-ion spray source was used 
at 2.5 kV with liquid coupling, with a declustering potential 
of 50 V, using an uncoated silica tip from New objectives 
(ringoes, NJ, uSA).
Proteins were identified by searching the MS/MS spectra 
against the SwissProt or NcBI databases using the Mascot in 
house search engine (Matrix Science, London, uK).
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Results and discussion
this study was focused on a simple and rapid procedure, 
depicted in Scheme 1, to obtain an overview of the glyco-
sylation profiling in different human sera. this was achieved by 
enriching for the N-linked glycopeptides resulting from tryptic 
digestion of sera samples in order to enhance the identifica-
tion of N-glycosylation sites using Lc-MS/MS and obtaining 
glycans distribution by MALDI-MS analysis. the strategy was 
applied to the analysis of the glycoproteome from myocarditis 
sera using sera from healthy donors as control.
Serum samples from patients suffering from myo cardial 
lesions represent a very good example of inflammatory disease. 
Myocarditis is a collection of diseases of infectious, toxic and 
autoimmune etiologies, characterized by inflammation of the 
heart, leading to myocytes necrosis. the initial insult, which 
causes the death of certain cells, is followed by macrophage 
and natural killer cells activation, which continue myocyte 
necrosis.16,17 Being an inflammatory disease, the glycan moiety 
might consist of oligosaccharide epitopes responsible for the 
leukocytes rolling along the damaged tissues. to the best of 
our knowledge, no data on the characterization of glycosyla-
tion patterns in myocarditis has been reported, yet.
the study was addressed to two main goals, (i) identifi-
cation of N-glycosylation sites in serum glycoproteins 
by Lc-MS/MS and (ii) glycan profiling of normal and myocar-
ditis serum samples.
Assessment of N­glycosylation sites in 
serum glycoproteins
Aliquots of serum samples from different donors were pooled 
in order to obtain an average distribution of glycoproteins. the 
analyses were performed on intact serum samples without any 
pre-purification step or removal of most abundant proteins. the 
two samples obtained corresponding to healthy and myocar-
dial lesions donors were reduced, alkylated and digested with 
trypsin as described in the Materials and Methods section. 
According to the procedure developed, glycopeptides were 
selectively enriched by concanavalin A affinity chromatography 
directly performed in batch after tryptic digestion. the recov-
ered glycopeptides were then  deglycosylated by PNGase 
f treatment and the peptide mixtures directly analysed by 
Lc-MS/MS.
the presence of putative N-glycosylation sites was inferred 
by the increase of 1 Da in the peptide mass values due to 
Scheme 1.
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the conversion of Asn into Asp after PNGase f incubation. 
fine location of the modification sites was then established 
by the occurrence of key signals in the MS/MS spectra. As 
an example, figure 1 shows the daughter ion mass spec-
trum of a peptide retained by the conA affinity medium and 
 deglycosylated by PNGase f treatment. the MS/MS spectrum 
of the precursor ion at m/z 878.96 exhibited a clear series of 
y-ions from which the sequence of the peptide could easily 
be inferred as yLGN*AtAIffLPDEGK. BLASt analysis of this 
sequence identified the peptide as the fragment 268–283 of the 
human alpha-1-antitrypsin precursor in which Asn271 shows 
the consensus sequence for glycosylation (Asn–X–Ser/thr). 
the effective occurrence of a N-glycosylation site at Asn-271 
was demonstrated by the key y12 fragment ion at m/z 1308.68 
in the MS/MS spectrum. this fragment occurred 1 Da lower 
than expected showing the loss of Asp271 instead of Asn thus 
confirming the conversion of the asparagine to aspartic acid 
following PNGase f stripping.
figure 2 shows the MS/MS spectrum of the triply charged 
precursor ion at m/z 536.52 corresponding to the fragment 
3405–3419 of Apolipoprotein B. the series of y ions from 
which peptide identification was inferred is clearly visible in 
the daughter ion spectrum. Again, the N-glycosylation site 
could easily be assigned by the presence of the key y8 fragment 
ion that occurred 1 Da lower than expected (836.40 instead 
of 837.47) demonstrating that Asn3411 was glycosylated and 
then had been converted to Asp by PNGase f.
Similar analyses were carried out on the unbound conA 
fractions, mainly containing non-glycosylated peptides and 
highly branched glycopeptides. the unbound fraction was also 
deglycosylated by PNGase f treatment, yielding a mixture 
of deglycosylated and unmodified peptides that was directly 
analyzed by Lc-MS/MS. figure 3 shows the daughter ion spec-
trum of the precursor ion at m/z  628.38 that was assigned 
to the peptide 1004–1014 from the alpha-2-macroglobulin 
precursor. the key y5 ion at m/z 624.48 clearly demonstrated 
the occurrence of an asparagine residue at position 1009 that 
resulted in being unmodified following the deglycosylation 
step.
the overall data from the Lc-MS/MS analyses of both the 
conA bound and unbound fractions were pooled and summa-
rized in table 1. A total of 49 glycoproteins were identified in 
this study which contained 68 N-glycosylation sites. Among 
these sites, 50 had already been described and were confirmed 
while 18 were only annotated as potential glycosylation sites 
due to the presence of the NX(S/t) consensus sequence and 
were then newly identified.
the results presented here demonstrated that conA 
affinity chromatography on serum tryptic digests was effec-
tive in entrapping most of the glycopeptides with specific 
glycan structures and to enhance their detection by Lc-MS/
MS. A further advantage of the strategy relies on the lectin 
affinity chromatography being performed on glycopeptides 
instead of glycoproteins, avoiding fractionation of the extract 
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Figure 1. MS/MS spectrum of the doubly charged precursor ion at m/z 878.96 corresponding to the peptide YLGN*ATAIFFLPDEGK of 
alpha­1­antitrypsin (position 268–283 in the protein sequence). The fragmentation spectrum shows the presence of a N­glycosylation 
site at Asn271.
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Figure 2. MS/MS spectrum of the triple charged precursor ion at m/z 536.14 corresponding to the peptide FVEGSHNSTVSLTTK of 
 apolipoprotein B (position 3405–3419 in the protein sequence). The fragmentation spectrum shows the increment of 1 Da as Asn3411 
was converted into Asp following PNGase F treatment.
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Figure 3. Fragmentation spectrum of the doubly charged precursor ion at m/z 628.38 corresponding to the peptide AIGYLNTGYQR of 
alpha­2­macroglobulin. The fragmenattion pattern showed that the asparagine residue was unmodified in this peptide.
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Protein Sequence Peptide Charge
P01011  Alpha-1-
antichymotrypsin 
ytGN*ASALfILPDQDKuL 268–283 2+ confirmed 
P02763 Alpha-1-acid glycoprotein SVQEIQAtffyftPN*KtEDtIfLrEH 
QDQcIyN*ttyLNVQruH,uL
58–81 
87–101
3+ 
2+
confirmed 
confirmed
P01009 Alpha-1-antitrypsin yLGN*AtAIffLPDEGKEH,uH,EL,uL 268–283 2+,3+ confirmed
P01023 Alpha-2-macroglobulin SLGNVN*ftVSAEALESQELcGtEVPSVPEHGrKEH 864–886 3+ confirmed
P43652 Afamin  DIENfN*StQKEH,EL 
yAEDKfN*EttEKEH
28–37 
396–407
2+ 
2+
confirmed 
confirmed
P01008 Antithrombin III  LGAcN*DtLQQLMEVfKEH 
SLtfN*EtyQDISELVyGAKEH
124–139 
183–201
2+ confirmed 
confirmed
P04114 
 
 
Apolipoprotein B-100  
 
 
fN*SSyLQGtNQItGrEH,EL 
fVEGSHN*StVSLttKEH 
AEEEMLEN*VSLVcPKEL 
yDfN*SSMLyStAKEL
1522–1536 
3405–3419 
27–41 
3462–3474
2+ 
2+ 
3+ 
2+
confirmed 
Potential 
Potential 
confirmed
P05090 Apolipoprotein D ADGtVNQIEGEAtPVN*LtEPAKEL 83–104 3+ confirmed
P02749  Apolipoprotein H VyKPSAGN*NSLyrEH 
LGN*WSAMPScKEL
155–167 
251–261
3+ 
2+
confirmed 
confirmed
o75882 
 
Attractin  IDStGN*VtNELrEH,EL 
GPVKMPSQAPtGNfyPQPLLN*SSMcLEDSrEH
411–422 
1023–1052
2+ 
2+
confirmed 
confirmed
P00450 ceruloplasmin 
EHEGAIyPDN*ttDfQrEH,EL 
EN*LtAPGSDSAVffEQGttrEH,EL
129–144 
396–414
2+ 
3+
confirmed 
confirmed
P08603 
 
 
complement factor H 
 
 
ISEEN*EttcyMGKEH 
MDGASN*VtcINSrEH,EL 
IPcSQPPQIEHGtIN*SSrEL 
SPDVIN*GSPISQKuH
907–919 
1024–1036 
868–885 
212–224
2+ 
2+ 
3+ 
2+
confirmed 
Potential 
confirmed 
Potential
P10909 clusterin LAN*LtQGEDQyyLrEH,EL 372–385 2+,3+ confirmed
Q8IWV2 contactin-4 LN*GtDVDtGMDfrEL 64–76 2+ confirmed
P05156 complement factor 1 fLNN*GtctAEGKEH,EL 100–111 2+ confirmed
P01024 complement c3 tVLtPAtNHMGN*VtftIPANrEH 74–94 3+ confirmed
P0c0L4 complement c4-A GLN*VtLSStGrEH,EL 1326–1336 2+ confirmed
P02748 complement 
component c9 
AVN*ItSENLIDDVVSLIrEH 413–430 2+ confirmed 
Q14517 Protocadherin-fat 1 QVyN*LtVrAKDKEL 
fSMDyKtGALtVQN*ttQLrSrEL
994–1005 
1930–1950
3+ 
3+
Potential 
Potential
P02765 
 
Alpha-2-HS-glycoprotein VcQDcPLLAPLN*DtrEH 
AALAAfNAQNN*GSNfQLEEISrEH
145–159 
166–187
2+,3+ 
2+,3+
confirmed 
confirmed
Q03591  complement factor H 
related protein 1 
LQNNENN*IScVErEH 120–132 2+ confirmed 
Q13439 Golgin subfamily A 
member 4
HN*StLKQLMrEfNtQLAQKEH 1990–2008 3+ Potential 
P02790 
 
Hemopexin  SWPAVGN*cSSALrEH,EL 
ALPQPQN*VtSLLGctHuH,EH,EL
181–193 
447–462
2+ 
2+,3+
confirmed 
P00738 Haptoglobin VVLHPN*ySQVDIGLIKuH,uL,EH,EL 
MVSHHN*LttGAtLINEQWLLttAKEH,EL
236–251 
179–202
2+,3+ 
2+
confirmed 
confirmed
P04196  Histidine rich 
glycoprotein 
VEN*ttVyyLVLDVQESDcSVLSrEH 
VIDfN*cttSSVSSALANtKEH,EL
61–83 
121–139
2+ 
2+,3+
confirmed 
confirmed
P05155  Plasma protease c1 
inhibitor
VGQLQLSHN*LSLVILVPQNLKEH 344–364 2+ confirmed 
Table 1. Identification of glycosylation sites by LC­MS/MS analysis. (UH = unbound fraction of healthy serum; UL = unbound fraction of myo­
cardial lesions serum; EH = bound fraction of healthy serum serum; EL = bound fraction of myocardial lesions serum).
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by chromatographic and/or electrophoretic methods. In 
fact, the affinity step allowed us to selectively capture the 
defined subset of glycopeptides, greatly reducing the influ-
ence of the largely abundant non-glycosylated proteome 
complement.
Moreover, the specific enrichment of glycopeptides allowed 
both the identification of the individual glycoprotein and the 
direct assessment of the N-glycosylation site in the same 
analysis. finally, the affinity procedure was instrumental for 
the detection of the less abundant glycopeptides together with 
the most abundant ones, such as those deriving from albu-
mins or immunoglobulins.
As shown in table 1, all the identified peptides contained 
the conserved N-glycosylation motif Asn-X-Ser/thr. Most of 
the retained peptides were effectively glycosylated by specific 
glycan structures, thus confirming the capability of conA to 
bind N-glycosylated peptides carrying biantennary and high 
mannose-type structures with high selectivity. It should be 
Protein Sequence Peptide Charge
P01857 Ig alpha-1 chain c region LSLHrPALEDLLLGSEAN*LtctLtGLrEH 127–153 2+,3+ Potential
P01859  Ig gamma-2 chain c 
region
tKPrEEQfN*StfrEH 
tPLtAN*ItKEH
168–180 
200–208
2+ 
2+
confirmed 
Potential
P01860  Ig gamma-1 chain c 
region
EEQyN*StyruH,EL 136–144 2+ Potential 
P01861  Ig gamma-4 chain c 
region
EEQfN*StyruH,EH,EL 173–181 2+ Potential 
P01591 Immunoglobulin J chain EN*ISDPtSPLrEH,EL 48–58 2+ confirmed
P40189  Interleukin-6 receptor 
beta 
QQyfKQN*cSQHESSPDISHfErEL 
812–833 3+ Potential
P56199  Integrin alpha-1 SyfSSLN*LtIrEL 1096–1106 2+ Potential
P29622 Kallistatin DfyVDEN*ttVrEH 232–242 2+ confirmed
P01042 Kininogen-1 LNAENN*AtfyfKuH,EL 389–400 2+ Potential
P11279  
 
Lysosome-associated 
membrane 
glycoprotein 1 
DPAfKAAN*GSLrEL 
 
314–325 
 
2+ 
 
confirmed 
 
P01871  Ig mu chain c region yKN*NSDISStrEH 
GLtfQQN*ASSMcVPDQDtAIrEL
44–54 
204–223
2+ 
2+
confirmed 
confirmed
Q9Hc10 otoferlin NEMLEIQVfN*ySKVfSNKuH,uL,EL 59–76 3+ Potential
Q5Vu65  
 
Nuclear pore 
membrane 
glycoprotein 210-like
EVVVN*ASSrEH 
 
1551–1559 
 
2+ 
 
Potential 
 
Q9y5E7 Protocadherin beta 2 EtrSEyN*ItItVtDfGtPrEL 414–432 3+ Potential
P36955  Pigment epithelium 
derived factor 
VtQN*LtLIEESLtSEfIHDIDrEH 282–303 3+ confirmed 
P27169  Serum paraoxanase/
arylesterase1
HAN*WtLtPLKEH 250–259 2+ confirmed 
P49908 Selenoprotein P EGySN*ISyIVVNHQGISSrEH 79–97 3+ confirmed
Q9y275  
 
tumor necrosis factor 
ligand superfamily 
member 13B
cIQNMPEtLPN*NScySAGIAKEL 
 
232–252 
 
3+ 
 
confirmed 
 
P40225 thrombopoietin IHELLN*GtrGLfPGPSrrEL 250–267 2+ confirmed
P02787 Serotransferrin QQQHLfGSN*VtDcSGNfcLfrEH,EL 622–642 2+ confirmed
P07996 thrombospondin 1 VVN*SttGPGEHLrEH,EL 1065–1077 2+ confirmed
P04004 Vitronectin NN*AtVHEQVGGPSLtSDLQAQSKEL 85–107 3+ confirmed
P25311  Zinc-alpha-2-
glycoprotein 
DIVEyyN*DSN*GSHVLQGrEH,EL 100–117 3+ confirmed 
Table 1. Identification of glycosylation sites by LC­MS/MS analysis. (UH = unbound fraction of healthy serum; UL = unbound fraction of myo­
cardial lesions serum; EH = bound fraction of healthy serum serum; EL = bound fraction of myocardial lesions serum).
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underlined that highly branched containing glycopeptides 
were not retained by the affinity medium according to the 
specificity of conA. Moreover, some peptides could be identi-
fied in both the conA bound and unbound fractions, possibly 
due to different branching structures of the glycan occurring 
at the same N-glycosylation site. finally, few non-glycosylated 
peptides were detected in the fraction retained by conA; 
they were identified as belonging to most abundant serum 
proteins.
Spontaneous deamidation of Asn residues, responsible for 
conversion of Asn into Asp, seems rather unlikely in generating 
the results presented, even because it preferentially occurs in 
Asn-Gly (reference 18 and references therein) sequences, 
although it cannot be excluded completely. Most MS/MS 
spectra giving positive hits were derived from doubly charged 
precursor ions that predominantly yielded the y-ion fragment 
series. Although a number of triply charged precursor ions 
were fragmented generating good daughter spectra from 
which the modification site could be determined, many others 
gave poor spectra that prevented the unambiguous assign-
ment of the glycosylation site. therefore, the majority of the 
68 identified sites were assigned by fragmentation of doubly 
charged precursors.
Almost similar results were obtained by the Lc-MS/MS 
analyses of glycopeptides from both myocardial lesion 
carriers and healthy donors sera, i.e. the same glycosylated 
proteins were identified in the two samples. However, some 
individual glycopeptides were only found in one sample or 
in the other and, in a few cases, the same glycopeptide was 
recovered in the conA bound fraction in one sample and in 
the unbound fraction in the other. this suggests that differ-
ences exist in the glycosylation profile of glycoproteins from 
healthy or pathological sera with these differences very 
likely confined to the branching structures of the glycan 
moieties.
Glycan profiling
to further highlight the differences in N-glycosylation possibly 
occurring between myocardial lesions and healthy donors sera, 
the overall glycan profiling of the two samples was investi-
gated. Several papers have demonstrated that N-glycosylation 
changes in the serum glycome of cancer patients include 
changes in the levels of highly branched glycan structures, 
sialyl Lewis X epitopes and agalactosylated bi-antennary 
glycans. Moreover, several of these glycans have been linked 
to chronic inflammatory diseases, thus leading to the hypoth-
esis of possible links between inflammation and cancer.19
Samples were treated as described above and following the 
conA affinity selection step, the entire oligosaccharides were 
released from glycopeptides occurring in both the conA bound 
and unbound fractions by incubation with PNGase f to isolate 
high mannose, hybrid and biantennary structures as well as 
higher branched glycans.
oligosaccharides released from enzymatic hydrolysis were 
desalted by in batch ion exchange chromatography on a 
Dowex mixed bed resin that retained most of the ions occur-
ring in the sample. Glycans were then directly analyzed by 
MALDI-MS on a reflectron instrument, both in positive and 
negative mode. Since significant desialylation might occur 
during analysis of the samples, MALDI mass spectra were 
also performed using tHAP as matrix that was reported to 
avoid most of the problems associated with loss of sialic 
acids by fragmentation.20 Each peak detected in the MALDI 
spectra was manually interpreted and tentatively attributed 
to a glycan structure according to the N-glycan biosynthetic 
pathway and literature data. Manual interpretations were 
confirmed by using the Expasy GlycoMod software, an online 
software for prediction the possible oligosaccharide struc-
tures in glycoproteins from their experimentally determined 
masses. the ultimate definition of the major glycan structures 
detected in the different mixtures, including the sequence 
and branching degree of the antennae, was achieved by MS/
MS experiments using the MALDI PSD technique. MALDI MS/
MS experiments allowed us to confirm glycan structures and 
to discriminate between isobaric components, as indicated 
in the tables 2 and 3.
As a whole, these MALDI analyses constituted the oligosac-
charide profiling of the samples allowing us to describe the 
microheterogeneity of glycosylation within the different serum 
samples in details and to identify specific changes in glycan 
structures occurring in the pathological sera.
figure 4 shows the positive MALDI spectra of glycans deriving 
from the (a) healthy and (b) pathological glycopeptides retained 
during the coA affinity step and incubated with PNGase f. the 
oligosaccharide composition and structures corresponding to 
the recorded mass signals are summarized in table 2. More 
than 50 structures were detected in the MALDI profilings, as 
indicated in table 2, essentially belonging to high mannose 
and biantennary type, thus indicating a high degree of glycan 
heterogeneity. these data indicated that the two conA bound 
fractions essentially consisted of peptides carrying bianten-
nary and hybrid, as well as high mannose structures. this 
finding is in perfect agreement with the reported affinity of 
conA that generally binds complex biantennary, hybrid type 
and high- mannose-type N-linked glycans.21,22
the MALDI profiling revealed the occurrence of only 
three mass signals, at m/z 2028.7, m/z 2174.8 and m/z 
2320.8, respectively, that were tentatively attributed to 
 triantennary structures, HexNAc5Hex6, fucHexNAc5Hex6 and 
HexNAc5Hex6Sia. PSD analysis performed on the precursor 
ion at m/z 2174.8 confirmed the structure of the triantennary 
glycan and localized the fucose residue on the 3-antenna. In 
the fucosylated triantennary structure, the position of the 
fucose residue plays a very important biological role. As 
an example, alpha-1-acid glycoprotein, one of the identi-
fied glycoproteins in this study, is an non specific marker, 
whose temporary increase in the serum level is generally 
associated with many acute phase syndromes (infections, 
inflammation, cancer etc…).23 Previous data reported that 
the fucose residue on the triantennary glycans in alpha-1-
acid glycoprotein was generally found on the 3-antenna and 
not on the terminal core GlcNAc.24,25
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MALDI (m/z [M + Na]+) Monosaccharides 
composition 
 
Structure 
 
 
Ref. 
 
 
PSD 
 
 Theoretical 
MW
Found
1 
 
 
 
1257.4 
 
 
 
1257.4H 
1257.3L 
 
 
HexNAc2Hex5 
 
 
 
High mannose 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 11
Table 2. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides retained on the ConA affinity step (H = healthy serum; L = myocardial lesions serum). ", 
Fucose; ", N-acetylglucosamine; ", Hexose;  N-acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod 
software only.  
 
 
MALDI (m/z [M+Na]+) 
 
  
Theoretical 
MW 
 
 
Found 
Monosaccharides 
composition 
 
Structure Ref  PSD 
1 
1257.4 
 
 
1257.4 H 
1257.3 L 
 
HexNAc2Hex5 High mannose 
 
(41) 
 
X 
2 
1298.5 
 
 
1298.4 H 
1298.3 L 
 
HexNAc3Hex4 
Complex, 
monoantennary 
 
(41) 
 
X 
3 
1419.5 
 
 
1419.5 H 
1419.3 L 
 
HexNAc2Hex6 High mannose 
 
(41) 
 
X 
4 
1444.5 
 
 
1444.5 H 
1444.4 L 
 
FucHexNAc3Hex4 Complex, fucosylated  
 
X 
5 
1460.5 
 
 
1460.4 H 
1460.4 L 
 
HexNAc3Hex5 Hybrid (41) 
 
 
6 
1485.5 
 
 
1485.4 H 
1485.4 L 
 
FucHexNAc4Hex3 
Complex, biantennary, 
fucosylated (41) 
 
X 
7 
1501.5 
 
 
1501.5 H 
1501.3 L 
 
HexNAc4Hex4 Complex, biantennary (41) 
 
X 
8 
1542.6 
 
 
1542.4 H 
1542.4 L 
 
HexNAc5Hex3 Complex, bisecting (41) 
 
X 
9 
1581.5 
 
 
1581.5 H 
1581.4 L 
 
HexNAc2Hex7 High mannose (41) 
 
 
X 
 
 
 
2 
 
 
 
 
 
1298.5 
 
 
 
 
 
1298.4H 
1298.3L 
 
 
 
 
HexNAc3Hex4 
 
 
 
 
 
complex, monoantennary 
 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 11
Table 2. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides retained on the ConA affinity step (H = healthy serum; L = myocardial lesions serum). ", 
Fucose; ", N-acetylglucosamine; ", Hexose;  N-acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod 
software only.  
 
 
MALDI (m/z [M+Na]+) 
 
  
Theoretical 
MW 
 
 
Found 
Monosaccharides 
composition 
 
Struct re Ref  PSD 
1 
1257.4 
 
 
1257.4 H 
1257.3 L 
 
HexNAc2Hex5 High mannose 
 
(41) 
 
X 
2 
1298.5 
 
 
1298.4 H 
1298.3 L 
 
HexNAc3Hex4 
Complex, 
monoantennary 
 
(41) 
 
X 
3 
1419.5 
 
 
1419.5 H 
1419.3 L 
 
HexNAc2Hex6 High mannose 
 
(41) 
 
X 
4 
1444.5 
 
 
1 4.5 H 
1444.4 L 
 
FucHexNAc3Hex4 Complex, fucosylated  
 
X 
5 
1460.5 
 
 
1460.4 H 
1460.4 L 
 
HexNAc3Hex5 Hybrid (41) 
 
 
6 
1485.5 
 
 
1485.4 H 
1485.4 L 
 
FucHexNAc4Hex3 
Complex, biantennary, 
fucosylated (41) 
 
X 
7 
1501.5 
 
 
1501.5 H 
1501.3 L 
 
HexNAc4Hex4 Complex, biantennary (41) 
 
X 
8 
1542.6 
 
 
1542.4 H 
1542.4 L 
 
HexNAc5Hex3 Complex, bisecting (41) 
 
X 
9 
1581.5 
 
 
1581.5 H 
1581.4 L 
 
HexNAc2Hex7 High mannose (41) 
 
 
X 
 
 
 
 
 
3 
 
 
 
1419.5 
 
 
 
1419.5H 
1419.3L 
 
 
HexNAc2Hex6 
 
 
 
High mannose 
 
 
 
(41) 
 
 
 
 
 
 
 
 11
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software only.  
 
 
MALDI (m/z [M+Na]+) 
 
  
Theoretical 
MW 
 
 
Found 
Monosaccharides 
composition 
 
Structure Ref  PSD 
1 
1257.4 
 
 
1257.4 H 
1257.3 L 
 
HexNAc2Hex5 High mannose 
 
(41) 
 
X 
2 
1298.5 
 
 
1298.4 H 
1298.3 L 
 
HexNAc3Hex4 
Complex, 
monoantennary 
 
(41) 
 
X 
3 
1419.5 
 
 
1419.5 H 
1419.3 L 
 
HexNAc2Hex6 High mannose 
 
(41) 
 
X 
4 
1444.5 
 
 
1444.5 H 
1444.4 L 
 
FucHexNAc3Hex4 Complex, fucosylated  
 
X 
5 
1460.5 
 
 
1460.4 H 
1460.4 L 
 
HexNAc3Hex5 Hybrid (41) 
 
 
6 
1485.5 
 
 
1485.4 H 
1485.4 L 
 
FucHexNAc4Hex3 
Complex, bi ntennary, 
fucosylated (41) 
 
X 
7 
1501.5 
 
 
1501.5 H 
1501.3 L 
 
HexNAc4Hex4 Complex, biantennary (41) 
 
X 
8 
1542.6 
 
 
1542.4 H 
1542.4 L 
 
HexNAc5Hex3 Complex, bisecting (41) 
 
X 
9 
1581.5 
 
 
1581.5 H 
1581.4 L 
 
HexNAc2Hex7 High mannose (41) 
 
 
X 
 
 
 
4 
 
 
 
 
 
1 .5 
 
 
 
 
 
1444.5H 
1444.4L 
 
 
 
 
fucHexNAc3Hex4 
 
 
 
 
 
complex, f lated 
 
 
 
 
 
 
 
 
 
 
 
 11
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GlycoMod software only.  
 
 
MALDI (m/z [M+Na]+) 
 
  
Theoretical 
MW 
 
 
Found 
onosaccharides 
composition 
 
Structure Ref  PSD 
1 
1257.4 
 
 
1257.4 H 
1257.3 L 
 
HexNAc2Hex5 High mannose 
 
(41) 
 
X 
2 
1298.5 
 
 
1298.4 H 
1298.3 L 
 
HexNAc3Hex4 
Complex, 
monoantennary 
 
(41) 
 
X 
3 
1419.5 
 
 
1419.5 H 
1419.3 L 
 
HexNAc2Hex6 High mannose 
 
(41) 
 
X 
4 
1444.5 
 
 
1444.5 H 
1444.4 L 
 
FucHexNAc3Hex4 Complex, fucosylated  
 
X 
5 
1460.5 
 
 
1460.4 H 
1460.4 L 
 
HexNAc3Hex5 Hybrid (41) 
 
 
6 
1485.5 
 
 
1485.4 H 
1485.4 L 
 
FucHexNAc4Hex3 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
7 
1501.5 
 
 
1501.5 H 
1501.3 L 
 
HexNAc4Hex4 Complex, biantennary (41) 
 
X 
8 
1542.6 
 
 
1542.4 H 
1542.4 L 
 
HexNAc5Hex3 Complex, bisecting (41) 
 
X 
9 
1581.5 
 
 
1581.5 H 
1581.4 L 
 
HexNAc2Hex7 High mannose (41) 
 
 
X 
 
 
 
 
 
5 
 
 
 
 
1460.5 
 
 
 
 
1460.4H 
1460.4L 
 
 
 
HexNAc3Hex5 
 
 
 
 
Hybrid 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 11
Table 2. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides retained on the ConA affinity step (H = healthy serum; L = myocardial lesions serum). ?, 
Fucose; ?, N-acetylglucosamine; ?, , Hexose; ?, N-acetylneuraminic acid. Calculated: attributed on the basis of 
GlycoMod software only.  
 
 
MALDI (m/z [M+Na]+) 
 
  
Theoretical 
MW 
 
 
Found 
Monosaccharides 
composition 
 
Structure Ref  PSD 
1 
1257.4 
 
 
1257.4 H 
1257.3 L 
 
HexNAc2Hex5 High annose 
 
(41) 
 
X 
2 
1298.5 
 
 
1298.4 H 
1298.3 L HexNAc3Hex4 
Complex, 
monoantennary 
 
(41) 
 
X 
3 
1419.5 
 
 
1419.5 H 
1419.3 L HexNAc2Hex6 High mannose 
 
(41) 
 
X 
4 
1444.5 
 
 
1444.5 H 
1444.4 L 
 
FucHexNAc3Hex4 Complex, fucosylated  
 
X 
5 
1460.5 
 
 
1460.4 H 
1460.4 L HexNAc3Hex5 Hybrid (41) 
 
 
6 
1485.5 
 
 
1485.4 H 
1485.4 L 
 
FucHexNAc4Hex3 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
7 
1501.5 
 
 
1501.5 H 
1501.3 L 
 
HexNAc4Hex4 Complex, biantennary (41) 
 
X 
8 
1542.6 
 
 
1542.4 H 
1542.4 L 
 
HexNAc5Hex3 Complex, bisecting (41) 
 
X 
9 
1581.5 
 
 
1581.5 H 
1581.4 L 
 
HexNAc2Hex7 High mannose (41) 
 
 
6 
 
 
 
1485.5 
 
 
 
1485.4H 
1485.4L 
 
 
fucHexNAc4Hex3 
 
 
 
complex, biantennary,  
fucosylated 
 
 
(41) 
 
 
 
 
 
 
 
 11
Table 2. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides retained on the ConA affinity step (H = healthy serum; L = myocardial lesions serum). ?, 
Fucose; ?, N-acetylglucosamine; ?, , Hexose; ?, N-acetylneuraminic acid. Calculated: attributed on the basis of 
GlycoMod software only.  
 
 
MALDI (m/z [M+Na]+) 
 
  
Theoretical 
MW 
 
 
Found 
Monosaccharides 
composition 
 
Structure Ref  PSD 
1 
1257.4 
 
 
1257.4 H 
1257.3 L 
 
HexNAc2Hex5 High mannose 
 
(41) 
 
X 
2 
1298.5 
 
 
1298.4 H 
1298.3 L 
 
HexNAc3Hex4 
Compl x, 
monoa tennary 
 
(41) 
 
X 
3 
1419.5 
 
 
1419.5 H 
1419.3 L 
 
HexNAc2H x6 High mannose 
 
(41) 
 
X 
4 
1444.5 
 
 
1 44.5 H 
1444.4 L 
 
FucHexNAc3Hex4 Complex, fucosylated  
 
X 
5 
1460.5 
 
 
1460.4 H 
1460.4 L 
 
HexNAc3Hex5 Hybrid (41) 
 
 
6 
1485.5 
 
 
1485.4 H 
1485.4 L 
 
FucHexNAc4Hex3 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
7 
1501.5 
 
 
1501.5 H 
1501.3 L 
 
HexNAc4Hex4 Complex, biantennary (41) 
 
X 
8 
1542.6 
 
 
1542.4 H 
1542.4 L 
 
HexNAc5Hex3 Complex, bisecting (41) 
 
X 
9 
1581.5 
 
 
1 81.5 H 
1581.4 L 
 
HexNAc2Hex7 High ma nose (41) 
 
 
X 
 
 
 
7 
 
 
 
 
1 01.5 
 
 
 
 
1501.5H 
1501.3L 
 
 
 
HexNAc4Hex4 
 
 
 
 
complex, biantennary 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 11
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MALDI (m/z [M+Na]+) 
 
  
Theoretical 
MW 
 
 
Found 
Monosacch rides 
comp siti n 
 
Structure f  PSD 
1 
1257.4 
 
 
1257.4 H 
1257.3 L 
 
HexNAc2Hex5 High mannose 
 
(41) 
 
X 
2 
1298.5 
 
 
1298.4 H 
1298.3 L 
 
HexNAc3Hex4 
Co plex, 
monoantennary 
 
(41) 
 
X 
3 
1419.5 
 
 
1419.5 H 
1419.3 L 
 
HexNAc2Hex6 High mannose 
 
(41) 
 
X 
4 
1444.5 
 
 
1444.5 H 
1444.4 L 
 
FucHexNAc3Hex4 Complex, fucosylated  
 
X 
5 
1460.5 
 
 
1460.4 H 
1460.4 L 
 
HexNAc3 ex5 Hybrid (41) 
 
 
6 
1485.5 
 
 
148 .4 H 
1485.4 L 
 
FucHexNAc4Hex3 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
7 
1501.5 
 
 
01.5 H 
01.3 L 
 
HexNAc4Hex4 Complex, biantennary (41) 
 
X 
8 
1542.6
 
 
42.4 H 
42.4 L 
 
HexNAc5Hex3 Complex, bisecting (41) 
 
X 
9 
1581.5 
 
 
1581.5 H 
1581.4 L 
 
HexNAc2Hex7 High mannose (41) 
 
 
X
Table 2. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures derived from glyco­
peptides retained on the ConA ffinity step (  = healthy serum; L = myocardial lesions serum). , Fucose; , N­acetylglucosamine; , 
Hexose; , N­acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod software only.
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Table 2 (continued). Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures derived from 
glycopeptides retained on the ConA affinity step (H = healthy serum; L = myocardial lesions serum). , Fucose; , N­acetylglucosamine; , 
Hexose; , N­acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod software only.
MALDI (m/z [M + Na]+) Monosaccharides 
composition 
 
Structure 
 
 
Ref. 
 
 
PSD 
 
 Theoretical 
MW
Found
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1542.6 
 
 
 
 
1542.4H 
1542.4L 
 
 
HexNAc5Hex3 
 
 
 
complex, bisecting 
 
 
 
(41) 
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MALDI (m/z [M+Na]+) 
 
  
Theoretical 
MW 
 
 
Found 
Monosaccharides 
composition 
 
Structure Ref  PSD 
1 
1257.4 
 
 
1257.4 H 
1257.3 L 
 
HexNAc2Hex5 High mannose 
 
(41) 
 
X 
2 
1298.5 
 
 
1298.4 H 
1298.3 L 
 
HexNAc3Hex4 
Complex, 
monoantennary 
 
(41) 
 
X 
3 
1419.5 
 
 
1419.5 H 
1419.3 L 
 
HexNAc2Hex6 High mannose 
 
(41) 
 
X 
4 
1444.5 
 
 
1444.5 H 
1444.4 L 
 
FucHexNAc3Hex4 Complex, fucosylated  
 
X 
5 
1460.5 
 
 
1460.4 H 
1460.4 L 
 
HexNAc3Hex5 Hybrid (41) 
 
 
6 
1485.5 
 
 
1485.4 H 
1485.4 L 
 
FucHexNAc4Hex3 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
7 
1501.5 
 
 
1501.5 H 
1501.3 L 
 
HexNAc4Hex4 Complex, biantennary (41) 
 
X 
8 
1542.6 
 
 
1542.4 H 
1542.4 L 
 
HexNAc5Hex3 Complex, bisecting (41) 
 
X 
9 
1581.5 
 
 
1581.5 H 
1581.4 L 
 
HexNAc2Hex7 High mannose (41) 
 
 
X 
 
 
 
9 
 
 
 
 
 
1581.5 
 
 
 
 
 
1581.5H 
1581.4L 
 
 
 
 
HexNAc2Hex7 
 
 
 
 
 
High mannose 
 
 
 
 
 
(41) 
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MALDI (m/z [M+Na]+) 
 
  
Theoretical 
MW 
 
 
Found 
Monosaccharides 
composition 
 
Structure Ref  PSD 
1 
1257.4 
 
 
1257.4 H 
1257.3 L 
 
HexNAc2Hex5 High mannose 
 
(41) 
 
X 
2 
1298.5 
 
 
1298.4 H 
1298.3 L 
 
HexNAc3Hex4 
Complex, 
monoantennary 
 
(41) 
 
X 
3 
1419.5 
 
 
1419.5 H 
1419.3 L 
 
HexNAc2Hex6 High mannose 
 
(41) 
 
X 
4 
1444.5 
 
 
1444.5 H 
1444.4 L 
 
FucHexNAc3Hex4 Complex, fucosylated  
 
X 
5 
1460.5 
 
 
1460.4 H 
1460.4 L 
 
HexNAc3Hex5 Hybrid (41) 
 
 
6 
1485.5 
 
 
1485.4 H 
1485.4 L 
 
FucHexNAc4Hex3 
Complex, biantennary, 
fucos lated 
(41) 
 
X 
7 
1501.5 
 
 
1501.5 H 
1501.3 L 
 
HexNAc4Hex4 Complex, biantennary (41) 
 
X 
8 
1542.6 
 
 
1542.4 H 
1542.4 L 
 
HexNAc5Hex3 Complex, bisecting (41) 
 
X 
9 
1581.5 
 
 
1581.5 H 
1581.4 L 
 
HexNAc2Hex7 High mannose (41) 
 
 
10 
 
 
 
1611.5 
 
 
 
1611.4H 
 
 
 
HexNAc3Hex4SiaNa 
 
 
 
complex, monoantennary, 
sialylated 
 
 
(42) 
 
 
 
 
 
 
 
 
 
 12
10 
1611.5 
 
 
1611.4 H HexNAc3Hex4SiaNa 
Complex, 
monoantennary, 
sialylated 
(42) 
 
 
11 
1622.5 
 
 
1622.5 H 
1622.4 L 
 
HexNAc3Hex6 Hybrid (41) 
 
 
12 
1647.6 
 
 
1647.5 H 
1647.3 L 
 
FucHexNAc4Hex4 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
13 
1663.6 
 
 
1663.5 H 
1663.3 L 
 
HexNAc4Hex5 Complex, biantennary (41) 
 
X 
14 
1685.6 
 
 
1685.8 H 
1685.4 L 
 
HexNAc4Hex5Na 
 
Complex, biantennary 
 
 Calculated  
15 
1688.6 
 
 
1688.5 H 
1688.3 L 
 
FucHexNAc5Hex3 
Complex, fucosylated, 
bisecting (41) 
 
X 
16 
1704.6 
 
 
1705.5 H 
 HexNAc5Hex4 Complex, bisecting (41) 
 
 
17 
1743.6 
 
 
1743.4 H 
 
HexNAc2Hex8 High mannose (41) 
 
 
18 
1809.6 
 
 
1809.5 H 
1809.3 L 
 
FucHexNAc4Hex5 
Complex, biantennary, 
fucosylated 
 
 
(41) 
 
X 
19 
1814.6 
 
 
1815.4 H 
1816.3 L 
 
HexNAc4Hex4SiaNa 
Complex, biantennary, 
sialylated 
 Calculated  
20 
1825.6 
 
 
1825.5 H 
1825.3 L 
 
HexNAc4Hex6 Hybrid  Calculated  
21 
1832.6 
 
 
1831.3 L 
 
FucHexNAc4Hex5Na 
 
Complex, fucosylated, 
biantennary 
 
 Calculated  
22 
1850.7 
 
 
1850.5 H 
1850.3 L 
 
FucHexNAc5Hex4 
Complex, fucosylated, 
bisecting 
(41) 
 
 
23 
1866.7 
 
 
1866.5 H 
1866.4 L 
 
HexNAc5Hex5 
Complex, bisecting 
 
 
(41) 
 
 
24 
1881.6 
 
 
1880.8 H 
1880.5 L 
 
Fuc2HexNAc3Hex4Sia 
Complex, difucosylated, 
sialylated, 
monoantennary 
 Calculated  
11 
 
 
 
 
1622.5 
 
 
 
 
1622.5H 
1622.4L 
 
 
 
HexNAc3Hex6 
 
 
 
 
Hybrid 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 12
10 
1611.5 
 
 
1611.4 H HexNAc3Hex4SiaNa 
Complex, 
monoantennary, 
sialylated 
(42) 
 
 
11 
1622.5 
 
 
1622.5 H 
1622.4 L 
 
HexNAc3Hex6 Hybrid (41) 
 
 
12 
1647.6 
 
 
1647.5 H 
1647.3 L 
 
FucHexNAc4Hex4 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
13 
1663.6 
 
 
1663.5 H 
1663.3 L 
 
HexNAc4Hex5 Complex, biantennary (41) 
 
X 
14 
1685.6 
 
 
1685.8 H 
1685.4 L 
 
HexNAc4Hex5Na 
 
Complex, biante nary 
 
 l   
15 
1688.6 
 
 
1688.5 H 
1688.3 L 
 
FucHexNAc5Hex3 
Complex, fucosylated, 
bisecting 
(41) 
 
X 
16 
1704.6 
 
 
1705.5 H 
 
HexNAc5Hex4 Complex, bisecting (41) 
 
 
17 
1743.6 
 
1743.4 H 
 
HexNAc2Hex8 High mannose (41) 
 
 
18 
1809.6 
 
 
1809.5 H 
1809.3 L 
 
FucHexNAc4Hex5 
Complex, biantennary, 
fucosylated 
 
 
(41) 
 
X 
19 
1814.6 
 
 
1815.4 H 
1816.3 L 
 
HexNAc4Hex4SiaNa 
Complex, biantennary, 
sialylated 
 Calculated  
20 
1825.6 
 
 
1825.5 H 
1825.3 L 
 
HexNAc4Hex6 Hybrid  Calculated  
21 
1832.6 
 
 
1831.3 L 
 
FucHexNAc4Hex5Na 
 
Complex, fucosylated, 
biantennary 
 
 Calculated  
22 
1850.7 
 
 
1850.5 H 
1850.3 L 
 
FucHexNAc5Hex4 
Complex, fucosylated, 
bisecting (41) 
 
 
23 
1866.7 
 
 
1866.5 H 
1866.4 L 
 
HexNAc5Hex5 
Complex, bisecting 
 
 
(41) 
 
 
24 
1881.6 
 
1880.8 H 
1880.5 L Fuc2HexNAc3Hex4Sia 
Complex, difucosylated, 
sialylated,  Calculated  
12 
 
 
 
1647.6 
 
 
 
1647.5H 
1647.3L 
 
 
fucHexNAc4Hex4 
 
 
 
complex, biantennary, 
fucosylated 
 
 
(41) 
 
 
 
 
 
 
 
 12
10 
1611.5 
 
 
1611.4 H HexNAc3Hex4SiaNa 
Complex, 
mono ntennary, 
sialylated 
(42) 
 
 
11 
1622.5 
 
 
1622.5 H 
1622.4 L 
 
HexNAc3Hex6 Hybrid (41) 
 
 
12 
1647.6 
 
 
1647.5 H 
1647.3 L 
 
FucHexNAc4Hex4 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
13 
1663.6 
 
 
1663.5 H 
1663.3 L 
 
HexNAc4Hex5 Complex, biantennary (41) 
 
X 
14 
1685.6 
 
 
1685.8 H 
1685.4 L 
 
HexNAc4Hex5Na 
 
Complex, biantennary 
 
 Calculated  
15 
1688.6 
 
 
1688.5 H 
1688.3 L 
 
FucHexNAc5Hex3 
Complex, fucosylated, 
bisecting (41) 
 
X 
16 
1704.6 
 
 
1705.5 H 
 HexNAc5Hex4 Complex, bisecting (41) 
 
 
17 
1743.6 
 
 
1743.4 H 
 
HexNAc2Hex8 High mannose (41) 
 
 
18 
1809.6 
 
 
1809.5 H 
1809.3 L 
 
FucHexNAc4Hex5 
Complex, biantennary, 
fucosylated 
 
 
(41) 
 
X 
19 
1814.6 
 
 
1815.4 H 
1816.3 L 
 
HexNAc4Hex4SiaNa 
Complex, biantennary, 
sialylated 
 Calculated  
20 
1825.6 
 
 
1825.5 H 
1825.3 L 
 
HexNAc4Hex6 Hybrid    
21 
1832.6 
 
 
831.3 L 
 
FucHexNAc4Hex5Na 
 
Complex, fucosylated, 
biante nary 
 
 l l t   
22 
1850.7 
 
 
1850.5 H 
1850.3 L 
 
FucHexNAc5Hex4 
Complex, fucosylated, 
bisecting 
(41) 
 
 
23 
1866.7 
 
 
1866.5 H 
1866.4 L 
 
HexNAc5Hex5 
Complex, bisecting 
 
 
(41) 
 
 
24 
1881.6 
 
1880.8 H 
1880.5 L 
Fuc2HexNAc3Hex4Sia 
Complex, difucosylated, 
sialylated, 
 Calculated  
X 
 
 
 
13 
 
 
 
1663.6 
 
 
 
1663.5H 
1663.3L 
 
 
HexNAc4Hex 
 
 
 
5
High mannose 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 12
10 
1611.5 
 
 
1611.4 H HexNAc3Hex4SiaNa 
Co plex, 
monoantennary, 
sialylated 
(42) 
 
 
11 
1622.5 
 
 
1622.5 H 
1622.4 L 
 
HexNAc3Hex6 Hybrid (41) 
 
 
12 
1647.6 
 
 
1647.5 H 
1647.3 L 
 
FucHexNAc4Hex4 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
13 
1663.6 
 
 
1663.5 H 
1663.3 L 
 
HexNAc4Hex5 Complex, biantennary (41) 
 
X 
14 
1685.6 
 
 
1685.8 H 
1685.4 L 
 
HexNAc4Hex5Na 
 
Complex, biantennary 
 
 Calculated  
15 
1688.6 
 
 
1688.5 H 
1688.3 L 
 
FucHexNAc5Hex3 
Complex, fucosylated, 
bisecting (41) 
 
X 
16 
1704.6 
 
 
1705.5 H 
 HexNAc5Hex4 Complex, bisecting (41) 
 
 
17 
1743.6 
 
 
1743.4 H 
 
HexNAc2Hex8 High mannose (41) 
 
 
18 
1809.6 
 
 
1809.5 H 
1809.3 L 
 
FucHexNAc4Hex5 
Complex, biantennary, 
fucosylated 
 
 
(41) 
 
X 
19 
1814.6 
 
 
1815.4 H 
1816.3 L 
 
ex 4 4SiaNa 
Complex, biantennary, 
sialylated 
Calculated  
20 
1825.6 
 
 
1825.5 H 
1825.3 L 
 
HexNAc4Hex6 Hybrid  Calculated  
21 
1832.6 
 
 
1831.3 L 
 
FucHexNAc4Hex5Na 
 
Complex, fucosylated, 
biantennary 
 
 Calculated  
22 
1850.7 
 
 
1850.5 H 
1850.3 L 
 
FucHexNAc5Hex4 
Complex, fucosylated, 
bisecting 
(41) 
 
 
23 
1866.7 
 
 
1866.5 H 
1866.4 L 
 
HexNAc5Hex5 
Complex, bisecting 
 
 
(41) 
 
 
24 
1881.6 
 
1880.8 H 
1880.5 L 
Fuc2HexNAc3Hex4Sia 
Complex, difucosylated, 
sialylated, 
 Calculated  
14 1685.6 1685.8H 
1685.4L
HexNAc4Hex5Na complex, biantennary calculated 
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Table 2 (continued). Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures derived from 
glycopeptides retained on the ConA affinity step (H = healthy serum; L = myocardial lesions serum). , Fucose; , N­acetylglucosamine; , 
Hexose; , N­acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod software only.
MALDI (m/z [M + Na]+) Monosaccharides 
composition 
 
Structure 
 
 
Ref. 
 
 
PSD 
 
 Theoretical 
MW
Found
15 
 
 
 
1688.6 
 
 
 
1688.5H 
1688.3L 
 
 
fucHexNAc5Hex3 
 
 
 
complex, fucosylated, 
bisecting 
 
 
(41) 
 
 
 
 
 
 
 
 12
10 
1611.5 
 
 
1611.4 H HexNAc3Hex4SiaNa 
Complex, 
monoantennary, 
sialylated 
(42) 
 
 
11 
1622.5 
 
 
1622.5 H 
1622.4 L 
 
HexNAc3Hex6 Hybrid (41) 
 
 
12 
1647.6 
 
 
1647.5 H 
1647.3 L 
 
FucHexNAc4Hex4 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
13 
1663.6 
 
 
1663.5 H 
1663.3 L 
 
HexNAc4Hex5 Complex, biantennary (41) 
 
X 
14 
1685.6 
 
 
1685.8 H 
1685.4 L 
 
HexNAc4Hex5Na 
 
Complex, biantennary 
 
 Calculated  
15 
1688.6 
 
 
1688.5 H 
1688.3 L 
 
FucHexNAc5Hex3 
Complex, fucosylated, 
bisecting (41) 
 
X 
16 
1704.6 
 
 
1705.5 H 
 HexNAc5Hex4 Complex, bisecting (41) 
 
 
17 
1743.6 
 
 
1743.4 H 
 
HexNAc2Hex8 High mannose (41) 
 
 
18 
1809.6 
 
 
1809.5 H 
1809.3 L 
 
FucHexNAc4Hex5 
Complex, biantennary, 
fucosylated 
 
 
(41) 
 
X 
19 
1814.6 
 
 
1815.4 H 
1816.3 L 
 
HexNAc4Hex4SiaNa 
Complex, biantennary, 
sialylated 
 Calculated  
20 
1825.6 
 
 
1825.5 H 
1825.3 L 
 
HexNAc4Hex6 Hybrid  Calculated  
21 
1832.6 
 
 
1831.3 L 
 
FucHexNAc4Hex5Na 
 
Complex, fucosylated, 
biantennary 
 
 Calculated  
22 
1850.7 
 
 
1850.5 H 
1850.3 L 
 
FucHexNAc5Hex4 
Complex, fucosylated, 
bisecting 
(41) 
 
 
23 
1866.7 
 
 
1866.5 H 
1866.4 L 
 
HexNAc5Hex5 
Complex, bisecting 
 
 
(41) 
 
 
24 
1881.6 
 
1880.8 H 
1880.5 L 
Fuc2HexNAc3Hex4Sia 
Complex, difucosylated, 
sialylated, 
 Calculated  
16 
 
 
 
1704.6 
 
 
 
1705.5H 
 
 
 
HexNAc5Hex4 
 
 
 
complex, bisecting 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 12
10 
1611.5 
 
 
1611.4 H HexNAc3Hex4SiaNa 
Complex, 
monoantennary, 
sialylated 
(42) 
 
 
11 
1622.5 
 
 
1622.5 H 
1622.4 L 
 
HexNAc3Hex6 Hybrid (41) 
 
 
12 
1647.6 
 
 
1647.5 H 
1647.3 L 
 
FucHexNAc4Hex4 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
13 
1663.6 
 
 
1663.5 H 
1663.3 L 
 
HexNAc4Hex5 Complex, biantennary (41) 
 
X 
14 
1685.6 
 
 
1685.8 H 
1685.4 L 
 
HexNAc4Hex5Na 
 
Complex, biantennary 
 
 Calculated  
15 
1688.6 
 
 
1688.5 H 
1688.3 L 
 
FucHexNAc5Hex3 
Complex, fucosylated, 
bisecting (41) 
 
X 
16 
1704.6 
 
 
1705.5 H 
 HexNAc5Hex4 Complex, bisecting (41) 
 
 
17 
1743.6 
 
 
1743.4 H 
 
HexNAc2Hex8 High mannose (41) 
 
 
18 
1809.6 
 
 
1809.5 H 
1809.3 L 
 
FucHexNAc4Hex5 
Complex, biantennary, 
fucosylated 
 
 
(41) 
 
X 
19 
1814.6 
 
 
1815.4 H 
1816.3 L 
 
HexNAc4Hex4SiaNa 
Complex, biantennary, 
sialylated 
 Calculated  
20 
1825.6 
 
 
1825.5 H 
1825.3 L 
 
HexNAc4Hex6 Hybrid  Calculated  
21 
1832.6 
 
 
1831.3 L 
 
FucHexNAc4Hex5Na 
 
Complex, fucosylated, 
biantennary 
 
 Calculated  
22 
1850.7 
 
 
1850.5 H 
1850.3 L 
 
FucHexNAc5Hex4 
Complex, fucosylated, 
bisecting 
(41) 
 
 
23 
1866.7 
 
 
1866.5 H 
1866.4 L 
 
HexNAc5Hex5 
Complex, bisecting 
 
 
(41) 
 
 
24 
1881.6 
 
1880.8 H 
1880.5 L 
Fuc2HexNAc3Hex4Sia 
Complex, difucosylated, 
sialylated, 
 Calculated  
17 
 
 
 
 
1743.6 
 
 
 
 
1743.4H 
 
 
 
 
HexNAc2Hex8 
 
 
 
 
High mannose 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 12
10 
1611.5 
 
 
1611.4 H HexNAc3Hex4SiaNa 
Complex, 
monoantennary, 
sialylated 
(42) 
 
 
11 
1622.5 
 
 
1622.5 H 
1622.4 L 
 
HexNAc3Hex6 Hybrid (41) 
 
 
12 
1647.6 
 
 
1647.5 H 
1647.3 L 
 
FucHexNAc4Hex4 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
13 
1663.6 
 
 
1663.5 H 
1663.3 L 
 
HexNAc4Hex5 Complex, biantennary (41) 
 
X 
14 
1685.6 
 
 
1685.8 H 
1685.4 L 
 
HexNAc4Hex5Na 
 
Complex, biantennary 
 
 Calculated  
15 
1688.6 
 
 
1688.5 H 
1688.3 L 
 
FucHexNAc5Hex3 
Complex, fucosylated, 
bisecting (41) 
 
X 
16 
1704.6 
 
 
1705.5  
 HexNAc5Hex4 Complex, bisecting (41) 
 
 
17 
1743.6 
 
 
1743.4 H 
 
HexNAc2Hex8 High mannose (41) 
 
 
18 
1809.6 
 
 
1809.5 H 
1809.3 L 
 
FucHexNAc4Hex5 
Complex, biante nary, 
fucosylated 
 
 
(4 ) 
 
X 
19 
1814.6 
 
 
1815.4 H 
1816.3 L 
 
HexNAc4Hex4SiaNa 
Complex, biantennary, 
sialylated 
 Calculated  
20 
1825.6 
 
 
1825.5 H 
1825.3 L 
 
HexNAc4Hex6 Hybrid  Calculated  
21 
1832.6 
 
 
1831.3 L 
 
FucHexNAc4Hex5Na 
 
Complex, fucosylated, 
biantennary 
 
 Calculated  
22 
1850.7 
 
 
1850.5 H 
1850.3 L 
 
FucHexNAc5Hex4 
Complex, fucosylated, 
bisecting 
(41) 
 
 
23 
1866.7 
 
 
1866.5 H 
1866.4 L 
 
HexNAc5Hex5 
Complex, bisecting 
 
 
(41) 
 
 
24 
1881.6 
 
1880.8 H 
1880.5 L 
Fuc2HexNAc3Hex4Sia 
Complex, difucosylated, 
sialylated, 
 Calculated  
18 
 
 
 
1809.6 
 
 
 
1809.5H 
1809.3L 
 
 
fucHexNAc4Hex5 
 
 
 
complex, biantennary, 
fucosylated 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 12
10 
1611.5 
 
 
1611.4 H HexNAc3Hex4SiaNa 
Complex, 
monoantennary, 
sialylated 
(42) 
 
 
11 
1622.5 
 
 
1622.5 H 
1622.4 L 
 
HexNAc3Hex6 Hybrid (41) 
 
 
12 
1647.6 
 
 
1647.5 H 
647.3 L 
 
FucHexNAc4 4 
Complex, iantennary, 
fucosylated 
(41) 
 
X 
13 
1663.6 
 
 
1663.5 H 
1663.3 L 
 
HexNAc4Hex5 Complex, biantennary (41) 
 
X 
14 
1685.6 
 
 
1685.8 H 
1685.4 L 
 
HexNAc4Hex5Na 
 
Complex, bianten ary 
 
 Calculated  
15 
1688.6 
 
 
1688.5 H 
1688.3 L 
 
FucHexNAc5Hex3 
Complex, fucosylated, 
bisecting (41) 
 
X 
16 
1704.6 
 
 
1705.5 H 
 HexNAc5H 4 Complex, bisecting (41) 
 
 
17 
1743.6 
 
 
743.4 H 
 
HexNAc2Hex8 High mannose (41) 
 
 
18 
1809.6 
 
 
1809.5 H 
1809.3 L 
 
FucHexNAc4Hex5 
Complex, biantennary, 
fucosylated 
 
 
(41) 
 
X 
19 
1814.6 
 
 
1815.4 H 
1816.3 L 
 
HexNAc4Hex4SiaNa 
Complex, biantennary, 
sialylated 
 Calculated  
20 
1825.6 
 
 
1825.5 H 
1825.3 L 
 
HexNAc4Hex6 Hybrid  alc lated  
21 
1832.6 
 
 
1831.3 L 
 
FucHexNAc4Hex5Na 
 
Complex, fucosylated, 
biantennary 
 
 Calculated  
22 
1850.7 
 
 
1850.5 H 
1850.3 L 
 
FucHexNAc5Hex4 
Complex, fucosylated, 
bisecting 
(41) 
 
 
23 
1866.7 
 
 
1866.5 H 
1866.4 L 
 
HexNAc5Hex5 
Complex, bisecting 
 
 
(41) 
 
 
24 
1881.6 
 
1880.8 H 
1880.5 L 
Fuc2HexNAc3Hex4Sia 
Complex, difucosylated, 
sialylated, 
 Calculated  
X 
 
 
 
19 1814.6 1815.4H 
1816.3L
HexNAc4Hex4SiaNa complex, biantennary,  
sialylated
calculated 
20 1825.6 1825.5H 
1825.3L
HexNAc4Hex6 Hybrid calculated 
21 1832.6 1831.3L fucHexNAc4Hex5Na complex, fucosylated,  
biantennary
calculated 
22 
 
 
 
 
 
1850.7 
 
 
 
 
 
5H 
1850.3L 
 
 
 
 
fucHexNAc5Hex4 
 
 
 
 
 
complex, fucosylated,  
bisecting 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 12
10 
1611.5 
 
 
1611.4 H HexNAc3Hex4SiaNa 
Complex, 
monoantennary, 
sialylated 
(42) 
 
 
11 
1622.5 
 
 
1622.5 H 
1622.4 L 
 
HexNAc3Hex6 Hybrid (41) 
 
 
2 
1647.6 
 
 
1647.5 H 
1647.3 L 
 
FucHexNAc4Hex4 
Complex, biantennary, 
fucosylated 
(41) 
 
X 
13 
1663.6 
 
 
1663.5 H 
663.3 L 
 
HexNAc4Hex5 Complex, bianten ary (41) 
 
X 
14 
1685.6 
 
 
1685.8 H 
1685.4 L 
 
HexNAc4Hex5Na 
 
Complex, biantennary 
 
 Calculated  
15 
1688.6 
 
 
1688.5 H 
1688.3 L 
 
FucHexNAc5Hex3 
Complex, fucosylated, 
bisecting (41) 
 
X 
16 
1704.6 
 
 
1705.5 H 
 HexNAc5Hex4 Complex, bisecting (41) 
 
 
17 
1743.6 
 
 
1743.4 H 
 
HexNAc2Hex8 High annose (41) 
 
 
18 
1809.6 
 
 
1809.5 H 
1809.3 L 
 
FucHexNAc4Hex5 
Complex, biantennary, 
fucosylated 
 
 
(41) 
 
X 
19 
1814.6 
 
 
1815.4 H 
1816.3 L 
 
HexNAc4Hex4SiaNa 
Complex, biantennary, 
sialylated 
 Calculated  
20 
1825.6 
 
 
1825.5 H 
1825.3 L 
 
HexNAc4Hex6 Hybrid  l l ted  
21 
1832.6 
 
 
1831.3 L 
 
FucHexNAc4Hex5Na 
 
Complex, fucosylated, 
biantennary 
 
 C ul ted  
22 
1850.7 
 
 
1850.5 H 
1850.3 L 
 
FucHexNAc5Hex4 
Complex, fucosylated, 
bisecting 
(41) 
 
 
23 
1866.7 
 
 
1866.5 H 
1866.4 L 
 
HexNAc5Hex5 
Complex, bisecting 
 
 
(41) 
 
 
24 1881.6 1880.8 H Fuc2HexNAc3Hex4Sia Complex, difucosylated,  Calculated  
23 
 
 
 
 
18 6.7 
 
 
 
 
66.5H 
1880.5L 
 
 
 
HexNAc5Hex5 
 
 
 
 
co plex, bisecting 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 12
10 
1611.5 
 
 
1611.4 H HexNAc3Hex4SiaNa 
Complex, 
monoantennary, 
sialylated 
(42)  
11 
1622.5 
 
 
1622.5 H 
1622.4 L 
 
HexNAc3Hex6 Hybrid (41) 
 
 
12 
1647.6 
 
 
1647.5 H 
1647.3 L 
 
FucHexNAc4Hex4 
Complex, biantennary, 
fucosylated 
( ) 
 
X 
13 
1663.6 
 
 
1663.5 H 
1663.3 L 
 
Hex Ac4Hex5 Complex, bia tennary (41) 
 
X 
14 
1685.6 
 
 
1685.8 H 
1685.4 L 
 
HexNAc4Hex5Na 
 
Complex, biantennary 
 
 Calculated  
15 
1688.6 
 
 
1688.5 H 
1688.3 L 
 
FucHexNAc5Hex3 
Complex, fucosylated, 
bisecting (41) 
 
X 
16 
1704.6 
 
 
1705.5 H 
 HexNAc5Hex4 Complex, bisecting (41) 
 
 
17 
1743.6 
 
 
1743.4 H 
 
HexNAc2Hex8 High mannose (41) 
 
 
18 
1809.6 
 
 
1809.5 H 
1809.3 L 
 
FucHexNAc4Hex5 
Complex, bia tennary, 
fucosylated 
 
 
(41) 
 
X 
19 
1814.6 
 
 
1815.4 H 
1816.3 L 
 
HexNAc4Hex SiaNa 
Complex, biantennary, 
sialylated 
 l   
20 
1825.6 
 
 
1825.5 H 
1825.3 L 
 
HexNAc4Hex6 Hybrid  Calculated  
21 
1832.6 
 
 
1831.3 L 
 
FucHexNAc4Hex5Na 
 
Complex, fucosylated, 
biantennary 
 
 Calculated  
22 
1850.7 
 
 
1850.5 H 
1850.3 L 
 
FucHexNAc5Hex4 
Complex, fucosylated, 
bisecting 
(41) 
 
 
23 
1866.7 
 
 
1866.5 H 
1866.4 L 
 
HexNAc5Hex5 
Complex, bisecting 
 
 
(41) 
 
 
24 1881.6 1880.8 H Fuc2HexNAc3Hex4Sia Complex, difucosylated,  Calculated  
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Table 2 (continued). Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures derived from 
glycopeptides retained on the ConA affinity step (H = healthy serum; L = myocardial lesions serum). , Fucose; , N­acetylglucosamine; , 
Hexose; , N­acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod software only.
MALDI (m/z [M + Na]+) Monosaccharides 
composition 
 
Structure 
 
 
Ref. 
 
 
PSD 
 
 Theoretical 
MW
Found
24 
 
1881.6 
 
1880.8H 
1880.5L 
fuc2HexNAc3Hex4Sia 
 
complex, difucosylated,  
sialylated, monoantennary 
calculated 
 
25 
 
 
 
 
 
1905.6 
 
 
 
 
 
1906.5H 
1905.4L 
 
 
 
 
HexNAc2Hex9 
 
 
 
 
 
High mannose 
 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 
 
 13
 
 
1880.5 L 
 
sialylated, 
monoantennary 
25 
1905.6 
 
 
1906.5 H 
1905.4 L 
 
HexNAc2Hex9 High mannose (41) 
 
 
26 
1910.7 
 
 
1910.5 H 
1910.3 L 
 
HexNAc5Hex5Na2 
 
Complex, 
triantennary/bisecting 
Complex, biantennary, 
fucosylated, sulfated 
 Calculated  
27 
1935.6 
 
 
1936.5 H 
1936.3 L 
 
HexNAc3Hex6SiaNa Hybrid, sialylated (42) 
 
 
28 
1955.7 
 
 
1954.5 H 
1954.3 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, biantennary, 
sialylated 
Complex, biantennary, 
difucosylated 
(41) 
 
X 
29 
1960.7 
 
 
1958.5 H 
1957.3 L 
 
FucHexNAc4Hex4SiaNa 
Complex, fucosylated, 
sialylated, biantennary 
 Calculated  
30 
1971.7 
 
1970.3 L 
 
FucHexNAc4Hex6 Hybrid, fucosylated  Calculated  
31 
1976.7 
 
 
1975.4 H 
1976.3 L 
 
HexNAc4Hex5SiaNa 
Complex, biantennary, 
sialylated 
(42) 
 
 
32 
1995.7 
 
1996.7 
 
1996.5 H 
 
1997.2 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Sialylated, 
triantennary/bisecting 
Difucosylated , 
triantennary/bisecting 
 Calculated  
33 
2012.7 
 
 
2012.5 H 
2012.3 L 
 
FucHexNAc5Hex5 
Complex, fucosylated, 
bisecting (41) 
 
 
34 
2028.7 
 
 
2029.5 H 
2029.3 L 
 
HexNAc5Hex6 Complex, triantennary (41) 
 
 
35 
2100.7 
 
 
2100.5 H 
2101.4 L 
 
FucHexNAc4Hex5Sia 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
36 
2123.7 
 
 
2122.5 H 
2122.3 L 
 
FucHexNAc4Hex5SiaNa 
Complex, fucosylated, 
sialylated, biantennary 
 Calculated  
37 
2 144.7 
 
 
2145.4 H 
2144.2 L 
 
FucHexNAc4Hex5SiaNa2 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
38 
2157.1 
 
 
2158.3 L HexNAc5Hex5Sia 
Complex, sialylated, 
triantennary/bisecting 
 Calculated  
26 
 
 
191 7 
 
 
1910.5H 
1910.3L 
 
HexNAc5Hex5Na2 
 
 
complex, triantennary/
bisecting 
complex, biantennary,  
fucosylated, sulfated
calculated 
 
 
27 
 
 
 
 
1935.6 
 
 
 
 
1936.5H 
1936.3L 
 
 
 
HexNAc3Hex6SiaNa 
 
 
 
 
Hybrid, sialylated 
 
 
 
 
(42) 
 
 
 
 
 
 
 
 
 
 
 37
22 
1850.7 
 
 
1850.5 H 
1850.3 L 
 
FucHexNAc5Hex4 
Complex, fucosylated, 
bisecting (41) 
 
 
23 
1866.7 
 
 
1866.5 H 
1866.4 L 
 
HexNAc5Hex5 
Complex, bisecting 
 
 
(41) 
 
 
24 
1881.6 
 
 
1880.8 H 
1880.5 L 
 
Fuc2HexNAc3Hex4Sia 
Complex, 
difucosylated, 
sialylated, 
monoantennary 
 Calculated  
25 
1905.6 
 
 
1906.5 H 
1905.4 L 
 
HexNAc2Hex9 High mannose (41) 
 
 
26 
1910.7 
 
 
1910.5 H 
1910.3 L 
 
HexNAc5Hex5Na2 
 
Complex, 
triantennary/bisecting 
Complex, biantennary, 
fucosylated, sulfated 
 Calculated  
27 
1935.6 
 
 
1936.5 H 
1936.3 L 
 
HexNAc3Hex6SiaNa Hybrid, sialylated (42) 
 
 
28 
1955.7 
 
 
1954.5 H 
1954.3 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, biantennary, 
sialylated 
Complex, biantennary, 
difucosylated 
(41) 
 
X 
29 
1960.7 
 
 
1958.5 H 
1957.3 L 
 
FucHexNAc4Hex4SiaNa 
Complex, fucosylated, 
sialylated, biantennary  Calculated  
30 1971.7  
1970.3 L 
 FucHexNAc4Hex6 Hybrid, fucosylated  Calculated  
31 
1976.7 
 
 
1975.4 H 
1976.3 L 
 
HexNAc4Hex5SiaNa 
Complex, biantennary, 
sialylated (42) 
 
 
32 
1995.7 
 
1996.7 
 
1996.5 H 
 
1997.2 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Sialylated, 
triantennary/bisecting 
Difucosylated , 
triantennary/bisecting 
 Calculated  
33 
2012.7 
 
 
2012.5 H 
2012.3 L 
 
FucHexNAc5Hex5 
Complex, fucosylated, 
bisecting (41) 
 
 
34 
2028.7 
 
 
2029.5 H 
2029.3 L 
 
HexNAc5Hex6 Complex, triantennary (41) 
 
 
35 
2100.7 
 
 
2100.5 H 
2101.4 L 
 
FucHexNAc4Hex5Sia 
Complex, fucosylated, 
sialylated, biantennary  
 
X 
36 
2123.7 
 
 
2122.5 H 
2122.3 L 
 
FucHexNAc4Hex5SiaNa 
Complex, fucosylated, 
sialylated, biantennary  Calculated  
28 
 
 
 
 
1955.7 
 
 
 
 
1954.5H 
 
1954.3L 
 
 
HexNAc4Hex5Sia 
 
fuc2HexNAc4Hex5 
 
 
complex, biantennary,  
sialylated 
complex, biantennary,  
difucosylated 
 
(41) 
 
 
 
 
 
 
 
 
 
 13
 
 
1880.5 L 
 
sialylated, 
monoantennary 
25 
1905.6 
 
 
1906.5 H 
1905.4 L 
 
HexNAc2Hex9 High mannose (41) 
 
 
26 
1910.7 
 
 
1910.5 H 
1910.3 L 
 
HexNAc5Hex5Na2 
 
Complex, 
triantennary/bisecti g 
Complex, biantennary, 
fucosylated, sulfated 
 Calculated  
27 
1935.6 
 
 
1936.5 H
1936.3 L 
 
HexNAc3Hex6SiaNa Hybrid, sialylated (42) 
 
 
28 
1955.7 
 
 
1954.5 H 
1954.3 L 
 
HexNAc4Hex Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, biant nn ry, 
sialylated 
Complex, biantennary, 
difucosylated 
(41) 
 
X 
29 
1960.7 
 
 
1958.5 H 
1957.3 L 
 
FucHexNAc4Hex4SiaNa 
Complex, fucosylated, 
sialylated, biantennary 
 Calculated  
30 
1971.7 
 
1970.3 L 
 
FucHexNAc4Hex6 Hybrid, fucosylated  Calculated  
31 
1976.7 
 
 
1975.4 H
1976.3 L 
 
HexNAc4Hex5SiaNa 
Complex, biantenn ry,
sialylated 
(42) 
 
 
32 
1995.7 
 
1996.7 
 
1996.5 H 
 
1997.2 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Sialylated, 
triantennary/bisecting 
Difucosylated , 
triantennary/bisecting 
 Calculated  
33 
2012.7 
 
 
2012.5 H 
2012.3 L 
 
FucHexNAc5Hex5 
Complex, fucosylated, 
bisecting 
(41) 
 
 
34 
2028.7 
 
 
2029.5 H 
2029.3 L 
 
HexNAc5Hex6 Complex, triantennary (41) 
 
 
35 
2100.7 
 
 
2100.5 H 
2101.4 L 
 
FucHexNAc4Hex5Sia 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
36 
2123.7 
 
 
2122.5 H 
2122.3 L 
 
FucHexNAc4Hex5SiaNa 
Complex, fucosylated, 
sialylated, biantennary 
 Calculated  
37 
2 144.7 
 
 
2145.4 H 
2144.2 L 
 
FucHexNAc4Hex5SiaNa2 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
38 
2157.1 
 
 
2158.3 L HexNAc5Hex5Sia 
Complex, sialylated, 
triantennary/bisecting 
 Calculated  
X 
 
 
 
 
29 1960.7 1958.5H 
1957.3L
fucHexNAc4Hex4SiaNa complex, fucosylated, 
sialylated, biantennary
calculated 
30 1971.7 1970.3L fucHexNAc4Hex6 Hybrid, fucosylated calc lated
31 
 
 
 
 
1976.7 
 
 
 
 
1975.4H 
1976.3L 
 
 
 
HexNAc4Hex5SiaNa 
 
 
 
 
complex, biantennary,  
sialylated 
 
 
 
(42) 
 
 
 
 
 
 
 
 
 
 
 13
 
1880.5 L 
 
sialylated, 
monoantennary 
25 
1905.6 
 
 
1906.5 H 
1905.4 L 
 
HexNAc2Hex9 High mannose (41) 
 
 
26 
1910.7 
 
 
1910.5 H 
1910.3 L 
 
HexNAc5Hex5Na2 
 
Complex, 
triantennary/bisecting 
Complex, biantennary, 
fucosylated, sulfated 
 Calculated  
27 
1935.6 
 
 
1936.5 H 
1936.3 L 
 
HexNAc3Hex6SiaNa Hybrid, sialylated (42) 
 
 
28 
1955.7 
 
 
1954.  H 
1954.3 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, biantennary,
sialylated 
Comp ex, bianten ary, 
difucosylated 
(41) 
 
X 
29 
1960.7 
 
 
1958.5 H 
1957.3 L 
 
FucHexNAc4Hex4Si Na 
Co lex, fucosylated, 
si l l ted, bia tennary 
 Calculated  
30 
971.7 
 
1970.3 L 
 
FucHexNAc4Hex6 Hybrid, fucosylated  Calculated  
31 
1976.7 
 
 
1975.4 H 
1976.3 L 
 
HexNAc4Hex5SiaNa 
Compl x, biantennary, 
si lylated (42) 
 
 
32 
1995.7 
 
1996.7 
 
1996.5 H 
 
1997.2 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Sialylated, 
triantennary/bisecting 
Difucosylated , 
triantennary/bisecting 
 Calculated  
33 
2012.7 
 
 
2012.5 H 
2012.3 L 
 
FucHexNAc5Hex5 
Compl x, fucosylated, 
bisecting 
(41) 
 
 
34 
2028.7 
 
 
2029.5 H 
2029.3 L 
 
HexNAc5Hex6 Complex, trianten ary (41) 
 
 
35 
2100.7 
 
 
2100.5 H 
2101.4 L 
 
FucHexNAc4Hex5Sia 
Complex, fucosylated, 
sialylated, biantennary  
 
X 
36 
2123.7 
 
 
2122.5 H 
2122.3 L 
 
FucHexNAc4Hex5SiaNa 
Complex, fucosylated, 
sialylated, biantennary 
 Calculated  
37 
2 144.7 
 
 
2145.4 H 
2144.2 L 
 
FucHexNAc4Hex5SiaNa2 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
38 
2157.1 
 
 
2158.3 L HexNAc5Hex5Sia 
Complex, sialylated, 
triantennary/bisecting 
 Calculated  
32 
 
 
1995.7 
 
1996.7 
1996.5H 
 
1997.2L 
HexNAc5Hex4Sia 
 
fuc2HexNAc5Hex4 
Sial lated, triantennary/
bisecting 
Difucosylated, trianten-
nary/bisecting
calculated 
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Table 2 (continued). Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures derived from 
glycopeptides retained on the ConA affinity step (H = healthy serum; L = myocardial lesions serum). , Fucose; , N­acetylglucosamine; , 
Hexose; , N­acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod software only.
MALDI (m/z [M + Na]+) Monosaccharides 
composition 
 
Structure 
 
 
Ref. 
 
 
PSD 
 
 Theoretical 
MW
Found
33 
 
 
 
 
2012.7 
 
 
 
 
2012.5H 
2012.3L 
 
 
 
fucHexNAc5Hex5 
 
 
 
 
complex, fucosylated,  
bisecting 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 13
 
 
1880.5 L 
 
sialylated, 
monoantennary 
25 
1905.6 
 
 
1906.5 H 
1905.4 L 
 
HexNAc2Hex9 High mannose (41) 
 
 
26 
1910.7 
 
 
1910.5 H 
1910.3 L 
 
HexNAc5Hex5Na2 
 
Complex, 
triantennary/bisecting 
Complex, biantennary, 
fucosylated, sulfated 
 Calculated  
27 
1935.6 
 
 
1936.5 H 
1936.3 L 
 
HexNAc3Hex6SiaNa Hybrid, sialylated (42) 
 
 
28 
1955.7 
 
 
1954.5 H 
1954.3 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, biantennary, 
sialylated 
Complex, biantennary, 
difucosylated 
(41) 
 
X 
29 
1960.7 
 
 
1958.5 H 
1957.3 L 
 
FucHexNAc4Hex4SiaNa 
Complex, fucosylated, 
sialylated, biantennary 
 Calculated  
30 
1971.7 
 
1970.3 L 
 
FucHexNAc4Hex6 Hybrid, fucosylated  Calculated  
31 
1976.7 
 
 
1975.4 H 
1976.3 L 
 
HexNAc4Hex5SiaNa 
Complex, biantennary, 
sialylated (42) 
 
 
32 
1995.7 
 
1996.7 
 
1996.5 H 
 
1997.2 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Sialylated, 
triantennary/bisecting 
Difucosylated , 
triantennary/bisecting 
 Calculated  
33 
2012.7 
 
 
2012.5 H 
2012.3 L 
 
FucHexNAc5Hex5 
Complex, fucosylated, 
bisecting 
(41) 
 
 
34 
2028.7 
 
 
2029.5 H 
2029.3 L 
 
HexNAc5Hex6 Complex, triantennary (41) 
 
 
35 
2100.7 
 
 
2100.5 H 
2101.4 L 
 
FucHexNAc4Hex5Sia 
Complex, fucosylated, 
sialylated, biantennary  
 
X 
36 
2123.7 
 
 
2122.5 H 
2122.3 L 
 
FucHexNAc4Hex5SiaNa 
Complex, fucosylated, 
sialylated, biantennary 
 Calculated  
37 
2 144.7 
 
 
2145.4 H 
2144.2 L 
 
FucHexNAc4Hex5SiaNa2 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
38 
2157.1 
 
 
2158.3 L HexNAc5Hex5Sia 
Complex, sialylated, 
triantennary/bisecting 
 Calculated  
34 1995.7 
1996.7
1996.5H 
1997.2L HexNAc5Hex6 c plex, triante nary (41)
calculated 
 
 
35 
 
 
 
 
2100.7 
 
 
 
 
2100.5H 
2101.4L 
 
 
 
fucHexNAc4Hex5Sia 
 
 
 
 
complex, fucosylated,  
sialylated, biantennary 
 
 
 
 
 
 
 
 
 
 13
 
 
1880.5 L 
 
sialylated, 
monoantennary 
25 
1905.6 
 
 
1906.5 H 
1905.4 L 
 
HexNAc2Hex9 High mannose (41) 
 
 
26 
1910.7 
 
 
1910.5 H 
1910.3 L 
 
HexNAc5Hex5Na2 
 
Complex, 
triantennary/bisecting 
Complex, biantennary, 
fucosylated, sulfated 
 Calculated  
27 
1935.6 
 
 
1936.5 H 
1936.3 L 
 
HexNAc3Hex6SiaNa Hybrid, sialylated (42) 
 
 
28 
1955.7 
 
 
1954.5 H 
1954.3 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, biantennary, 
sialylated 
Complex, biantennary, 
difucosylated 
(41) 
 
X 
29 
1960.7 
 
 
1958.5 H 
1957.3 L 
 
FucHexNAc4Hex4SiaNa 
Complex, fucosylated, 
sialylated, biantennary 
 Calculated  
30 
1971.7 
 
1970.3 L 
 
FucHexNAc4Hex6 Hybrid, fucosylated  Calculated  
31 
1976.7 
 
 
1975.4 H 
1976.3 L 
 
HexNAc4Hex5SiaNa 
Complex, biantennary, 
sialylated (42) 
 
 
32 
1995.7 
 
1996.7 
 
1996.5 H 
 
1997.2 L 
 
HexNAc5H x4Si  
 
Fuc2HexNAc5Hex4 
Sialylated, 
triantennary/bisecting 
Difucosylated , 
triante nary/bisecting 
 Calculated  
33 
2012.7 
 
 
2012.5 H 
2012.3 L 
 
FucHexNAc5Hex5 
Complex, fucosylated, 
bisecting 
(41) 
 
 
34 
2028.7 
 
 
2029.5 H 
2029.3 L 
 
HexNAc5Hex6 Complex, triantennary (41) 
 
 
35 
2100.7 
 
 
2100.5 H 
2101.4 L 
 
FucHexNAc4Hex5Sia 
Complex, fucosylated, 
sialylated, bianten ary 
 
 
X 
36 
2123.7 
 
 
2122.5 H 
2122.3 L 
 
FucHexNAc4Hex5SiaNa 
Complex, fucosylated, 
sialylated, biantennary 
 Calculated  
37 
2 144.7 
 
 
2145.4 H 
2144.2 L 
 
FucHexNAc4Hex5SiaNa2 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
38 
2157.1 
 
 
2158.3 L HexNAc5Hex5Sia 
Complex, si lylated, 
triantennary/bisecting 
 Calculated  
X 
 
 
 
 
36 2123.7 2122.5H 
2122.3L
fucHexNAc4Hex5SiaNa complex, fucosylated,  
sialylated, biantennary
calculated 
37 
 
 
 
 
2 144.7 
 
 
 
 
2145.4H 
2144.2L 
 
 
 
fucHexNAc4Hex5SiaNa2 
 
 
 
 
complex, fucosylated,  
sialylated, biantennary 
 
 
 
 
 
 
 
 
 
 13
 
 
1880.5 L 
 
sialylated, 
monoantennary 
25 
1905.6 
 
 
1906.5 H 
1905.4 L 
 
HexNAc2Hex9 High mannose (41) 
 
 
26 
1910.7 
 
 
1910.5 H 
1910.3 L 
 
HexNAc5Hex5Na2 
 
Complex, 
triantennary/bisecting 
Complex, biantennary, 
fucosylated, sulfated 
 Calculated  
27 
1935.6 
 
 
1936.5 H 
1936.3 L 
 
HexNAc3Hex6SiaNa Hybrid, sialylated (42) 
 
 
28 
1955.7 
 
 
1954.5 H 
1954.3 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, biantennary, 
sialylated 
Complex, biantennary, 
difucosylated 
(41) 
 
X 
29 
1960.7 
 
 
1958.5 H 
1957.3 L 
 
FucHexNAc4Hex4SiaNa 
Complex, fucosylated, 
sialylated, biantennary 
 Calculated  
30 
1971.7 
 
1970.3 L 
 
FucHexNAc4Hex6 Hybrid, fucosylated  Calculated  
31 
1976.7 
 
 
1975.4 H 
1976.3 L 
 
HexNAc4Hex5SiaNa 
Complex, biantennary, 
sialylated (42) 
 
 
32 
1995.7 
 
1996.7 
 
1996.5 H 
 
1997.2 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Sialylated, 
triantennary/bisecting 
Difucosylated , 
triantennary/bisecting 
 Calculated  
33 
2012.7 
 
 
2012.5 H 
2012.3 L 
 
FucHexNAc5Hex5 
Complex, fucosylated, 
bisecting 
(41) 
 
 
34 
2028.7 
 
 
2029.5 H 
2029.3 L 
 
HexNAc5Hex6 Complex, triantennary (41) 
 
 
35 
2100.7 
 
 
2100.5 H 
2101.4 L 
 
FucHexNAc4Hex5Sia 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
36 
2123.7 
 
 
2122.5 H 
2122.3 L 
 
FucHexNAc4Hex5SiaNa 
Complex, fucosylated, 
sialylated, biantennary 
 Calculated  
37 
2 144.7 
 
 
2145.4 H 
2144.2 L 
 
FucHexNAc4Hex5SiaNa2 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
38 
2157.1 
 
 
2158.3 L HexNAc5Hex5Sia 
Complex, sialylated, 
triantennary/bisecting 
 Calculated  
X 
 
 
 
 
38 2157.1 2158.3L HexNAc5Hex5Sia complex, sialylated,  
triantennary/bi ecting
calculated
39 
 
 
 
 
2166.7 
 
 
 
 
2166.3H 
 
 
 
 
fucHexNAc4Hex5SiaNa3 
 
 
 
 
complex, fucosylated,  
sialylated, biantennary 
 
 
 
 
 
 
 
 
 14
39 
2166.7 
 
 
2166.3 H FucHexNAc4Hex5SiaNa3 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
40 2174.8 2175.5 
H 
2175.2 L 
FucHexNAc5Hex6 
Complex, fucosylated, 
triantennary 
(41) 
   
 
41 
2197.7 
 
 
2193.6 H 
2194.5 L 
 
FucHexNAc5Hex6Na 
Complex, fucosylated, 
triantennary 
 Calculated  
42 
2245.8 
 
 
2246.5 H 
2245.3 L 
 
HexNAc4Hex5Sia2 
Complex, disialylated, 
biantennary 
(42) 
 
X 
43 
2262.8 
 2262.2
 L FucHexNAc4Hex6Sia 
Hybrid, sialylated, 
fucosylated  Calculated  
44 
2268.8 
 
 
2267.5 H 
2267.4 L 
 
HexNAc4Hex5Sia2Na 
Complex, disialylated, 
biantennary 
(42) 
 
X 
45 
2284.8 
 
 
2283.4 H 
2283.2 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, fucosylated, 
sialylated 
 
 
X 
46 2290.8 
 
2289.5 H 
2289.3 L 
 
HexNAc4Hex5Sia2Na2 
Complex, disialylated, 
biantennary 
(42) 
 
 
47 
2306.8 
 
2305.4 H 
 FucHexNAc4Hex6SiaNa2 
Hybrid, fucosylated, 
sialylated  Calculated  
48 
2325.8 
 
 
2326.5 H FucHexNAc5Hex5SiaNa 
Complex, fucosylated, 
sialylated, 
triantennary/bisecting 
 Calculated  
49 2434.8 
 
2435.5 H 
 
FucHexNAc4Hex5Sia2Na2 
Complex, fucosylated, 
disialylated, 
biantennary 
 Calculated  
50 
2627.9 
 
 
2625.4 H 
2625.5 L 
 
FucHexNAc5Hex7Sia Hybrid, sialylated  Calculated  
54 
2649.8 
 2647.0
 L FucHexNAc5Hex7SiaNa 
Hybrid, fucosylated, 
sialylated  Calculated  
X 
 
 
 
 
40 
 
 
 
 
2174.8 
 
 
 
 
2175.5H 
2175.2L 
 
 
 
fucHexNAc5Hex6 
 
 
 
 
complex, fucosylated,  
triantennary 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 14
39 
2166.7 
 
 
2166.3 H FucHexNAc4Hex5SiaNa3 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
40 2174.8 2175.5 
H 
2175.2 L 
FucHexNAc5Hex6 
Complex, fucosylated, 
triantennary 
(41) 
   
 
41 
2197.7 
 
 
2193.6 H 
2194.5 L 
 
FucHexNAc5Hex6Na 
Complex, fucosylated, 
triantennary 
 Calculated  
42 
2245.8 
 
 
2246.5 H 
2245.3 L 
 
HexNAc4Hex5Sia2 
Complex, disialylated, 
biantennary 
(42) 
 
X 
43 
2262.8 
 2262.2
 L FucHexNAc4Hex6Sia 
Hybrid, sialylated, 
fucosylated  Calculated  
44 
2268.8 
 
 
2267.5 H 
2267.4 L 
 
HexNAc4Hex5Sia2Na 
Complex, disialylated, 
biantennary 
(42) 
 
X 
45 
2284.8 
 
 
2283.4 H 
2283.2 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, fucosylated, 
sialylated 
 
 
X 
46 2290.8 
 
2289.5 H 
2289.3 L 
 
HexNAc4Hex5Sia2Na2 
Complex, disialylated, 
biantennary 
(42) 
 
 
47 
2306.8 
 
2 05.4 H 
 FucHexNAc4Hex6SiaNa2 
Hybrid, fucosylated, 
sialylated  Calculated  
48 
2325.8 
 
 
2326.5 H FucHexNAc5Hex5SiaNa 
Complex, fucosylated, 
sialylated, 
triantennary/bisecting 
 Calculated  
49 2434.8 
 
2435.5 H 
 
FucHexNAc4Hex5Sia2Na2 
Complex, fucosylated, 
disialylated, 
biantennary 
 Calculated  
50 
2627.9 
 
 
2625.4 H 
2625.5 L 
 
FucHexNAc5Hex7Sia Hybrid, sialylated  Calculated  
54 
2649.8 
 2647.0
 L FucHexNAc5Hex7SiaNa 
Hybrid, fucosylated, 
sialylated  Calculated  
41 2197.7 2193.6H 
2194.5L
fucHexNAc5Hex6Na complex, fucosylated,  
triantennary
calculated 
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Table 2 (continued). Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures derived from 
glycopeptides retained on the ConA affinity step (H = healthy serum; L = myocardial lesions serum). , Fucose; , N­acetylglucosamine; , 
Hexose; , N­acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod software only.
MALDI (m/z [M + Na]+) Monosaccharides 
composition 
 
Structure 
 
 
Ref. 
 
 
PSD 
 
 Theoretical 
MW
Found
42 
 
 
 
 
 
2245.8 
 
 
 
 
 
2246.5H 
2245.3L 
 
 
 
 
HexNAc4Hex5Sia2 
 
 
 
 
 
complex, disialylated,  
biantennary 
 
 
 
 
(42) 
 
 
 
 
 
 
 
 
 
 
 
 
 14
39 
2166.7 
 
 
2166.3 H FucHexNAc4Hex5SiaNa3 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
40 2174.8 2175.5 
H 
2175.2 L 
FucHexNAc5Hex6 
Complex, fucosylated, 
triantenn ry 
(41) 
   
 
41 
2197.7 
 
 
2193.6 H 
2194.5 L 
 
FucHexNAc5Hex6Na 
Complex, fucosylated, 
triantennary 
 Calculated  
42 
2245.8 
 
 
2246.5 H 
2245.3 L 
 
HexNAc4Hex5Sia2 
Complex, disialylated, 
biantennary 
(42) 
 
X 
43 
2262.8 
 2262.2
 L FucHexNAc4Hex6Sia 
Hybrid, sialylated, 
fucosylated  Calculated  
44 
2268.8 
 
 
2267.5 H 
2267.4 L 
 
HexNAc4Hex5Sia2Na 
Complex, disialylated, 
biantennary 
(42) 
 
X 
45 
2284.8 
 
 
2283.4 H 
2283.2 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, fucosylated, 
sialylated 
 
 
X 
46 2290.8 
 
2289.5 H 
2289.3 L 
 
HexNAc4Hex5Sia2Na2 
Complex, disialylated, 
biantennary 
(42) 
 
 
47 
2306.8 
 
2305.4 H 
 FucHexNAc4Hex6SiaNa2 
Hybrid, fucosylated, 
sialylated  Calculated  
48 
2325.8 
 
 
2326.5 H FucHexNAc5Hex5SiaNa 
Complex, fucosylated, 
sialylated, 
triantennary/bisecting 
 Calculated  
49 2434.8 
 
2435.5 H 
 
FucHexNAc4Hex5Sia2Na2 
Complex, fucosylated, 
disialylated, 
biantennary 
 Calculated  
50 
2627.9 
 
 
2625.4 H 
2625.5 L 
 
FucHexNAc5Hex7Sia Hybrid, sialylated  Calculated  
54 
2649.8 
 2647.0
 L FucHexNAc5Hex7SiaNa 
Hybrid, fucosylated, 
sialylated  Calculated  
43 2262.8 2262.2L fucHexNAc4Hex6Sia Hybrid, sialylated,  
fucosylated
calculated 
44 
 
 
 
 
 
2268.8 
 
 
 
 
 
2267.5H 
2267.4L 
 
 
 
 
HexNAc4Hex5Sia2Na 
 
 
 
 
 
complex, disialylated, 
biantennary 
 
 
 
 
(42) 
 
 
 
 
 
 
 
 
 
 
 
 14
39 
2166.7 
 
 
2166.3 H FucHexNAc4Hex5SiaNa3 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
40 2174.8 175.5 
H 
2175.2 L 
FucHexNAc5Hex6 
Complex, fucosylated, 
triantennary 
(41) 
   
 
41 
2197.7 
 
 
2193.6 H 
2194.5 L 
 
FucHexNAc5Hex6Na 
Co plex, fucosylated, 
triantennary 
 Calculated  
42 
2245.8 
 
 
2246.5 H 
2245.3 L 
 
ex Ac4 ex5Sia2 
Co plex, disialylated, 
biantennary 
(42) 
 
X 
43 
2262.8 
 2262.2
 L Fuc ex c4 ex6 ia 
ybrid, sialylated, 
f cosylate   alc lated  
44 
2268.8 
 
 
2267.5 H 
2267.4 L 
 
ex c4 ex5 i 2  
l , i i lyl t , 
i t r  
( ) 
 
 
45 
2284.8 
 
 
2283.4 H 
2283.2 L 
 
Fuc ex c4 x6 i  
i , l , 
i l l  
  
46 2290.8 
 
2289.5 H 
2289.3 L 
 
ex c4 ex5 i 2 2 
l , 
i
47 
2306.8 
 
2305.4 H 
 Fuc ex c4 x6 i 2 
i , 
i l l
48 
2325.8 
 
 
2326.5 H Fuc ex c5 x5 i  
l , 
i l l
t i
49 2434.8 
 
2435.5 H 
 
Fuc ex c4 x5 i 2 2 
l , 
i i l
i
50 
2627.9 
 
 
2625.4 H 
2625.5 L 
 
Fuc ex c5 x7 i  i , i
54 
2649.8 
 2647.0
 L Fuc ex c5 x7 i  
i , , 
i l l   l l   
X 
 
 
 
 
 
45 
 
 
 
 
2284.8 
 
 
 
 
2283.4H 
2283.2L 
 
 
 
fucHexNAc4Hex6SiaNa 
 
 
 
 
Hybrid, fucosylated,  
sialylated 
 
 
 
 
 
 
 
 
 
 14
39 
2166.7 
 
 
2166.3 H FucHexNAc4Hex5SiaNa3 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
40 2174.8 2175.5 
H 
2175.2 L 
FucHexNAc5Hex6 
Complex, fucosylated, 
triantennary 
(41) 
   
 
41 
2197.7 
 
 
2193.6 H 
2194.5 L 
 
FucHexNAc5 6N  
Complex, fucosylated, 
triantennary 
 Calculated  
42 
2245.8 
 
 
2246.5 H 
2245.3 L 
 
HexNAc4Hex5Sia2 
Complex, disialylated, 
biantennary 
(42) 
 
X 
43 
2262.8 
 2262.2
 L FucHexNAc4Hex6Sia 
Hybrid, sialylated, 
fucosylated  Calculated  
44 
2268.8 
 
 
2267.5 H 
2267.4 L 
 
HexNAc4Hex5Sia2Na 
Complex, disialylated, 
biantennary 
(42) 
 
X 
45 
2284.8 
 
 
2283.4 H 
283.2 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, fucosylated, 
sialylated 
 
 
X 
46 2290.8 
 
2289.5 H 
2289.3 L 
 
HexNAc4Hex5Sia2Na2 
Complex, disialylated, 
biantennary 
(42) 
 
 
47 
2306.8 
 
2305.4 H 
 FucHexNAc4Hex6SiaNa2 
Hybrid, fucosylated, 
sialylated  Calculated  
48 
2325.8 
 
 
2326.5 H FucHexNAc5Hex5SiaNa 
Complex, fucosylated, 
sialylated, 
triantennary/bisecting 
 Calculated  
49 2434.8 
 
2435.5 H 
 
FucHexNAc4Hex5Sia2Na2 
Complex, fuco yla ed, 
disia ylated, 
biantennary 
 Calculated  
50 
2627.9 
 
 
2625.4 H 
2625.5 L 
 
FucHexNAc5Hex7Sia Hybrid, sialylated  Calculated  
54 
2649.8 
 2647.0
 L FucHexNAc5Hex7SiaNa 
Hybrid, fucosylated, 
sialylated  Calculated  
X 
 
 
 
 
46 
 
 
 
 
2290.8 
 
 
 
 
2289.5H 
2289.3L 
 
 
 
HexNAc4Hex5Sia2Na2 
 
 
 
 
complex, disialylated,  
biantennary 
 
 
 
(42) 
 
 
 
 
 
 
 
 
 
 
 
 14
39 
2166.7 
 
 
2166.3 H FucHexNAc4Hex5SiaNa3 
Complex, fucosylated, 
sialylated, biantennary 
 
 
X 
40 2174.8 2175.5 
H 
2175.2 L 
FucHexNAc5Hex6 
Co plex, fuc sylated, 
triantennary 
(41) 
   
 
41 
2197.7 
 
 
2193.6 H 
2194.5 L 
 
FucHexNAc5Hex6Na 
Complex, fucosylated, 
triantennary 
 Calculated  
42 
2245.8 
 
 
2246.5 H 
2245.3 L 
 
HexNAc4Hex5Sia2 
Complex, disialylated, 
biantennary 
(42) 
 
X 
43 
2262.8 
 2262.2
 L FucHexNAc4Hex6Sia 
Hybrid, sialylated, 
fucosylated  Calculated  
44 
2268.8 
 
 
2267.5 H 
2267.4 L 
 
HexNAc4Hex5Sia2Na 
Complex, disial l t , 
biantennary 
(42) 
 
X 
45 
2284.8 
 
 
2283.4 H 
2283.2 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, fucosylated, 
sialylated 
 
 
X 
46 2290.8 
 
.5 H 
2289.3 L 
 
HexNAc4Hex5Sia2Na2 
Complex, disialylated, 
biantennary 
(42) 
 
 
47 
2306.8 
 
2305.4 H 
 FucHexNAc4Hex6SiaNa2 
Hybrid, fucosylated, 
sialylated  Calculated  
48 
2325.8 
 
 
2326.5 H FucHexNAc5Hex5SiaNa 
Compl x, fucosylated, 
si lylated, 
triantennary/bisecting 
 Calculated  
49 2434.8 
 
2435.5 H 
 
FucHexNAc4Hex5Sia2Na2 
Complex, fucosylated, 
disialylated, 
biantennary 
 Calculated  
50 
2627.9 
 
 
.4 H 
2625.5 L 
 
FucHexNAc5Hex7Sia Hybrid, sialylated  Calculated  
54 
2649.8 
 2647.0
 L FucHexNAc5Hex7SiaNa 
Hybrid, fucosylated, 
sialylated  Calculated  
47 2306.8 2305.4H fucHexNAc4Hex6SiaNa2 Hybrid, fucosylated,  
sialylated
calculated 
48 
 
2325.8 
 
2326.5H 
 
fucHexNAc5Hex5SiaNa 
 
complex, fucosylated,  
sialylated, triantennary/
bisecting
calculated 
 
49 2434.8 2435.5H fucHexNAc4Hex5Sia2Na2 complex, fucosylated,  
disialylated, biantennary
calculated 
50 2627.9 2625.4H 
2625.5L
fucHexNAc5Hex7Sia Hybrid, sialylated calculated 
51 2649.8 2647.0L fucHexNAc5Hex7SiaNa Hybrid, fucosylated,  
sialylated
calculated 
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MALDI (m/z [M+Na]+) Monosaccharides  
composition 
Structure 
 
Ref. 
 
PSD 
 Theoretical 
MW
Found 
1 
 
 
 
 
1282.4 
 
 
 
 
1282.1H 
 
 
 
 
fucHexNAc3Hex3 
 
 
 
 
complex, fucosylated, 
monoantennary 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 15
Table 3. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardial lesions serum). ", 
Fucose; ", N-acetylglucosamine; ", Hexose;       N-acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod 
software only.  
 
 
MALDI (m/z [M+Na]+) 
 
PSD 
  
Theoretical 
MW 
 
Found 
Monos ccharides 
composition 
Str cture 
 Ref   
1 
1282.4 
 
 
1282.1 H FucHexNAc3Hex3 
Complex, 
fucosylated, 
monoantennary 
(41) 
 
 
2 
1298.5 
 
 
1298.1 H 
 HexNAc3Hex4 
Complex, 
monoantennary (41) 
 
X 
3 
1339.5 
 
 
1339.1H 
 HexNAc4Hex3 
Complex, 
biantennary (41) 
 
 
4 
1485.5 
 
 
1485.1 H 
1485.0 L 
 
FucHexNAc4Hex3 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
5 
1501.5 
 
 
1501.0 H 
1500.9 L 
 
HexNAc4Hex4 
Complex, 
biantennary (41) 
 
X 
6 
1542.6 
 
 
1542.0 H 
 HexNAc5Hex3 
Complex, bisecting 
 (41) 
 
X 
7 
1647.6 
 
 
1647.0 H 
1646.9 L 
 
FucHexNAc4Hex4 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
8 
1663.6 
 
 
1663.0 H 
1662.9 L 
 
HexNAc4Hex5 
Complex, 
biantennary (41) 
 
X 
9 
1685.6 
 
 
1684.6 H 
1685.1 L 
 
HexNAc4Hex5Na 
 
 
Complex, 
biantennary 
 
 
 Calculated  
10 
1688.6 
 
 
1688.0 H 
 FucHexNAc5Hex3 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
2 
 
 
 
 
1298.5 
 
 
 
 
1298.1H 
 
 
 
 
HexNAc3Hex4 
 
 
 
 
complex, monoantennary 
 
 
 
 
(41) 
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Table 3. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardial lesions serum). ", 
Fucose; ", N-acetylglucosamine; ", Hexose;       N-acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod 
software only.  
 
 
MALDI (m/z [M+Na]+) 
 
PSD 
  
Theoretical 
MW 
 
Found 
Monosaccharides 
composition 
Structure 
 Ref   
1 
1282.4 
 
 
1282.1 H FucHexNAc3Hex3 
Complex, 
fucosylated, 
monoantennary 
(41) 
 
 
2 
1298.5 
 
 
 
1298.1 H 
 HexNAc3Hex4 
Complex, 
monoantennary (41) 
 
X 
3 
1339.5 
 
 
1339.1H 
 HexNAc4Hex3 
Complex, 
biantennary (41) 
 
 
4 
1485.5 
 
 
1485.1 H 
1485.0 L 
 
FucHexNAc4Hex3 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
5 
1501.5 
 
 
1501.0 H 
1500.9 L 
 
HexNAc4Hex4 
Complex, 
biantennary (41) 
 
X 
6 
1542.6 
 
 
1542.0 H 
 HexNAc5Hex3 
Complex, bisecting 
 (41) 
 
X 
7 
1647.6 
 
 
1647.0 H 
1646.9 L 
 
FucHexNAc4Hex4 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
8 
1663.6 
 
 
1663.0 H 
1662.9 L 
 
HexNAc4Hex5 
Complex, 
biantennary (41) 
 
X 
9 
1685.6 
 
 
1684.6 H 
1685.1 L 
 
HexNAc4Hex5Na 
 
 
Complex, 
biantennary 
 
 
 Calculated  
10 
1688.6 
 
 
1688.0 H 
 FucHexNAc5Hex3 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
X 
 
 
 
 
3 
 
 
 
1339.5 
 
 
 
1339.1H 
 
 
 
HexNAc4Hex3 
 
 
 
complex, biantennary 
 
 
 
(41) 
 
 
 
 
 
 
 
 15
Table 3. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardial lesions serum). ", 
Fucose; ", N-acetylglucosamine; ", Hexose;       N-acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod 
software only.  
 
 
MALDI (m/z [M+Na]+) 
 
PSD 
  
Theoretical 
MW 
 
Found 
Monosaccharides 
composition 
Structure 
 Ref   
1 
1282.4 
 
 
1282.1 H FucHexNAc3Hex3 
Complex, 
fucosylated, 
monoantennary 
(41) 
 
 
2 
1298.5 
 
 
 
1298.1 H 
 HexNAc3Hex4 
Complex, 
monoantennary (41) 
 
X 
3 
1339.5 
 
 
1339.1H 
 HexNAc4Hex3 
o plex, 
biantennary (41) 
 
 
4 
1485.5 
 
 
1485.1 H 
1485.0 L 
 
FucHexNAc4Hex3 
Complex, 
fuc sylated, 
bianten ar  
(41) 
 
X 
5 
1501.5 
 
 
1501.0 H 
1500.9 L 
 
HexNAc4Hex4 
Complex, 
biantennary (41) 
 
X 
6 
1542.6 
 
 
1542.0 H 
 HexNAc5Hex3 
Complex, bisecting 
 (41) 
 
 
7 
1647.6 
 
 
1647.0 H 
1646.9 L 
 
FucHexNAc4Hex4 
o plex, 
fucosylated, 
biantennary 
(41) 
 
X 
8 
1663.6 
 
 
1663.0 H 
1662.9 L 
 
HexNAc4Hex5 
Complex, 
biantennary (41) 
 
X 
9 
1685.6 
 
 
1684.6 H 
1685.1 L 
 
HexNAc4Hex5Na 
 
 
Complex, 
biantennary 
 
 
 Calculated  
10 
1688.6 
 
 
1688.0 H 
 FucHexNAc5Hex3 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
4 
 
 
 
1485.5 
 
 
 
H 
L 
 
 
fucHexNAc4Hex3 
 
 
 
complex, fucosylated,  
biantennary 
 
 
(41) 
 
 
 
 
 
 
 
 
 15
Table 3. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardial lesions serum). ", 
Fucose; ", N-acetylglucosamine; ", Hexose;       N-acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod 
software only.  
 
 
MALDI (m/z [M+Na]+) 
 
PSD 
  
Theoretical 
MW 
 
Found 
Monosaccharides 
mposition 
Structure 
 Ref   
1 
1282.4 
 
 
1282.1 H FucHexNAc3Hex3 
Complex, 
fucosylated, 
monoantennary 
(41) 
 
 
2 
1298.5 
 
 
 
1298.1 H 
 HexNAc3Hex4 
Co plex, 
mo oa tennary (41) 
 
X 
3 
1339.5 
 
 
1339.1H 
 HexNAc Hex3 
Complex, 
biante nary (41) 
 
 
4 
1485.5 
 
 
1485.1 H 
1485.0 L 
 
FucHexNAc4Hex3 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
5 
1501.5 
 
 
1501.0 H 
1500.9 L 
 
HexNAc4Hex4 
Complex, 
biantennary (41) 
 
X 
6 
1542.6 
 
 
1542.0 H 
 HexNAc5Hex3 
Complex, bisecting 
 (41) 
 
X 
7 
1647.6 
 
 
1647.0 H 
1646.9 L 
 
FucHexNAc4Hex4 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
8 
1663.6 
 
 
1663.0 H 
1662.9 L 
 
HexNAc4Hex5 
Complex, 
bianten ary (41) 
 
X 
9 
1685.6 
 
 
1684.6 H 
1685.1 L 
 
HexNAc4Hex5Na 
 
 
Complex, 
biantennary 
 
 
 Calculated  
10 
1688.6 
 
 
1688.0 H 
 FucHexNAc5Hex3 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
X 
 
 
 
5 
 
 
 
1501.5 
 
 
 
1501.0H 
1500.9L 
 
 
HexNAc4Hex4 
 
 
 
complex, biantennary 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 15
Table 3. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardial lesions serum). ", 
Fucose; ", N-acetylglucosamine; ", Hexose;       N-acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod 
software only.  
 
 
MALDI (m/z [M+Na]+) 
 
PSD 
  
Theoretical 
MW 
 
Found 
Monosaccharides 
composition 
Structure 
 Ref   
1 
1282.4 
 
 
1282.1 H FucHexNAc3Hex3 
Complex, 
fucosylated, 
monoantennary 
(41) 
 
 
2 
1298.5 
 
1298.1 H 
 HexNAc3Hex4 
Complex, 
monoantennary (41) 
 
X 
3 
1339.5 
 
 
1339.1H 
 HexNAc4 3 
C mplex, 
biantennar  (41) 
 
 
4 
1485.5 
 
 
1485.1 H 
1485.0 L 
 
FucHexNAc4Hex3 
Co plex, 
fucosylated, 
biantennary 
(41) 
 
X 
5 
1501.5 
 
 
1501.0 H 
1500.9 L 
 
HexNAc4Hex4 
Complex, 
biantennary (41) 
 
X 
6 
1542.6 
 
 
1542.0 H 
 HexNAc5Hex3 
Complex, bisecting 
 (41) 
 
X 
7 
1647.6 
 
 
1647.0 H 
1646.9 L 
 
FucHexNAc4Hex4 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
8 
1663.6 
 
 
1663.0 H 
1662.9 L 
 
HexNAc4Hex5 
Complex, 
biantennary (41) 
 
X 
9 
1685.6 
 
 
1684.6 H 
1685.1 L 
 
HexNAc4Hex5 a 
 
 
C mplex, 
bianten ary 
 
 
 Calculated  
10 
1688.6 
 
 
1688.0 H 
 FucHexNAc5Hex3 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
X 
 
 
 
6 
 
 
 
 
1542.6 
 
 
 
 
1542.0H 
 
 
 
 
HexN c5 ex3 
 
 
 
 
complex, bisecting 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 15
Table 3. Compositio  and str ctures of the glycans detected by MALDI MS analy is of the oligosa charide mixtures 
d rived from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardia  lesions seru ). ", 
Fucose; ", N-acetylglucosamine; ", Hexose;       N-acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod 
software only.  
 
 
MALDI (m/z [M+Na]+) 
 
PS  
  
Theoretical 
MW 
 
Found 
Monosaccharides 
composition 
Structure 
 Ref   
1 
1282.4 
 
 
1282.1 H FucHexNAc3Hex3 
Complex, 
fucosylated, 
monoantennary 
(41) 
 
 
2 
1298.5 
 
 
 
1298.1 H 
 HexNAc3Hex4 
Complex, 
monoantennary (41) 
 
X 
3 
1339.5 
 
 
1339.1H 
 HexNAc4Hex3 
Complex, 
biantenn ry (41) 
 
 
4 
1485.5 
 
 
1485.  H 
1485.0 L 
 
FucHexNAc4Hex3 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
5 
1501.5 
 
 
1501.0 H 
1500.9 L 
 
HexNAc4Hex4 
Complex, 
biantennary (41) 
 
X 
6 
1542.6 
 
 
1542.0 H 
 HexNAc5Hex3 
Complex, bisecting 
 (41) 
 
X 
7 
1647.6 
 
 
1647.0 H 
1646.9 L 
 
FucHexNAc4Hex4 
Complex, 
fucosylat d
bianten ary 
(41) 
 
X 
8 
1663.6 
 
 
1663.0 H 
1662.9 L 
 
HexNAc4Hex5 
Complex, 
biantennary (41) 
 
X 
9 
1 85.6 
 
 
1684.6 H 
1685.1 L 
 
HexNAc4Hex5Na 
 
 
Complex, 
biantennary 
 
 
 Calculated  
10 
1 88.6 
 
 
1688.0 H 
 FucHexNAc5Hex3 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
X 
 
 
 
 
7 
 
 
 
1647.6 
 
 
 
1647.0H 
1646.9L 
 
 
fucHexNAc4Hex4 
 
 
 
complex, fucosylated,  
biantennary 
 
 
(41) 
 
 
 
 
 
 
 
 15
Table 3. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardial lesions serum). ", 
Fucose; ", N-acetylglucosamine; ", Hexose;       N-acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod 
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MALDI (m/z [M+Na]+) 
 
PSD 
  
Theoretical 
MW 
 
Found 
M n s ccharide  
com osition 
Structu e 
 Ref  
1 
1282.4 
 
 
1282.1 H FucHexNAc3Hex3 
Complex, 
fucosylated, 
monoantennary 
(41) 
 
 
2 
1298.5 
 
 
 
1298.1 H 
 HexNAc3 ex4 
Complex, 
monoantennary (41) 
 
X 
3 
1339.5 
 
 
1339.1H 
 HexNAc4Hex3 
Complex, 
biantennary (41) 
 
 
4 
1485.5 
 
 
1485.1 H 
1485.0 L 
 
FucHexNAc4Hex3 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
5 
1501.5 
 
 
1.0 H 
1500.9 L 
 
HexNAc4Hex4 
Complex, 
bianten ary (41) 
 
X 
6 
1542.6 
 
 
1542.0 H 
 HexNAc5Hex3 
Complex, bisecting 
 (41) 
 
X 
7 
1647.6 
 
 
1647.0 H 
1646.9 L 
 
FucHexNAc4Hex4 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
8 
1663.6 
 
 
1663.0 H 
1662.9 L 
 
HexNAc4 ex5 
Complex, 
biantennary (41) 
 
X 
9 
1685.6 
 
 
1684.6 H 
1685.  L 
 
HexNAc4Hex5Na 
 
 
Complex, 
biantennary 
 
 
 Calculated  
10 
1688.6 
 
 
1688.0 H 
 FucHexNAc5Hex3 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
X 
 
 
 
8 
 
 
 
1663.6 
 
 
 
1663.0H 
1662.9L 
 
 
HexNAc4Hex5 
 
 
 
complex, biantennary 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 15
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MALDI (m/z [M+Na]+) 
 
PSD 
  
Theoretical 
MW 
 
Found 
Monosaccharides 
composition 
Structure 
 Ref   
1 
1282.4 
 
 
1282.1 H FucHexNA 3Hex3 
Complex, 
fucosylated, 
monoantenn ry 
(41) 
 
 
2 
1298.5 
 
 
 
1298.1 H 
 HexNAc3Hex4 
Complex, 
monoantennary (41) 
 
X 
3 
1339.5 
 
 
1339.1H 
 HexNAc4Hex3 
Complex, 
biantennary (41) 
 
 
4 
1485.5 
 
 
1485.1 H 
1485.0 L 
 
FucHexNAc4 ex3 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
5 
1501.5 
 
 
1501.0 H 
1500.9 L 
 
HexNAc4Hex4 
lex, 
biant nnary (41) 
 
X 
6 
1542.6 
 
 
1542.0 H 
 HexNAc5Hex3 
Complex, isecting 
 (41) 
 
X 
7 
1647.6 
 
 
1647.0 H 
1646.9 L Fuc exNAc4Hex4 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
8 
1663.6 
 
 
1663.0 H 
16 2.9 L 
 
HexNAc4Hex5 
Complex, 
biantennary (41) 
 
X 
9 
1685.6 
 
 
1684.6 H 
1685.1 L 
 
HexNAc4Hex5Na 
 
 
Complex, 
biantennary 
 
 
 Calculated  
10 
1688.6 
 
 
1688.0 H 
 FucHexNAc5Hex3 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
X 
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MALDI (m/z [M+Na]+) Monosaccharides  
composition 
Structure 
 
Ref. 
 
PSD 
 Theoretical 
MW
Found 
9 1685.6 1684.6H 
1685.1L
HexNAc4Hex5Na complex, biantennary calculated 
10 
 
 
 
1688.6 
 
 
 
1688.0H 
 
 
 
fucHexNAc5Hex3 
 
 
 
complex, fucosylated, 
bisecting 
 
 
(41) 
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Table 3. Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardial lesions serum). ", 
Fucose; ", N-acetylglucosamine; ", Hexose;       N-acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod 
software only.  
 
 
MALDI (m/z [M+Na]+) 
 
PSD 
  
Theoretical 
MW 
 
Found 
Monosaccharides 
composition 
Structure 
 Ref   
1 
1282.4 
 
 
1282.1 H FucHexNAc3Hex3 
Complex, 
fucosylated, 
monoantennary 
(41) 
 
 
2 
1298.5 
 
 
 
1298.1 H 
 HexNAc3Hex4 
Complex, 
monoantennary (41) 
 
X 
3 
1339.5 
 
 
1339.1H 
 HexNAc4Hex3 
Complex, 
biantennary (41) 
 
 
4 
1485.5 
 
 
1485.1 H 
1485.0 L 
 
FucHexNAc4Hex3 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
5 
1501.5 
 
 
1501.0 H 
1500.9 L 
 
HexNAc4Hex4 
Complex, 
biantennary (41) 
 
X 
6 
1542.6 
 
 
1542.0 H 
 HexNAc5Hex3 
Complex, bisecting 
 (41) 
 
X 
7 
1647.6 
 
 
1647.0 H 
1646.9 L 
 
FucHexNAc4Hex4 
Complex, 
fucosylated, 
biantennary 
(41) 
 
X 
8 
1663.6 
 
 
1663.0 H 
1662.9 L 
 
HexNAc4Hex5 
Complex, 
biantennary (41) 
 
X 
9 
1685.6 
 
 
1684.6 H 
1685.1 L 
 
HexNAc4Hex5Na 
 
 
Complex, 
biantennary 
 
 
 Calculated  
10 
1688.6 
 
 
1688.0 H 
 FucHexNAc5Hex3 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
11 
 
 
 
 
1704.6 
 
 
 
 
1705.0H 
1703.9L 
 
 
 
HexNAc5Hex4 
 
 
 
 
complex, bisecting 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 16
11 
1704.6 
 
 
1705.0 H 
1703.9 L 
 
HexNAc5Hex4 Complex, bisecting (41) 
 
 
12 
1809.6 
 
 
1809.0 H 
1809.9 L 
 
FucHexNAc4Hex5 
Complex, 
biantennary, 
fucosylated 
 
 
(41) 
 
X 
13 
1831.6 
 
 
1830.1 H 
1830.8 L 
 
FucHexNAc4Hex5Na 
Complex, 
fucosylated, 
biantennary 
 
 
X 
14 
1850.7 
 
 
1850.0 H 
1849.9 L 
 
FucHexNAc5Hex4 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
15 
1866.7 
 
 
1867.2 H 
1865.8 L 
 
HexNAc5Hex5 Complex, bisecting (41) 
 
 
16 
 
1889.7 
 
 
1889.2 H 
1886.4 L 
 
HexNAc5Hex5Na 
 
Complex, 
triantennary/bisect
ing 
 
 Calculated  
17 
1913.7 
 
 
1912.0 H 
1911.8 L 
 
HexNAc3Hex6Sia Hybrid, sialylated (42) 
 
X 
18 
1955.7 
 
 
1954.0 H 
 
1953.8 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, 
sialylated, 
biantennary 
 
Complex, 
biantennary, 
difucosylated 
 
 
(41) 
 
X 
19 
1977.7 
 
 
1975.9 H 
1975.8 L 
 
HexNAc4Hex5SiaNa 
Complex, 
sialylated, 
biantennary 
(42) 
 
X 
20 
1995.7 
 
1996.7 
 
 
1996.0 H 
 
1996.8 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Complex, 
sialylated, 
triantennary - 
bisecting 
 
Complex, 
difucosylated, 
triantennary/bisect
ing 
 Calculated  
21 
2012.7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc5Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
12 
 
 
 
 
1809.6 
 
 
 
 
1809.0H 
1809.9L 
 
 
 
fucHexNAc4Hex5 
 
 
 
 
complex, biantennary,  
fucosylated 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 16
11 
1704.6 
 
 
1705.0 H 
1703.9 L 
 
HexNAc5Hex4 Complex, bisecting (41) 
 
 
12 
1809.6 
 
 
1809.0 H 
1809.9 L 
 
FucHexNAc4Hex5 
Complex, 
biantennary, 
fucosylated 
 
 
(41) 
 
X 
13 
1831.6 
 
 
1830.1 H 
1830.8 L 
 
FucHexNAc4Hex5Na 
Complex, 
fucosylated, 
biantennary 
 
 
X 
14 
1850.7 
 
 
1850.0 H 
1849.9 L 
 
FucHexNAc5Hex4 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
15 
1866.7 
 
 
1867.2 H 
1865.8 L 
 
HexNAc5Hex5 Complex, bisecting (41) 
 
 
16 
 
1889.7 
 
 
1889.2 H 
1886.4 L 
 
HexNAc5Hex5Na 
 
Complex, 
triantennary/bisect
ing 
 
 Calculated  
17 
1913.7 
 
 
1912.0 H 
1911.8 L 
 
HexNAc3Hex6Sia Hybrid, sialylated (42) 
 
X 
18 
1955.7 
 
 
1954.0 H 
 
1953.8 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, 
sialylated, 
biantennary 
 
Complex, 
biantennary, 
difucosylated 
 
 
(41) 
 
X 
19 
1977.7 
 
 
1975.9 H 
1975.8 L 
 
HexNAc4Hex5SiaNa 
Complex, 
sialylated, 
biantennary 
(42) 
 
X 
20 
1995.7 
 
1996.7 
 
 
1996.0 H 
 
1996.8 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Complex, 
sialylated, 
triantennary - 
bisecting 
 
Complex, 
difucosylated, 
triantennary/bisect
ing 
 Calculated  
21 
2012.7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc5Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
X 
 
 
 
 
13 
 
 
 
 
1831.6 
 
 
 
 
1830.1H 
1830.8L 
 
 
 
fucHexNAc4Hex5Na 
 
 
 
 
complex, fucosylated, 
biantennary 
 
 
 
 
 
 
 
 
 
 16
11 
1704.6 
 
 
1705.  H 
1703.9 L 
 
HexNAc5Hex4 Complex, bisecting (41) 
 
 
12 
1809.6 
 
 
1809.0 H 
1809.9 L 
 
FucHexNAc4Hex5 
Complex, 
biantennary, 
fucosylated 
 
 
(41) 
 
X 
13 
1831.6 
 
 
1830.1 H 
1830.8 L 
 
FucHexNAc4Hex5Na 
Complex, 
fucosylated, 
biantennary 
 
 
X 
14 
1850.7 
 
 
1850.0 H 
1849.9 L 
 
FucHexNAc5Hex4 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
15 
1866.7 
 
 
1867.2 H 
1865.8 L 
 
HexNAc5Hex5 Complex, bisecting (41) 
 
 
16 
 
1889.7 
 
 
1889.2 H 
1886.4 L 
 
HexNAc5Hex5Na 
 
Complex, 
triantennary/bisect
ing 
 
 Calculated  
17 
1913.7 
 
 
1912.0 H 
1911.8 L 
 
HexNAc3Hex6Sia Hybrid, sialylated (42) 
 
X 
18 
1955.7 
 
 
1954.0 H 
 
1953.8 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, 
sialylated, 
biantennary 
 
Complex, 
biantennary, 
difucosylated 
 
 
(41) 
 
X 
19 
1977.7 
 
 
1975.9 H 
1975.8 L 
 
HexNAc4Hex5SiaNa 
Complex, 
sialylated, 
biantennary 
(42) 
 
X 
20 
1995.7 
 
1996.7 
 
 
1996.0 H 
 
1996.8 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Complex, 
sialylated, 
triantennary - 
bisecting 
 
Complex, 
difucosylated, 
triantennary/bisect
ing 
 Calculated  
21 
2012.7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc5Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
X 
 
 
 
 
14 
 
 
 
 
1850.7 
 
 
 
 
1850.0H 
1849.9L 
 
 
 
fucHexNAc5Hex4 
 
 
 
 
complex, fucosylated,  
bisecting 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 16
11 
1704.6 
 
 
1705.0 H 
1703.9 L 
 
HexNAc5Hex4 Complex, bisecting (41) 
 
 
12 
1809.6 
 
 
1809.0 H 
1809.9 L 
 
FucHexNAc4Hex5 
Complex, 
biantennary, 
fucosylated 
 
 
(41) 
 
X 
13 
1831.6 
 
 
1830.1 H 
1830.8 L 
 
Fuc exNAc4Hex5Na 
Complex, 
fucosyl ted, 
biantennary 
 
 
X 
14 
1850.7 
 
 
1850.0 H 
1849.9 L 
 
FucHexNAc5Hex4 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
15 
1866.7 
 
 
1867.2 H 
1865.8 L 
 
exNAc5Hex5 Complex, bisecting (41) 
 
 
16 
 
1889.7 
 
 
1889.2 H 
1886.4 L 
 
HexNAc Hex5Na 
 
Complex, 
tria tennary/bisect
ing 
 
 lated  
17 
1913.7 
 
 
1912.0 H 
1911.8 L 
 
HexNAc3Hex6Sia Hybrid, sialylated (42) 
 
X 
18 
1955.7 
 
 
1954.0 H 
 
1953.8 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, 
sialylated, 
biantennary 
 
Complex, 
biantennary, 
difucosylated 
 
 
(41) 
 
X 
19 
1977.7 
 
 
1975.9 H 
1975.8 L 
 
HexNAc4Hex5SiaNa 
Complex, 
sialylated, 
biantennary 
(42) 
 
X 
20 
1995.7 
 
1996.7 
 
 
1996.0 H 
 
1996.8 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Complex, 
sialylated, 
triantennary - 
bisecting 
 
Complex, 
difucosylated, 
triante nary/bisect
ing 
 lated  
21 
2012.7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc5Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
15 
 
 
 
 
1866.7 
 
 
 
 
1867.2H 
1865.8L 
 
 
 
HexNAc5Hex5 
 
 
 
 
complex, bisecting 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 16
11 
1704.6 
 
 
1705.0 H 
1703.9 L 
 
HexNAc5Hex4 Complex, bisecting (41) 
 
 
12 
1809.6 
 
 
1809.0 H 
1809.9 L 
 
FucHexNAc4Hex5 
Complex, 
biantennary, 
fucosylated 
 
 
(41) 
 
X 
13 
1831.6 
 
 
1830.1 H 
1830.8 L 
 
FucHexNAc4Hex5Na 
Complex, 
fucosylated, 
biantennary 
 
 
X 
14 
1850.7 
 
 
1850.0 H 
1849.9 L 
 
FucHexNAc5Hex4 
Co lex, 
fucosylated, 
bisecting 
(41) 
 
 
15 
1866.7 
 
 
1867.2 H 
1865 8 L 
 
HexNAc5Hex5 Complex, bisecting (41) 
 
 
16 
 
1889.7 
 
 
1889.2 H 
1886.4 L 
 
HexNAc5Hex5Na 
 
Complex, 
triantennary/bisect
ing 
 
 Calculated  
17 
1913.7 
 
 
1912.0 H 
1911.8 L 
 
HexNAc3Hex6Sia Hybrid, sialylated (42) 
 
X 
18 
195 .7 
 
 
1954.0 H 
 
1953.8 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, 
sialylated, 
bianten ary 
 
Complex, 
biantennary, 
difucosylated 
 
 
(41) 
 
X 
19 
1977.7 
 
 
1975.9 H 
1975.8 L 
 
HexNAc4Hex5SiaNa 
Complex, 
sialylated, 
biante nary 
(42) X 
20 
1995.7 
 
1996.7 
 
 
1996.0 H 
 
1996.8 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Complex, 
sialylated, 
tria te nary - 
bisecting 
 
Complex, 
difucosylated, 
triantennary/bisect
ing
 alc lated  
21 
2012.7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc5Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
16 1889.7 1889.2H 
1886.4L
HexNAc5Hex5Na complex, 
triantennary/bisecting
calculated 
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MALDI (m/z [M+Na]+) Monosaccharides  
composition 
Structure 
 
Ref. 
 
PSD 
 Theoretical 
MW
Found 
17 
 
 
 
 
1913.7 
 
 
 
 
1912.0H 
1911.8L 
 
 
 
HexNAc3Hex6Sia 
 
 
 
 
Hybrid, sialylated 
 
 
 
 
(42) 
 
 
 
 
 
 
 
 
 
 
 16
11 
1704.6 
 
 
1705.0 H 
1703.9 L 
 
HexNAc5Hex4 Complex, bisecting (41) 
 
 
12 
1809.6 
 
 
1809.0 H 
1809.9 L 
 
FucHexNAc4Hex5 
Complex, 
biantennary, 
fucosylated 
 
 
(41) 
 
X 
13 
1831.6 
 
 
1830.1 H 
1830.8 L 
 
FucHexNAc4Hex5Na 
Complex, 
fucosylated, 
biantennary 
 
 
X 
14 
1850.7 
 
 
1850.0 H 
1849.9 L 
 
FucHexNAc5Hex4 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
15 
1866.7 
 
 
1867.2 H 
1865.8 L 
 
HexNAc5Hex5 Complex, bisecting (41) 
 
 
16 
 
1889.7 
 
 
1889.2 H 
1886.4 L 
 
HexNAc5Hex5Na 
 
Complex, 
triantennary/bisect
ing 
 
 Calculated  
17 
1913.7 
 
 
1912.0 H 
1911.8 L 
 
HexNAc3Hex6Sia Hybrid, sialylated (42) 
 
X 
18 
1955.7 
 
 
1954.0 H 
 
1953.8 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, 
sialylated, 
biantennary 
 
Complex, 
biantennary, 
difucosylated 
 
 
(41) 
 
X 
19 
1977.7 
 
 
1975.9 H 
1975.8 L 
 
HexNAc4Hex5SiaNa 
Complex, 
sialylated, 
biantennary 
(42) 
 
X 
20 
1995.7 
 
1996.7 
 
 
1996.0 H 
 
1996.8 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Complex, 
sialylated, 
triantennary - 
bisecting 
 
Complex, 
difucosylated, 
triantennary/bisect
ing 
 Calculated  
X 
 
 
 
 
18 
 
 
 
 
1955.7 
 
 
 
 
1954.0H 
 
 
1953.8L 
HexNAc4Hex5Sia 
 
 
fuc2HexNAc4Hex5 
 
complex, sialylated, 
biantennary 
 
complex, biantennary,  
difucosylated 
(41 
 
 
 
 
)
 
 
 
 
 
 
 16
11 
1704.6 
 
 
1705.0 H 
1703.9 L 
 
HexNAc5Hex4 Complex, bisecting (41) 
 
 
12 
1809.6 
 
 
1809.0 H 
1809.9 L 
 
FucHexNAc4Hex5 
Complex, 
biantennary, 
fucosylated 
 
 
(41) 
 
X 
13 
1831.6 
 
 
1830.1 H 
1830.8 L 
 
FucHexNAc4Hex5Na 
Complex, 
fucosylated, 
biantennary 
 
 
X 
14 
1850.7 
 
 
1850.0 H 
1849.9 L 
 
FucHexNAc5Hex4 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
15 
1866.7 
 
 
1867.2 H 
1865.8 L 
 
HexNAc5Hex5 Complex, bisecting (41) 
 
 
16 
 
1889.7 
 
 
1889.2 H 
1886.4 L 
 
HexNAc5Hex5Na 
 
Complex, 
triantennary/bisect
ing 
 
 Calculated  
17 
1913.7 
 
 
1912.0 H 
1911.8 L 
 
HexNAc3Hex6Sia Hybrid, sialylated (42) 
 
X 
18 
1955.7 
 
 
1954.0 H 
 
1953.8 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
 
Complex, 
sialylated, 
biantennary 
 
Complex, 
biantennary, 
difucosylated 
 
 
(41) 
 
X 
19 
1977.7 
 
 
1975.9 H 
1975.8 L 
 
HexNAc4Hex5SiaNa 
Complex, 
sialylated, 
biantennary 
(42) 
 
X 
20 
1995.7 
 
1996.7 
 
 
1996.0 H 
 
1996.8 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Complex, 
sialylated, 
triantennary - 
bisecting 
 
Complex, 
difucosylated, 
triantennary/bisect
ing 
 Calculated  
X 
 
 
 
 
19 
 
 
 
 
1977.7 
 
 
 
 
197 .9H 
1975.8L 
 
 
 
HexNAc4Hex5SiaNa 
 
 
 
 
complex, sialylated, 
biantennary 
 
 
 
(42) 
 
 
 
 
 
 
 
 
 
 
 16
11 
1704.6 
 
 
1705.0 H 
1703.9 L 
 
HexNAc5Hex4 Complex, bisecting (41) 
 
 
12 
1809.6 
 
 
1809.0 H 
1809.9 L 
 
FucHexNAc4Hex5 
Complex, 
biantennary, 
fucosylated 
 
 
(41) 
 
X 
13 
1831.6 
 
 
1830.1 H 
1830.8 L 
 
FucHexNAc4Hex5Na 
Complex, 
fucosylated, 
biantennary 
 
 
X 
14 
1850.7 
 
 
1850.0 H 
1849.9 L 
 
FucHexNAc5Hex4 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
15 
1866.7 
 
 
1867.2 H 
1865.8 L 
 
HexNAc5Hex5 Complex, bisecting (41) 
 
 
16 
 
1889.7 
 
 
1889.2 H 
1886.4 L 
 
HexNAc5Hex5Na 
 
Complex, 
triantennary/bisect
ing 
 
 Calculated  
17 
1913.7 
 
 
1912.0 H 
1911.8 L 
 
HexNAc3Hex6Sia Hybrid, sialylated (42) 
 
X 
18 
1955.7 
 
 
1954.0 H 
 
1953.8 L 
 
HexNAc4Hex5Sia 
 
Fuc2HexNAc4Hex5 
Complex, 
sialylated, 
biantennary 
 
Complex, 
biantennary, 
difucosylated 
 
 
(41) 
 
X 
19 
1977.7 
 
 
1975.9 H 
1975.8 L 
 
HexNAc4Hex5SiaNa 
Complex, 
sialylated, 
biantennary 
(42) 
 
X 
20 
1995.7 
 
1996.7 
 
 
1996.0 H 
 
1996.8 L 
 
HexNAc5Hex4Sia 
 
Fuc2HexNAc5Hex4 
Complex, 
sialylated, 
triantennary - 
bisecting 
 
Complex, 
difucosylated, 
triantennary/bisect
ing 
 Calculated  
X 
 
 
 
 
20 
 
 
 
1995.7 
 
 
1996.7 
1996.0H 
 
 
1996.8L 
HexNAc5Hex4Sia 
 
 
fuc2HexNAc5Hex4 
complex, sialylated,  
triantennary/bisecting 
 
complex, difucosylated,  
triantennary/bisecting
calculated 
 
 
 
21 
 
 
 
2012.7 
 
 
 
2011.9H 
2011.8L 
 
 
fucHexNAc5Hex5 
 
 
 
complex, fucosylated, 
bisecting 
 
 
(41) 
 
 
 
 
 
 
 
 
 17
21 
2012.7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc5Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
22 
2028.7 
 
 
2028.0 H 
2028.7 L 
 
HexNAc5Hex6 
Complex, 
triantennary (41) 
 
X 
23 
2050.7 
 
 
2049.9 H 
2047.8 L 
 
HexNAc5Hex6Na 
Complex, 
triantennary  Calculated  
24 
2081.6 
 
 
2081.3 H 
2081.7 L 
 
FucHexNAc3Hex6Sia 
Hybrid, 
fucosylated, 
sialylated 
 Calculated  
25 
2123.7 
 
 
2121.9 H 
 FucHexNAc4Hex5SiaNa 
Complex, 
fucosylated, 
sialylated, 
biantennary 
 
 
X 
26 
2174.8 
 
 
2174.7 L 
 FucHexNAc5Hex6 
Complex, 
fucosylated, 
triantennary 
(41) 
 
 
27 
2179.8 
 
 
2179.6 L 
 HexNAc5Hex5SiaNa 
Complex, 
sialylated, 
triantennary/bisect
ing 
 Calculated  
28 
2245.8 
 
 
2244.9 H 
 HexNAc4Hex5Sia2 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
29 
2267.8 
 
 
2266.9 H 
2267.5 L 
 
HexNAc4Hex5Sia2Na 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
30 
2284.8 
 
 
2282.8 H 
2283.7 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, 
fucosylated, 
sialylated 
 Calculated  
31 
2290.8 
 
 
2288.9 H 
 HexNAc4Hex5Sia2Na2 
Complex, 
disialylated, 
biantennary 
(42) 
 
 
32 
2320.8 
 
 
2318.8 H 
 
2319.7 L 
 
HexNAc5Hex6Sia 
 
Fuc2HexNAc5Hex6 
Complex, 
sialylated, 
triantennary 
 
Complex, 
difucosylated, 
triantennary 
 
 
(41) 
  
X 
33 
2325.8 
 
 
2324.9 H 
2324.7 L 
 
FucHexNAc5Hex5SiaNa 
Complex, 
fucosylated, 
sialylated, 
 Calculated  
22 
 
 
 
 
2028.7 
 
 
 
 
2028.0H 
2028.7L 
 
 
 
HexNAc5Hex6 
 
 
 
 
complex, triantennary 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 17
21 
2012.7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc5Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
22 
2028.7 
 
 
2028.0 H 
2028.7 L 
 
exNAc5Hex6 
Complex, 
triantennary (41) 
 
X 
23 
2050.7 
 
 
2049.9 H 
2047.8 L 
 
HexNAc5Hex6Na 
Complex, 
triantennary  Calculated  
24 
2081.6 
 
 
2081.3 H 
2081.7 L 
 
FucHexNAc3Hex6Sia 
Hybrid, 
fucosylated, 
sialylated 
 Calculated  
25 
2123.7 
 
 
2121.9 H 
 FucHexNAc4Hex5SiaNa 
Complex, 
fucosylated, 
sialylated, 
biantennary 
 
 
X 
26 
2174.8 
 
 
2174.7 L 
 FucHexNAc5Hex6 
Complex, 
fucosylated, 
triantennary 
(41) 
 
 
27 
2179.8 
 
 
2179.6 L 
 HexNAc5Hex5SiaNa 
Complex, 
sialylated, 
triantennary/bisect
ing 
 Calculated  
28 
2245.8 
 
 
2244.9 H 
 HexNAc4Hex5Sia2 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
29 
2267.8 
 
 
2266.9 H 
2267.5 L 
 
HexNAc4Hex5Sia2Na 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
30 
2284.8 
 
 
2282.8 H 
2283.7 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, 
fucosylated, 
sialylated 
 Calculated  
31 
2290.8 
 
 
2288.9 H 
 HexNAc4Hex5Sia2Na2 
Complex, 
disialylated, 
biantennary 
(42) 
 
 
32 
2320.8 
 
 
2318.8 H 
 
2319.7 L 
 
HexNAc5Hex6Sia 
 
Fuc2HexNAc5Hex6 
Complex, 
sialylated, 
triantennary 
 
Complex, 
difucosylated, 
triantennary 
 
 
(41) 
  
X 
33 2325.8  
2324.9 H 
2324.7 L FucHexNAc5Hex5SiaNa 
Complex, 
fucosylated,  Calculated  
X 
 
 
 
 
23 2050.7 2049.9H 
2047.8L
HexNAc5Hex6Na compl x, triantennary calculated 
24 2081.6 2081.3H 
2081.7L
fucHexNAc3Hex6Sia Hybrid, fucosylated,  
sialylated
c lated 
Table 3 (continued). Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures derived 
from glycopeptides recovered in the ConA unbound fraction (H = hea thy serum; L = myocardial lesions serum). , Fucose; , N­acetylglu­
cosamine; , Hexose; , N­acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod software only. 
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MALDI (m/z [M + Na]+) Monosaccharides  
composition 
Structure 
 
Ref. 
 
PSD 
 Theoretical 
MW
Found 
25 
 
 
 
 
2123.7 
 
 
 
 
2121.9H 
 
 
 
 
fucHexNAc4Hex5SiaNa 
 
 
 
 
complex, fucosylated,  
sialylated, biantennary 
 
 
 
 
 
 
 
 
 
 17
21 
2012.7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc5Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
22 
2028.7 
 
 
2028.0 H 
2028.7 L 
 
HexNAc5Hex6 
Complex, 
triantennary (41) 
 
X 
23 
2050.7 
 
 
2049.9 H 
2047.8 L 
 
HexNAc5Hex6Na 
Complex, 
triantennary  Calculated  
24 
2081.6 
 
 
2081.3 H 
2081.7 L 
 
FucHexNAc3Hex6Sia 
Hybrid, 
fucosylated, 
sialylated 
 Calculated  
25 
2123.7 
 
 
2121.9 H 
 FucHexNAc4Hex5SiaNa 
Complex, 
fucosylated, 
sialylated, 
biantennary 
 
 
X 
26 
2174.8 
 
 
2174.7 L 
 FucHexNAc5Hex6 
Complex, 
fucosylated, 
triantennary 
(41) 
 
 
27 
2179.8 
 
 
2179.6 L 
 HexNAc5Hex5SiaNa 
Complex, 
sialylated, 
triantennary/bisect
ing 
 Calculated  
28 
2245.8 
 
 
2244.9 H 
 HexNAc4Hex5Sia2 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
29 
2267.8 
 
 
2266.9 H 
2267.5 L 
 
HexNAc4Hex5Sia2Na 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
30 
2284.8 
 
 
2282.8 H 
2283.7 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, 
fucosylated, 
sialylated 
 Calculated  
31 
2290.8 
 
 
2288.9 H 
 HexNAc4Hex5Sia2Na2 
Complex, 
disialylated, 
biantennary 
(42) 
 
 
32 
2320.8 
 
 
2318.8 H 
 
2319.7 L 
 
HexNAc5Hex6Sia 
 
Fuc2HexNAc5Hex6 
Complex, 
sialylated, 
triantennary 
 
Complex, 
difucosylated, 
triantennary 
 
 
(41) 
  
X 
33 2325.8 2324.9 H FucHexNAc5Hex5SiaNa Complex,  Calculated  
X 
 
 
 
 
26 
 
 
 
 
2174.8 
 
 
 
 
2174.7L 
 
 
 
 
fucHexNAc5Hex6 
 
 
 
 
complex, fucosylated, 
triantennary 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 
 17
21 
2012.7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc5Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
22 
2028.7 
 
 
2028.0 H 
2028.7 L 
 
HexNAc5Hex6 
Complex, 
triantennary (41) 
 
X 
23 
2050.7 
 
 
2049.9 H 
2047.8 L 
 
HexNAc5Hex6Na 
Complex, 
triantennary  Calculated  
24 
2081.6 
 
 
2081.3 H 
2081.7 L 
 
FucHexNAc3Hex6Sia 
Hybrid, 
fucosylated, 
sialylated 
 Calculated  
25 
2123.7 
 
 
2121.9 H 
 FucHexNAc4Hex5SiaNa 
Complex, 
fucosylated, 
sialylated, 
biantennary 
 
 
X 
26 
2174.8 
 
 
2174.7 L 
 FucHexNAc5Hex6 
Complex, 
fucosylated, 
triantennary 
(41) 
 
 
27 
2179.8 
 
 
2179.6 L 
 HexNAc5Hex5SiaNa 
Complex, 
sialylated, 
triantennary/bisect
ing 
 Calculated  
28 
2245.8 
 
 
2244.9 H 
 HexNAc4Hex5Sia2 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
29 
2267.8 
 
 
2266.9 H 
2267.5 L 
 
HexNAc4Hex5Sia2Na 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
30 
2284.8 
 
 
2282.8 H 
2283.7 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, 
fucosylated, 
sialylated 
 Calculated  
31 
2290.8 
 
 
2288.9 H 
 HexNAc4Hex5Sia2Na2 
Complex, 
disialylated, 
biantennary 
(42) 
 
 
32 
2320.8 
 
 
2318.8 H 
 
2319.7 L 
 
HexNAc5Hex6Sia 
 
Fuc2HexNAc5Hex6 
Complex, 
sialylated, 
triantennary 
 
Complex, 
difucosylated, 
triantennary 
 
 
(41) 
  
X 
27 2179.8 2179.6L HexNAc5Hex5SiaNa complex, sialylated, 
triantennary/bisecting
calculated 
28 
 
 
 
 
2245.8 
 
 
 
 
2244.9H 
 
 
 
 
HexNAc4Hex5Sia2 
 
 
 
 
complex, disialylated,  
biantennary 
 
 
 
(42) 
 
 
 
 
 
 
 
 
 
 17
21 
201 .7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
22 
2028.7 
 
 
2028.0 H 
2028.7 L 
 
HexNAc5Hex6 
Complex, 
triantennary (41) 
 
X 
23 
2050.7 
 
 
2049.9 H 
2047.8 L 
 
HexNAc5Hex6Na 
Complex, 
triant nnary  Calculated  
24 
2081.6 
 
 
2081.3 H 
2081.7 L 
 
FucHexNAc3Hex6Sia 
Hybrid, 
fucosylated, 
sialylated 
 Calculated  
25 
2123.7 
 
 
2121.9 H 
 FucHexNAc4Hex5SiaNa 
Complex, 
fucosyl ted, 
sialylated, 
biantennary 
 
 
X 
26 
2174.8 
 
 
2174.7 L 
 FucHexNAc5Hex6 
Complex, 
fucosylated, 
triant nnary 
(41) 
 
 
27 
2179.8 
 
 
2179.6 L 
 HexNAc5Hex5SiaNa 
Complex, 
sialylated, 
triantennary/bisect
i g 
 Calculated  
28 
2245.8 
 
 
244.9 H 
 HexNAc4Hex5Sia2 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
29 
2267.8 
 
 
2266.9 H 
2267.5 L 
 
HexNAc4Hex5Sia2Na 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
30 
2284.8
 
 
2282.8 H 
2283.7 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, 
fucosyl ted, 
sialylated 
 Calculated  
31 
2290.8 
 
 
2288.9 H 
 HexNAc4Hex5Sia2Na2 
Complex, 
disialylated, 
biantennary 
(42) 
 
 
32 
2320.8 
 
 
2318.8 H 
 
2319.7 L 
 
HexNAc5Hex6Sia 
 
Fuc2HexNAc5Hex6 
Complex, 
sialylated, 
triantennary 
 
Complex, 
difucosylated, 
tria tennary 
 
(41) 
  
X 
X 
 
 
 
 
29 
 
 
 
 
2267.8 
 
 
 
 
2266.9H 
2267.5L 
 
 
 
HexNAc4Hex5Sia2Na 
 
 
 
 
complex, disialylated, 
biantennary 
 
 
 
(42) 
 
 
 
 
 
 
 
 
 
 
 17
21 
2012.7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc5Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
22 
2028.7 
 
 
2028.0 H 
2028.7 L 
 
HexNAc5Hex6 
Complex, 
triantennary (41) 
 
X 
23 
2050.7 
 
 
2049.9 H 
2047.8 L 
 
HexNAc5Hex6Na 
Complex, 
triantennary  Calculated  
24 
081.6 
 
 
2081.3 H 
2081.7 L 
 
Fu HexNAc3Hex6Sia 
Hybrid, 
fucosylated, 
sialylated 
 Cal ted  
25 
2123.7 
 
 
2121.9 H 
 FucHexNAc4Hex5SiaNa 
Complex, 
fucosylated, 
sialylated, 
biantennary 
 
 
X 
26 
2174.8 
 
 
2174.7 L 
 FucHexNAc5Hex6 
Compl x, 
fucosylated, 
triantennary 
(41) 
 
 
27 
2179.8 
 
 
2179.6 L 
 HexNAc5Hex5SiaNa 
Complex, 
sialylated, 
triantennary/bisect
ing 
 Cal   
28 
2245.8 
 
 
2244.9 H 
 HexNAc4Hex5Sia2 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
29 
2267.8 
 
 
2266.9 H 
2267.5 L 
 
HexNAc4Hex5Sia2Na 
Complex, 
d sialylated, 
biante nary 
(42) 
 
X 
30 
2284.8 
 
 
2282.8 H 
2283.7 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, 
fucosylated, 
sialylated 
 alculated  
31 
2290 8 
 
 
2288.9 H 
 HexNAc4Hex5Sia2Na2 
Complex, 
disialylated, 
biantennary 
(42) 
 
 
32 
2320.8 
 
 
2318.8 H 
 
2319.7 L 
 
HexNAc5Hex6Sia 
 
Fuc2HexNAc5Hex6 
Complex, 
sialylated, 
triantennary 
 
Complex, 
difucosylated, 
triantennary 
 
(41) 
  
X 
X 
 
 
 
 
30 2284.8 2282.8H 
2283.7L
fucHexNAc4Hex6SiaNa Hybrid, fucosylated, 
sialylated
calculated 
31 
 
 
 
 
2290.8 
 
 
 
 
2288.9H 
 
 
 
 
HexNAc4Hex5Sia2Na2 
 
 
 
 
complex, disialylated, 
biantennary 
 
 
 
(42) 
 
 
 
 
 
 
 
 
 
 
 17
21 
2012.7 
 
 
2011.9 H 
2011.8 L 
 
FucHexNAc5Hex5 
Complex, 
fucosylated, 
bisecting 
(41) 
 
 
22 
2028.7 
 
 
2028.0 H 
2028.7 L 
 
H xNAc5Hex6 
Complex, 
triantennary (41) 
 
X 
23 
2050.7 
 
 
2049.9 H 
2047.8 L 
 
HexNAc5Hex6Na 
Complex, 
triantennary  Calc lated  
24 
2081.6 
 
 
2081.3 H 
2081.7 L 
 
FucHexNAc3Hex6Sia 
Hybrid, 
fucosylated, 
sialylated 
 Calculated  
25 
2123.7 
 
 
2121.9 H 
 FucHexNAc4Hex5SiaNa 
Complex, 
fucosylated, 
sialylated, 
biantennary 
 
 
 
26 
2174.8 
 
 
2174.7 L 
 FucHexNAc5Hex6 
Complex, 
fucosylated, 
triantennary 
( )  
27 
2179.8 
 
 
2179.6 L 
 HexNAc5Hex5SiaNa 
Complex, 
sialylated, 
triantennary/bisect
ing 
 l l t   
28 
2245.8
 
 
2244.9 H 
 HexNAc4Hex5Sia2 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
29 
2267.8 
 
 
2266.9 H 
2267.5 L 
 
HexNAc4Hex5Sia2Na 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
30 
2284.8 
 
 
2282.8 H 
2283.7 L 
 
FucHexNAc4Hex6SiaNa 
Hyb id, 
fucosylated, 
sialylated 
 Calculated  
31 
2290.8 
 
 
2288.9 H 
 HexNAc4Hex5Sia2Na2 
Complex, 
disialylated, 
biantennary 
(42) 
 
 
32 
320.8 
 
 
231 .8 H 
 
2319.7 L 
 
HexNAc5 6Sia 
 
Fuc2HexNAc5Hex6 
Compl x, 
sialylated, 
triantennary 
 
Complex, 
difucosylated, 
triantennary 
 
( ) 
  
X 
32 
 
 
 
 
2320.8 
 
 
 
 
2318.8H 
 
 
2319.7L 
 
HexNAc5Hex6Sia 
 
 
fuc2HexNAc5Hex6 
 
complex, sialylated, 
triantennary 
 
complex, difucosylated,  
triantennary 
(41)
 
 
 
 
 
 
 17
21 
2012.7 
 
 
9 H 
2011.8 L 
 
FucHexNAc5Hex5 
C mplex, 
fucosylated, 
bisecting 
(41) 
 
 
22 
2028.7 
 
 
0 H 
2028.7 L 
 
HexNAc5Hex6 
Complex, 
triantennary (41) 
 
X 
23 
2050.7 
 
 
9 9 H 
2047.8 L 
 
HexNAc5Hex6Na 
Complex, 
triantennary  Calcul t  
24 
2081.6 
 
 
3 H 
2081.7 L 
 
FucHexNAc3Hex6Sia 
Hybrid, 
fucosylated, 
sialylated 
 Calculated  
25 
2123.7 
 
 
2121.9 H 
 FucHexNAc4Hex5SiaNa 
C mplex, 
fucosylated, 
sialylated, 
biantennary 
 
 
X 
26 
2174.8 
 
 
2174.7 L 
 FucHexNAc5Hex6 
C mplex, 
fucosylated, 
triantennary 
(41) 
 
 
27 
2179.8 
 
 
2179.6 L 
 HexNAc5Hex5SiaNa 
Compl x, 
sialylated, 
triantennary/bisect
ing 
 Calcul d  
28 
2245.8 
 
 
2244.9 H 
 HexNAc4Hex5Sia2 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
29 
2 67.8 
 
 
2266.9 H 
2267.5 L 
 
HexNAc4Hex5Sia2Na 
Complex, 
disialylated, 
biantennary 
(42) 
 
X 
30 
2284.8 
 
 
2282.8 H 
2283.7 L 
 
FucHexNAc4Hex6SiaNa 
Hybrid, 
fucosylated, 
sialylated 
 Calcul t  
31 
2290.8 
 
 
2288.9 H 
 HexNAc4Hex5Sia2Na2 
Complex, 
disialylated, 
biantennary 
(42) 
 
 
32 
2320.8 
 
 
2318.8 H 
 
2319.7 L 
 
HexNAc5Hex6Sia 
 
Fuc2HexNAc5Hex6 
Complex, 
sialylated, 
tri ntennary 
 
Complex, 
difucosylated, 
triantennary 
 
(41) 
  
X 
X 
 
 
 
 
Table 3 (continued). Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures derived 
from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardial lesions serum). , Fucose; , N­acetylglu­
cosamine; , Hexose; , N­acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod software only. 
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Negative MALDI spectra performed on the same conA 
bound fractions essentially confirmed the above reported 
data showing the presence of a few sialylated variants, corre-
sponding to biantennary glycans.
Higher branched glycopeptides were not retained onto 
the lectin originating the unbound fraction of the affinity 
 purification. thus, conA affinity chromatography led to the 
relative concentration of tri- and tetrantennary oligosac-
charides in this fraction. Without this step, these usually 
less abundant glycans could have been escaped detec-
tion. PNGase f was directly added to the unbound fraction, 
glycans were separated from peptides by HPLc and directly 
analysed by MALDI-MS following the procedures described 
above.
figure 5 shows the positive MALDI-MS analyses of glycans 
deriving from the unbound fractions of the (a) healthy and (b) 
MALDI (m/z [M+Na]+) Monosaccharides  
composition 
Structure 
 
Ref. 
 
PSD 
 Theoretical 
MW
Found 
33 
 
2325.8 
 
2324.9H 
2324.7L 
fucHexNAc5Hex5SiaNa 
 
complex, fucosylated,  
sialylated, 
triantennary/bisecting
calculated 
 
34 2342.8 2341.8H 
2340.7L
HexNAc5Hex6SiaNa complex, sialylated, 
triantennary
calculated 
35 2360.9 2359.9H 
2359.8L
HexNAc6Hex5Sia complex, sialylated,  
tetraantennary
calculated 
36 
 
 
 
 
2393.7 
 
 
 
 
2392.9H 
2392.6L 
 
 
 
HexNAc6Hex7 
 
 
 
 
complex, tetraantennary 
 
 
 
 
(41) 
 
 
 
 
 
 
 
 
 
 18
 
33 
2325.8 
 
 
2324.9 H 
2324.7 L 
 
FucHexNAc5Hex5SiaNa 
Complex, 
fucosylated, 
sialylated, 
triantennary/bisect
ing 
 Calculated  
34 
2342.8 
 
 
2341.8 H 
2340.7 L 
 
HexNAc5Hex6SiaNa 
Complex, 
sialylated, 
triantennary 
 Calculated  
35 
2360.9 
 
 
2359.9 H 
2359.8 L 
 
HexNAc6Hex5Sia 
Complex, 
sialylated, 
tetraantennary 
 Calculated  
36 
 
2393.7 
 
 
 
2392.9 H 
2392.6 L 
 
HexNAc6Hex7 
 
Complex, 
tetraantennary 
 
(41) 
 
 
 
X 
37 
2413.8 
 
 
2412.3 L 
 FucHexNAc4Hex5Sia2Na 
Complex, 
fucosylated, 
disialylated, 
biantennary 
 Calculated  
38 
2466.8 
 
 
2465.6 L 
 FucHexNAc5Hex6Sia 
Complex, 
fucosylated, 
sialylated, 
triantennary 
 Calculated  
39 
 
2488.8 
 
 
2487.7 L 
 FucHexNAc5Hex6SiaNa 
Complex, 
fucosylated, 
sialylated, 
triantennary 
 Calculated  
40 2539.9  2539.4
 L FucHexNAc6Hex7 
Complex, 
fucosylated, 
tetraantennary 
 
 
(41) 
 
 
41 
2611.9 
 
 
2610.7 H HexNAc5Hex6Sia2 
Complex, 
disialylated, 
triantennary 
 Calculated  
42 
2633.9 
 
 
2632.8 H 
2632.6 L 
 
HexNAc5Hex6Sia2Na 
Complex, 
disialylated, 
triantennary 
 Calculated  
43 
2651.9 
 
 
2649.7 H 
2648.6 L 
 
HexNAc6Hex5Sia2 
Complex, 
disialylated, 
tetraantennary 
 Calculated  
44 
2654.9 
 
 
2653.8 H 
 HexNAc5Hex6Sia2Na2 
Complex, 
disialylated, 
triantennary 
 Calculated  
 
X 
 
 
 
 
37 2413.8 2412.3L fucHexNAc4Hex5Sia2Na complex, fucosylated,  
disialylated, biantennary
calculated 
38 2466.8 2465.6L fucHexNAc5Hex6Sia complex, fucosylated,  
sialylated, triantennary
calculated 
39 2488.8 2487.7L fucHexNAc5Hex6SiaNa complex, fucosylated, 
sialylated, trianten ary
calculated 
40 
 
 
 
2539.9 
 
 
 
2539.4L 
 
 
 
fucHexNAc6Hex7 
 
 
 
complex, fucosylated, 
tetraantennary 
 
 
(41) 
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33 
2325.8 
 
 
2324.9 H 
2324.7 L 
 
FucHexNAc5Hex5SiaNa 
Complex, 
fucosylated, 
sialylated, 
triantennary/bisect
ing 
 Calculated  
34 
2342.8 
 
 
2341.8 H 
2340.7 L 
 
HexNAc5Hex6SiaNa 
Compl x, 
sialylated, 
triant nnary 
 l l   
35 
2360.9 
 
 
2359.9 H 
2359.8 L 
 
HexNAc6Hex5Sia 
Complex, 
sia ylated, 
tetraantennary 
 C t d  
36 
 
2393.7 
 
 
 
2392.9 H 
2392.6 L 
 
HexNAc6Hex7 
 
Complex, 
tetra nten ary 
 
(41) 
 
 
 
X 
37 
2413.8 
 
 
2412.3 L 
 FucHexNAc4Hex5Sia2Na 
Complex, 
fucosylated, 
disialylated, 
biantennary 
 Calculated  
38 
2466.8 
 
 
2465.6 L 
 FucHexNAc5Hex6Sia 
Complex, 
fucosylated, 
sialylated, 
triantennary 
 Calculated  
39 
 
2488.8 
 
 
2487.7 L 
 FucHexNAc5Hex6SiaNa 
Complex, 
fucosylated, 
sialylated, 
triantennary 
 Calculated  
40 2539.9  2539.4
 L FucHexNAc6Hex7 
Complex, 
fucosylated, 
tetraantennary 
 
 
(41) 
 
 
41 
2611.9 
 
 
2610.7 H HexNAc5Hex6Sia2 
Complex, 
disialylated, 
triantennary 
 Calculated  
42 
2633.9 
 
 
2632.8 H 
2632.6 L 
 
HexNAc5Hex6Sia2Na 
Complex, 
disialylated, 
triantennary 
 Calculated  
43 
2651.9 
 
 
2649.7 H 
2648.6 L 
 
HexNAc6Hex5Sia2 
Complex, 
disialylated, 
tetraantennary 
 Calculated  
44 
2654.9 
 
 
2653.8 H 
 HexNAc5Hex6Sia2Na2 
Complex, 
disialylated, 
triantennary 
 Calculated  
 
41 2611.9 2610.7H HexNAc5Hex6Sia2 complex, disialylated,  
triantennary
calculated 
42 2633.9 2632.8H 
2632.6L
HexNAc5Hex6Sia2Na complex, disialylated, 
triantennary
cal l t  
43 2651.9 2649.7H 
2648.6L
HexNAc6Hex5Sia2 complex, disialylated, 
tetraantennary
cal l t  
44 2654.9 2653.8H HexNAc5Hex6Sia2Na2 complex, disialylated,  
triantennary
c l l t d
Table 3 (continued). Composition and structures of the glycans detected by MALDI MS analysis of the oligosaccharide mixtures derived 
from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardial lesions serum). , Fucose; , N­acetylglu­
cosamine; , Hexose; , N­acetylneuraminic acid. Calculated: attributed on the basis of GlycoMod software only. 
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pathological serum samples. Mass signals were tentatively 
assigned as described before and, when necessary, confirmed 
by PSD fragmentation experiments. figures 6(a)–(c) shows the 
PSD analysis of the non sialylated, monosialylated and disia-
lylated biantennary structure respectively. the PSD spectra 
were dominated by y and B ions containing the non reducing 
or the reducing end of the glycan moiety as well as a large 
number of internal fragment ions formed by multiple glyco-
sidic cleavages. Sequence and branching information could 
then be inferred from y and B ions and were confirmed by 
internal fragment ions
As an example, figure 6(b) shows the PSD spectrum 
obtained by selecting the precursor ion at m/z 2100.9 corre-
sponding to the putative monosialylated biantennary struc-
 8
             
 
             
(a)
(b)
Relative  
intensity 
Relative  
intensity 
Figure 4. Positive ion mode MALDI spectra of glycans deriving from the healthy [panel (a)] and the myocardial lesions [panel (b)] 
glycopeptides retained on the ConA affinity step and incubated with PNGase F. The identified glycan structures are numbered and the 
corresponding assignments are reported in Table 2.
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ture. the complete series of y ions from both antennae (ya 
and yb ions) could be detected in the spectrum together 
with a number of B ions. these data led to the complete 
assignment of the monosialylated fucosylated biantennary 
structure that was further confirmed by a series of internal 
fragments. Similar results were obtained for the remaining 
oligosaccharides.
Negative MALDI analyses were also performed on the 
same conA unbound fractions to highlight the presence of 
sialylated structures. All the data are summarised in tables 
3 and 4.
compared to the glycans of the bound fraction, these 
oligosaccharides showed the presence of higher branched, 
sialylated and fucosylated structures. table 3 shows the pres-
ence of essentially sialylated triantennary glycans with the 
occurrence of some fucosylated and sialylated  tetrantennary 
structures and few biantennary  oligosaccharides. When peaks 
could not be unambiguously interpreted, the ultimate  definition 
of the correct glycan structure was achieved by MS/MS experi-
ments using the MALDI PSD technique. As an example, the 
signal at m/z 2392.8 in the MALDI spectrum was tentatively 
assigned to two different isobaric structures. following PSD 
 8
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Figure 5. Positive ion mode MALDI spectra of the oligosaccharide deriving from healthy (panel A) and the myocardial lesions (panel B) 
glycopeptides recovered in the ConA unbound fractions and incubated with PNGase F. The identified glycan structures are numbered 
and the corresponding assignments are reported in Table 3.
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Figure 6. Panel (a )MALDI­PSD analyses of non sialylated, panel (b) monosialylated and panel (c) disialylated biantennary structures. 
, Fucose; , N­acetylglucosamine; , Hexose; , N­acetylneuraminic acid.
(a)
(b)
(c)
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MALDI (m/z [M+Na]+) Monosaccharide 
composition 
Structure 
 Theoretical 
MW
Found 
1 1930.7 1929.6H 
1929.9L
HexNAc4Hex5Sia complex, sialylated, biantennary 
2 1953.7 1952.4H 
1952.2L
HexNAc4Hex5SiaNa complex, sialylated, biantennary 
3 2076.8 2074.5H 
2075.8L
fucHexNAc4Hex5Sia complex, fucoylated, sialylated, biantennary 
4 2133.7
2133.8L 
HexNAc5Hex5Sia complex, sialylated, triantennary/bisecting
5 2179.7 2178.6H HexNAc5Hex5SiaNa complex, sialylated, triantennary/bisecting
6 
2220.8 
 
2222.8
2220.4H 
2221.7L 
HexNAc4Hex5Sia2 
 
fuc2 HexNAc4Hex5Sia
complex, disialylated, biantennary 
 
complex, difucosylated, sialylated, biantennary
7 
 
2243.8 
 
2245.8
2242.4H 
2242.7L 
HexNAc4Hex5Sia2Na 
 
fuc2 HexNAc4Hex5SiaNa
complex, disialylated, biantennary 
 
complex, difucosylated, sialylated, biantennary
8 2279.8 2279.4H 
2278.8L
fucHexNAc5Hex5Sia complex, fucosylated, sialylated, 
triantennary/bisecting
9 2295.7 2294.4H 
2294.8L
HexNAc5Hex6Sia complex, sialylated, triantennary 
10 2318.7 2316.2H 
2316.3L
HexNAc5Hex6SiaNa complex, sialylated, triantennary 
11 2348.8 2349.8H 
2348.7L
fucHexNAc3Hex6Sia2Na Hybrid, trifucosylated, disialylated 
12 2389.9 2389.3 fucHexNAc4Hex5Sia2Na complex, fucosylated, disialylated, biantennary
13 2441.8 2441.7L fucHexNAc5Hex6Sia complex, fucosylated, sialylated
14 2464.8 2461.8L fucHexNAc5Hex6SiaNa complex, fucosylated, sialylated
15 2536.0 2537.1H fuc2HexNAc4Hex5Sia2Na complex, difucosylated, disialylated, biantennary
16 2569.9 2570.1H 
2570.6L
fucHexNAc5Hex5Sia2 complex, fucosylated, disialylated, 
triantennary/bisecting
17 2586.8 2586.3H 
2585.7L
HexNAc5Hex6Sia2 complex, disialylated,triantennary 
18 2608.8 2607.2H 
2608.6L
HexNAc5Hex6Sia2Na complex, disialylated,triantennary 
19 2615.9 2615.0H 
2615.2L
fucHexNAc5Hex5Sia2Na2 complex, fucosylated, disialylated,  
triantennary/bisecting
20 2631.8 2630.2H 
2630.3L
HexNAc5Hex6Sia2Na2 complex, disialylated,triantennary 
21 2660.9 2660.1H 
2660.6L
HexNAc6Hex7Sia complex, sialylated, tetraantennary 
22 2682.1 2681.9H 
2680.6L
fuc3HexNAc4Hex5Sia2Na complex, trifucosylated, disialylated, biantennary 
23 2731.8 2731.6L fucHexNAc5Hex6Sia2 complex, fucosylated, disialylated
24 2754.8 2754.5L fucHexNAc5Hex6Sia2Na fucHexNAc5Hex6Sia
Table 4. Composition and structures of the glycans detected by negative ion mode MALDI MS analysis of the oligosaccharide mixtures 
derived from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardial lesions serum).
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fragmentation, the correct biantennary sialylated and fuco-
sylated glycoform could be inferred.
As shown in tables 2–4, the microheterogeneity of glycans 
detected in the healthy sera resulted to be, in general, very 
similar to the glycan profiling observed for the myocardial 
lesions serum. However, a number of differences could be 
detected in the high mass region of the spectra and  particularly 
in the unbound fraction of the myocarditis sample with respect 
to the healthy glycans. 
As serum is a very complex system, this analysis is far 
from being non-exhaustive. A complete profiling of the 
glycosylation in the different sera would have needed a 
detailed quantitative evaluation of all the oligosaccharide 
structures detected, which was outside the scope of this 
paper. However, preliminary semi quantitative data could be 
obtained on the most abundant glycan structures observed 
in the pathological sera in comparison with the healthy 
sera by measuring the ratio of peak areas. As summarized 
in tables 5 and 6, most glycoforms displayed quantitative 
differences when pathological samples were compared to 
the healthy ones.
the analysis of the conA eluted glycan fractions (table 
5) showed a three to five times decrease in the relative 
abundance of most glycan structures in the pathological 
sample compared to the healthy oligosaccharides. on the 
contrary, the same analysis carried out on the unbound 
MALDI (m/z [M + Na]+) Monosaccharide 
composition 
Structure 
 Theoretical 
MW
Found 
25 2806.9 2806.5L fucHexNAc6Hex7Sia complex, fucosylated, sialylated, tetraantennary
26 2875.9 2876.0H 
2876.4L
HexNAc5Hex6Sia3 complex, trisialylated, triantennary 
27 2898.9 2899.0H 
2899.5L
HexNAc5Hex6Sia3Na complex, trisialylated, triantennary 
28 2921.9 2921.0H 
2920.4L
HexNAc5Hex6Sia3Na2 complex, trisialylated, triantennary 
29 2951.0 2951.9H 
2951.5L
HexNAc6Hex7Sia2 complex, disialylated, tetraantennary 
30 2974.0 2973.9H HexNAc6Hex7Sia2Na complex, disialylated, tetraantennary
31 3021.9 3022.7H fucHexNAc5Hex6Sia3 complex, fucosylated, trisialylated, triantennary
Table 4 (continued). Composition and structures of the glycans detected by negative ion mode MALDI MS analysis of the oligosaccharide 
mixtures derived from glycopeptides recovered in the ConA unbound fraction (H = healthy serum; L = myocardial lesions serum).
Calculated m/z [M + Na]+ Structure LM/healthy serum ratio
1257.4 High mannose  0.172
1419.5 High mannose  0.211
1485.5 complex, biantennary, fucosylated  0.200
1647.6 complex, biantennary, fucosylated  0.212
1663.6 complex, biantennary  0.818
1809.6 complex, biantennary, fucosylated  0.337
1976.7 complex, biantennary, sialylated  0.189
2123.7 complex, fucosylated, sialylated, biantennary   0.0991
2245.8 complex, disialylated, biantennary 1.16
2290.8 complex, disialylated, biantennary   0.0604
Table 5. Semiquantitative analysis of ConA eluted fraction oligosaccharides in pathological samples in comparison to the reference one LM: 
myocardial lesions.
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conA fractions (table 6) revealed a higher level of hetero-
geneity within the relative abundance of the glycan struc-
tures. In fact, most species remained unchanged in the two 
samples while the relative abundance of two structures 
increased three to four times in the pathological glycan 
profiling. Moreover, the  pathological sample showed the 
occurrence of specific structures completely absent in the 
normal sample.
As a whole, the myocardial glycan profiling showed the 
occurrence of peculiar structures, the persistence of incom-
plete and truncated structures, the accumulation of precur-
sors and the appearance of novel structures, thus leading to 
a higher degree of heterogeneity, with respect to the healthy 
one. In particular, the myocardial lesions serum revealed the 
presence of hyper-fucosylated oligosaccharides. It has been 
demonstrated that the N-linked glycans attached to proteins 
generally associated with inflammation, such as haptoglobin, 
alpha1-acid glycoprotein and a1-antichymotrypsin, have 
increased SLex epitopes, during chronic inflammation 
(reference 18 and references therein). further analyses are 
currently in progress to deliver assignments of the glycan 
structure on individual glycosylation sites of the glycoproteins 
identified.
Conclusions
this report describes an integrated single-step proteomic 
approach for the assessment of the N-glycosylation profil-
ings occurring in human sera. More interestingly, the glyco-
sylation pattern of glycoproteins occurring in the serum of 
myocarditis patients was investigated for the first time. this 
procedure combines a simple affinity chromatography step 
with sophisticated Lc-MS/MS analyses and led to the iden-
tification of several N-glycosylation sites in serum proteins, 
some of which had never been detected before. the advan-
tages of this protocol was clearly demonstrated through 
differentiation of glycan profiling of sera from healthy and 
pathological donors.
A comparative study of the N-glycosylation pattern of the 
entire human serum glycoproteome, here applied to the 
study of myocarditis, could be considered an excellent probe, 
although preliminary, for other specific pathologies. finally, 
this glycobiological approach represents a new opportunity 
for therapeutics and diagnostics, for the screening of oligo-
saccharide biomarkers in pathological status, but also to 
biotechnologies, as bio-analytical procedure aimed at the 
characterization of glycosylation pattern of different complex 
samples, in order to manufacture correctly glycosylated 
molecules.
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By generating mRNA containing a premature termination codon (PTC), alternative splicing (AS) can
quantitatively regulate the expression of genes that are degraded by nonsense-mediated mRNA decay
(NMD). We previously demonstrated that AS-induced retention of part of intron 3 of rpL3 pre-mRNA
produces an mRNA isoform that contains a PTC and is targeted for decay by NMD. We also demonstrated that
overexpression of rpL3 downregulates canonical splicing and upregulates the alternative splicing of its pre-
mRNA. We are currently investigating the molecular mechanism underlying rpL3 autoregulation. Here we
report that the heterogeneous nuclear ribonucleoprotein (hnRNP) H1 is a transacting factor able to interact
in vitro and in vivo with rpL3 and with intron 3 of the rpL3 gene. We investigated the role played by hnRNP
H1 in the regulation of splicing of rpL3 pre-mRNA by manipulating its expression level. Depletion of hnRNP
H1 reduced the level of the PTC-containing mRNA isoform, whereas its overexpression favored the selection
of the cryptic 3′ splice site of intron 3. We also identiﬁed and characterized the cis-acting regulatory
elements involved in hnRNP H1-mediated regulation of splicing. RNA electromobility shift assay
demonstrated that hnRNP H1 speciﬁcally recognizes and binds directly to the intron 3 region that contains
seven copies of G-rich elements. Site-directed mutagenesis analysis and in vivo studies showed that the G3
and G6 elements are required for hnRNP H1-mediated regulation of rpL3 pre-mRNA splicing. We propose a
working model in which rpL3 recruits hnRNP H1 and, through cooperation with other splicing factors,
promotes selection of the alternative splice site.
©2010 Elsevier B.V. All rights reserved.
1. Introduction
Alternative splicing (AS) is one of themain regulatorymechanisms
of gene expression; it results in a repertoire of mRNAs, and con-
sequently of proteins, much larger than expected from the number of
genes. This process contributes substantially to cell-speciﬁc and
tissue-speciﬁc gene expression; it is estimated that over 60% of human
genes are alternatively spliced [1].
Splicing is modulated by cis elements in intron or exon sequences
that, associated with speciﬁc transacting factors, can negatively
(intronic or exonic splicing silencer sequences, ISS or ESS) or
positively (intronic or exonic splicing enhancing sequences, ISE or
ESE) affect splicing [2]. Although ESE elements differ in sequence,
most share a consensus sequence (GAR)n. The UGCAUG esanucleotide
is a frequent element in ISE sequences [3]. Most regulatory sequences
are a complex combination of multiple elements that mediate positive
or negative effects on gene splicing [4–6]. Intronic stretches of three or
four Gs called “G runs” are involved in the splicing of a number of
genes [7–13].
Among the factors found to control the selection of the splice site,
components of the SR protein family have been shown to antagonize
the activity of protein components of heterogeneous nuclear
ribonucleoproteins (hnRNPs) [14,15]. hnRNPs are a large group of
nuclear RNA-binding proteins that share a common structural domain
denoted “qRRM” and are implicated in a variety of processes including
RNA stability and translation. Accumulating evidence indicates that
these proteins may play an important role in the control of splice site
selection [16,17]. hnRNP H1 is a member of the hnRNPH/F family. It is
able to bind the splicing regulatory cis elements, i.e. ESE, ISE, ESS and
ISS. Depending on the interacting cis element and on the gene context,
hnRNP H1 can affect the selection of the splice site and consequently
promote either constitutive or alternative splicing [9–13,18].
Data from several laboratories demonstrate that some evolution-
arily conserved AS events give rise to aberrant transcripts, which are
substrate of nonsense-mediated mRNA decay (NMD). NMD is an RNA
Biochimica et Biophysica Acta 1799 (2010) 419–428
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surveillance mechanism that selectively degrades aberrant mRNAs
that contain a premature termination codon (PTC), thus preventing
the production of truncated polypeptides potentially deleterious to
the cell. This process is highly conserved in eukaryotes. A PTC may
arise through a nonsense or frameshift mutation of DNA, as a con-
sequence of DNA rearrangement, or through splicing errors that
produce aberrant mRNAs [19]. A PTC could also arise from alternative
splicing that produces an intron-derived nonsense codon or a shift in
the ORF that generates a downstream nonsense codon. The resulting
aberrant mRNA is targeted for NMD rather than being translated into
protein. Thus, the AS–NMD association results in quantitative post-
transcriptional regulation of gene expression [20].
Genes that encode ribosomal proteins (rp) are regulated by AS–
NMD. This regulatory strategy appears to be evolutionarily conserved
in nematodes [21] andmammals [22]. We recently demonstrated that
AS of genes for human proteins rpL3 and rpL12 generates alternative
RNA isoforms consequent to the removal of part of intron 3 and of
intron 1, respectively. The resultingmRNAs include intronic sequences
that contain a PTC and are targeted for decay by NMD. We also
demonstrated that overexpression of rpL3 results in the down-
regulation of canonical splicing and upregulation of the alternative
splicing of rpL3 pre-mRNA [22]. Here we report that hnRNP H1 is an
rpL3 partner and plays an important role in the splicing regulation of
rpL3 pre-mRNA. We also report that G-rich sequences in intron 3 are
cis-regulatory elements involved in hnRNP H1-mediated regulation.
2. Materials and methods
2.1. Cell cultures, transfections and drug treatment
Human cell lines HeLa and Calu6 were cultured in Dulbecco's
ModiﬁedEagle'sMedium(DMEM)withglutamax (Invitrogen, Carlsbad,
California) supplemented with 10% fetal bovine serum (FBS). In
addition, Calu6 culture medium was supplemented with 0.1 mM non-
essential amino acids (Euroclone, West York, UK). siRNA transfections
were performed in HeLa cells (1×106 cells, 6 mm-well plate) at a
concentration of 150 nM by using Oligofectamine Reagent (Invitrogen)
according to the manufacturer's instructions.
Plasmids were transfected in HeLa cells (2.5×106 cells, 6 mm-well
plate) by using Lipofectamine 2000 (Invitrogen) or Fugene6 (Roche
Applied Science, Mannheim, Germany) according to the manufac-
turer's instructions. 24 h after DNA or siRNA transfections, cells were
treated with 100 μg/ml cycloheximide for 4 h to block NMD. Then,
RNA and proteins were extracted by using the Trizol procedure
(Invitrogen) for RT-PCR analysis and western blot, respectively.
Transfection efﬁciency was assessed by co-transfecting a GFP-
expressing vector and normalizing RNA levels against GFP mRNA
levels (data not shown).
2.2. Constructs, mutagenesis, and RNA interference
The cDNAs of hnRNP H1 and rpL3 were obtained by RT-PCR from
HeLa cells using speciﬁc primers (Table 1) and cloned into the pro-
karyotic expression vector pGEX4T3 (GE Healthcare, Waukesha,
Wisconsin). The cDNA of hnRNP H1 was also cloned into a version
of the eukaryotic expression vector pcDNA4/HisMax C (Invitrogen)
containing the HA epitope. The full intron 3 of rpL3 gene, or regions A,
B and C (Fig. 3A) were obtained by RT-PCR using speciﬁc primers
(Table 1) and cloned into the pGEM-4Z vector (Promega, Madison,
Wisconsin) to obtain constructs pGEM4Z-Int3, pGEM4Z-IntA,
pGEM4Z-IntB and pGEM4Z-IntC, respectively. The wt-rpL3 minigene
was kindly provided by Y. Tang (Dr S. Stamm's laboratory, Institute for
Biochemistry, University of Erlangen—Nurenberg, Germany). It con-
tains the genomic region of the rpL3 gene spanning from exon 3
to exon 5 ﬂanked by insulin exon sequences (Fig. 5A) cloned in
the Exontrap vector (MoBiTec, Gottingen, Germany). The constructs
carrying the disruption of single or multiple G runs, i.e., GGG/GAT
mutation, were obtained by PCR site-directed mutagenesis (primers
in Table 1) using the QuickChange® Lightning Site-Directed Muta-
genesis Kit (Stratagene, La Jolla, California) and the wt-rpL3 minigene
as template. All constructs were veriﬁed by DNA sequencing.
The small interfering RNAs (siRNA) targeting hnRNP H1 were:
5′-GGAAATAGCTGAAAAGGCT-3′ and 5′-CCACGAAAGCTTATGGCCA-3′.
The siRNA and the Silencer® Negative Control #1 siRNAwere purchased
from Ambion (Foster City, California).
2.3. Nuclear extracts
Nuclear extracts were prepared from Calu6 cells. Brieﬂy, cells from
twenty-one 100-mm plates (1.4×108 cells) were washed with ice
cold PBS and collected in 7 ml of lysis buffer containing 20 mM
Hepes–KOH, pH 8.0, 5 mM MgCl2, 25 mM KCl, 0.5% NP40, 0.25%
sodium-deoxycholate, 5 mM DTT and Protease Inhibitor Mix 1X
(Roche), and passed through a needle (23 gauge). The cell lysate was
incubated for 10 min on ice, then cell nuclei were separated from the
cytoplasmic fraction by centrifugation for 5 min at 1000 ×g at 4 °C.
Nuclei from twenty-one 100-mm plates were resuspended in 2 ml of
nuclear lysis buffer (20 mM Hepes–KOH, 5 mM MgCl2, 0.5 M NaCl,
20% glicerol, 1 mM EDTA, 5 mM DTT and Protease Inhibitor Mix 1X)
and incubated for 10 min on ice, then clariﬁed by centrifugation for
10 min at 10,000 ×g at 4 °C.
2.4. GST pull-down, mass spectrometry and protein identiﬁcation
The recombinant proteins GST-rpL3 and GST were expressed in
Escherichia coli and puriﬁed by using glutathione-Sepharose 4B beads
according to the manufacturer's instructions (GE Healthcare). For GST
pull-down assay, 100 µg of GST-rpL3 fusion protein, or GST control,
was immobilized on glutathione-Sepharose beads and incubated with
10 mg of nuclear extract from Calu6 cells in pull-down buffer (50 mM
Tris–HCl pH 7.5, 0.4 mM EDTA, 150 mM NaCl, 10% glicerol, 1% NP40,
1 mM sodium–ortovanadate, 50 mM NaF, 5 mM DTT and Protease
Inhibitor Mix 1X) at 4 °C for 1.5 h. The beads were washed extensively
and boiled in SDS sample buffer. The eluted proteins were loaded on
12% SDS-PAGE. Gels were stained with a colloidal blue staining kit
(Invitrogen) and protein bands were excised from the gel and
destained by repetitive washes with 0.1 M NH4HCO3, pH 7.5 and
acetonitrile. Samples were reduced by incubationwith 50 µl of 10 mM
DTT in 0.1 M NH4HCO3 buffer, pH 7.5 and carboxyamidomethylated
with 50 µl of 55 mM iodoacetamide in the same buffer. Enzymatic
digestion was carried out with trypsin (12.5 ng/µl) in 10 mM am-
monium bicarbonate, pH 7.8. Gel pieces were incubated at 4 °C for 2 h.
Trypsin solution was then removed and a new aliquot of the digestion
solution was added; samples were incubated for 18 h at 37 °C. A
minimum reaction volume was used to obtain complete rehydration
of the gel. Peptides were then extracted by washing the gel particles
Table 1
Oligonucleotides sequences.
5′-Primer (5′–3′) 3′-Primer (3′–5′)
GST-rpL3 ATGTCTCACAGAAAGTTC AGCTCCTTCTTCCTTTGC
Int3 AATTGGTAAGGGAGGAG TATGCCTTCAGGAGCAGA
rpL3-a CTCCGCTGGGCTCTGCCC CTTCAGGAGCAGAGCAGA
rpL3-c GGGCATTGTGGGCTACGT GTAAAGGCCTTCTTCTTAG
IntA AAGAATTGGTAAGGGAGG GGAAGCCCACTCAGTGAT
IntB CCAGGGCAAAAGGTTTG GTAAAGGCCTTCTTCTTAG
IntC AAGAATTGGTAAGGGAGG TCAGAATGAGGGTGTTAGC
GST-hnRNP H1 ATGATGTTGGGCACGGAA CTATGCAATGTTTGATTG
hnRNP H1-HA ATGATGTTGGGCACGGAA CTATGCAATGTTTGATTG
β-Actin GGCACCACCTTCTACA CAGGAGGACAATGAT
Insulin GCGAAGTGGAGGACCCACAA ACCCAGCTCCAGTTGTGCCA
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with 10 mM ammonium bicarbonate and 1% formic acid in 50%
acetonitrile at room temperature.
Liquid chromatography and tandem mass spectrometry (LC/MS/
MS) analyses were performed on an LC/MSD Trap XCT Ultra (Agilent
Technologies, Palo Alto, CA) equipped with a 1100 nanoHPLC system
and a chip cube (Agilent Technologies). Peptides were analyzed using
data-dependent acquisition of one MS scan (mass range from 300 to
1800m/z) followed by MS/MS scans of the three most abundant ions
in each MS scan. Raw data from nanoLC/MS/MS analyses were used
to query a non-redundant protein database using in-house MASCOT
software (Matrix Science, Boston, Massachusetts) [23].
2.5. Immunoprecipitation and western blotting
For immunoprecipitation assay, 1 mg of HeLawhole cell lysate was
incubated with 30 µl of protein A/G agarose beads coated with 5 µg of
antibody against rpL3 (Primm Milan, Italy), hnRNP H1 and SH-PTP1
(Santa Cruz Biotechnology, Santa Cruz, California) at 4 °C for 12 h. The
beads were washed and boiled in the SDS sample buffer. The eluted
proteins were loaded on 12% SDS-PAGE and detected by western
blotting. Aliquots of protein samples (30 µg) were resolved by 12%
SDS-gel electrophoresis and transferred into nitrocellulose ﬁlters. The
membranes were blocked in PBS, 0.2% Tween and 5% dry milk for 2 h,
and then challenged with anti-rpL3 (Primm), anti-hnRNP H1, anti-α-
tubulin, anti-SH-PTP1 (Santa Cruz Biotechnology), and anti-HA
(Roche). The proteins were visualized with enhanced chemilumines-
cence detection reagent according to the manufacturer's instructions
(Pierce, Rockford, Illinois).
2.6. RNA pull-down assay
To identify proteins that bind speciﬁcally to the intron 3 transcript,
we carried out an RNA pull-down assay using adipic acid dehydrazide
beads. Brieﬂy, 20 μg of intron 3 RNA, transcribed in vitro from
pGEM4Z-Int3, was placed in a 400 µl reaction mixture containing
100 mM NaOAc, pH 5.2 and 5 mM sodium m-periodate (Sigma, St.
Louis, Missouri), incubated for 1 h in the dark at room temperature,
ethanol-precipitated, and resuspended in 100 μl of 100 mM NaOAc,
pH 5.2. Then 300 μl of adipic acid dehydrazide agarose beads 50%
slurry (Sigma) equilibrated in 100 mM NaOAc, pH 5.2 was added to
this mixture, which was then incubated for 12 h at 4 ° C on a rotator.
The beads with the bound RNA were pelletted, washed twice with
1 ml of 2 MNaCl, and equilibrated in washing buffer (5 mMHepes, pH
7.9, 1 mM MgCl2, and 0.8 mM magnesium acetate). The intron 3 RNA
was then incubated with 6 mg of protein extract from HeLa cells for
30 min at room temperature in a ﬁnal volume of 0.6 ml. Heparin was
also added to a ﬁnal concentration of 7 μg/μl. The beads were then
washed four times in 1.5 ml of washing buffer. Bound proteins were
Fig. 1. In vitro and in vivo binding of hnRNP-H1 to rpL3. (A) In vitro binding of hnRNP H1 to rpL3. Coomassie Blue-stained gel of a GST pull-down experiment. The recombinant GST-
rpL3 proteins and the GST control were incubated with nuclear extracts from Calu6 cells in the presence of glutathione-Sepharose beads. The eluted proteins were resolved by SDS-
PAGE. M indicates themobility of protein size markers. The arrows indicate the bands corresponding to GST-rpL3, hnRNP H1 and GST. The rpL3 partner proteins are listed. (B) In vivo
binding of hnRNP H1 to rpL3. hnRNP H1 or rpL3 were immunoprecipitated from HeLa cells extracts with antibodies against hnRNP H1 and rpL3, respectively. Immunoprecipitates
were separated by SDS-PAGE and immunoblotted for the proteins indicated at the left of the panel. These results are representative of three independently performed experiments.
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eluted in SDS sample buffer and loaded on a 12% gel for SDS-PAGE to
proceed to a MS analysis (see 2.4).
2.7. RNP immunoprecipitation assay (RIPA)
For RNP immunoprecipitation assay, HeLa cells (2×106 cells) were
lysed in 600 μl RIPA buffer 1× (10 mM Tris–HCl, pH 7.5, 150 mMNaCl,
0.1 mM EDTA, 1 mM Na ortovanadate, 0.05 M NaF, and 0.5% NP40)
with protease inhibitors (Roche) for 60 min on ice and then
centrifuged at 10,000 ×g at 4 °C for 15 min. The supernatant was
subjected to a preclearing step in which it was incubated with 50 μl of
protein A/G plus agarose for 1 h at 4 °C. The precleared cell extracts
were then incubated with antibodies speciﬁc for each protein (Santa
Cruz) overnight at 4 °C. Protein G–Sepharose beads (50 μl of 50%
slurry)were then added and themixwas incubated for 1 h at 4 °Cwith
gentle shaking and centrifuged. The immunoprecipitates were
suspended in 100 μl TES buffer (10 mM Tris–HCl, pH 7.5, 0.5 mM
EDTA, and 0.5% SDS), incubated at 65 °C for 10 min and centrifuged for
1 min at 10,000 ×g. Tenmicroliters was stored as immunoprecipitated
samples and subsequently fractionated by SDS-PAGE to be analyzed by
western blotting. RNA was extracted from 90 μl using the Trizol
(Invitrogen) procedure.
2.8. RNA electromobility shift assay (REMSA)
RNA probes were transcribed in vitro using 32P-NTPs and SP6
polymerase according to themanufacturer's instructions (Roche), and
construct pGEM4Z-IntA, pGEM4Z-IntB, or PGEM4Z-IntC as template.
The probes were puriﬁed using Sephadex G-25 columns (Roche).
5×105 counts/min of each RNA probe were incubated in binding
buffer containing 20 mM Hepes, pH 7.9, 150 mM KCl, 1.5 mM MgCl2,
0.2 mM EDTA, 0.1% Triton, 1 mg/ml tRNA, and 0.4 U/μl RNase
Inhibitor (Roche) in the presence or absence of the recombinant
protein GST-hnRNP H1 or GST for 1 h at 4 °C. The complexes formed
were then resolved onto a 5% polyacrylamide (37.5:1 acrylamide:bis-
acrylamide ratio) RNA native gel. The gel was dried at 80 °C for 30 min
and the results visualized by autoradiography.
Fig. 2. Interaction of intron 3 of the rpL3 gene with hnRNP H1 in vitro and in vivo. (A) In vitro binding of the intron 3 transcript to hnRNP H1. Coomassie Blue-stained gel of a RNA
pull-down experiment, using adipic acid dehydrazide agarose beads coated with intron 3 transcript was incubated with HeLa nuclear protein extract. The mobility of protein size
markers is shown (M). The arrow indicates the protein band corresponding to hnRNP H1 identiﬁed by mass spectrometry analysis of eluted peptides. The intron 3 RNA interacting
proteins identiﬁed are listed. (B) In vivo binding of the intron 3 transcript to hnRNP H1.Western blotting (WB) of hnRNP H1 or SH-PTP1 immunoprecipitates fromHeLa cells, and RT-
PCR of RNA extracted from the same immunoprecipitates by using primers against intron 3 (Table1). Note the absence of signal in SH-PTP1 immuno-complex. These results are
representative of three independently performed experiments.
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2.9. RT-PCR
For RT-PCR analysis, 1 μg of total RNAwas reverse-transcribed into
cDNA with the random hexamer technique using 200U of Superscript
II RNase H− Reverse Trancriptase (Invitrogen). The reaction was
carried out at 42 °C for 50 min and was terminated by heating to 75 °C
for 15 min. Ten of the 40 μl of reaction mix were PCR-ampliﬁed in a
ﬁnal volume of 50 μl, using 5 μM of each speciﬁc primer (Table 1),
10 mM dNTPs, and 0.5U of Taq DNA polymerase (Invitrogen).
Typically, 25–30 cycles of ampliﬁcation were performed. In separate
experiments, we ascertained that the cycle number was within the
linear range of ampliﬁcations. PCR products were visualized on 1%
agarose gel containing the ﬂuorescent Vistra Green dye (Amersham
Pharmacia Biotech). The labeling intensity of the PCR product, which
is linear to the amount of DNA, was quantiﬁed using the Phosphor-
Imager (Bio-Rad, Haercules, California).
3. Results
3.1. rpL3 interacts with hnRNP H1 in vitro and in vivo
An important issue concerning the autoregulation of rpL3 ex-
pression via AS–NMD coupling is to identify molecular partners of
rpL3 involved in the splicing event. We previously found that rpL3
does not bind its pre-mRNA. Speciﬁcally, ﬁlter-binding experiments
with the recombinant GST-rpL3 and GST alone as control showed that
rpL3 could interact with intron 3 RNA as well as with unrelated RNA
(data not shown). These ﬁndings favored the hypothesis that rpL3
modulates the splicing of its own gene by interacting with one or
more regulatory proteins. Consequently, to search for rpL3 transacting
factors, we carried out an in vitro GST pull-down assay. Recombinant
GST-rpL3 and GST proteins were puriﬁed from E. coli cells, im-
mobilized using GSH-Sepharose beads and incubated with a nuclear
extract from Calu6 cells. The proteins speciﬁcally bound to GST-rpL3
and GST were pulled down, fractionated by SDS-PAGE and then
visualized by Coomassie Blue staining.
The whole gel was cut in slices and protein bands, destained by
repetitive washings, were excised and in situ-digested with trypsin.
We also analyzed the control (proteins bound to GST) to check for
nonspeciﬁc proteins. The resulting peptide mixtures were extracted
from the gel and directly analyzed by LC/MS/MS to obtain sequence
information on individual peptides. This information together with
the peptide mass values was then used to search protein databases for
corresponding proteins. The comparison of GST-rpL3 beads versus
control GST beads revealed several speciﬁc proteins. Among these,
sequence analysis by MS of an excised 50-kDa band yielded several
peptides amongwhich is hnRNP H1 (Fig. 1A). hnRNP H1 plays a major
role in the regulation of alternative splicing of various genes. Recent
studies showed that hnRNP H1 is able to bind speciﬁcally G runs on a
transcript molecule [9–13,18].
To verify the interaction between rpL3 and hnRNP H1 in vivo, we
performed co-immunoprecipitation experiments. hnRNP H1 (Fig. 1B,
Fig. 3. hnRNP H1 binding to region A within intron 3 in vitro. (A) Schematic representation of regions A (365 nt), B (289 nt) and C (209 nt) of intron 3. The sequence of part of the
region C of intron 3 including the G-run motifs is shown (boldface). (B) Gel mobility shift analysis of hnRNP H1 challenged with regions A, and B of intron 3 (left panel), or with
region C of intron 3 (right panel). The results are representative of three independently performed experiments.
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left panel) and rpL3 (Fig. 1B, right panel) were speciﬁcally immuno-
precipitated from HeLa cell extracts and the immunoprecipitated
complexes were tested by western blotting. A signal for both proteins
appeared in immuno-complexes probed with antibodies against rpL3
and hnRNP H1, thus conﬁrming that the two proteins speciﬁcally
interact in vivo (Fig. 1B). A control immunoprecipitate obtained with
an arbitrary antibody, anti-SH-PTP1, did not give any signal when
probed with anti-hnRNP H1 or anti-rpL3 (Fig. 1B).
3.2. hnRNP H1 binds to the intron 3 of the rpL3 gene transcript in vitro
and in vivo
We next performed an in vitro RNA pull-down assay to identify
and isolate the RNA-binding proteins taking part in the alternative
splicing event and, speciﬁcally, to determine whether hnRNP H1 was
able to interact not only with rpL3 but also with its pre-mRNA. A
transcript corresponding to the entire intron 3 of rpL3 pre-mRNA was
used as bait for pull-down interacting proteins. The beads coated with
the intron 3 transcript were incubated with a total protein extract
from HeLa cells. After stringent washing, RNA-associated proteins
were eluted and analyzed by SDS-PAGE. The comparison of the
proteins bound to the intron 3 RNA-coated beads versus control beads
with no RNA showed various speciﬁc bands (Fig. 2A). Each protein
slice was cut and in situ-digested as previously described. Mass
spectral analysis of the protein mixtures revealed several proteins
among which is hnRNP H1.
To evaluate whether intron 3 and hnRNP H1 speciﬁcally interacted
in vivo, we immunoprecipitated hnRNP H1 from HeLa cell extracts
and looked for the intron 3 transcript and rpL3 in the RNA–protein
immunoprecipitate complex (Fig. 2B). The speciﬁc primers, used in
the RT-PCR to detect the intron 3 transcript were 18-mer oligonucleo-
tides mapping 5 nt upstream from the 5′ splice donor site and 5 nt
downstream from the 3′ splice acceptor site (Int3 in Table 1).We used
western blot and anti-rpL3 antibodies to detect rpL3 in the immuno-
complex. Ampliﬁcation of the signal corresponding to the intron 3
transcript indicated that hnRNP H1 was able to bind rpL3 pre-mRNA
in vivo. Moreover, the co-presence of rpL3 in the immuno-complex
suggests that rpL3 pre-mRNA is present in a ribonucleoprotein
complex that includes rpL3 and hnRNP H1, although the possibility
of two independent complexes cannot be ruled out. The absence of
Fig. 4. (A) Effects of RNAi-mediated depletion of hnRNP H1 on rpL3-a mRNA levels. Left panel: protein samples from CHX-treated HeLa cells transfected with hnRNP H1-siRNA
(hnRNP H1), with unrelated siRNA (control) or untransfected (−), were analyzed by western blotting (WB) with antibody speciﬁc for endogenous hnRNP H1. Loading in the gel
lanes was controlled by detection of tubulin protein. Right panel: representative RT-PCR analysis of total RNA from the same samples. β-actin was used as a control of RNA loading.
Quantiﬁcation of hnRNP H1 protein and of the level of rpL3-a mRNA by PhosphorImager (Bio-Rad) is shown. (B) Effects of hnRNP H1 overexpression on rpL3-a mRNA levels. Left
panel: protein overexpression detected with an antibody directed against the HA tag. Right panel: representative RT-PCR analysis of total RNA from CHX-treated HeLa cells
untransfected or transfected with increasing amounts of hnRNP H1-HA. Quantiﬁcation of hnRNP H1-HA protein and of the level of rpL3-a mRNA by PhosphorImager (Bio-Rad) is
shown. These results are representative of three independently performed experiments.
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signal in the immunoprecipitate with anti-SH-PTP1 conﬁrmed the
validity of this assay (Fig. 2B).
3.3. hnRNP H1 binds selectively to 5′ portion of intron 3
To identify the cis-acting elements of intron 3 that participate in the
regulation of rpL3 pre-mRNAsplicing, we used a computational analysis
of this region to look for hnRNPH1-binding sequencemotifs. The search
revealed seven G-rich motifs that could be hnRNP H1-binding sites in
the 5′moiety on intron 3. Because of experimental evidence that hnRNP
H1activity in the splicingevent ismediatedby thebindingof theprotein
to G runs, we performed REMSA experiments to assess whether the
putative binding sites are necessary for the interaction of hnRNP H1
with intron 3 in the pre-mRNA transcript. We evaluated the hnRNP H1
bindingof three intron3 regions: regionA spanning365 ntdownstream
from the 5′ splice donor splice site containing seven G-run elements;
region B (289 nt) constituted by the 3′ moiety of intron 3 and 27 nt of
exon 4; and region C (209 nt), a more restricted region encompassing
the seven G runs (Fig. 3A). The three regions were transcribed in vitro
using 32P-NTPs. The RNA probeswere incubatedwith GST-hnRNPH1 or
GST recombinant protein. The resulting RNA–protein complexes were
analyzed on a native polyacrylamide gel and the results visualized by
autoradiography.
As shown in Fig. 3, GST-hnRNP H1 was able to interact speciﬁcally
with RNA transcribed on regions A (Fig. 3B, left panel) and C (Fig. 3B,
right panel) of intron 3, but failed to do so when challengedwith the B
region transcript (Fig. 3B). No mobility shift was observed when
recombinant GST was challenged with a transcript constituted by the
three regions of intron 3 (Fig. 3B). These results indicate that hnRNP
H1 binds in vitro to the region of the intron 3 transcript that contains
seven G runs.
3.4. hnRNP H1 regulates the alternative splicing of rpL3 pre-mRNA
To determine the role played by hnRNP H1 in the alternative
splicing of rpL3 primary transcript, we evaluated the effects of altered
hnRNP H1 expression on the selection of the alternative 3′ acceptor
splice site in intron 3 of the rpL3 gene. To this aimwe switched-off the
expression of the gene encoding hnRNPH1 by using RNA interference.
siRNAs against hnRNP H1 or unrelated siRNAs were transiently
transfected in HeLa cells. After transfection, cells were treated with
CHX to stabilize the otherwise labile alternative splice form, and
harvested; then RNA and protein were extracted. Lysates from cells
transfected with unrelated siRNAs (control), speciﬁc siRNAs (hnRNP
H1), or untransfected were probed with hnRNP H1 antibodies. As
shown in Fig. 4A, the residual level of hnRNP H1 was about 30% of the
protein detected in the control lysates. To examine the effects of the
impaired production of hnRNP H1 on the splicing pattern of rpL3 pre-
mRNA, we examined the rpL3 mRNA isoforms using RT-PCR. Removal
of hnRNP H1 resulted in a decrease (about 70%) of the alternative
mRNA (rpL3-a) level compared to controls.
To investigate the effects of hnRNP H1 overexpression we fused a
cDNA encoding hnRNP H1 to an HA tag in the expression vector
pcDNA3. Increasing amounts of this construct were transiently
transfected in HeLa cells. 24 h after transfection, the production of
hnRNP H1 was measured by western blotting (Fig. 4B). Total RNA was
Fig. 5. (A) Schematic representation of wt-rpL3 minigene. The canonic acceptor site AG and the alternative acceptor site AG′ are indicated in boldface. The score of acceptor splice
sites calculated using the Splice Site Prediction by Neural Network program (SSPNN, http://www.fruitﬂy.org/seq_tools/splice.html) is indicated. (B) Scheme of G-run mutants. The
G runs within rpL3 intron 3 are numbered 1 to 7, and the G-run mutants are indicated by ⁎.
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analyzed by RT-PCR by using speciﬁc primers (Table 1) to amplify
canonical (rpL3-c) or alternative (rpL3-a) isoforms of rpL3 mRNA.
Overexpressionof hnRNPH1caused adose-dependent increase in rpL3-
a mRNA level (Fig. 4B).
3.5. G runs are involved in the control of 3′ splice site selection within
rpL3 intron 3
To investigate whether guanosine stretches within intron 3 play a
role in the control of splicing, we exploited a minigene containing a
genomic region spanning from exon 3 to exon 5 (Fig. 5A, wt-rpL3
minigene) of the rpL3 gene. Using site-directed mutagenesis we
changed GGG to GAT in all the G-run elements (G[1–7]⁎ in Fig. 5B).
After transfection of the constructs in HeLa cells, we carried out an RT-
PCR analysis to determine the splicing pattern of the corresponding
transcripts. Speciﬁc primers, designed on the insulin gene sequences
ﬂanking rpL3 gene sequences, were used to discriminate theminigene
splicing products from the products derived from the endogenous
gene (Table 1). As shown in Fig. 6A, the wt-rpL3 minigene reproduced
the splicing pattern of the endogenous gene and hence it contained
the information necessary for correct rpL3 splicing. Differently, pre-
mRNA processing was greatly impaired in the G[1–7]⁎mutant, with a
consequent decrease in the level of the alternative isoform of rpL3
mRNA to 20% versus the control wt-rpL3 minigene. These results
show that the guanosine-rich elementswithin intron 3 are involved in
the control of the 3′ splice site selection in rpL3 intron 3.
3.6. Functional mapping of the G motifs within intron 3
To evaluate the role of each G run in the regulation of the splicing
of rpL3 pre-mRNA, we produced a series of wt-rpL3 minigene
mutants. Mutation of elements G1, G2 and G3 (G[1–3]⁎ in Fig. 5B)
reduced the level of rpL3-a mRNA by 50% (Fig. 6A). The same result
was obtained with mutants G[2,3]⁎ and G[3]⁎. Consequently, the
alteration of the splicing pattern in these mutants can be ascribed
solely to disruption of the G3 element. Differently, the splicing pattern
of the G[7]⁎ mutant (Fig. 5B) shows that mutation of a single G run
does not alter the level of rpL3-a mRNA. In another set of mutants, we
evaluated the role of elements G3, G4, G5 and G6 in the splicing
modulation of rpL3 intron 3. Mutants G[2,3,5]⁎ and G[2–5]⁎ yielded
levels of rpL3-a mRNA similar to that of the G[2,3]⁎minigene mutant.
On the contrary, the addition of themutated G6 element in G[2,3,5,6]⁎
reduced the splicing of rpL3-a mRNA to 20% of that of the control, as
observed with mutant G[1–7]⁎ (Fig. 6A). The results reported above
strongly suggest that elements G3 and G6 are directly involved in the
regulation of the splicing of rpL3 transcript intron 3.
To verify the role of G3 andG6 elements,we generated and analyzed
another set of minigenes (see Fig. 5B): one with a mutation of element
G6 (G[6]⁎), onewithmutation of elements G3 andG6(G[3,6]⁎), and one
Fig. 6. (A and B) Functional mapping of the G-run elements within intron 3. Representative RT-PCR of total RNA extracted from CHX-treated HeLa cells transfected with the wt-rpL3
minigene or mutated constructs (Fig. 5) by using oligonucleotides that amplify minigene products (Table 1). β-actin was used as a control of RNA loading. Quantiﬁcation of rpL3-a
mRNA level using PhosphorImager (Bio-Rad) is shown.
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with mutation of all G runs except elements G3 and G6 (G[1,2,4,5,7]⁎).
Mutation of element G6 alone resulted in a splicing pattern inwhich the
rpL3-a mRNA isoform was about 45% that of the control. A stronger
effect (80% reduction of the rpL3-a mRNA isoform)was observed in the
splicing pattern of the double mutant G[3,6]⁎ (Fig. 6B); the level of the
rpL3-a mRNA isoform was similar to the level obtained with mutant G
[2,3,5,6]⁎ or G[1–7]⁎ (Fig. 6A). Thus, the G3 and G6 elements cooperate
to control the selection of the alternative 3′ splice site in intron 3. Finally,
mutant G[1,2,4,5,7]⁎ (see Fig. 5B) had the same splicing pattern as the
endogenous gene (Fig. 6B), thereby conﬁrming that elements G3 andG6
play a relevant role in the selection of splicingmodality of the rpL3 gene.
These data demonstrate that the G3 and G6 motifs cooperatively
drive the recognition of the alternative 3′ splice site in intron 3,
thereby leading to the inclusion of part of intron 3 in the rpL3-a
mRNA. Furthermore, these results together with data from hnRNP H1
silencing provide strong evidence that the effects on the splicing
pattern of rpL3 pre-mRNA could be mediated directly by the
interaction of hnRNP H1 with G3 and G6 elements. To verify these
ﬁndings, we overexpressed hnRNP H1 in HeLa cells transfected with
the wt-rpL3, G[2,3,5,6]⁎ or G[3,6]⁎ minigenes under conditions that
could lead to a larger than three-fold increase of the rpL3-a transcript
level. Despite hnRNP H1 overexpression, the splicing pattern of the
double mutant G[3,6]⁎ showed that the level of alternative transcript
was 60% lower than the level of the control wt-rpL3 minigene (Fig. 7).
These data indicate that the G3 and G6 elements represent the
consensus bindingmotifs of hnRNPH1 and are required for the hnRNP
H1-mediated regulation of rpL3 pre-mRNA splicing.
4. Discussion
Ribosome biosynthesis requires the coordinated expression of the
genes coding for the structural components, rRNA and r-proteins [24].
To maintain ribosome synthesis at the appropriate level, r-protein
expression is regulated by multiple control mechanisms mostly at
post-transcriptional and translational level. Moreover, r-proteins also
exert a variety of extra-ribosomal functions for which additional and
speciﬁc regulatory strategies are required [25–29]. In eukaryotes,
several post-transcriptional regulation mechanisms have been de-
scribed that control the level of rp-mRNA in the cell by modulating
transcript processing, splicing, and stability. Autoregulation mechan-
isms appear to be a strategy by which each individual r-protein may
control the level of its own expression [21,22,30–32].
We previously demonstrated that, as a consequence of a partial
retention of intronic sequences, splicing of the human rpL3 transcript
gives rise to a canonical mRNA and to an alternative mRNA isoform
containing a PTC that is targeted to NMD. Moreover, our ﬁnding that
rpL3 overexpression downregulates the level of the canonically spliced
mRNA, and upregulates the production of the alternatively spliced
isoform demonstrated that production of human rpL3 is regulated via
a negative feedback loop [22]. Coupling of AS and NMD appears to be a
tool by which to ﬁne tune ribosomal protein levels. However, the
molecular mechanism through which the process occurs is unknown.
In an attempt to shed light on this mechanism we looked for
molecular partners of rpL3, and identiﬁed a number of proteins able to
bind in vitro rpL3, the intron 3 of rpL3 gene, or both (Figs. 1 and 2). In
vivo experiments conﬁrmed that the splicing factor hnRNP H1 could
bind rpL3 as well as its pre-mRNA, and REMSA experiments showed
that this interaction occurs through a pre-mRNA region containing
seven G-run elements (Fig. 3). In addition, depletion of hnRNP H1 by
siRNA resulted in a signiﬁcant reduction of alternative splicing of rpL3
pre-mRNA (Fig. 4A), whereas its overexpression resulted in increased
production of the aberrant rpL3 mRNA (Fig. 4B), which indicates that
hnRNP H1 overexpression was associated with a more efﬁcient usage
of the alternative 3′ acceptor site in intron 3.
G-run motifs are found preferentially in intronic sequences ﬂanking
a splicing site andappear to affect the recognition of anadjacent5′ splice
site or 3′ splice site of the intron. However, they can also functionwhen
located in exons [33].
Mutational analysis of the seven G-run elements in rpL3 intron 3
showed that G3 and G6 affected splicing (see Figs. 5B and 6). In fact,
when both elements were mutated (G[3,6]⁎ in Figs. 5B and 6B), the
level of the alternativemRNA isoformwas reduced by 80%, as occurred
when all G-runmotifs weremutated.Whenwild-type G3 andG6were
conserved and all other G runs mutated (see G[1,2,4,5,7]⁎ in Figs. 5B
and6B), the amount of alternative rpL3mRNA isoformwas the same as
the amount obtained from the wt-rpL3 primary transcript. Moreover,
when G3 and G6 motifs were mutated, hnRNP H1 overexpression did
not affect the level of the alternatively spliced mRNA isoform (Fig. 7).
Given these results we concluded that G3 and G6 form a functional
unit, and that its interaction with hnRNP H1 promotes the selection of
a weak alternative 3′ splice site of intron 3. Cooperation between
different G-richmotifs has beenwidely documented.More copiesmay
increase the afﬁnity of an associated factor and/or recruit more copies
of an interacting factor [33]. For instance, multiple intronic G motifs
regulate the splicing of the thrombopoietin gene through a complex
combinatorial mechanism [11].
The molecular mechanism by which hnRNP H1 regulates AS of the
rpL3 transcript remains to be clariﬁed. Using proteomic analysis, we
identiﬁed several proteins that interacted in vitro with rpL3 and with
the pre-mRNA of the rpL3 gene (Figs. 1A and 2A). It is plausible that
more complex protein–protein interactions between RNA-binding
proteins, hnRNP H1 and rpL3 are involved in the regulation of rpL3
gene splicing. In this context, our results are consistent with a model
in which the rpL3 protein directs the splicing reaction towards the
alternative mode by speciﬁcally interacting with hnRNP H1 (Fig. 8).
In a splicing process leading to the exclusion of exon IIIC of the
FGR2 gene, Fox2 recruits silencing factors and assists hnRNP H1 in
binding an exonic splicing silencer thereby resulting in exon exclusion
[34]. Regarding the rpL3 gene, the process may serve to prevent
wasteful production of the protein. Binding to rpL3 could cause
conformational changes in hnRNP H1 that favor interaction with the
Fig. 7. hnRNP H1 regulates rpL3 pre-mRNA alternative splicing by binding to G3 and G6
elements. (A) hnRNP H1-HA was detected by western blotting (WB) using antibodies
against the HA epitope. Loading in the lanes was controlled by detection of tubulin
protein. (B) Representative RT-PCR of total RNA extracted from CHX-treated HeLa
cells transfected with hnRNP H1-HA (4 μg, control) or co-transfected with G[2,3,5,6]⁎ or
G[3,6]⁎ or the wt-rpL3 minigene (Fig. 5) and hnRNP H1-HA (4 μg). β-actin was used to
control RNA loading. Quantiﬁcation of rpL3-a mRNA level using PhosphorImager (Bio-
Rad) is shown. These results are representative of three independently performed
experiments.
427A. Russo et al. / Biochimica et Biophysica Acta 1799 (2010) 419–428
alternative splicing enhancer unit G3+G6 within intron 3, thereby
allowing correct positioning of the spliceosome, and recruitment of
additional protein factors. Ultimately, such a complex could favor the
selection of the alternative 3′ splice site.
The ongoing analysis of protein components of the RNP complex
involved in the selection of the alternative 3′ splice site will help to
elucidate the ﬁne autoregulatory network of rpL3 expression.
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Fig. 8. Schematic representation of rpL3 feedback regulation mediated by hnRNP H1.
rpL3 binds to hnRNP H1 and recruits it on intron 3. hnRNP H1 interacts with G3+G6
units within intron 3, and, through interaction with other transacting proteins, an RNP
complex promotes the selection of the weak 3′ acceptor site in intron 3.
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Abstract
In the presence of a bacteriophage (a bacteria-attacking virus) resistance is clearly beneficial to the bacteria. As expected in
such conditions, resistant bacteria emerge rapidly. However, in the absence of the phage, resistant bacteria often display
reduced fitness, compared to their sensitive counterparts. The present study explored the fitness cost associated with
phage-resistance as an opportunity to isolate an attenuated strain of S. aureus. The phage-resistant strain A172 was isolated
from the phage-sensitive strain A170 in the presence of the MSa phage. Acquisition of phage-resistance altered several
properties of A172, causing reduced growth rate, under-expression of numerous genes and production of capsular
polysaccharide. In vivo, A172 modulated the transcription of the TNF-a, IFN-c and Il-1b genes and, given intramuscularly,
protected mice from a lethal dose of A170 (18/20). The heat-killed vaccine also afforded protection from heterologous
methicillin-resistant S. aureus (MRSA) (8/10 mice) or vancomycin-intermediate S. aureus (VISA) (9/10 mice). The same vaccine
was also effective when administered as an aerosol. Anti-A172 mouse antibodies, in the dose of 10 ml/mouse, protected the
animals (10/10, in two independent experiments) from a lethal dose of A170. Consisting predominantly of the sugars
glucose and galactose, the capsular polysaccharide of A172, given in the dose of 25 mg/mouse, also protected the mice (20/
20) from a lethal dose of A170. The above results demonstrate that selection for phage-resistance can facilitate bacterial
vaccine preparation.
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Introduction
Staphylococcus aureus can cause minor infections as well as life-
threatening diseases. Endocarditis, osteomyelitis, pneumonia,
surgical wound and intravascular device infections caused by S.
aureus represent a major public health concern [1–3]. In the United
States, about 60% of nosocomial S. aureus bloodstream infections
and 40–60% of surgical wound infections are caused by
methicillin-resistant strains of S. aureus (MRSA) [3]. One of these
MRSA strains has been reported to cause an alarming number of
necrotizing fasciitis cases [3]. Strains of S. aureus with reduced
susceptibility to vancomycin are also emerging [2,4]. In the wake
of the rising antimicrobial resistance [5], new strategies for the
control of S. aureus infections are needed. This study describes the
development of a vaccine active against S. aureus.
In the presence of an antibiotic or a bacteriophage (a bacteria-
attacking virus), resistance is clearly beneficial to the bacteria. As
might be expected, in such conditions, resistant bacteria are swift
to emerge [6]. However, in vivo and in vitro experiments
demonstrate that, in the absence of the antibiotic or phage,
resistant bacteria often display reduced fitness compared to their
sensitive counterparts [6–8]. This fitness cost is particularly high in
the case of phage-resistant bacterial strains. To infect bacteria,
phages often select an essential component of the bacterial cell wall
as a receptor [8]. To gain resistance, bacteria must dispose of this
component or alter its conformation [8]. However, this strategy is
costly to bacteria, which often become less virulent or avirulent.
The present study explored the cost of phage resistance to isolate
an attenuated strain of S. aureus. In a mouse model of infection, this
phage-resistant strain prevented infections from diverse and
clinically relevant S. aureus strains.
Materials and Methods
Bacteria
S. aureus strains A170, A177, A179 and A181 were isolated from
clinical samples collected from patients with infected surgical
wounds (one of the patients had diabetes; one wounds from a car
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incident; the remaining two were patients who underwent
abdominal surgery). Patients were hospitalized at the Medical
School of the University of Naples Federico II. Clinical samples
were streaked on trypticase soy agar (TSA) (Oxoid, Milan, Italy)
and single colonies expanded in trypticase soy broth (TSB)
(Oxoid). The strains listed above and their phage-resistant mutants
(A172, A178, A180, A182) were all identified as S. aureus [9]. For
in vivo and in vitro experiments, bacteria were grown in TSB at
37uC, harvested while in exponential growth phase (OD600: 1.5 to
1.8), centrifuged (861036g for 10 min) and washed with saline
(0.15 M NaCl). Serial 10-fold dilutions in saline were then plated
on TSA.
Mice
Experiments were carried out on female Balb/c mice (aged 8 to
10 weeks) at the animal facility of the University of Naples. Mice
were infected via the intramuscular or aerosol routes. In the case of
the intramuscular infection, mice received 56106–108 bacteria (as
detailed in each experiment) suspended in sterile saline (100 ml/
mouse). In the case of aerosol infection, mice were placed in a
nebulizing chamber and exposed to an aerosol solution (107 CFU/
ml) for 10 min. When inspected on the day of infection, the lungs
displayed about 1.6610565.56103 CFU/g/mouse (average of 3
mice). Organs were dissected and weighed. Samples were
homogenized in 1 ml saline and serially diluted in saline. Colony
forming units (CFU) were evaluated by the plate count assay and
expressed as CFU/g. Animal experiments were approved by the
Animal Care Committee of the University of Naples (permit
number 86/609/EEC).
Isolation of the phage-resistant strains
Phage MSa was isolated from the S. aureus strain A170 following
induction with mitomycin [10]. Phages MSa1, MSa2 and MSa3 were
isolated from S. aureus strains A177, A179 and A181, respectively;
phage release was again induced with mitomycin [10]. Phage-
resistant S. aureus strains A172, A178, A180 and A182 were
isolated by plating dilutions of overnight susceptible cultures on
TSA containing increasing concentrations of the phage used for
selection. Ten single colonies growing at the highest phage
concentration were selected and subcultured twice on TSA agar in
the absence of phage. To ensure stability of resistance, two
colonies from each phage-resistant strain were further subcultured
(20 times or more) in the absence of phage. Induction of the
phage-resistant strains (including A172) with mitomycin excluded
the presence of prophages in these strains.
Titration of anti-A172 antibodies
Mice were immunized with the A172 strain (108 CFU/mouse)
and two weeks later sacrificed and the blood pooled. The protein
A gene is under-expressed in the A172 strain. Yet, to avoid
interference with the protein A possibly present on the bacterial
surface, the wells of a 96-well plate (Falcon, Milan) were coated
with the S. aureus protein A negative strain Wood 46 [11],
quenched with 3% bovine serum albumin (50 ml/well; 2 h),
washed with PBS, incubated with anti-A172 serum diluted (1022–
1024) in PBS (50 ml/well; 2 h), washed with PBS and incubated, in
succession, with peroxidase-labelled rat anti mouse IgG (50 ml/
well; 2h) and peroxidase substrate (100 ml/well; Bio-Rad, Milan).
Carbohydrate analysis
Teichoic acids from the A170 (A170TA) and A172 (A172TA)
isolates were prepared as described [12] and analyzed gas
chromatography-combined mass spectrometry. Monosaccharides
were identified as acetylated O-methyl glycosides derivatives, fatty
acids or O-methyl ester derivatives. After methanolysis with
methanolic HCl (2M HCl/CH3OH; 85uC, 24 h) and acetylation
with acetic anhydride in pyridine (85uC; 20 min), samples were
analyzed by gas chromatography-combined mass spectrometry
(GC-MS) and compared with standards. GC-MS analyses were
carried out on a Hewlett-Packard 5890 instrument using SPB-5
capillary column (0.2563 m; Supelco, PA). Ring size and
attachment points were determined by methylation analysis as
described [13]. The sample (1–2 mg) was methylated with CH3I/
NaOH in DMSO, hydrolysed with 2M trifluoroacetic acid (100uC,
for 4 h), reduced with NaBD4, acetylated with acetic anhydride in
pyridine and analyzed by GC-MS. The temperature programme
was: 150uC for 5 min and then 5uC/min to 300uC over 10 min.
Capsular polysaccharide purification
The A172 strain (100 ml) was grown in TSB. When in the
exponential growth phase, the culture was centrifuged (861066g for
10 min) and the supernatant precipitated with ethanol (four
volumes) in the cold (220C overnight). Supernatant and precipitate
were separated by centrifugation (861066g for 10 min). The
precipitate, insoluble in H2O and several organic solvents
(methanol, ethanol, chloroform, or dimethyl sulfoxide), was
discarded. The supernatant was dialyzed (cut-off of the dialysis
tube: 3500 Daltons) against water (3 days), lyophilised, weighed and
tested for the capacity to protect mice. Mice vaccinated with the
supernatant (25 mg/mouse) were fully protected against a lethal
Figure 1. Pulsed field electrophoresis pattern of Sma I digests
from the Staphylococcus aureus A170 strain. The A172 strain (not
shown) displayed an identical pattern. M: DNA Size Standard, Lambda
Ladder (Concatemers of l cl857 Sam7) (Bio-Rad Laboratories, Hercules,
CA).
doi:10.1371/journal.pone.0011720.g001
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dose of A170 bacteria. This biologically active fraction (3.4 g) was
hydrolysed with 0.1 M HCl at 100uC for 48 h. The mixture was
neutralized with 2 MNaOH and reduced with sodium borohydride
in distilled water (3 g/0.5 ml). The alditols were acetylated with
pyridine (100 ml) and acetic anhydride (100 ml) at 85uC for 30 min.
The monoses were identified as acetate alditols by gas liquid
chromatography (GLC) [14] using the Agilent GC-MS 7890A
instrument (Waghaeusel-Wiesental, Germany) equipped with a
capillary column (30 m60.25 mm, 0.25 mm film thickness) of SPB-
5 (Sigma Aldrich, Milan, Italy) and applying a temperature gradient
of 150uC (3 min) to 320uC at 3uC/min.
Detection of A172 revertants
Individual wells of 96-well plates were filled with 200 ml TSB
medium and inoculated with one colony of A172 bacteria isolated
from mice vaccinated with the same strain and then grown in vitro
for 15 generations under stress conditions (10 mg/ml novobiocin)
[15]. Bacteria were grown for 3 h at 37uC. Individual cultures (109
CFU/200 ml) were quantitatively spread over a phage lawn (1012
PFU/5 ml soft agar). Bacteria were thus surrounded by large
numbers of virus particles. Plates were inspected for the presence
of plaques of lysis during the next 4 days. The detection limit of the
test was established by carrying out the test on the same A172
cultures spiked with 12, 6, 3 or 1 A170 MSa-sensitive bacteria. The
dilutions with 12, 6, 3 or 1 A170 bacteria were assayed by plate
count in triplicate.
The presence of revertants was also investigated by an
independent method, based on the increase of phage titre of a
liquid culture upon addition of phage-sensitive bacteria [16]. A172
bacteria grown in the presence of novobiocin (109 CFU/200 ml)
were incubated for 1 h with the MSA phage (105 PFU). The
cultures were then transferred quantitatively on a lawn of the A170
MSa-sensitive bacteria (105 CFU/4 ml soft agar) to determine
whether the original phage titre increased. The detection limit of
the test was established by testing in parallel the phage titre
increase that occurred in the same A172 cultures (109 CFU/
200 ml) spiked with 12, 6, 3 or 1 A170 MSa-sensitive bacteria. The
dilutions with 12, 6, 3 or 1 A170 bacteria were assayed as
described above.
Phage lysis inhibition
A170 or A172 bacteria (105 CFU/100 ml) were grown (4 h) in
2 ml TSB, in the presence or absence of: 5–20 mM N-acetyl-
glucosamine (GlcNAc), 5–20 mM glucose (Sigma, Milan), 0.1–
4 nmol/tube teichoic acid from A170 (A170TA) or A172 (A172TA).
The MSa phage (109 PFU7tube) was then added and bacterial
growth (OD600) measured 30 min later.
Phage inactivation by N-acetyl-glucosaminidase
A170 or A172 bacteria (105 CFU/100 ml) were grown (4 h) in
2 ml TSB, in the presence or absence of N-acetyl-glucosaminidase
from Canavalia ensiformis (Sigma; 4 U/tube). The MSa phage was
then added (109 PFU) and bacterial growth (OD600) measured
30 min later.
Pulsed-field electrophoresis of S. aureus strains
The procedure adopted was that described in [17]. Briefly,
inserts of intact DNA were digested in 200 ml of appropriate buffer
supplemented with 40 U of Sma I (Promega, Milan). Pulsed field
gel electrophoresis (PFGE) of the restriction digests was performed
by using the CHEF system (Bio-Rad Laboratories, Hercules, CA,
USA) with 1% (wt/vol) agarose gels and 0.56TBE as running
buffer, at 10uC. Restriction fragments were resolved in a single
run, at constant voltage of 6 V cm2 and an orientation angle of
120u between electric fields, by a single phase procedure for 24 h
with a pulse ramping between 1 and 50s.
Other methods
The transcription level of bacterial virulence genes and mouse
cytokine genes was analyzed by real-time reverse transcription PCR
(RT-PCR) as described [18]. Fluorescein isothiocyanate labelled
A170 (A170FITC) and A172 (A172FITC) bacteria were prepared as
described [19]. Troponin was measured using the Mini Vidas
automated immunoassay analyzer and the Vidas troponin kit
(bioMereux, Florence, Italy). The sequence type of the S. aureus
strains were determined by sequencing the hypervariable region of
S. aureus protein A gene (spa) as described [20]. The spa types were
assigned using the Ridom spa-server (http://spaserver .de).
Multilocus sequence typing (MLST) of S. aureus strains was carried
out as described [21]. The bacterial genes eta, etb, tst, lukS-PV–lukF-
PV, lukE-lukD and lukM, (coding for the exfoliative toxin A,
exfoliative toxin B, toxic shock syndrome toxin1, Panton-Valentine
leukocidin components S and F, the leukotoxin LukELukD, and the
leukotoxin LukM, respectively) were detected by PCR [10]. The
staphylococcal enterotoxin (se) genes se-a, se-b, se-c, se-d, and se-ewere
detected as described [22]. The restriction endonucleases analysis-
enterotoxin gene cluster (REA-egc) type was carried out as described
[23]. Survival rates of mice were analyzed using Fisher’s exact test.
Bacterial counts and gene expression levels were analyzed using the
Figure 2. Differences between the phage MSa-sensitive strain A170 and the phage MSa-resistant strain A172. The strain A172 grows in
larger clumps (A) compared to the strain A170 (B). Bacteria were grown in liquid culture and collected for microscopic examination at the early
stationary phase. (C) The A172 strains displays also a slower growth rate, compared to A170.
doi:10.1371/journal.pone.0011720.g002
Figure 3. In S. aureus, phage-resistance comes with production
of capsular polysaccharide. (A) Strains A170, A177, A179, A181
(sensitive to the phages MSA, MSA1, MSa2, MSA3, respectively). (B) Strains
A172, A178, A180, A182 (resistant to the phages MSA, MSA1, MSa2, MSA3,
respectively).
doi:10.1371/journal.pone.0011720.g003
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paired t test (P values are two-tailed values). The molar
concentration of the teichoic acids from the S. aureus strains A170
and A172 were calculated attributing to A170 and A172 the
molecular weight of 6350 daltons (the average molecular weight of
the teichoic acid from S. aureus strain Copenhagen, which ranges
from 5400 to 7300 daltons) [24]
Results
Isolation and characterization of A172
The strains A170 and A172 were positive for the exfoliative toxin
B, the Panton-Valentine leukocidin, while negative for the
exfoliative toxin A, toxic shock syndrome toxin 1, the leukotoxin
LukELukD, the leukotoxin LukM and the staphylococcal entero-
toxins-a, -b, -c, -d and –e. The strains A170 and A172 displayed also
the same egc type (egc-4), the multilocus sequence type (ST 45) and
spa-type (t6668) (spa-type repeats succession: 08-16-02-16-34-13-
17-34-34-34-34-34, equivalent to Kreiswirth’s IDs: XKAK-
BEMBBBBB). According to the Ridom  -server (http://
spaserver.ridom.de), t6668 represents a novel spa type. PFGE
analysis displayed a close genetic relation between the parental
phage MSa-sensitive strain A170 and the derivative phage-resistant
strain A172, as proved by the identical PFGE pattern of the Sma I
digests (Figure 1). A172 was isolated by growing the parental strain
A170 in the presence of increasing concentrations of the MSa phage
[10]. In addition to MSa, the strain A172 is also resistant to phages
MSa1, MSa2 and MSa3. Prolonged liquid subculture for several
months in the absence of phage or prolonged storage at280uC did
not alter the resistance of A172 to MSa.
The strain was also highly stable in vivo. A172 bacteria were
isolated from a vaccinated mouse, grown for 15 generations under
stress conditions (10 mg/ml novobiocin) [15] and used to establish
400 independent bacterial cultures, which yielded a total number
of about 461011 bacteria (109, the number of cells/culture6400,
the number of cultures). Plated with phage in excess (1012 PFU/
5 ml soft agar), the 400 independent bacterial cultures did not
yield any plaque of lysis. Control cultures (109 CFU A172/200 ml
spiked with 3 A170 bacteria), assayed in triplicate in three
independent experiments, displayed all at least one plaque and, on
average, 2.260.7 plaques/culture (number of replicas: 9). The
absence of A172 revertants was confirmed in a second indepen-
dent experiment. When the MSa phage (105 PFU) was mixed with
the A172 bacteria grown under stress conditions (109 CFU/
200 ml), no measurable increase in the phage titre occurred.
Control cultures (109 CFU A172/200 ml spiked with 3 A170
bacteria), compared to the non-spiked cultures, displayed an
increase in phage titre from 1.461056246103 to 1.261066
0.56103 (n: 9; P: 0.0057). Conservatively, it is estimated that A172
revertants occur at a frequency ,361029.
In liquid culture, compared to the parental strain, A172 formed
colonies with the tendency to clump together starting at the early
stationary phase (Figure 2A–B). Bacterial suspensions of A170 and
A172 with the same density (OD600: 0.6) were assayed by plate
count. In three independent experiments, A170 cultures contained
about 3 fold as many CFU as the A172 cultures (3.461076
6.76106 vs 1.2610762.56106; P 0.003). A172 displayed reduced
growth rate during the exponential phase (Figure 2C) and reduced
doubling time (A172: 45 min62.8 min; A170: 3062.5 min; P
0.002). Also, unlike A170, A172 produced capsular polysaccharide
(Figure 3). Phage resistance altered the transcription of several
virulence factors. Among 14 ORFs of A172 analyzed, 13 were
significantly down-regulated compared to A170 (Figure 4). Down-
regulated ORFs comprise 9 genes, which control virulence factors
[25].
The receptor of the MSa phage is the N-
acetylglucosamine
Phages often use teichoic acids for adsorption on the cell wall of
Gram positive bacteria. They can use as receptor the glucose side
chains of Bacillus subtilis teichoic acids [26,27] or the N-
acetylglucosamine (GlcNAc) side chains of S. aureus [28]. To
identify the receptor site of the MSa phage, the A170 and A172
strains were grown in the presence or absence of 5–20 mM
GlcNAc or 5–20 mM glucose. GlcNAc inhibited the lysis of A170
by phage MSA, while glucose did not. GlcNAc inhibition was dose-
dependent (Figure 5A–B). The experiment was repeated using the
teichoic acid from (A170TA) or from (A172TA) as inhibitor. Since
Figure 4. Expression levels of S. aureus A170 and A172 virulence factors. Acquisition of phage-resistance by A172 is accompanied by
extensive alterations in virulence gene expression levels. Out of the 14 ORFs examined, 13 are significantly under-expressed, compared to the phage-
sensitive strain A170. Bacteria were collected for transcriptional analysis during the exponential growth phase. SA0107 (spa, IgG binding protein A
precursor); SA0112 (hypothetical protein, similar to cysteine synthase); SA0184 (hypothetical protein); SA039 (geh; glycerol ester hydrolase); SA1007
(a-haemolysin); SA1160 (nuc; thermonuclease); SA1898 (hypothetical protein, similar to SceD precursor); SA2097 (hypothetical protein, similar to
secretory antigen precursor SsaA); SA2206 (sbi; IgG-binding protein SBI); SA2255 (oligopeptide transporter substrate binding protein); SA2406 (gbsA;
glycine betaine aldehyde dehydrogenase gbsA); SA2459 (ica; N-glycosyltransferase); SAR216 (groEL; chaperonin GROEL); SAR2117 (groES; co-
chaperonin GRES). ORFs numbers correspond to the S. aureus N315 genome sequence. Gene designations (when known) and proteins function are
shown in parentheses.
doi:10.1371/journal.pone.0011720.g004
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the quantity of teichoic acid that is isolated from the A170 or A172
strains varies significantly (2.4 mg from 1010 CFU A170; 0.9 mg
from 1010 CFU A172), the experiment was conducted using an
ample concentration range of the A170TA and A172TA reagents.
Under these conditions, phage inactivation occurred with A170TA,
but not with A172TA (Figure 5C). A170 bacteria were then treated
with N-acetylglucosaminidase (4 U/tube; 2 h at 37uC). Enzymatic
hydrolysis of GlcNAc from the A170 bacteria destroyed phage lysis
capacity (Figure 5D). Finally, analysis of teichoic acids from the
A170 (wild) and A172 (mutant) strains of S. aureus displayed the
absence of ribitol (Figure 6A) and terminal GlcNAc (t-GlcNAc)
residues (Figure 6B) from A172TA. Collectively, the experiments
described above demonstrate that A172 conforms with the
tendency of several bacterial species - B. subtilis [26,27], S. aureus
[28], Salmonella enterica [18,29] - to acquire phage-resistance by
altering a cell wall polysaccharide component.
The A172 strain prevents S. aureus infection
For a more succinct presentation of the results, the distinctive
features of the experiments described in this and the following
sections are detailed in the Tables. One group of mice was
immunized with A172 live (A172-L) and two weeks later
infected with a lethal dose of A170. At the time of infection, in
the serum of immunized animals the titre of the antibodies
against A172-L ranged from 1:5000 to 1:12000. Control mice
were also infected with a lethal dose of A170. The A172-L
vaccine protected 90% of the mice (surviving mice: 18/20) from
A170, while the control mice (10/10) died within 4 days (P:
0.008; Table 1, experiment 1). When examined at the end of the
experiment (14 days after challenge), the kidneys of surviving
A172-L treated animals displayed significantly fewer CFU
compared to the kidneys of the control mice at the time of
death (Table 1, experiment 1).
Figure 5. Phage MSA is inhibited by N-acetyl-glucosamine (GlcNAc), the teichoic acid from A170 (A170TA) or by treatment with N-
acetyl-glucosaminidase (GlcNA-ase) from Canavalia ensiformis; phage MSA is not inhibited by the teichoic acid from A172 (A172TA) or
glucose. (A) GlcNAc inhibits the lysis of the A170 strain by the phage MSa, while glucose (B) does not. (C) A170TA inhibits the lysis of the A170 strain
by the phage MSA, while A172TA does not. (D) The phage-sensitive strain A170 grows in the presence of the MSa phage, if pre-treated with GlcAc-ase
(4 U/tube; 2 h at 37uC).
doi:10.1371/journal.pone.0011720.g005
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To exclude that the above results represented the response
elicited by a sublethal infection with live S. aureus, mice were
infected with a sublethal dose of A170 and two weeks later
challenged with a lethal dose of A170. There was no significant
difference in surviving between immunized and control mice (P: 1;
Table 1, experiment 2). Thus, the protective response described
above is to be ascribed specifically to A172.
Being a live vaccine, A172 poses the risk of reverting to the
virulent phenotype. This risk is remote (see the section ‘‘Isolation
and morphological characterization of A172’’), albeit considerable
when the use of a large number of vaccine doses is prospected.
The study therefore explored whether A172 remained protective
once it was heat-killed (15 min at 100uC). Mice were vaccinated
with heat-killed vaccine (A172-HK) and 2 weeks later infected
with a lethal dose of A170. The vaccine was protective also in this
form (P: 0.004; Table 1, experiment 3).
When the interval between vaccination and challenge was
extended to 20 weeks, control mice all died within 4 days (10/10);
the vaccinated mice (37/40) were alive 14 days after challenge (P:
0.004; Table 1, experiment 4). Thus, the protection provided by
the vaccine lasts at least 20 weeks.
One more experiment was designed to ascertain whether also
A170 - in the heat-killed form (A170-HK; 15 min at 100uC)- was
protective. No significant difference in survival between immu-
nized and control mice was observed (P: 1; Table 2, experiment 5).
Additional properties of the A172 vaccine
The efficacy of the A172-HK vaccine was tested against two
methicillin-resistant S. aureus (MRSA) (A174 and A175) and one
vancomycin-intermediate S. aureus (VISA) (A176) isolates derived
from patients with staphylococcal infections. Three groups of mice
were immunized with A172-HK and 20 weeks later infected with a
lethal dose of the A174, A175 or A176 isolates. The difference in
survival between vaccinated and control mice was statistically
significant in each case (P: 0.01–0.02; Table 2).
Patients with cystic fibrosis are highly susceptible to S. aureus
lung infection [30]. S. aureus is also one of the most common
causes of pneumonia in paediatric and adult populations [31].
The study therefore explored the efficacy of A172-HK against
lung infections. Mice were immunized by aerosol with A172-HK
and 20 weeks later infected with A170 by the same route. The
vaccine was also effective when administered by aerosol (P: 0.004;
Table 3).
Collectively, the experiments described in this and the preceding
section demonstrate that A172-HK protects mice against a lethal
dose of S. aureus; protection correlates with increased survival and
reduced colonization lasting at least 20 weeks and extending into
drug-resistant isolates of S. aureus; the vaccine is effective when
administered, in single dose and without adjuvant, by the
intramuscular or aerosol routes.
Anti-A172 antibodies protect against S. aureus A170
infection in vivo
Two groups of mice (control mice) were injected intramus-
cularly with normal mouse serum (10 ml or 20 ml diluted 1:10
with sterile saline, respectively). Two more groups of mice were
treated intramuscularly with serum from mice immunized with
A172-HK (10 ml or 20 ml diluted 1:10 with sterile saline,
Figure 6. Gas chromatography-combined mass spectrometry spectra of the teichoic acids from the A170 and A172 strains.
Acetylated O-methyl glycosides from the phage–sensitive A170 and phage-resistant A172 strains of S. aureus. Loss of ribitol (A) and t-GlcNAc linked to
ribitol (B) in the teichoic acids is part of the strategy adopted by A172 to gain phage-resistance. The peak of 4-GlcNAc was chosen as reference. Gro:
glycerol; GlcNAc: N-acetylglucosamine; ManN: N-acetylmannosamine; MurNAc: N-acetyl muramic acid; Glc: glucose; C15:0: pentadecanoic acid; C16:0:
esadecanoic acid; C18:0: octadecanoic acid; C20:0: eicosanoic acid; 4-GlcNAc: 4-linked N-acetylglucosamine; 3GlcAcNMaN: 3-linked N-
acetylmannosamine; t-GlcNAc: terminal GlcNAc.
doi:10.1371/journal.pone.0011720.g006
Table 1. Active protection of A172 in mice challenged with S. aureus strain A170.
Vaccination
Interval vaccination
challenge (weeks) Challenge
Exp
Dose CFU/
mouse Vaccine Route
Dose CFU/
mouse Pathogen Route Survival P valueb
CFU/ga
(mean ± SD)
1 108 A172-Lc Imd 2 108 A170 Im 18/20 0.008 266611e
- - - 0/10 5.6610863.56108
2 56106 A170 - 2 108 A170 Im 0/10 1 5.7610863.26108
- - - 0/10 5.2610861.56108
3 108 A172-HKf - 2 108 A170 Im 19/20 0.004 260625e
- - - 0/10 3.5610861.86108
4 108 A172-HK - 20 108 A170 Im 37/40 0.004 200611e
- - - 0/10 5.7610863.36108
5 108 A170-HK - 2 108 A170 Im 0/10 1 5.2610861.86108
- - - 0/10 4.7610862.36108
aColony forming units per g of kidneys (experiments 1–4) or lungs (experiment 5); values calculated on 3 mice.
bTwo tailed Fisher’s exact test.
cA172 Live.
dIntramuscular.
eP,0.001.
fHeat killed A172.
doi:10.1371/journal.pone.0011720.t001
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respectively). The titre of the antibodies against A172-HK was
1:8000. The next day, the mice were all challenged with a lethal
dose of S. aureus A170. Survival was monitored for seven days.
In two independent experiments, the antibodies against A172-
HK - given at the dose of 10 ml/mouse - provided protection to
all the mice (10/10) (P 0.01;Table 4, experiments 1 and 2).
Instead, the same serum - given at the dose of 20 ml/mouse -
killed 40%–50% of the mice (P 0.05–0.06; Table 4, experiments
1 and 2). Thus, anti-A172 antibodies can be protective or
detrimental, depending upon the dose being given. This
phenomenon has been described since the development of
serum therapy [32]. In mouse models of Streptococcus pneumoniae
[32] and Cryptococcus neoformans [33], antibody-mediated pro-
tection was also observed within a narrow dose range. Since the
therapeutic use of antibodies in humans is sometimes associated
with myocardial damage [34,35], mice passively immunized
with antibodies against A172-HK were tested for evidence of
heart damage by measuring the level of the cardiac troponin T
in the serum. This marker is highly specific for myocardial
damage [34]. Mice treated with 20 ml antibodies, compared to
those treated with 10 ml, displayed a statistically significant
higher level of serum troponin T (0.0960.01 ng/ml vs
0.0260.01 ng/ml; P: 0.001). It was not investigated whether
heart damage was the primary cause of death or a secondary
complication of antibody administration. Mice treated with
10 ml or 20 ml antibodies displayed both significantly fewer
CFU compared to the mice treated with normal mouse serum
(Table 4, experiments 1 and 2).
In an independent experiment, mice were immunized with
10 ml of anti-A172 mouse serum absorbed with rat anti total
mouse immunoglobulin fraction (5–10 ml) and diluted to 100 ml
with sterile saline. The next day, the mice were challenged with a
lethal dose of S. aureus A170. Absorption of anti-A172 mouse
serum completely eliminated the protective effect of the serum
(Table 4, experiments 3). Collectively, the above results demon-
strate that the passive protection shown by the antibodies against
A172-HK is dose dependent and specific (residing in the antibody
fraction of the serum).
The A172 strain controls inflammation
Ten mice were immunized intramuscularly with A172-HK (108
CFU/mouse). A172 modulated transcription of the genes coding
for the pro-inflammatory cytokines TNF-a, IFN-c and IL-1b,
while inducing that of the genes coding for the anti-inflammatory
cytokines Il-4 and Il-6, when these genes were analyzed by RT-
PCR, 24 and 48 h after immunization (Figure 7). The same
pattern of cytokine production was observed in mice immunized
with A172-HK and 20 weeks later infected with A170 (data not
shown). Given the abundant release of pro-inflammatory cytokines
during S. aureus infection [36–37], this property of A172 is
biologically relevant.
Table 2. Protection of heat killed vaccine A172 against drug-resistant S. aureus strains.
Vaccination
Interval vaccination
challenge (weeks) Challenge
Dose
(CFU/mouse) Vaccine Route
Dose
(CFU/mouse) Pathogen Route Survival P valueb
CFU/ga
(mean ± SD)
108 A172-HKc Imd 20 108 A174 Im 8/10 0.02 250622e
- - - 0/10 6.7610861.86108
108 A172-HK - 20 108 A175 Im 9/10 0.01 330637e
- - - 0/10 5.86108616108
108 A172-HK - 20 108 A176 Im 9/10 0.01 380626e
- - - 0/10 5.5610863.66108
aColony forming units per g of kidneys; values calculated on 3 mice.
bTwo tailed Fisher’s exact test.
cHeat killed A172.
dIntramuscular.
eP,0.001.
doi:10.1371/journal.pone.0011720.t002
Table 3. Protection of heat killed vaccine A172 administered by aerosol.
Vaccination
Interval vaccination
challenge (weeks) Challenge
Dose
(CFU/mouse) Vaccine Route
Dose
(CFU/mouse) Pathogen Route Survival P valueb
CFU/ga
(mean ± SD)
108 A172-HKc Aerd 20 108 A170 Aer 19/20 0.004 21663e
- - - 0/10 7.1610863.16108
aColony forming units per g of kidneys; values calculated on 3 mice.
bTwo tailed Fisher’s exact test.
cHeat killed A172.
dAerosol.
eP,0.001.
doi:10.1371/journal.pone.0011720.t003
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Selection for phage resistance as a general approach for
vaccine production
Three groups of mice were immunized (108 CFU/mouse,
intramuscularly) with the MSa1-resistant strain A178 (derived from
the MSa1-susceptible isolate A177), MSa2-resistant strain A180 (derived
from the MSa2-susceptible isolate A179) or MSa3-resistant strain A182
(derived from the MSa3-susceptible isolate A181), respectively. Two
weeks later, immunized and control mice were challenged with A170
(108 CFU, intramuscularly). The phage-resistant strains all provided
protection in terms of survival and level of host colonization (Table 5;
P: 0.01–0.02) and – like A172 - all lost t-GlcNAc (data not shown) while
all gained the capacity to secrete capsular polysaccharide (Figure 3).
The experiment demonstrates the general applicability of selection for
phage resistance as a means to curb bacterial virulence. The
experiment demonstrates also how different S. aureus isolates use the
same defence strategy against different phages.
The capsular polysaccharide from A172 provides
protection
Capsular polysaccharide (CP) production is a characteristic
common to the four protective strains (A172, A178, A180, A182)
(Figure 3). In an attempt to identify the protective component of
A172, the CP from this strain (CP-A172) was purified and
analyzed by gas liquid chromatography (GLC). CP-A172 contains
glucose and mannose in the molar ratio of 3:1 and traces (molar
ratio: 0.3) of galactose and GlcN (Figure 8). Immunization of mice
with CP-A172 (25 mg/mouse) or treatment with the serum from
mice immunized with CP-A172 (10 ml diluted 1:10 with sterile
saline/mouse) protected mice against a lethal dose of A170 (P:
0.004; Table 6, experiments 1–2).
Discussion
Several virulence factors of S. aureus are being investigated for
their potential use as vaccines [37–38]. However, in view of the
numerous virulence factors produced by this pathogen [39], it is
unlikely that a single component vaccine might protect against a
multitude of virulence factors. Also, virulence genes often display
high levels of variability, as result of the selection pressure to evade
the immune system of the host [40]. The single antigen may
therefore have limited distribution among clinical isolates or may
not be expressed in vivo. The objective of the present study was to
Table 4. Mouse anti A172-HK antibodies protect mice challenged with S. aureus A170 strain.
Passive vaccination Challenge
Exp Treatment
Dose
(ml/mouse) Route
Dose
(CFU for mouse) Strain Route Survival P valueb
CFU/ga
(mean ± SD)
1 Normal mouse serum 10 Imc 108 A170 Im 0/10 0.01 5.86108616108d
Anti-A172-HK serum - - - - - 10/10 9067
Normal mouse serum 20 Im 108 A170 Im 0/10 0.05 4.76108626107d
Anti-A172-HK serum - - - - - 6/10 5.5610563.66104
2 Normal mouse serum 10 Im 108 A170 Im 0/10 0.01 3.56108626108d
Anti-A172-HK serum - - - - - 10/10 7366
Normal mouse serum 20 Im 108 A170 Im 0/10 0.06 6.36108616108d
Anti-A172-HK serum - - - - - 5/10 2.661056105
3 Anti-A172-HK serum absorbed
with rat anti-mouse IgG
10 Im 108 A170 Im 0/10 5.4610864.26107
aColony forming units per g of kidneys; values calculated on 3 mice.
bTwo tailed Fisher’s exact test.
cIntramuscular.
dP,0.0001.
doi:10.1371/journal.pone.0011720.t004
Figure 7. Anti-inflammatory activity of the A172 vaccine. A172 modulates transcription of the genes coding for pro-inflammatory cytokines
(TNF-a, INF-c and IL-1b) and induces transcription of the genes coding for anti-inflammatory cytokines (Il-4 and Il-6).
doi:10.1371/journal.pone.0011720.g007
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develop a live attenuated S aureus strain containing multiple
antigens and therefore likely to elicit cross-protection against a
spectrum of pathogenic strains. The attenuated strain (A172)
proved effective as vaccine even when heat-killed. Thus, heat-
killed A172 (A172-HK) possesses the advantages of a multiple
component vaccine, without the problems of safety (reversion to
phage sensitivity and the accompanying virulent phenotype),
distribution and manufacturing of the live vaccines [41].
Phage-resistance often (though not always) occurs at a fitness
cost [6,7]. This trade-off explains why phage-resistant and phage-
sensitive bacteria coexist [42]. Bacterial selection for phage-
resistance was therefore exploited as an approach to isolating an
attenuated strain of S. aureus. The approach had already been used
successfully to produce a vaccine against Salmonella enterica serovar
Paratyphi B [18]. The phage-sensitive strain A170, following
growth in vitro in the presence of the MSa phage, yielded the
phage-resistant strain A172. Given their common origin, the two
strains share several properties, but display also crucial differences.
They share the spa-type (t6668), the MLST type (ST 45), the egc
type (egc-4) and part of the genome (Figure 1). At the same time,
A170 and A172 differ in their teichoic acid structure and the
capacity to secrete CP. The teichoic acids of A172 lack the
terminal GlcNAc residues (Figure 6B) that phages often use for
adsorption on the cell wall of S. aureus [28]. More importantly,
GlcNAc and the teichoic acids from A170 (A170TA) inhibit lysis by
the MSa phage, while glucose or the teichoic acids from A172
(A172TA) do not (Figure 5C). These results suggest that A172
gained phage-resistance by losing the phage adsorption site
(terminal GlcNA). However, A172 also displays CP production,
a strategy that some bacteria put in action to mask their phage
adsorption site [43]. In conclusion, while teichoic acid alteration is
the likely mechanism adopted by A172 to gain phage resistance,
the contribution of CP production cannot be excluded.
In a mouse model of infection, A172-HK elicited high levels of
protection against lethal doses of the A170 strain (P 0.004; Table 1,
experiment 3). A single dose of A172-HK, without use of adjuvant,
was fully protective after vaccine administration by the intramus-
cular or aerosol routes and protection lasted at least 20 weeks
(Tables 1–3). Significantly, A172-HK was effective against
methicillin- resistant (MRSA) or vancomycin-intermediate clinical
isolates of S aureus (VISA) (Table 2). Sometime cross-protection has
been attributed to the persistence of the vaccine strain within the
host [44]. This possibility can be excluded in the present study
since the vaccine persists in the immunized animals for only 8
Table 5. Selection for phage-resistance as a general approach for S. aureus vaccine production.
Vaccination
Interval vaccination-challenge
(weeks) Challenge
Dose
(CFU/mouse) Strain Route
Dose
(CFU/mouse) Strain Route Survival P valueb
CFU/ga
(mean ± SD)
108 A178 Im 20 108 A177 Im 9/10 0.01 230640c
- - - - 0/10 4.6610861.56108
108 A180 - 20 108 A179 Im 10/10 0.01 160634c
- - - - 0/10 5.36108626108
108 A182 - 20 108 A181 Im 8/10 0.02 180625c
- - - - 0/10 3.5610861.26108
aColony forming units per g of kidneys; value calculated on 3 mice.
bTwo tailed Fisher’s exact test.
cP,0.001.
doi:10.1371/journal.pone.0011720.t005
Figure 8. Gas liquid chromatography profile of monosaccharides obtained by acid hydrolysis of the capsular polysaccharide from
S. aureus A172. Abundance expresses the relative ratio between monosaccharides.
doi:10.1371/journal.pone.0011720.g008
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days, while mice were challenged with virulent S. aureus 20 weeks
after vaccine administration (Table 1).
Passive immunization of mice with sera from A172-HK
vaccinated mice provided protection against the challenge with a
lethal dose of S. aureus A170. In two independent experiments, 10/
10 of the animals passively immunized with an individual dose of
10 ml immune serum (diluted 1:10 with sterile saline) survived,
while 10/10 untreated control mice died (P: 0.01; Table 4,
experiment 1). When the experiment was repeated using a higher
dose (20 ml immune serum diluted 1:10 with sterile saline/mouse),
40%–50% of the animals died (Table 5, experiment 2). These
results indicate that high antibody doses can be detrimental. This
possibility must be considered when interpreting passive protection
experiments.
A172-HK was protective in vivo, while A170-HK was not
(Table 1). This suggested that A172, along with the resistance to
the MSa phage, also acquired the capacity to express a new
molecule, that acts as a protective antigen. Also, the phage-
resistant strains (A172, A178, A180, A182) all display the
characteristic of secreting CP (Figure 3). CPs are heat stable and
can confer protection [45–46]. Taken together, these facts
provided sufficient ground to claim that the protective efficacy of
A172 could reside in its CP (CP-A172). The results confirmed that
CP-A172 provides mice with both active and passive resistance
against a lethal dose of A170 (Table 6). The main components of
CP-A172 are mannose and glucose (Figure 8). This feature
distinguishes CP-A172 from the poly-N-succinyl b-1-6 glucos-
amine vaccine described by McKenney [45] and the capsular
polysaccharide vaccine, that has acetylated fucosamine and
mannosamine as major components [46].
When compared with A170 infected mice, A172-HK vaccinat-
ed animals displayed an elevated transcription level of IL-6
(Figure 7). IL-6 is an anti-inflammatory cytokine controlling
the expression of pro-inflammatory cytokines (IFN-c, I1-b and
TNF-a) [36–38]. Staphylococcal infections cause a profound
release of proinflammatory cytokines, which enhance endothelial
cell permeability and extravasation of bacteria from blood to the
tissues [38]. In particular, elevated levels of IFN-c cause necrosis in
the kidneys of S. aureus-infected mice [37]. Thus, the A172 vaccine,
inducing a balanced pro- and anti-inflammatory response, tempers
the detrimental effects of an excessive inflammation.
It is not uncommon for clinical isolates to be resistant to
staphylococcal phages. This finding deserves a final comment.
Resistant bacteria, despite of their reduced fitness, sometimes
persist because they attenuate the impact of phages on sensitive
bacteria and thus contribute to maintain diversity within the
bacterial population [47].
In conclusion, given the multiple virulence factors expressed by
S. aureus, a whole cell bacterial vaccine would have significant
potential. However, the application of these vaccines (against S.
aureus and bacterial pathogens in general) is limited by the difficulty
of developing reliable procedures of bacterial attenuation [41].
Selection for phage resistance promises to serve this purpose well.
Of course, it must be recalled that the trade-off associated with
phage resistance can be paid by the pathogen in a form other than
lowered virulence. With these caveats, the evidence so far available
– [18] and this article - suggests that selection for phage resistance
as a means to curb bacterial virulence is not particular to the
phage MSa or the bacterial strain A172, but more general. Phage
resistance, long considered a problem in the fight against bacteria
[48], is shown here to be an opportunity.
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1. Introduction 
Myocarditis is an inflammatory disease of the cardiac muscle which might be related to viral 
(mainly parvovirus B19 and many others), protozoan (Borrellia burgdoferi, Trypanosoma cruzi, 
Toxoplasma gondi),  bacterial (Brucella, Corynebacterium diphtheriae, Gonococcus, Haemophilus 
influenzae, Actinomyces, Tropheryma whipplei, Vibrio cholerae, Borrelia burgdorferi, Leptospira, 
Rickettsia), fungal (Aspergillus) and other non viral pathogens (Rezkalla SH et al., 2010, 
Blauwet LA et al., 2010, Cihakova D et al., 2010) infections; It has been reported, however, 
that this kind of inflammation might be caused by an hypersensitivity response to drugs 
(Kühl U et al., 2009). The final effect in each case is represented by myocardial infiltration of 
immunocompetent cells following any kind of cardiac injury.  
Myocarditis presents with many symptoms, from chest pain that spontaneously resolves 
without treatment to cardiogenic shock and sudden death (Kühl U et al., 2010, Taylor CL et 
al 2010). The major long-term consequence is dilated cardiomyopathy with chronic heart 
failure(Lv H et al. 2011, Stensaeth KH et al 2011).  
Nowadays, diagnostic tools available for this disease are mainly related to general 
investigations (such as electrocardiography) and analysis of the most abundant serum 
proteins, whose alteration is related to cardiac pathology, even if it’s not specifically 
connected to myocarditis itself.  Here we propose preliminary speculations on the serum 
proteins profiling (both in the expression level and in the characterization of post 
translational modifications) and on free peptides identification in myocardytis affected 
patients (compared to healthy individual), that could be helpful in finding specific markers 
for this pathology.   
As many other inflammatory events this disease involves in fact different kinds of biological 
macromolecules, here we focus in particular on proteins. More than 50% of total protein 
content in a cell is post translationally modified. The pattern of Post Translational 
Modifications (PTMs) on proteins constitute a molecular code that dictates protein 
conformation, cellular location, macromolecular interactions and activities, depending on 
cell type, tissue and environmental conditions (Diernfellner AC et al., 2011, Savidge TC, 
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2011, Hao P et al.,2011). It is very well known that biological function of many proteins is 
strictly related to the presence of the appropriate set of PTMs. Most importantly, PTMs 
deregulation might be involved in the development of diseases , in fact, as a consequence of 
many pathologies, PTMs set might be altered (Dell A  et al., 2001, Kim YJ. Et al 1997, Dube 
DH. Et al., 2005, Granovsky M. Et al 2000). 
Proteomics investigations offer all useful tools to deeply investigate this kind of alterations. 
Two dimensional electrophoresis coupled with software mediated image analysis, affinity 
chromatographies and especially Mass Spectrometry (MS) present high levels of sensitivity, 
accuracy and reproducibility and these are all fundamental requirements that this kind of 
study needs.   
As previously described by our group (Carpentieri A, Giangrande C, et al., 2010), serum 
glycoproteome characterization might be crucial in clinical investigation.  In fact we showed 
that the N-glycan profiling of serum glycoproteins extracted from myocarditis affected 
donors compared to the ones of healthy people shows many peculiarities. We demonstrated 
that many of the extracted oligosaccharides are in fact incomplete or truncated structures 
whilst others show a high level of fucosylation, all these results fully matched previously 
published data about the glycosylation in proteins during chronic inflammation events (Dell 
A  et al., 2001, Kim YJ. Et al 1997, Dube DH. Et al., 2005, Granovsky M. Et al 2000, 
Carpentieri A, Giangrande C, et al., 2010).  
Thanks to the high sensitivity of the most modern analytical techniques, several research 
groups focus the research at level of peptides rather than at protein level (Taylor-
Papadimitriou J.  et al., 1994 Amado F et al., 2010, Menschaert G et al. 2010). In fact, these 
endogenous peptides are referred to as the peptidome. Initially, peptidomic analyses were 
conducted as a method to study neuropeptides and peptide hormones; these are signaling 
molecules that function in a variety of physiological processes (Ludwig M. 2011, Colgrave 
ML et al., 2011). Recent studies have found large numbers of cellular peptides with half-lives 
of several seconds, raising the possibility that they may be involved in biological functions 
(Gorman PM  et al 2003). 
Here we propose preliminary data to show molecular basis of myocarditis using a 
proteomic approach. The analyses were focused on the serum proteins profiling, namely the 
study of the expression level and the characterization of glycoproteins involved in the 
pathology.  A classical two-dimensional gel electrophoresis procedure to obtain protein 
maps and a “gel-free” comparison of the glycoproteomes in healthy and myocarditis human 
sera by using advanced mass spectrometry were reported. Free peptides identification in 
myocardytis affected patients (compared to healthy individual), was achieved in order to 
provide possible specific markers for this pathology.   
2. Materials and methods 
2.1 Materials 
Human serum samples from 8 healthy donors (all Caucasian 4 males and 4 females aged 
between 60 and 80 years, all other clinical informations were covered by laws on privacy) 
and from 5 myocarditis affected patients (all Caucasian 3 males and 2 females aged between 
60 and 85 years, all other clinical informations were covered by laws on privacy), 
respectively, have been obtained from the “Servizio Analisi” Policlinico, Napoli.  Aliquots of 
serum samples from different donors were pooled in order to obtain an average overview of 
glycoforms distribution. 
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Guanidine, dithiothreitol (DTT), trypsin, α-cyano-4-hydroxycinnamic acid were purchased 
from Sigma. Iodoacetamide (IAM), tris(hydroxymethyl)aminomethane, calcium chloride 
and ammonium bicarbonate (AMBIC) were purchased from Fluka as well as the MALDI 
matrix 2,5-, α-cyano-4-hydroxycinnamic. Methanol, trifluoroacetic acid (TFA) and 
acetonitrile (ACN) are HPLC grade type from Carlo Erba, whereas the other solvents are 
from Baker. Gel filtration columns PD-10 are from Pharmacia, the HPLC ones from 
Phenomenex, whereas the pre-packed columns Sep-pak C-18 are from Waters. 
Comassie Brilliant Blue was from Bio-Rad. PNGase F were purchased from Boheringer. Ion 
exchange resins Dowex H+ (50W-X8 50-100 mesh) was provided by BDH. Concanavalin A 
sepharose resin was purchased from Amersham Biosciences.  
2.2 Protein concentration determination 
Sera protein concentration was determined by Bradford assay method, using bovine serum 
albumin (BSA) as standard. Known amounts of BSA were diluted in 800 μL of H2O and 
then mixed to 200 μL of Comassie Brilliant Blue. 5 different BSA concentrations were 
determined by measuring absorbance at 595 nm and used to obtain a linear calibration 
curve. Three different sera dilutions were measured at 595 nm. Absorbance data were 
interpoled on the calibration curve, allowing the determination of protein concentration in 
the different samples.  
2.3 Serum depletion 
The depletion of the most abundant proteins from each serum sample was performed using 
Multiple Affinity Removal Spin Cartridges from Agilent. The procedure was performed at 
room temperature according to manufacturer’s instructions and then immediately frozen to 
-20°C. 
2.4 Free peptides analysis 
300 μL acetonitrile was added to 100 μL of serum, incubated at room temperature for 30 
minutes and then centrifuged at 13000 rpm. Supernatants were collected and concentrated 
by vacuum centrifugation (SAVANT) and resuspended in 20 μL formic acid 0.1%. Samples 
were desalted by C18  Zip Tip (Millipore) and diluted 100 times prior mass spectrometry 
analyses.  
LC/MS-MS HPLC-Chip/Q-TOF 6520 
Peptides were analyzed by a HPLC-Chip/Q-TOF 6520 (Agilent Technologies). The capillary 
column works at a flow of 4 μL/min, concentrating and washing the sample in a 40 nL 
enrichment column. The sample was then fractionated on a C18 reverse-phase capillary 
column (75 μm~43 mm in the Agilent Technologies chip) at flow rate of 400 nl/min, with a 
linear gradient of eluent B (0.2% formic acid in 95% acetonitrile) in A (0.2% formic acid in 
2% acetonitrile) from 7% to 60% in 50 min. 
Data were acquired through MassHunter software (Agilent Technologies). Proteins 
identification was achieved by using Mascot software (Matrix science), with a tolerance of 10 
ppm on peptide mass, 0.6 Da on MS/MS, and choosing methionine oxidation and glutamine 
conversion in pyro-glutamic acid as variable modifications. 
MALDI-TOF/TOF 
Peptides were also analyzed by MALDI-TOF/TOF using a 4800 Plus MALDI-TOF/TOF 
(Applied Biosystems). Samples were mixed on MALDI plate to the matrix consisting of a 
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solution of 10 mg/mL α-cyano-4-hydroxycinnamic, whose preparation consisted in the 
resuspension of α-cyano-4-hydroxycinnamic in water and acetonitrile 10:1 (v/v). The 
instrument was calibrated using a mixture of standard peptides (Applied Biosystems). 
Spectra were register even in reflector positive. MS/MS spectra were performed with CID 
using air as collision gas. Spectra were manually interpreted. 
2.5 2D-gel electrophoresis  
IEF (first dimension) was carried out on non-linear wide-range immobilized pH gradients 
(pH 4-7; 7 cm long IPG strips; GE Healthcare, Uppsala, Sweden) and achieved using the 
EttanTM IPGphorTM system (GE Healthcare, Uppsala, Sweden). Analytical-run IPG-strips 
were rehydrated with 125μg of total proteins in 125μl of rehydratation buffer (urea 8 M, 
CHAPS 2%, 0,5% (v/v) IPG Buffer, bromophenol blue 0,002%) for 12 h at 20°C. The strips 
were then focused according to the following electrical conditions at 20°C: 500 V for 30 min, 
from 1000 V for 30 min, 5000 V  until a total of 15000 Vt was reached. After focusing IPG 
strips were equilibrated for 15 min in 6 M urea, 30% (vol/vol) glycerol, 2% (wt/vol) SDS, 
0.05 M Tris-HCl, pH 6.8, 2% (wt/vol) DTT, and subsequently for 15 min in the same 
urea/SDS/Tris buffer solution but substituting the 2% (wt/vol) DTT with 2.5% (wt/vol) 
iodoacetamide. The second dimension was carried out on 12% polyacrylamide gels  at 25 
mA/gel constant current until the dye front reached the bottom of the gel. MS gel was 
stained with colloidal comassie. 
2.6 Image analysis 
Gels images were acquired with an Epson expression 1680 PRO scanner. Computer-aided 
2-D image analysis was carried out using the ImageMasterTM 2D Platinum software (GE 
Healthcare, Uppsala, Sweden).  Differentially expressed spots were selected for MS 
analysis. 
In order to find differentially expressed proteins, comassie stained gel image of serum 
proteins from healthy individual was matched with the one of myocarditis affected patient. 
The apparent isoelectric points and molecular masses of the proteins were calculated with 
ImageMaster 2D Platinum 6.0 using identified proteins with known parameters as 
references. 
Relative spot volumes (%V) (V=integration of OD over the spot area; %V = V single spot/V 
total spot) were used for quantitative analysis in order to decrease experimental errors. The 
normalized intensity of spots on three replicate 2-D gels was averaged and standard 
deviation was calculated for each condition. 
2.7 Protein identification by mass spectrometry 
In situ digestion 
Protein spots were excised from the gel and destained by repetitive washes with 0.1 M 
NH4HCO3 pH 7.5 and acetonitrile. Enzymatic digestion was carried out with trypsin (12.5 
ng/µl) in 10 mM ammonium bicarbonate buffer pH 7.8. Gel pieces were incubated at 4 °C 
for 2 h. Trypsin solution was then removed and a new aliquot of the same solution was 
added; samples were incubated for 18 h at 37 °C. A minimum reaction volume was used as 
to obtain the complete rehydratation of the gel. Peptides were then extracted by washing the 
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gel particles with 10mM ammonium bicarbonate and 1% formic acid in 50% acetonitrile at 
room temperature. 
Mass spectrometry and protein identification 
LC-MS/MS analyses were performed as previously described for free peptides. 
Mass spectrometric obtained data were used for protein identification using the software 
MASCOT that compare peptide masses obtained by MS and MS/MS data of each tryptic 
digestion with the theoretical peptide masses from all the proteins accessible in the 
databases (Peptide Mass Fingerprinting, PMF). Database searches were performed in NBCI 
databank (National Center for Biotechnology Information), restricting the analysis to the 
pertinent taxonomies. The parameters used for the identification were: tolerance of 10 ppm 
on peptide mass, 0.6 Da on MS/MS, and cysteine carbamidomethylation as fixed 
modification. Variable modifications were methionine oxidation, glutamine conversion in 
pyro-glutamic acid, and asparagine deamidation. 
2.8 Boronate affinity chromatography 
Glycoproteins were purified using PBA-bound agarose (Sigma-Aldrich, Munich, Germany). 
500 µl of sample previously diluted (1 : 1) with equilibration buffer (50 mM taurine/NaOH, 
pH 8.7, containing 3–10 mM MgCl 2 ) was incubated with 200 µl of pre-washed immobilized 
ligand resin for 1 h on ice and with gentle shaking. After transfer of the resin into 1,5 ml 
eppendhorf tubes, the non-binding fraction was collected by low speed centrifugation (10 s, 
500 × g). The resin was then thoroughly rinsed with equilibration buffer (six washes of 150 
µl each) and 1 N NaCl (three washes of 150 µl each). For final elution of the bound fraction, a 
total of six washes (150 µl each) with taurine buffer containing 50 mM sorbitol were used. 
Three successive fractions (150 µl each) were pooled before further analysis. 
2.9 Deglycosylation 
Glycopeptides were lyophilized, resuspended in 10 mM AMBIC and incubated with 
PNGase F (5 U), for 12-16 h at 37°C. Deglycosylation was carried out also on unbound 
peptides, in order to release the glycans not recognized by Boronate affinity 
chromatography. 
3. Results and discussion 
3.1 Free peptides analysis  
The analyses to investigate the “peptidomic” both in healthy and in pathological samples 
were accomplished by using a gel-free approach. The peptide component of the eluted 
fraction was analyzed by tandem mass spectrometry. The stringency of scoring parameters 
of the MASCOT algorithm minimized the number of false positive identifications. Most 
MS/MS spectra giving positive hits were derived from doubly and triply charged precursor 
ions that resulted predominantly in y-ion series. 
Triplicate LC-MS/MS analysis of supernatants after ACN precipitation of serum proteins, 
showed the occurrence of many free peptides in both analyzed sera. As reported in Table 1, 
the total number of detected and identified peptides was 41. Among these, 9 peptides were 
unique in the pathologic sample. It should be noted that some peptides were identified in 
both samples.   
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m/z RT Sequence Peptide Protein H/M ratio 
567.95 17.09 QAGAAGSRMNFRPGVLS (650-666) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
513.78 17.70 YYLQGAKIPKPEASFSPR (627-644) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
823.17 22.11 MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF (658-687) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
1005.98 22.78 QLGLPGPPDVPDHAAYHPF (669-687) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
0.68±0.18 
757.71 19.96 SRQLGLPGPPDVPDHAAYHPF (667-687) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
0.27±0.09 
681.85 22.07 PGVLSSRQLGLPGPPDVPDHAAYHPF (662-687) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
0.18±0.03 
576.90 20.69 PGVLSSRQLGLPGPPDVPDHAAYHPFR (662-688) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
379.71 0.55 LAEGGGVR (28-35) P02671 Fibrinogen alpha chain 25±3.11 
453.24 3.65 FLAEGGGVR (27-35) P02671 Fibrinogen alpha chain 2.48±0.57 
510.76 11.29 DFLAEGGGVR (26-35) P02671 Fibrinogen alpha chain 1.33±0.76 
539.27 11.70 GDFLAEGGGVR (25-35) P02671 Fibrinogen alpha chain 3.15±1.02 
597.77 15.59 SGEGDFLAEGGGV (22-34) P02671 Fibrinogen alpha chain 0.85±0.23 
603.79 12.57 EGDFLAEGGGVR (24-35) P02671 Fibrinogen alpha chain 2.42±0.63 
632.30 13.50 GEGDFLAEGGGVR (23-35) P02671 Fibrinogen alpha chain 2.72±0.71 
655.28 16.03 DSGEGDFLAEGGGV (21-34) P02671 Fibrinogen alpha chain 1.23±0.36 
675.81 13.67 SGEGDFLAEGGGVR (22-35) P02671 Fibrinogen alpha chain 2.32±0.58 
690.80 16.13 ADSGEGDFLAEGGGV (20-34) P02671 Fibrinogen alpha chain 3.25±0.82 
733.33 14.04 DSGEGDFLAEGGGVR (21-35) P02671 Fibrinogen alpha chain 1.59±0.12 
768.85 14.08 ADSGEGDFLAEGGGVR (20-35) P02671 Fibrinogen alpha chain 6.16±1.01 
851.71 13.58 SSSYSKQFTSSTSYNRGDSTFES (576-598) P02671 Fibrinogen alpha chain 0.65±0.17 
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m/z RT Sequence Peptide Protein H/M ratio 
693.06 13.06 SSSYSKQFTSSTSYNRGDSTFESKS (576-600) P02671 Fibrinogen alpha chain 
M: not 
detected 
733.83 14.48 SSSYSKQFTSSTSYNRGDSTFESKSY (576-601) P02671 Fibrinogen alpha chain 
M: not 
detected 
619.75 17.89 QGVNDNEEGFF (31-41) P02675 Fibrinogen beta chain 3.25±0.89 
663.26 16.54 QGVNDNEEGFFS (31-42) P02675 Fibrinogen beta chain 1.97±0.41 
696.28 17.64 QGVNDNEEGFFSA (31-43) P02675 Fibrinogen beta chain 2.31±0.53 
404.55 18.90 RIHWESASLL (1310-1319) P01024 Complement C3 
H: not 
detected 
402.22 14.29 THRIHWESASLLR (1308-1320) P01024 Complement C3 
H: not 
detected 
445.25 16.98 SKITHRIHWESASLL (1305-1319) P01024 Complement C3 
H: not 
detected 
415.20 7.60 HWESASL (1312-1318) P01024 Complement C3 
H: not 
detected 
471.74 16.21 HWESASLL (1312-1319) P01024 Complement C3 
H: not 
detected 
851.07 22.22 TLEIPGNSDPNMIPDGDFNSYVR (957-979) P0C0L4 Complement C4-A 
H: not 
detected 
1054.53 25.86 DDPDAPLQPVTPLQLFEGR (1429-1447) 
P0C0L4 Complement 
C4-A 
H: not 
detected 
489.96 20.26 RHPDYSVVLLLR (169-180) P02768 Serum Albumin 0.43±0.17 
417.91 16.67 KFQNALLVRY (426-435) P02768 Serum Albumin H: not detected 
547.31 16.25 KVPQVSTPTLVEVSR (438-452) P02768 Serum Albumin H: not detected 
868.11 21.57 AVPPNNSNAAEDDLPTVELQGVVPR (14-38) 
P00488 Coagulation 
factor XIII A 2.40±0.84 
920.14 21.09 RAVPPNNSNAAEDDLPTVELQGVVPR (13-38) 
P00488 Coagulation 
factor XIII A 23.60±3.61 
837.93 21.39 TAFGGRRAVPPNNSNAAEDDLPTVELQGVVPR (7-38) 
P00488 Coagulation 
factor XIII A 91.32±7.39 
781.37 17.84 TATSEYQTFFNPR (315-327) P00734 Prothrombin H: not detected 
868.46 25.47 TGIFTDQVLSVLKGEE (86-101) P02655Apolipoprotein C-II 
H: not 
detected 
572.95 12.91 DALSSVQESQVAQQAR (45-60) P02656Apolipoprotein C-III 
H: not 
detected 
803.76 21.14 AATVGSLAGQPLQERAQAWGERL (210-232) P02649Apolipoprotein E 0.02 
Table 1. List of free peptides identified by LC-MS/MS. Averaged area of chromatographic 
peaks from healthy(H) and myocarditis (M) ratio, indicates that some of them were 
differently represented. Peptide sequences were validated by MALDI-TOF/TOF analyses 
too. 
 
Myocarditis 
 
356 
As a whole, the LC-MS/MS proved to be a very sensitive and reproducible analysis which 
led to the identification of very weakly present peptides, these data were confirmed by 
another fragmentation technique, MALDI-TOF/TOF. As Fig. 1 shows, the fragmentation 
pattern of the peptide –ADSGEGDFLAEGGGVR- (from alpha fibrinogen protein) confirm 
what we found using LC-MS/MS analysis.  Some of these peptides are related to different 
proteolytic activities on proteins involved in acute phase or inflammatory events, such as 
myocarditis itself. Among identified peptides, the molecular species , namely, peptide 662-
668 from inter-alpha-trypsin inhibitor heavy chain H4 and peptide 1305-1319 from 
complement C3 correspond to free bioactive peptides, whose activity might be related again 
to inflammatory events (van den Broek I et al, 2010, ter Weeme M, et al, 2009).   Preliminary 
qualitative and quantitative differences were detected in the analysis of the peptidomas 
from healthy and pathological samples. In fact, as reported in the Table 1 , averaged area of 
each peak of all detected peptides resulted to be different, showing that some of them were 
differently represented in each sample. The above mentioned peptides from complement C3 
and inter-alpha trypsin inhibitor were poorly represented in the healthy serum samples, 
whereas fibrinogen alpha chain peptides were strongly represented in these sera, as well as 
coagulation factor XIII A peptides. 
 
 
Fig. 1. Positive ion mode MALDI-TOF/TOF fragmentation spectrum of m/z 1536.44 
corresponding to peptide 20-35 from fibrinogen alpha chain protein from healthy serum.  
3.2 The proteins profile from 2D-electrophoresis is different 
After depletion of the most abundant proteins, a two dimensional electrophoretic separation 
of the two sera samples was performed, thus leading to the construction of 2D protein maps 
of healthy and myocarditis samples.  Each gel was blue comassie stained.  Image analysis 
was performed on the two sets of 2D maps (from healthy control and pathologic sera) 
clearly showing that the protein profile is quite different, as reported in figure 2. The protein 
spots which resulted to be differentially expressed in the two samples were then submitted 
to mass spectral identification. Fig 2 shows all the spots we chose.  
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        (a)        (b) 
Fig. 2. Two-dimensional electrophoresis gels of healthy (A) and myocarditis affected (B) sera 
proteins. Arrows and numbers in (B) correspond to numbers of identified spots in Table 2. 
It should be underlined that all the spots we further analysed were taken from the 
pathologic serum and results are summarized in Table 2. 
 
Spot Accession number Protein
1 P02790 Hemopexin
2 P02790 Hemopexin
3 P02790 Hemopexin
4 P02790 Hemopexin
5 P02790 Hemopexin
6 P02787 Serotransferrin
7 P01008 Antithrombin III
8 P01008 Antithrombin III
9 P01011 Alpha-1 antichymotrypsin 
10 P01024 Complement C3
11 P04196 Histidine rich glycoprotein 
12 P01024 Complement C3
13 P00738 Haptoglobin
14 P04196 Histidine rich glycoprotein 
15 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 
16 P08603 Complement factor H
17 P08603 Complement factor H
18 P03952 Plasma kallikrein
19 P06727 Apolipoprotein A-IV
20 P00738 Haptoglobin
21 P00738 Haptoglobin
22 P36955 Pigment epithelium-derived factor 
23 P36955 Pigment epithelium-derived factor 
24 P36955 Pigment epithelium-derived factor 
Table 2. List of proteins identified by LC-MS/MS of spots excised from two-dimensional 
gels of sera taken from myocarditis affected patients. 
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Proteins excised from the gel were reduced alkylated and, in situ, digested with trypsin. The 
resulting peptide mixtures were directly analysed by LC-MS/MS according to the peptide 
mass fingerprinting procedure. MS and MS-MS obtained data were used to search for a non-
redundant sequence using the in-house MASCOT software, taking advantage of the 
specificity of trypsin and of the taxonomic category of the samples. The number of 
measured masses that matched within the given mass accuracy of 20 ppm was recorded and 
the proteins that had the highest number of peptide matches were examined.  
Thanks to this approach, we could identify many proteins differently expressed in the two 
sera. Among identified proteins, hemopexin (Dooley H et al., 2010) , complement C3 
(Adamsson Eryd S et al., 2011, Onat A et al., 2011), plasma kallikrein (Kolte D et al.,2011) are 
undoubtedly related to inflammatory events and most interestingly they resulted clearly 
over expressed in the pathologic sample.  
A preliminary speculation on identified proteins might involve the function of hempopexin. 
As shown by literature data (Dooley H et al., 2010, : Mauk MR et al., 2011, Larsen R et 
al.,2010), hemopexin is a serum protein with the very well known function of scavenging the 
heme released or lost by the turnover of heme proteins such as haemoglobin or by 
haemolysis caused by parasitic infection, and thus protects the body from the oxidative 
damage that free heme can cause (Larsen R et al.,2010).  Myocarditis itself it’s not related to 
haemolysis phenomena, but some viral infections may cause it, therefore, finding a very 
high level of hempoxin in a myocarditis affected patient might be a putative marker of the 
inflammation itself (quite common are in fact viral myocarditis). 
Moreover we found some connections between differently expressed proteins in pathologic 
serum and identified free peptides; in particular we could detect some free peptides some 
peptides from proteins Complement C3, Inter-alpha-trypsin inhibitor heavy chain H4, 
Antithrombin III which results over expressed in pathologic serum, (see Tab 1). 
3.3 Boronate affinity chromatography 
The third part of this work focus on the investigation of one of the most important post-
translational modification, the glycosylation. The importance of investigation of post-
translational modifications (PTM) is notably increased in the proteomic era, as they play a 
critical role in cellular functioning and they vary in response to environmental stimuli, 
signalling modulators or development of diseases (Laurell E et al., 2011). PTMs can affect 
biological functions thus playing a critical role in cellular functioning. Moreover, they can 
vary in response to environmental stimuli, thus finely tuning cellular mechanisms and their 
deregulation might be involved in the development of diseases. A huge number of different 
types of PTMs have been identified but only a few are reversible and important for 
regulation of biological processes (Wu C et al. 2011). The pattern of PTMs on proteins 
constitute a molecular code that dictates protein conformation, cellular location, 
macromolecular interactions and activities, depending on cell type, tissue and 
environmental conditions. Understanding this code is the major challenge of proteomics in 
post-genomic era. Existing methodologies for PTMs identification essentially rely on specific 
enrichment procedures able to selectively increase the amount of modified peptides. These 
procedures have to be integrated with sophisticated mass spectrometric experiments to 
address the identifications of PTMs. The development of a variety of new technologies for 
exploring the structures of the sugar chains has opened up a new frontier in the glycomics 
field. Moreover recent progress in mass spectrometry led to new challenges in glycomics, 
including the development of rapid glycan enrichment. Recently our group introduced an 
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easy to handle strategy to give preliminary insights for the comparison of glycoproteomes in 
healthy and pathological human sera, by using a single Con A affinity chromatography step 
coupled with mass spectrometry techniques. The strategy led both to the identification of 69 
different glycosylation sites within 49 different proteins and to the definition of the 
glycosylation patterns. Moreover, glycoform distribution in myocarditis and hepatic 
carcinoma has been reported. The analysis of glycan profiling, once extracted from serum 
glycopeptides, is essential for comparative studies on different sera samples thus providing 
a useful tool for the development of screening procedures (Carpentieri A, Giangrande C, et 
al., 2010). 
In this paper, a different simple and rapid procedure to obtain an overview of the 
glycosylation sites profiling in the two samples was accomplished. This was achieved by 
enriching for the N-linked glycopeptides resulting from trypsin digestion of sera samples in 
order to enhance the identification of N-glycosylation sites using LC-MS/MS. The analyses 
have been carried out by using healthy sera as control.  
To reduce the complexity of the whole sample, Boronate affinity purification was rapidly 
performed in batch after tryptic digestion. Thanks to the vicinal diols binding capacity no 
discrimination on the basis of the glycan type was performed thus, in a proof of principle, 
all glycopeptides could be selected. The recovered glycopeptides were then deglycosylated 
by PNGase F treatment and the peptide mixtures directly analysed by LC-MS/MS. 
The analyses were performed on intact serum samples without any pre-purification step or 
removal of most abundant proteins. The peptide component of the eluted fraction was 
analysed by tandem mass spectrometry. Similar analyses were carried out on the unbound 
Boronate fractions, mainly containing non-glycosylated peptides.  
The data were then pooled and summarised in Table 3. The results presented here 
demonstrated that Boronate affinity chromatography on serum tryptic digests is a useful 
tool to enhance the detection by LC-MS/MS of glycopeptide. Another advantage of the 
strategy relies on the fact that it was performed on glycopeptides instead of glycoproteins, 
therefore there were no SDS-PAGE step, no isolation of the individual glycoproteins and no 
in situ digestion. This allowed the detection of less abundant glycopeptides together with 
the most represented ones, such as those deriving from albumins or immunoglobulins. 
As shown in Table 3, all the selected peptides still contained the conserved N-glycosylation 
motif (Asn-X-Ser/Thr), thus indicating that N-glycosylation peptides were isolated with 
high selectivity. This analysis led both to the localization of the modification sites and 
identification of glycoproteins. 
The presence of a putative N-glycosylation site was confirmed by the fact that peptides mass 
was increase of 1 Da, due to the conversion of Asn into Asp after PNGase F incubation. 
However, some non-specific peptides, namely non-glycosylated peptides, were detected in 
the eluted Boronate fraction, and identified as belonging to most abundant proteins like 
albumin. 
Spontaneous deamidation seems rather unlikely for generating the results presented, 
although it cannot be excluded completely. Most MS/MS spectra giving positive hits were 
derived from doubly charged precursor ions that resulted predominantly in y-ion series.  
As a whole, using Boronate affinity approach we could confirm the previously identified 
glycosylation sites based on ConcanavalinA enrichment and 5 more glycosylation sites were 
identified thus refining previous data (Carpentieri A, Giangrande C, et al., 2010) on 
myocarditis glycoproteome.  
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 Protein Sequence Peptide 
P01011 Alpha-1-antichymotrypsin YTGN*ASALFILPDQDKH,M 268-283 
P02763 Alpha-1-acid glycoprotein 
SVQEIQATFFYFTPN*KTEDTIFLRH,M 
QDQCIYN*TTYLNVQRH,M 
58-81 
87-101 
P01009 Alpha-1-antitrypsin 
YLGN*ATAIFFLPDEGKH,M 
QLAHQSN*STNIFFSPVSIATAFAMLSL
GTKH 
ADTHDEILEGLNFN*LTEIPEAQIHEGF
QELLRH,M 
268-283 
64-93 
94-125 
P01023 Alpha-2-macroglobulin 
SLGNVN*FTVSAEALESQELCGTEVPS
VPEHGRKH 864-886 
P43652 Afamin DIENFN*STQKH,M YAEDKFN*ETTEKH 
28-37 
396-407 
P01008 Antithrombin III LGACN*DTLQQLMEVFKH,M SLTFN*ETYQDISELVYGAKH,M 
124-139 
183-201 
P04114 Apolipoprotein B-100 
FN*SSYLQGTNQITGRH,M 
FVEGSHN*STVSLTTKH 
AEEEMLEN*VSLVCPKM 
YDFN*SSMLYSTAKM 
1522-1536 
3405-3419 
27-41 
3462-3474 
P05090 Apolipoprotein D ADGTVNQIEGEATPVN*LTEPAKM 83-104 
P02749 Apolipoprotein H VYKPSAGN*NSLYRH LGN*WSAMPSCKM 
155-167 
251-261 
O75882 Attractin 
IDSTGN*VTNELRH,M 
GPVKMPSQAPTGNFYPQPLLN*SSMC
LEDSRH 
411-422 
1023-1052 
P00450 Ceruloplasmin EHEGAIYPDN*TTDFQRH,M EN*LTAPGSDSAVFFEQGTTRH,M 
129-144 
396-414 
P08603 Complement factor H 
ISEEN*ETTCYMGKH 
MDGASN*VTCINSRH,M 
IPCSQPPQIEHGTIN*SSRM 
SPDVIN*GSPISQKH 
907-919 
1024-1036 
868-885 
212-224 
P10909 Clusterin LAN*LTQGEDQYYLRH,M 372-385 
Q8IWV2 Contactin-4 LN*GTDVDTGMDFRM 64-76 
P05156 Complement factor 1 FLNN*GTCTAEGKH,M 100-111 
P01024 Complement C3 TVLTPATNHMGN*VTFTIPANRH 74-94 
P0C0L4 Complement C4-A GLN*VTLSSTGRH,M 1326-1336 
P02748 Complement component C9 AVN*ITSENLIDDVVSLIRH,M 413-430 
Q14517 Protocadherin-fat 1 QVYN*LTVRAKDKM FSMDYKTGALTVQN*TTQLRSRM 
994-1005 
1930-1950 
P02765 Alpha-2-HS-glycoprotein 
VCQDCPLLAPLN*DTRH,M 
AALAAFNAQNN*GSNFQLEEISRH 
145-159 
166-187 
Q03591 Complement factor H related protein 1 LQNNENN*ISCVERH 120-132 
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 Protein Sequence Peptide 
Q13439 Golgin subfamily A member 4 HN*STLKQLMREFNTQLAQKH 1990-2008 
P02790 Hemopexin SWPAVGN*CSSALRH,M ALPQPQN*VTSLLGCTHH,M 
181-193 
447-462 
P00738 Haptoglobin 
VVLHPN*YSQVDIGLIKH,M 
MVSHHN*LTTGATLINEQWLLTTAKH
,M 
NLFLN*HSEN*ATAKH,M 
236-251 
179-202 
203-215 
P04196 Histidine rich glycoprotein 
VEN*TTVYYLVLDVQESDCSVLSRH 
VIDFN*CTTSSVSSALANTKH,M 
61-83 
121-139 
P05155 Plasma protease C1 inhibitor VGQLQLSHN*LSLVILVPQNLKH,M 344-364 
P01857 Ig alpha-1 chain C region 
LSLHRPALEDLLLGSEAN*LTCTLTGL
RH 127-153 
P01859 Ig gamma-2 chain C region 
TKPREEQFN*STFRH 
TPLTAN*ITKH 
168-180 
200-208 
P01860 Ig gamma-1 chain C region EEQYN*STYRH,M 136-144 
P01591 Immunoglobulin J chain EN*ISDPTSPLRH,M 48-58 
P40189 Interleukin-6 receptor beta QQYFKQN*CSQHESSPDISHFERM 812-833 
P56199 Integrin alpha-1 SYFSSLN*LTIRM 1096-1106 
P29622 Kallistatin DFYVDEN*TTVRH 232-242 
P01042 Kininogen-1 LNAENN*ATFYFKH,M 389-400 
P11279 
Lysosome-associated 
membrane 
glycoprotein 1 
DPAFKAAN*GSLRM 314-325 
P01871 Ig mu chain C region YKN*NSDISSTRH GLTFQQN*ASSMCVPDQDTAIRM 
44-54 
204-223 
Q9HC10 Otoferlin NEMLEIQVFN*YSKVFSNKH,M 59-76 
Q5VU65 
Nuclear pore 
membrane 
glycoprotein 210-like 
EVVVN*ASSRH 1551-1559 
Q9Y5E7 Protocadherin beta 2 ETRSEYN*ITITVTDFGTPRM 414-432 
P36955 Pigment epithelium derived factor VTQN*LTLIEESLTSEFIHDIDRH 282-303 
P27169 
Serum 
paraoxanase/arylester
ase1 
HAN*WTLTPLKH 250-259 
P49908 Selenoprotein P EGYSN*ISYIVVNHQGISSRH 79-97 
Q9Y275 
Tumor necrosis factor 
ligand superfamily 
member 13B 
CIQNMPETLPN*NSCYSAGIAKM 232-252 
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 Protein Sequence Peptide 
P40225 Thrombopoietin IHELLN*GTRGLFPGPSRRM 250-267 
P02787 Serotransferrin 
QQQHLFGSN*VTDCSGNFCLFRH,M 
CGLVPVLAENYN*KSDNCEDTPEAGY
FAVAVVKM 
622-642 
421-452 
P07996 Thrombospondin 1 VVN*STTGPGEHLRH,M 1065-1077 
P04004 Vitronectin NN*ATVHEQVGGPSLTSDLQAQSKM 85-107 
P25311 Zinc-alpha-2-glycoprotein DIVEYYN*DSN*GSHVLQGRH,M 100-117 
P02766 Transthyretin ALGISPFHEHAEVVFTAN*DSGPRH 101-123 
Table 3. LC/MSMS analysis for the identification of glycosylation sites, H indicates peptides 
deriving from healthy serum and M indicates the ones from myocarditis serum. 
4. Conclusions 
In biomedical applications, a comparative approach is usually employed to identify proteins 
that are up and down regulated in a disease specific manner for use as diagnostic markers 
or therapeutic targets. This report represents an overview of the investigation at molecular 
level of myocarditis by using a proteomic approach .  
Serum proteins (including the N-glycosylation sites profiling) and glycoproteins and free 
peptides occurring in human sera from healthy donors were compared to the ones from 
myocarditis patients. This procedure, allowed the identification of several N-glycosylation 
sites by a single-step proteomic approach, contemporarily probing an entire complex 
sample by LC-MS/MS. Thanks to the depletion of the serum most abundant proteins, we 
could detect some of the very weakly represented free peptides, whose presence is 
connected to the pathology itself.   The high resolution, the sensitivity and the 
reproducibility of the used techniques led to the identification of some up regulated proteins 
in the serum from a myocarditis affected patient, all these proteins are connected to 
inflammatory events and one in particular (hemopexin) opens the way to new speculations 
in serum proteins as a specific marker for pathologic state. 
 Finally, this proteomic approach represents a new opportunity for therapeutics and early 
diagnostics, for the screening of proteic biomarkers in pathological status. Finding a 
biomarker molecule that precisely indicates certain kind of pathology, is something quite 
difficult to achieve since it requires a huge background in many different fields of clinical 
investigation.  Here we contribute with putative diagnostic species that could really be 
helpful for an early diagnosis myocarditis event. 
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ABSTRACT. This work aims at the development and set up of a new methodological platform based on 
the integration of affinity chromatography, a novel derivatization procedure and multistage mass 
spectrometry (MSn) for the glycan characterization. In order to improve ionization an aromatic moiety 
and a charged basic group are introduced by dansyl derivatization of carbohydrate by using 
dansylhydrazine. This procedure has been set up firstly on synthetic oligosaccharides, revealing that 
dansyl derivatization improves fragmentation properties both in MALDI-TOF/TOF and in ESI-MS/MS 
experiments. This derivatisation method  has been successfully applied to the glycan population from a 
complex matrix made of oligosaccharides extracted by white and yolk egg glycoproteins. A sub-
glycoproteome characterisation was achieved by analysing glycopeptide component integrating ConA 
affinity purification and LC-MS/MS protein identification. 
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INTRODUCTION. Post-translational modifications (PTMs) play a critical role in cellular functioning 
and they vary in response to environmental stimuli, signalling modulators or development of diseases. 
Thus PTMs can affect biological functions finely tuning cellular mechanisms. Among PTMs, 
glycosylation is a co- and post-translational modification through which oligosaccharide chains are 
covalently attached to proteins. Glycoproteins are ubiquitous proteins characterized by the presence of 
oligosaccharide moieties. They are synthetised by any living organisms, from eubacteria to 
eukaryotes(1) and as complex mixtures of glycosylated variants (glycoforms). The micro-heterogeneity 
is due to the incomplete nature of glycosylation and deglycosylation reactions (2) and depends on cell 
type and physiological status. Anomalous pattern of glycosylation may be caused by several patho-
physiological conditions or even by developmental events (3). Nowadays mass spectrometry is 
answering to most of the challenges connected to the study of glycans: the problem of glycans 
heterogeneity has been overcome by mass spectrometry methodologies, which allow to achieve 
qualitative and semi-quantitative information on oligosaccharides structures present in the mixture, with 
high sensitivity (21 and referecnces therein). 
Analysis of glycoproteome can be performed by treating the entire protein extract with endoglycosidases 
so that oligosaccharides and peptides can be analysed separately. Experimental procedures are needed to 
explore glycan sequences and their function. Such procedures are difficult due to the fact that glycan 
synthesis is not a template-driven and thus no mechanism amplifying glycan structures is available. 
Moreover carbohydrates detection is not an easy task  since no chromophores are available so far. In 
order to facilitate their detection, chromophores are generally introduced at the reducing end of 
oligosaccharides. Hydrazine derivatives are generally used to derivatize carbohydrates and their reaction 
leads up to hydrazone derivatives that, if needed, can be reduced to open ring structures (4). Derivatized 
sugars can be analysed by mass spectrometry techniques in order to produce structural information. Both 
ESI-MS and MALDI-MS are generally used for oligosaccharides analysis. Derivatization strongly 
affects ionization efficiency by introducing additional charges and giving sugars a more hydrophobic 
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character. Moreover, labels influence glycans fragmentation behaviour and help the assignment of 
fragmentation spectra by tagging the reducing end (5). 
Our group has already reported a new approach involving dansyl derivatives to selectively label specific 
PTMs (6, 7, 8, 9, 10, 11, 12). The dansyl-derivatization introduces an hydrophobic and aromatic moiety 
and basic secondary nitrogen into the molecule thus enhancing ionization efficiency. Furthermore the 
dansyl moiety shows a distinctive fragmentation pattern with product ions at m/z 170 and 234 in MS2 
and the diagnostic m/z  234→170 fragmentation inthe MS3 mode (12). Recently we demonstrated that 
peptide dansylation resulted to be a rapid and convenient method to improve the performances in 
MALDI-MS/MS analysis at proteomic scale (13). 
Here, we suggest a new derivatisation protocol of glycans reducing ends by dansylhydrazide. Once set 
up, the procedure was successfully applied to the characterisation of oligosaccharides from a complex 
matrix such as egg yolk and white. 
EXPERIMENTAL SECTION. Protein extraction from egg white and yolk. Eggs were purchased at 
the local market. White and yolk were separately diluted in 10 mL of MilliQ water and centrifuged at 
13000 rpm for 30 min, in order to separate the soluble fraction from the other components. This fraction 
was then subjected to ammonium sulphate precipitation. 76 g of ammonium sulphate (Sigma Aldrich) 
were added to 1 L of solution. After 12-16 h at 4°C the solution was centrifuged for 30 min at 13000 
rpm in order to induce proteins precipitation. The excess of salts was removed using Centricon 
(Millipore). 
Protein concentration determination. Egg protein concentration was determined by Bradford assay 
method, using BSA as standard. Known amounts of BSA were diluted in 800 μL of H2O and then 
mixed to 200 μL of Comassie Brilliant Blue. 5 different BSA concentrations were determined by 
measuring absorbance at 595 nm. Determined absorbance data were interpoled on the calibration curve, 
allowing the determination of protein concentration in the different samples. 
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Reduction and alkylation. Samples were dissolved in 200 μL of denaturation buffer (guanidine 6 M, 
TRIS 0.3 M, EDTA 10 mM, pH 8). Reduction was carried out by using a 10:1 DTT : cysteins molar 
ratio. DTT was purchased from Fluka. After incubation at 37°C for 2 h, iodoacetamide (Fluka) was 
added to perform carboxyamidomethylation using an excess of alkylating agent of 5:1 with respect to 
the moles of thiolic groups. The mixture was then incubated in the dark at room temperature for 30 min. 
The alkylation reaction was stopped by addition of formic acid, in order to achieve an acidic pH. The 
excess of salts and reagents was then removed by gel filtration on PD-10 columns (GE Healthcare). 
Elution was performed using ammonium bicarbonate (Fluka) 10 mM buffer. The collected fractions 
were analyzed by a spectrophotometer Beckman DU 7500, measuring the absorbance at 220 and 280 
nm. Protein containing fractions were collected and concentrated in a centrifuge Speed-Vac. 
Trypsin digestion. Digestion was carried out in AMBIC 10 mM buffer using trypsin (Sigma Aldrich) at 
a 50:1 trypsin : protein mass ratio (w/w). The sample was incubated at 37°C for 12-16 h. 
Concanavalin A affinity chromatography. The peptide mixtures were incubated for 2 h with 500 μL 
of ConA Sepharose resin (Amersham Biosciences), which had been activated and washed in a 20mM 
Tris-HCl buffer; 0,5M NaCl; 1mM CaCl2at 4°C and pH 7.4. After 2 h the ConA containing Eppendorf 
was centrifuged at 3000 rpm at 4°C. The unbound peptides were removed in the supernatant. The resin 
was then washed six times with the same buffer described before. The elution phase was based on 
methyl-α-D-mannopyranoside (Sigma Aldrich) 0,25 M competition with glycopeptides and was 
performed for 30 min at 4°C. This procedure was repeated twice in order to be sure of having eluted all 
the glycopeptides bound to ConA. 
RP-HPLC. Both the peptides and the glycopeptides needed a desalting step in order to remove salts and  
methyl-α-D-mannopyranoside.  
Both the unbound and eluted peptides were desalted by HPLC on a C-18 resin. HPLC was performed on 
an Agilent chromatograph, at a flow rate of 0,2 ml/min and a linear gradient from 5% B (95% 
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acetonitrile, 5% H2O e 0,07% trifluoroacetic acid) to 95% B in 1 min, allowing the fast elution of the 
unfractionated peptides. 
Deglycosylation. Egg glycopeptides were treated with PNGase F in 50 mM ammonium bicarbonate. 
Reactions were performed for 12-16 h at 37°C. Deglycosylation was carried out also on unbound 
peptides, in order to release the glycans that had not been recognized by ConA. 
Oligosaccharide purification. For glycan purification, the sample was loaded on a C-18 silica based 
bonded phase (Sep-pak, Waters). The column was activated with 10 mL methanol and equilibrated with 
10 mL isopropanol, 10 mL H2O and 10 mL acetic acid 5%. The oligosaccharide component was eluted 
in 3 mL of 5% acetic acid as eluent whereas peptides were collected in 3 mL of 40% isopropanol and 
5% acetic acid.  Alternatively an RP-HPLC step was performed by using a C-18 column and a gradient 
profile as follows: 7 min at 5% B, 5 to 95% B in 2 min and 10 min at 95% B. 
LC-MS/MS. Peptides were analyzed by a HPLC-Chip/Q-TOF 6520 (Agilent Technologies). The 
capillary column works at a flow of 4 μL/min, concentrating and washing the sample in a 40 nL 
enrichment column. The sample was then fractionated on a C18 reverse-phase capillary column (75 
μm~43 mm in the Agilent Technologies chip) at flow rate of 300 nl/min, with a linear gradient of eluent 
B (0.2% formic acid in 95% acetonitrile) in A (0.2% formic acid in 2% acetonitrile) from 7% to 60% in 
50 min. Data were acquired through MassHunter software (Agilent Technologies). Proteins 
identification was achieved by using Mascot software (Matrixscience), with a tolerance of 10 ppm on 
peptide mass, 0.6 Da on MS/MS, and choosing cysteine carbamidomethylation as fixed modification. 
Variable modifications were methionine oxidation, glutamine conversion in pyro-glutamic acid, and 
asparagine deamidation. 
Oligosaccharides derivatization. Glycans were subjected to chemical derivatization with dansyl-
hydrazine. Liophylized sugars were dissolved in 3-6 μL of water, to which a solution containing 200 
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mM dansyl-hydrazine in 90% acetonitrile (Romil) and 10% TFA (Carlo Erba) was added. The reaction 
was carried out in the dark at 37°C for 3 h.  
MALDI-TOF/TOF analysis of glycans. Oligosaccharides were analysed on a 4800 Plus MALDI-
TOF/TOF (Applied Biosystems). Samples were mixed on MALDI plate to the matrix consisting of a 
solution of 20 mg/mL DHB (Fluka), whose preparation consisted in the resuspension of DHB in water 
and acetonitrile 10:1 (v/v). The instrument was calibrated using a mixture of standard peptides (Applied 
Biosystems). Spectra were register even in reflector positive or negative mode. MS/MS spectra were 
performed with CID using air as collision gas. Spectra were manually interpreted and checked against 
GlycoWorkbench software (14).  
Q-TRAP analysis of glycans. Supplementary MS experiments were performed on a 4000 Q-Trap 
system (Applied Biosystems). A micro-ionspray source was used at 2 kV with liquid coupling, with a 
declustering potential of 50 V, using an uncoated silica tip (o.d. 150 ím, i.d. 20 ím, tip diameter 10 ím) 
from New Objectives. In product ion scanning the scan speed was set to 4000 Da/s, the resolution of Q1 
was set to “low” and the best collision energy was calculated as 35.  
RESULTS AND DISCUSSION. In this study we provided a new methodology for the full 
characterization of glycome in a complex sample probed by a proteomics approach. As a valid step for 
enrichment, selecting specific glycoforms and simplifying the initial peptidic mixture, concanavalin A 
affinity chromatography was applied to complex matrix from egg fractions.  
Concanavalin A affinity chromatography on egg proteins. White and yolk fractions were separated 
and proteins were precipitated in ammonium sulphate as described. SDS-PAGE was carried out on 50 
µg of proteins deriving from both the white and the yolk to verify the correctness of separation 
procedure. Aliquots of the two samples were reduced, carbamidomethylated and trypsin digested. 
Concanavalin A affinity chromatography was performed on both the digested fractions (15).  
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Characterization and derivatization of oligosaccharides. Oligosaccharides characterization is 
arousing a particular interest even being a challenging analytical problem. Glycan molecules present 
extremely various structures as concerning the type of monosaccharides they are built of, the branching, 
the anomericity of the glycosydic linkage and the global structure that the carbohydrate moieties confer 
to protein. Nowadays mass spectrometry methodologies resolve most of the challenges connected to the 
study of glycans such as the glycoforms heterogeneity achieving qualitative and quantitative information 
on oligosaccharides structures present in the analyte, with enormous sensitivity (21). MALDI-TOF mass 
spectrometry technique was able to detect any difference between the analytes in terms of speed and 
sensitivity in the analyses. 
Oligosaccharides characterization by MALDI-MS was achievable on the basis of the m/z value together 
with the knowledge of oligosaccharides biosynthesis. Hypothetical structures were then confirmed 
through tandem mass spectrometry. MS/MS spectra were interpreted using the software 
Glycoworkbench (14), which simulates glycans fragmentation and compares the theoretical fragments 
with the experimental ones. 
MALDI-TOF spectra of oligosaccharides, released from protein bachbone as described, were recorded 
in reflector mode. Peaks were manually attributed and then confirmed by MALDI-MS/MS. 
The bound or the unbound ConA fractions both from yolk and white were treated with PNGase F. 
Oligosaccharides were purified from peptides by RP-HPLC and analysed by MALDI-MS in reflectron 
positive and negative mode. In positive ion mode oligosaccharides usually ionize as MNa+ but 
sometimes we noticed the presence of sodium adducts, especially when the structure contains sialic acid 
residues. It is quite useful to register negative spectra in order to detect oligosaccharides bearing sialic 
acid residues due to ionize as MH- of sugars. Fig. 1  shows the mass spectra in positive ion mode of the 
ConA bound and unbound fraction from egg white.  The attribution of each peak is reported in Table 1. 
The glycans detected belonged to the complex type as confirmed by MS/MS data. However, it should be 
noted that some peak could be attributed to more than one structure. The MS/MS analysis let us to 
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confirm the presence of isobaric structures or to discriminate between the different structure only for the 
most abundant species. As an example, the peak occurring at m/z 1542,5 was identified as a biantennary 
glycan carrying a GlcNAc bisecting rather then as a triantennary complex structure.  The heterogeneity 
in the peak attribution still remained for the less abundant ones.  The main differences between the 
fractions consisted in the higher branching of unbound oligosaccharides. 
Fig. 2 displays the positive ion mode mass spectra of ConA bound and unbound fractions of yolk. In 
both fraction the presence of sialylated structures, which were not detected in the white sample can be 
observed. These structures were identified in positive ion mode due to the presence of a negative charge 
for each sialic acid, which was neutralized by a sodium ion. For this reason we performed the analyses 
in negative ion mode in order to confirm the presence of sialic acid residues. A high heterogeneity was 
found in the MALDI spectra of the glycan moieties essentially belonging to the complex type. 
Moreover, differences between egg white and yolk could be appreciated and were essentially ascribed to 
the total absence of sialic acid in the oligosaccharides from white egg fraction.  
In order to improve MS/MS glycan fragmentation a novel derivatisation method was proposed. Despite 
the fact that the MALDI ionization mechanism is not yet completely understood, it is widely 
acknowledged that the ionization efficiency depends on the chemical physical properties of the analyte. 
In particular, the presence of basic and/or hydrophobic groups (16) enhances the yields of the ionization 
process. Dansyl chloride (DNS-Cl) is a fluorescent reagent which has extensively used in biochemistry 
during the eighties (17) and used by our group to selectively label specific post-translational 
modification in a selective proteomics approach (11, 12, 18). 
In a recent paper we demonstrated that dansylation labeling improves the MALDI ionization and 
fragmentation of peptides (13); moreover this derivatisation was applied to fragmentation of 
glycosylated peptides whose analysis is often problematic (19). On the basis of the experience recently 
made with dansyl chloride and other dansyl derivatives, we used a commercially available dansylated 
reagent, namely dansyl-hydrazine, to selectively label free oligosaccharides. 
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Our experimental procedure was set up on a synthetic oligosaccharide, maltoheptaose, by using dansyl-
hydrazine as label. The reaction was carried out as described in the experimental section. The unlabeled 
sample was 2-fold more concentrated in comparison with dansylated samples, because of the dilution in 
the reagent solution. To monitor the effects of glycan dansylation, we diluted the unlabeled sample with 
a volume of ACN and we used it as control for the further experiments. The analyses were carried out by 
MALDI-TOF mass spectrometry where the labelled oligosaccharides showed an increment of 247.3 Da 
compared to the unmodified signal. Tandem mass spectrometry was performed on both the labelled and 
unlabelled oligosaccharide. Signals were assigned according to the nomenclature proposed by Domon 
and Costello (20). 
Fig.3 shows the MS/MS spectra of maltoheptaose registered on a MALDI-TOF/TOF mass spectrometer 
where the DNS-sugar undergoes a loss of 234 Da, corresponding to the dansyl unit. We noticed the 
presence of Y and B ions, as well as cross-ring cleavages. As shown in the figure, the intensity strongly 
increased for the labelled specie. The difference in ionization efficiency could be appreciated in  the 
difference in quality of the MS/MS data between dansylated and native oligosaccharides because the 
fragmentation profiles are modified. The fragmentation pattern of dansylated oligosaccharide exhibited 
enhanced B-ion and C-ion series in MS/MS experiments (Fig. 3B) compared to the native ones (Fig. 
3A). This improvement in fragmentation could be attributed to the presence of the dansyl fluorescent 
moiety at the reducing end. This behavior was in agreement with previous data where dansyl moiety was 
added at the N-terminus of different peptides (13). 
The same analysis was performed by using an hybrid Q-Trap instruments and the results are reported in 
Fig.4. As shown, the ESI/MS/MS spectrum of the DNS- oligosaccharide reveals a better fragmentation, 
when compared to the unmodified one. Even in this case both Y and B ions were present, but cross-ring 
cleavages were less frequent than for MALDI-MS. 
Once set up, the dansyl labelling procedure was applied to the characterisation of glycans in a real 
sample, namely the oligosaccharides released from egg glycoproteins. The N-glycans enzymatically 
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released from glycoproteins were derivatised and subjected to MS/MS analysis in order to assign the 
correct structure. As an example, Fig 5 showed the MALDI-MS/MS spectrum of the precursor ion at 
m/z 1419.39, compared to the dansyl-labelled form.  
The oligosaccharide was identified as a high mannose structure on the basis of the interpretation of the 
fragmentation spectrum. Similar analyses were carried out on the other glycans thus confirming previous 
results. As a whole the data obtained by MALDI-MS/MS analyses of glycans are summarised in Table 
2. It should be worth noting that DNS-derivatives are characterized by higher ionization efficiency than 
the unlabelled ones, producing better spectra with a higher S/N ratio with respect to the unmodified ones 
(Fig. 5B). Thus, the derivatization protocol by dansyl-hydrazine was effective in the improvement of 
ionization efficiency, introducing a strong basic group. This labelling strategy not only increased peaks 
resolution in MS/MS spectra, but also introduced the possibility for further analysis of sugars by 
exploiting the potential of precursor ion scan analysis (manuscript in preparation) as already performed 
for the selective identification of other PTMs (12). 
Protein identification. Identification of proteins and the direct localization of N-glycosylation sites was 
achieved by LC-MS/MS analysis. In ConA bound fractions proteins identification was obtained 
exclusively by taking in account the peptides containing the N-glycosylation consensus sequence. As 
described before (15), in order to identify not glycosylated peptides and glycopeptides bearing a 
different glycosylation pattern (not recognized by concanavalin A) an LC-MS/MS experiment was 
performed on the unbound fraction. 
Proteins identification was carried out by using a bioinformatics tool, namely Mascot MS/MS ion search 
program through the NCBI database, specifying Gallus gallus as taxonomy. The NCBI identified 
proteins were then searched against Swiss-prot database, in order to univocally recognize each protein. 
For the identification, we considered asparagine deamidation as a possible variable modification that 
took place in the consensus sequence N-X-S/T after glycosidase treatment. The data obtained are 
summarized in Table 2. It should be noted that several glycopeptides where detected in the unbound 
 11 
fraction from egg samples and identified by the diagnostic increment of 1 Da respect to the theoretical 
mass. Some proteins, as the vitellogenin-2, ovalbumin, ovotransferrin and clusterin, are indicated to be 
glycosylated on the basis of similarity with the counterpart from other species. For several egg proteins,  
the glycosylation sites are indicated in the SwissProt database as putative N-glycosylation sites. The MS 
analyses performed in this work, led to the direct identification of N-glycosylation sites for several egg 
proteins. To the best of our knowledge, these results represent the first  data on the fine localisation of 
N-glycosylation sites thus complementing the data already available on the characterisation of egg 
proteome. 
CONCLUSIONS. As a whole, in this work an optimized dansylation protocol for glycoproteomic 
studies by MALDI-MS/MS analysis is reported. The presence of the aromatic 
dimethylaminonaphthalene group at the reducing end increased the glycan fragmentation leading to a 
better coverage of the oligosaccharide sequence. This tendency could be rationalized considering that 
the UV-adsorbing naphthalene group in the reducing end could increase the energy transfer from the 
laser in PSD-like fragmentation, favoring the glycan bond destabilization/protonation as observed for 
peptides. Glycan dansylation was demonstrated to be a rapid and cost-effectively valuable method useful 
to optimize the ionization efficiency of oligosaccharides. Well established techniques were conjugated 
with novel derivatisation procedure thus providing a new method for the glycoproteome investigation. 
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Table 1: list of the oligosaccharides structures detected by MALDI-MS, where BY=ConA bound 
fraction of yolk, UY=ConA Unbound fraction of yolk, BW=ConA bound fraction of white, 
UW=ConA unbound fraction of white. 
 
m/z Composition Structure 
1095.37
BY
 HexNac2Hex4 
  
1136.39
BY
 HexNAc3Hex3 
  
1257.42
 BY,BW
 HexNac2Hex5 
  
1298.42
BY
 HexNAc3Hex4 
  
1339.44
 
BY,BW,UY,UW
 
HexNAc4Hex3 
  
1419.47
 BY,BW
 HexNAc2Hex6 
  
1460.50
 BY,BW,UY
 HexNAc3Hex5 
 
 
 
1501.53
 
BY,BW,UY,UW
 
HexNAc4Hex4 
  
1542.55
 
BY,BW,UY,UW
 
HexNAc5Hex3 
  
1581.52
 BY
 HexNAc2Hex7 
  
1622.55 
 BW
 HexNAc3Hex6 
  
1663.58
 BY,BW
 HexNac4Hex5 
  
 15 
1704.61
 
BY,BW,UY,UW
 
HexNAc5Hex4 
  
1745.63
 
BY,BW,UY,UW
 
HexNAc6Hex3 
  
1850.66
 BY,UY
 FucHexNAc5Hex4 
 
1866.66
 
BW,UY,UW
 
 
HexNAc5Hex5 
 
1905.63
 BY UY
 HexNAc2Hex9 
  
1907.68
 BW,UW
 HexNac6Hex4 
 
 
1948.71
 BW, 
UY,UW
 
HexNac7Hex3 
 
 
1954.67
 BY, UY
 HexNac4Hex5Sia 
  
2028.71
 BW, UY
 HexNac5Hex6 
 
 
2067.69
 BY,UY
 HexNAc2Hex10 
  
2110.76
 UY,UW
 HexNAc7Hex4 
 
2151.79
 UY,UW
 HexNAc8Hex3 
 
2245.77
 BY, UY
 HexNAc4Hex5Sia2 
  
2272.82
 UY,UW
 HexNAc7Hex5 
 
 16 
2303.81
 BY,UY
 FucHexNAc5Hex5Si
a  
2313.84
 UY,UW
 HexNAc8Hex4 
 
2319.81
 BY, UY
 HexNac5Hex6Sia 
  
2475.90
 UY,UW
 HexNac8Hex5 
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Table 2: List of the proteins identified by LC-MS/MS analyses. N-glycosylation sites are marked with an asterisk 
after the asparagines residue. BY and BW indicate the bound fraction of egg yolk and white samples, respectively; 
UY and UW indicate the unbound fraction of egg yolk and white, respectively. 
 Protein Sequence 
Vitellogenin-1 (P87498)  MSFTCSFN
*
K 
BY, UY, UW
 
EVHINTSSAN
*
ITICPAADSSLLVTCNK
 BY
 
Ovomucoid (P01005) FPN
*
ATDK
 BY, BW, UY, UW
 
PMN
*
CSSYAN
*
TTSEDGK
 BY, BW, UY, UW
 
CNFCNAVVESN
*
GTLTLSHFGK
 BY, BW, UY, UW
 
LAAVSVDCSEYPKPDCTAEDRPLCGSDN
*
K
 BY, BW, UY, UW
 
Vitellogenin-2 (P02845) VQVFVTN
*
LTDSSK
 BY
 
LLVDGAESPTAN
*
ISLISAGASLWIHNENQGFALAAPGHGIDK
 BY, UY
 
Apovitellenin-1 (P02659) NFLIN
*
ETAR
 BY, UY, UW
 
 
Serum albumin (P19121) KQETTPINDN
*
VSQCCSQLYANR
 BY
 
 
Apolipoprotein B 
(Q197X2) 
VASPLYN
*
VTWR
 BY, BW
 
SLHN
*
STLGSLVPK
 BY, BW
 
NQYGMMTEVN
*
QTLK
 BY, BW
 
INSPSNQILIPAMGN
*
ITYDFSFK
 BY, BW
 
LNIPEADFSSQADLVNN
*
MTTEVEAGR
 BY, BW
 
VASPFFTLSTQAEVHN
*
TTASANSPEFDTSLSAQATSK
BY,BW
 
Complement C3 
(Q90633) 
FEIDHALSN
*
R
 BY
 
AAN
*
LSDIVPNTESETK
 BY
 
Ig mu chain C region* 
(P01875) 
VNVSGTDWR
 BY, UY 
VTHN
*
GTSITK
 UW 
 
Cathepsin D* 
(Q057441) 
DTLQISN
*
ISIK
 BY
 
 
Arylsulfatase K* 
(Q5ZK90) 
NDFLN
*
VSAPR
 BY
 
Complement factor B-like protease* 
(P81475) 
TGN
*
WSTKPSCK
 BY
 
Ovotransferrin 
(P02789) 
TAGWVIPMGLIHN
*
R
 BW
 
FGVN
*
GSEK
 BW, UY, UW
 
Ovalbumin-related protein Y 
(P10114) 
SAN
*
LTGISSVDNLMISDAVHGVFMEVNEEGTEATGSTGAIGNIK
BW, UW
 
 
Ovoglycoprotein 
(Q8JIG5) 
LN
*
ETCVVK
 BW, UY, UW
 
HN
*
STLTHEDGQVVSMAELTHSDK
 BW
 
Clusterin 
(P14018) 
RYDDLLSAFQAEMLN
*
TSSLLDQLNR
 UY, UW
 
 
Ovalbumin 
(P01012) 
YN
*
LTSVLMAMGITDVFSSSANLSGISSAESLK
 UW
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Fig. 1: positive ion mode MALDI-MS spectrum of ConA bound (panel A) and unbound fraction (panel B) 
oligosaccharides released from egg white glycoproteins. 
 19 
 
Fig. 2: positive ion mode MALDI-MS spectrum of ConA bound (panel A) and unbound fraction (panel B) 
oligosaccharides released from egg yolk glycoproteins. 
 20 
 
Fig. 3: positive ion mode MALDI-MS/MS spectrum of DNS-labelled maltoheptaose (B) compared to the unmodified 
one(A). 
 21 
 
Fig. 4: ESI-MS/MS spectrum of DNS-labelled maltoheptaose (B) compared to the unmodified one(A) performed on a 
4000 Q-TRAP. 
 22 
 
Fig. 5: positive ion mode MALDI-MS/MS spectrum of DNS-labelled oligosaccharide at m/z 1666.38 released from egg 
white ConA eluted fraction (B) compared to the unmodified one(A) 
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Lipopolysaccharides (LPSs) are ubiquitous and vital components of the cell surface of Gram-negative bacteria that have been shown to 
play a relevant role in the induction of the immuno system response. In animal and plant cells innate immune defenses toward 
microrganisms are triggered by the perception of pathogen associated molecular patterns (PAMPs). These are conserved and generally 
indispensable microbial structures such as LPSs that are fundamental in the Gram negative immunity recognition.  10 
This paper reports the development of an integrated strategy based on lipopolysaccharide affinity methodology that represents a new 
starting point to elucidate the molecular mechanisms elicited by bacterial LPS and involved in the different steps of innate immunity 
response. Biotin-tagged LPS was immobilized on streptavidin column and used as a bait in an affinity capture procedure to identify 
protein partners from human serum specifically interacting with this effector. The complex proteins/lipopolysaccharide was isolated and 
the protein partners were fractionated by gel electrophoresis and identified by mass spectrometry. 15 
This procedure proved to be very effective in specifically binding proteins functionally correlated with the biological role of LPS. 
Proteins specifically bound to LPS essentially gathered within two functional groups, regulation of the complement system (Factor H, 
C4b, C4BP and alpha 2 macroglobulin) and inhibition of LPS induced inflammation (HRG and Apolipoproteins). 
The reported strategy might have important applications in the elucidation of biological mechanisms involved in the LPSs-mediated 
molecular recognition and anti-infection responses. 20 
 
Introduction 
In a biological context, the term immunity refers to the set of 
events and biological cascades that protect organisms against 
infectious diseases. This protection system is based on complex 25 
interconnections between cells and molecules whose synergic 
action determines immune response. The main physiological 
function of immune system is the protection against infectious 
agents or simply against exogenous elements. The ability to 
distinguish “self” from “non-self” is critical to prepare an 30 
effective immune response (1). 
Immune system response can be classified into two categories: 
adaptive immunity and innate immunity. The adaptive immune 
system is based on specialized processes whose function is to 
eliminate external threats during the late phase of infection with 35 
the generation of  immunological memory. Specificity is 
developed by clonal gene rearrangements form a range of 
antigen-specific receptors on lymphocytes (2). Only vertebrates 
are provided with this type of immunity, allowing the organism to 
recognize and remember the “non-self”. Innate immune system is 40 
necessary to activate adaptive immune system. It acts in a non-
specific manner and does not confer any memory of the 
challenge. It is widespread amongst all animals and even in 
plants, and its main function is to provide immediate protection 
against pathogens. Innate immunity relies on specific cells as 45 
primary mediators, namely phagocytic cells and antigen 
presenting cells (APCs), such as granulocytes, macrophages, and 
dendritic cells (DCs) (3). Innate immunity mechanisms do not 
have specific pathogen targets, the principal targets are 
evolutionarily conserved molecular structures, termed “pathogen 50 
associated molecular patterns” (PAMPs) whose expression is 
common to different pathogens. These structures are generally 
recognized by receptors on the membrane of the host cells that 
are responsible for the immune response. Such structures are 
called “pattern recognition receptors” (PRR). PRRs are 55 
constitutively expressed in the host on all cells of a given type 
(4). Lipopolysaccharide (LPS) is a glycolipid, generally referred 
to as endotoxin in Gram negative bacteria, belonging to PAMP 
family. It is a potent inducer of the innate immune system and the 
main cause of septic shock (5). 60 
The recognition of this endotoxin is achieved by the interplay of a 
variety of proteins, either receptors or serum secreted proteins. 
The cascades of events following LPS infection has been 
investigated in numerous studies. However, most of them focused 
on the interaction of single specific proteins with LPS, such as the 65 
LPS-binding protein (LBP), whose mechanism of action was 
clarified in many works (6; 7). Further studies showed that other 
proteins possess LPS-binding domains (8; 9; 10). Intracellular 
pathways elicited by LPS infection was investigated by in vitro 
and in vivo analyses on different cell types, ranging from  70 
immune cells to epithelial cells (11;  12).  
Toll-like receptor 4 (TLR-4) is the signal transducing receptor of 
lipopolysaccharides; lipid A is the real effector required to 
activate TLR4 signalling pathway in conjunction with a soluble 
co-receptor protein myeloid differentiation protein 2 (MD2), 75 
which directly and physically binds to LPS (13; 14). Entry of LPS 
or lipid A into the blood stream is responsible for the onset of 
septic shock (15). Aggregates of LPS bind to certain plasma 
proteins, such as albumin, LBP and soluble CD14 to facilitate the 
interaction with host cells, via TLR4. The complex of protein 80 
bound LPS, TLR4, and MD2, activates two intracellular 
pathways (16): the MyD88-dependent pathway, responsible for 
early-phase NF-κB and MAPK activation, which controls the 
induction of proinflammatory cytokines TNF-a, IL-1, IL-6, and 
the MyD88-independent, TRIF-dependent pathway that activates 
IRF3, which is necessary for the induction of IFN-β- and IFN-5 
inducible genes (17). The activation of the TLR4-MD2 complex 
triggers the induction of inflammatory cytokines acting as 
endogenous mediator of infection, as well as the superoxide anion 
(O2-), hydroxyl radicals (OH), nitric oxide and antimicrobial 
peptides (18). 10 
The low and balanced concentrations of these mediators and 
soluble immune response modulators leads to a resulting 
inflammation, one of the most important and ubiquitous aspect of 
the immune host defence against invading microorganisms. 
Beside these positive effects, an uncontrolled and massive 15 
immune response, due to the circulation of large amount of 
endotoxins, leads to the symptoms of the sepsis and of the septic 
shock. Therefore identification of all the molecular actors 
involved in the recognition cascade is of pivotal importance with 
particular emphasis on the differences in elicitation and reaction 20 
by different LPSs. 
Numerous studies have been performed following pro-
inflammatory expression patterns via microarray analyses (19) 
and the phage display method was used to capture new LPS-
binding peptides (20). 25 
Recently, proteomics approaches were addressed to the study of 
innate immunity. Comparative analysis of the human plasma 
proteome prior and after LPS injection was performed (21) and 
the human innate immunity interactome was investigated using 
58 genes involved in transcriptional regulation of type I IFN 30 
tagged with the FLAG epitope following cells stimulation with 
LPS (22).  
The aim of this study was the setting up of a new methodology 
for the development of lipopolysaccharides analyses to be used to 
capture LPS-interacting proteins in order to better elucidate the 35 
molecular mechanism of the innate immunity. Here, a strategy 
based on chemical manipulations, biochemical procedure and 
mass spectrometry techniques integrated in a functional 
proteomic workflow is proposed. The procedure was developed 
using an LPS derived from Salmonella typhimurium and the 40 
proteomic study was carried out by using human serum from a 
healthy donor as a model. 
Materials and methods 
LPS extraction 
Dried cells of Salmonella typhimurium were extracted by the 45 
phenol/water method (23). The extracted phases were dialysed 
three times against distilled water and subjected to enzymatic 
digestions in order to remove nucleic acids and protein 
contaminants. Both water and phenol fractions were analysed 
through SDS.PAGE 13.5%. 50 
LPS biotinylation 
LPS biotinylation was achieved by a transesterification reaction 
with biotin-p-nitrophenylester (Sigma Aldrich). Lyophilized LPS 
was solubilised in 200 µL pyridine (Romil), to which a certain 
amount of biotin-p-nitrophenylester was added. LPS: biotin-p-55 
nitrophenylester ratio was calculated as 1:3 (weight:weight). The 
reaction was carried out in the dark for 2 hours at 80°C.  The 
reaction mixture was dried under nitrogen and then the sample 
was dissolved in MilliQ water. The excess of reagents was 
removed by molecular exclusion chromatography on PD-10 60 
columns (GE-Healthcare). LPS containing fractions were pooled 
and lyophilized. Unlabelled and biotinylated LPS were dissolved 
in Laemmli buffer, supplemented with 100 mM DTT and 
separated by SDS-PAGE in a 12.5% polyacrylamide gel. LPS 
was detected by silver nitrate staining for carbohydrates (Tsai 65 
Frash, 1982) or electrotransferred onto a PVDF membrane 
(Millipore). The membrane was blocked with 3% non fat dry 
milk, 1% BSA (Sigma Aldrich), in PBS containing 0.05% Tween 
20 (Sigma Aldrich). Then it was incubated with 1:1000 
streptavidin/HRP conjugate (Sigma Aldrich). Biotinylated sample 70 
was detected using SuperSignal West Femto Chemiluminescent 
Kit from Pierce. 
LPS immobilization onto avidin beads 
Biotin-LPS immobilization was carried out using 3 mg biotin-
LPS/mL of settled avidin agarose resin (settled gel, Pierce) 75 
An aliquot of resin was extensively washed with binding buffer 
(0.1 M Na3PO4; 0.3 M NaCl; pH 7.2) and incubated with biotin-
LPS at 4°C overnight under shaking. Then the resin was washed 
three times with binding buffer. 
Biotin-LPS and human serum interaction 80 
The affinity experiment was preceded by a “precleaning step”. A 
protease inhibitors cocktail (Sigma Aldrich) was added to 5 mg 
human serum (Servizio Analisi, Policlinico), to a final 
concentration of 1 mM. This sample was diluted to a final volume 
of 600 µL with binding buffer and incubated with 150 μL of 85 
settled resin overnight at 4°C. The unbound fraction of 
precleaning step was therefore incubated with 150 μL of biotin-
LPS immobilized resin overnight at 4°C. Later on, the two 
aliquots of resin, that we term “control” and “test” were subjected 
to repeated washes with binding buffer. Elution was performed 90 
boiling the resin in Laemmli buffer and DTT. 
SDS-PAGE was performed, loading on a 1.5 mm, 12.5 % gel all 
the samples deriving from the different steps of the fishing 
experiment. The gel was run at constant 25 mA for 1h. The gel 
was stained with colloidal Coomassie (Pierce). 95 
In gel trypsin digestion 
The analysis was performed on the Coomassie blue-stained 
protein bands excised from the gels. Gel particles were washed 
first with acetonitrile and then with 0.1 M ammonium 
bicarbonate. Protein samples were reduced incubating the bands 100 
with 10 mM dithiothreitol (DTT) for 45 min at 56 C. Cysteines 
were alkylated by incubation in 5 mM iodoacetamide for 15 min 
at room temperature in the dark. The bands were then washed 
with ammonium bicarbonate and acetonitrile. Enzymatic 
digestion was carried out with trypsin (12.5 ng/μl) in 50 mM 105 
ammonium bicarbonate buffer, pH 8.5. Gel particles were 
incubated at 4°C for 2h, in order to allow the enzyme to enter the 
gel. The buffer solution was then removed and a new aliquot of 
buffer solution was added for 18 h at 37 C. A minimum reaction 
volume, enough for complete gel rehydration was used. At the 110 
end of the incubation the peptides were extracted by washing the 
gel particles 0.1% formic acid in 50% acetonitrile at room 
temperature and then lyophilised. 
LC-MS/MS analyses 
Peptides mixtures were analyzed by LC-MS/MS, using a HPLC-115 
Chip LC system (Agilent 1200) connected to a Q-TOF 6520 
(Agilent Technologies). Samples were diluted in 10 µL 0.1% 
formic acid. After loading, the peptide mixtures were  
concentrated and washed at 4 µL/min in 40 nL enrichment 
column with 0.2% formic acid in 2% acetonitrile. Fractionation 5 
was carried out on a C-18 reverse phase column (75 µm x 43 
mm) at a flow rate of 0,4 µL/min with a linear gradient of eluent 
B (95% acetonitrile and 0.2% formic acid) in A (2% acetonitrile  
and 0.1% formic acid) from 7% to 80% in 51 min.  
Mass spectrometry analyses were performed using data 10 
dependent acquisition MS scans (mass range 300-2400 m/z), 
followed by MS/MS scans (mass range 100-2000 m/z) of the 
most intense ions of a chromatographic peak.  
Raw data from LC-MS/MS were converted to mzData. The 
spectra were searched against the NCBI database (2006.10.17 15 
version) using the licensed version of Mascot 2.1 (Matrix 
Science). The MASCOT search parameters were: taxonomy 
Homo sapiens; allowed number of missed cleavages 2; enzyme 
trypsin; variable post-translational modifications, methionine 
oxidation, pyro-glu N-term Q; peptide tolerance 10 ppm and 20 
MS/MS tolerance 0.6 Da; peptide charge, from +2 to +3.  
Results 
LPS were extracted by Salmonella typhimurium cells as described 
in Materials and Methods section and analysed by SDS-PAGE. 
The LPS fraction was found exclusively in the water phase as 25 
suggested by the presence of the typical ladder pattern in the gel 
analysis (data not shown). 
LPS tagging 
Immobilisation of the LPS represents the key step in the entire 
strategy to generate a labeled bait that could be linked to agarose 30 
beads. Biotinylation of LPS was chosen as the best suited 
derivatization process both for the simple modification reaction 
and to take advantage of the strong and specific interaction of 
biotin with avidin. 
Biotinylated LPS was analysed by SDS-PAGE following both 35 
silver staining and immunodetection with streptavidin/HRP 
conjugate. Figure 1 shows the corresponding gel. Staining 
procedures displayed the occurrence of two sample bands. The 
low molecular mass bands corresponds to the LipidA core 
component of LPS (R-type LPS) whereas the high molecular 40 
mass band represents the whole LPS molecule comprising the O-
chain moiety (S-type LPS). Both components were responsive to 
western blot analysis demonstrating that they had been 
derivatised by biotin. 
LPS immobilization 45 
Biotin-LPS was conjugated to avidin agarose beads by incubation 
in 0.1 M Na3PO4 overnight. Both unbound and bound fractions 
were analyzed by SDS-PAGE followed by blotting and 
incubation with streptavidin/HRP conjugate. Fig. 2 shows the 
results of the immobilization procedure; two immunoresponsive 50 
bands corresponding to LPS and the Lipid A moiety were clearly 
detected in the bound fraction while no immunoresponsive bands 
occurred in the unbound material.  
Identification of LPS-interacting proteins 
Fig. 1:SDS-PAGE of 
LPS after biotin-p-
nitrophenylester 
derivatition detected 
by silver staining 
(on the left) and 
blotting with 
streptavidin/HRP 
incubation (on the 
right) 
Fig. 2: immobilization 
procedure probed by 
blotting with 
streptavidin/HRP 
incubation. Two bands 
corresponding to LPS 
and Lipid A moiety were 
clearly detected in the 
bound fraction while no 
bands occurred in the 
unbound material 
The final step of the proposed strategy relies on the use of the 
immobilised LPS as bait in a functional proteomic experiment 
(24) aiming at capturing specific LPS interactors to investigate 
innate immunity molecular mechanisms in human serum. An 
aliquot of human serum proteins was incubated with 5 
underivatised avidin agarose beads overnight at 4°C as a pre-
cleaning step to remove all the proteins that non specifically 
interact with agarose or avidin. The unbound fraction was then 
incubated with biotin-LPS avidin agarose beads and after 
extensively washing in binding buffer both the bound fractions 10 
(control and sample) were eluted in Laemmli buffer and 
fractionated by SDS-PAGE gel. An aliquot of 15 μg of human 
serum was also loaded onto the gel (Fig.3). Due to the complexity 
of the gel patterns and the low resolution of 1D electrophoresis, 
several proteins can occur in the same gel band. Therefore, 15 
protein bands specifically present in the sample lane and absent in 
the control lane cannot be identified by simply comparing the two 
gel profiles. Thus the entire sample lane of the gel was cut in 25 
slices. Each slice was destained and in situ trypsin digested. To 
check for non specific proteins, the same procedure was applied 20 
to the control lane. The resulting peptide mixtures were extracted 
from the gel and submitted to nanoLC/MS/MS analysis 
generating sequence information on individual peptides. 
This information, together with the peptide mass values, was then 
used to search protein databases, leading to the identification of 25 
the protein components. The experiments were performed in two 
biological replicates and each protein mixture was run through 
LC/MS/MS three times. All proteins identified in both the sample 
and control lanes were discarded, while only those solely 
occurring in the sample lane and absent in the control lane were 30 
selected as putative LPS interactions. As further selection criteria, 
only proteins found in both biological replicates and identified 
with at least 2 significative peptides in MASCOT search were 
considered, providing a full list of putative LPS interactors. The 
results are summarised in Table 1. 35 
Discussion 
Lipopolysaccharides are major constituents of the outer 
membrane of Gram-negative bacteria and important molecules in 
the induction of the immuno system response. The innate immune 
system constitutes the first line of defence against 40 
Fig. 3: 12,5% SDS-PAGE gel containing 15 μg of human 
serum together with control and sample bound fractions after 
elution in Laemmli buffer.  The entire control and sample 
lanes of the gel were cut in 25 slices. Each slice was destained 
and trypsin digested, in situ.  
Table 1: list  of putative LPS-interacting proteins after in situ digestion of the bands from control and sample bound fractions. 
As selection criteria only proteins solely present in the sample lane and completely absent in the control lane were considered 
putative interactors. Analyses were carried out in replicates and only proteins proteins present in both replicates and identified 
with at least 2 peptides in MASCOT search were considered 
microorganisms and plays a primordial role in the activation and 
regulation of adaptive immunity. In humans, components of the 
innate immune system include members of the complement 
cascade and soluble pattern recognition molecules (PRRs), 
functional ancestors of antibodies (25) In particular, the 5 
complement system plays a key role in the elimination of micro-
organisms after entrance in the human host. 
The integrated strategy based on functional proteomic approach 
described in this paper represents a new starting point to elucidate 
the molecular mechanisms elicited by bacterial LPS and involved 10 
in the different steps of innate immunity response. Identification 
of the specific LPS-binding proteins in human serum was rarely 
addressed since most investigations focused on the LPS-mediated 
effects on cellular pathways and transcriptional responses. Only 
recently, a single example was reported using a solid-phase 15 
chemically immobilised LPS (26). 
The strategy based on affinity capture procedure using biotin LPS 
as a bait was optimized and human serum from a healthy donor 
was used as model. A number of proteins were specifically 
retained by the LPS bait and subsequently identified by mass 20 
spectrometric methodologies. The identity of these proteins 
represented per se a validation of the developed affinity-capture 
procedure. These proteins, in fact, essentially gathered within two 
functional groups, regulation of the complement system (Factor 
H, C4b, C4BP and alpha 2 macroglobulin) and inhibition of LPS 25 
induced inflammation (HRG and Apolipoproteins). Both groups 
are functionally correlated with the biological role of LPS. 
The complement system is an essential component of the innate 
immune system that participates in elimination of pathogens. 
Three different pathways synergistically contribute to the 30 
protection mechanism elicited by the complement proteins, the 
classical pathway, the alternative pathway and the lectin pathway. 
Despite the specific pathway they belong to, complement proteins 
provide host defence towards bacterial infections by binding to 
cell surface components of exogenous microorganisms. In 35 
contrast, pathogenic microorganisms have evolved several 
strategies to escape these defence mechanisms. The most 
common procedure consists in the recruitment of complement 
inhibitory proteins to the bacterial surface thus impairing the 
immune system.  40 
In this respect, the identification of well characterized protein 
inhibitors of the complement system among the LPS interactors 
has a clear biological significance. C4BP, Factor H and alpha 2 
macroglobulin are all complement inhibitors able to 
downregulate activation of the classical, alternative and lectin 45 
pathways respectively. Streptococcus pyrogenes, the ethiologic 
agent of important human infections, was shown to bind Factor 
H, C4BP and other complement proteins as a crucial step in the 
pathogenesis of these infections (27). Bordetella pertussis was 
able to escape the classical pathway of complement by binding 50 
the classical pathway inhibitor C4BP. In addition, very recently it 
was shown that this pathogen can also evade the alternative 
complement pathway by recruitment of Factor H on the cell 
surface (28). 
On the other hand, alpha 2 macroglobulin exerts a specific 55 
inhibitory activity towards the lectin pathway by binding the 
mannose-binding lectin (MBL) and the MBL associated serine 
proteases MASP-1 and MASP-2 (29). Adding of alpha 2 
macroglobulin to human serum totally reversed killing of 
Neisseria gonorrhoeae, preventing MBL mediated activation of 60 
the complement system (30). 
However, the most effective complement inhibitor is Factor H, a 
soluble protein regulator essential for controlling the alternative 
immune pathway (31). Recognition and binding Factor H 
constitutes the infection mechanism adopted by several pathogens 65 
as a common immune evasion strategy. In addition several recent 
reports pointed out that besides its role as an alternative pathway 
downregulator, Factor H has an additional complement regulatory 
role in inhibiting activation of the classical pathway (32; 33). 
A totally different biological role can be ascribed to the second 70 
group of proteins identified by the LPS affinity capture strategy. 
HRG and Apolipoproteins, in fact, are known to exert protective 
effects against LPS induced systemic inflammation preventing 
inhibition of the complement immune system. HRG binds 
strongly to several complement protein inhibitors including 75 
Factor H and C4BP thus assisting in maintainance of normal 
immune function and enhancing complement activation (34). S. 
pyrogenes was shown to grow more efficiently in HRG-deficient 
plasma while the presence of overexpressed HRG greatly 
increased clots formation, bacterial entrapment and killing (35). 80 
Apolipoproteins AI, A-IV and D are all components of the high 
density lipoproteins (HDL) that have long been reported to bind 
bacterial LPS neutralizing its toxicity and preventing initiation of 
innate immunity. More recently evidences for an Apo AI-LPS 
specific interaction have been obtained (36). Moreover, the 85 
adenovirus mediated overexpression of this protein led to 
protection of mice against LPS-mediated systemic inflammation 
(37). 
 
Conclusions 90 
In conclusion, the novel LPS-mediated affinity capture strategy 
developed in this paper proved to be very effective in specifically 
binding proteins involved either in inhibiting the activation of the 
complement system or in preventing bacterial infection by 
sequestering the LPS moiety. Both processes are of relevant 95 
biological significance and the results obtained makes sense with 
the bait used. Moreover, although a proper sensitivity test was not 
performed, the LPS affinity procedure led to the identification of 
low abundant serum proteins even without any depletion step. 
The sensitivity of the LC-MS/MS analyses allowed us to identify 100 
specific proteins even when the protein band showed only a very 
faint staining. A further advantage of this procedure concerns the 
possibility of determining both the proteins directly bound to LPS 
bait and other components involved in the functional complex but 
not linking the LPS moiety. It will be now possible to foresee 105 
applications of this strategy to investigate biological mechanisms 
exerted by pathogenic bacteria at the molecular level and to 
possibly define new mechanisms of infection. 
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